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Abstract 
 
This thesis examines and compares the demographics, clinical phenotype, radiological 
findings and response to medical and surgical treatments of SUNCT (short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing) and 
SUNA (short-lasting unilateral neuralgiform headache attacks with autonomic 
symptoms). Given the similarities between SUNCT, SUNA and trigeminal neuralgia 
(TN), the demographics and clinical phenotype of these disorders were also compared.  
In the first study (Chapter 2) a cohort of 133 patients (SUNA=63 and SUNCT=70) was 
phenotyped and the clinical characteristics of SUNA compared to those of SUNCT. 
Statistically significant predictors for SUNCT rather than SUNA were only found for 
ipsilateral ptosis [OR: 3.37 (95% CI: 1.50, 7.66), p<0.0001] and rhinorrhoea [OR: 2.42 
(95% CI: 1.09, 5.41), p=0.034]. Furthermore, a significantly higher proportion of 
SUNCT patients (n=56, 80.0%) reported marked lacrimation compared to SUNA 
patients (n=20, 46.5%) (P<0.001).  
In the second study (Chapter 3) 45 SUNCT and 34 SUNA  patients had high-resolution 
cisternal imaging MRI scans to asses the presence of trigeminal neurovascular conflict. 
The prevalence of neurovascular contact on the symptomatic trigeminal nerves was 
higher (57.3%) than on the asymptomatic trigeminal nerves (25%) (P≤0.001). Severe 
neurovascular contacts were considerably more prevalent on the symptomatic side 
(47.6%), compared to the asymptomatic side (11.8%) (P≤0.001). There was no 
statistically significant difference in the proportion of neurovascular contacts on the 
symptomatic nerves between SUNCT (61.7%) and SUNA (57.1%) (P=0.67). The 
presence of a vascular contact and its location at the root entry zone were strong 
predictors for the nerve to be symptomatic rather than asymptomatic.  
In the third study (Chapter 4) the response to treatments of 161 SUNCT and SUNA 
patients was analysed. Our findings suggest that lamotrigine was the most effective 
treatment (responders: SUNCT= 53.5%, SUNA= 57.9%) followed by oxcarbazepine 
(responders: SUNCT= 44.8%, SUNA= 47.0%); duloxetine and topiramate were more 
effective in SUNCT rather than SUNA (duloxetine responders: SUNCT= 45.0%, 
SUNA: 11.8%; p= 0.027; topiramate responders: SUNCT= 33.3%, SUNA= 10.7%; p= 
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0.028). Amongst transitional treatments intravenous lidocaine led to a significant 
headache improvement in 83.3% SUNCT (n=25) and in 76.5% SUNA (n=13) patients 
(p=0.73). A greater occipital nerve block was beneficial in 27.3% (n=21) of patients for 
a median of 21 days (IQR: 53 days; range: 1 to 150 days), without any significant 
difference between SUNCT (24.4%; n=11) and SUNA (37.0%; n=10) patients 
(p=0.42). We found intravenous dihidroergotamine able to worsen or even to 
precipitate a de novo SUNCT/SUNA when administered to manage a different primary 
headache disorder.   
In the fourth study (Chapter 5) occipital nerve stimulation (ONS) was tried in nine and 
trigeminal microvascular decompression was tried in ten refractory, chronic SUNCT 
and SUNA patients. At a median follow-up of 38 months (range 24-55 months) ONS 
led to a marked headache improvement in eight of the nine patients (89%). One patient 
did not report any benefit from the stimulator at 24 months’ follow-up and opted to 
have the ONS explanted. At a mean follow-up fo 19.6 months (range: 12-36 months) 
after trigeminal microvascular decompression surgery, seven patients (70%) became 
headache-free after the operation. Five of the seven patients (71.4%) remained 
headache-free at the last follow-up. The remaining two patients were headache-free 
respectively for 9 and 12 months before the headache relapsed. There were no major 
surgical and post-surgical complications.  
A comparison of the clinical phenotype of SUNA (n=133) and TN (n=79) was 
undertaken in the last study (Chapter 6). Several similarities between SUNA and TN 
were found. Furthermore, some clinical features, namely pain location in V1 (OR: 
11.29 95%CI: 3.92, 35.50, p<0.001), spontaneous only attacks (OR: 44.40, 95%CI: 
4.50, 437.83, p=0.001) and a chronic pain pattern (OR: 13.19, 95%CI: 4.04, 43.08, 
p<0.001) predicted the diagnosis of SUNA rather than TN. Similarly duration of the attacks 
<1 minute (OR: 7.95, 95%CI: 2.30, 27.57, p=0.001) and the presence of a refractory 
period in between triggered attacks (OR: 0.06; 95%CI: 0.02, 0.28, p-value <0.001) were 
predictors for TN rather than SUNA.  
In summary our novel findings advance the clinical understanding of SUNCT and 
SUNA and suggest that their relationship with TN may represent` a clinical continuum 
between disorders. This view will hopefully open novel research directions towards a 
better understanding of these complex clinical entities. 
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Chapter 1.  SUNCT, SUNA and Trigeminal Neuralgia: focus on 
demographic, clinical characteristics, management 
strategies and pathophysiological hypotheses  
 
 
1.1. Introduction 
The International Headache Society (IHS) classifies headaches and facial pain 
conditions in three broad chapters. The primary headaches chapter recognises four 
groups of headaches: migraine, tension-type headache, trigeminal autonomic 
cephalalgias (TACs) and other primary headache disorders, which encompasses a 
heterogeneous group of poorly understood headache disorders. These conditions are 
considered primary, because the headache and associated symptomatology represents 
the symptom and no identifiable underlying pathological process can be found. The 
secondary headaches chapter encompasses headaches, which have an underlying 
pathology that can be established with appropriate investigations. The third chapter 
includes a miscellaneous group of painful cranial neuropathies and less prevalent forms 
of headache and facial pain (Headache Classification Subcommittee of The 
International Headache, 2013). 
 
A primary headache disorder called SUNCT (Short-lasting Unilateral Neuralgiform 
Headache attacks with Conjunctival injection and Tearing) has recently been validated 
and included in the International Classification of Headache Disorders (ICHD-2) 
(Headache Classification Subcommittee of The International Headache Society., 2004; 
Headache Classification Subcommittee of The International Headache, 2013). SUNCT 
is currently classified within the TACs group along with cluster headache (CH), 
paroxysmal hemicrania (PH) and hemicrania continua (HC) in view of laterality and 
trigeminal distribution of pain that occurs in association with ipsilateral cranial 
autonomic features. In particular, to fulfill the IHS diagnostic criteria for SUNCT both 
conjunctival injection and tearing should accompany the pain. Clinical data though 
suggests that this is not invariably the case, since patients with very similar phenotypes 
can report only one of the two cranial autonomic symptoms or some of the other cranial 
autonomic signs and symptoms that invariably accompany the TACs. For this reason, 
the IHS has proposed the term short-lasting unilateral neuralgiform headache attacks 
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with cranial autonomic symptoms (SUNA), where only one cranial autonomic signs or 
symptoms would be sufficient to make the diagnosis. However, since this terminology 
proposal, only a few cases of SUNA have been published, hence no systematic clinical 
comparison between SUNCT and SUNA has been undertaken. It has therefore been 
difficult to formally establish whether SUNCT and SUNA are the same clinical entity 
or two distinct conditions. This paucity of clinical data is partly due to the low 
prevalence of SUNCT and SUNA, which are considered very rare in the general 
population. Additionally, the diagnosis of SUNCT and SUNA is often challenging in 
view of their clinical overlap with some of the TACs and mostly with other trigeminal 
neuralgiform paroxysmal disorders, such as classical trigeminal neuralgia (TN), purely 
paroxysmal and classical TN with concomitant persistent facial pain. SUNCT and 
SUNA share striking clinical similarities with TN. This clinical overlap between the 
three conditions has raised the question whether they are different entities or whether 
they constitute a clinical continuum (Sesso, 2001). At present the recent revision of the 
ICHD has kept SUNCT and SUNA as separate entities within the grouping of the TACs 
and TN within the group of painful cranial neuropathies and other headaches and facial 
pains (Headache Classification Subcommittee of The International Headache, 2013). 
The limited research on the phenotype of these disorders has prevented any progress in 
the understanding of the neurobiological basis for SUNCT and SUNA, and in turn has 
limited the development of effective medical and surgical treatments, leaving sufferers 
in severe disability. 
 
The aims of this thesis were to: 
1) Assess whether SUNCT and SUNA are the same or whether they are different clinical 
entities and to formulate new diagnostic criteria accordingly. 
2) To assess the prevalence of trigeminal neurovascular conflict on trigeminal MRI 
sequences in SUNCT and SUNA patients. 
3)  To assess the outcome of medical and surgical treatments of SUNCT and SUNA.  
4) To assess any clinical similarities and differences between large series of SUNCT, 
SUNA and TN aiming to ultimately shed light on the nosological position of these 
disorders within the IHS classification.  
 
This thesis encompasses seven Chapters: 
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Chapter 1 provides an overview of demographic, clinical characteristics, aetiology, 
management and pathophysiological hypotheses for the trigeminal autonomic 
cephalalgias group, with a focus on SUNCT and SUNA syndromes. It also provides an 
overview of demographic, clinical characteristics, aetiology, management and 
pathophysiological hypotheses for TN, detailing the research questions that are ongoing 
matter of debate in the headache literature on SUNCT, SUNA and TN. The aims of this 
study are also outlined. 
 
Chapters 2 provides the description of the SUNCT and SUNA phenotyping study, 
including the clinical comparison between the two conditions and the proposed 
diagnostic criteria.  
 
Chapters 3 provides the description of the structural MRI study in SUNCT and SUNA. 
 
Chapter 4 provides a description of the efficacy of a variety of pharmacological 
treatments in the cohorts of SUNCT and SUNA patients. 
 
Chapter 5 provides a description of the efficacy of some surgical approaches in a 
subgroup of SUNCT and SUNA patients refractory to pharmacological treatments. 
 
Chapter 6 provides the comparison between the series of SUNCT, SUNA and a large 
series of TN patients.  
 
Chapter 7 outlines the summary of the main findings and conclusions of the thesis. 
 
1.2. Trigeminal Autonomic Cephalalgias  
The trigeminal autonomic cephalalgias (TACs) are a group of primary headache 
disorders that are characterised by strictly unilateral trigeminal distribution pain 
occurring in association with ipsilateral cranial autonomic symptoms. This group 
includes cluster headache (CH), paroxysmal hemicrania (PH), short-lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), short-
lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms 
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(SUNA) and hemicrania continua (HC). CH, PH, SUNCT, SUNA and HC are currently 
grouped into section three of the IHS classification (Headache Classification 
Subcommittee of The International Headache, 2013). The TACs seems to constitute a 
clinical spectrum that differs in attack duration and frequency as well as response to 
therapy. Cluster headache has the longest attack duration and relatively low attack 
frequency. PH has intermediate duration and intermediate attack frequency. SUNCT 
and SUNA have the shortest attack duration and the highest attack frequency. HC is 
characterised by a unilateral continuous headache with superimposed moderate/severe 
exacerbations of the headache accompanied by ipsilateral cranial autonomic features. 
The importance of recognizing these syndromes resides in their excellent, but highly 
selective, response to treatment. 
 
1.2.1. Cluster Headache 
 
 
1.2.1.1.    Introduction and background 
CH is a strictly unilateral headache that occurs in association with cranial autonomic 
features and, in most patients, has a striking circannual and circadian periodicity. It is 
an excruciating headache syndrome and is probably one of the most painful conditions 
known to mankind.  
 
1.2.1.2.    Epidemiology 
The prevalence of CH is estimated to be 0.1% (D'Alessandro, et al., 1986), although a 
recent study suggests that the prevalence of CH may be as high as two per 1000 (Torelli, 
et al., 2005). The male: female ratio is 2.5:1 (Bahra, et al., 2002). It can begin at any 
age, though the most common age of onset is the third or fourth decade of life. 
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1.2.1.3.    Clinical features 
Cluster attacks are excruciatingly severe, strictly unilateral, episodes of headache, 
which are located mainly around the orbital and temporal regions, although any part of 
the head can be affected. The headache episodes usually last 45–90 minutes, but can 
range from 15 minutes to three hours. It has an abrupt onset and cessation, and attacks 
are accompanied by cranial autonomic symptoms. The cluster attacks occur from one 
every other day to eight daily. To fulfil the IHS diagnostic criteria (Headache 
Classification Subcommittee of The International Headache, 2013) the cluster 
headache pain needs to be accompanied by at least one of the cranial autonomic signs 
and symptoms, ipsilaterally to the side of the pain, namely: conjunctival injection, 
lacrimation, miosis, ptosis, eyelid oedema, rhinorrhoea, nasal blockage and forehead or 
facial sweating, forehead and facial flushing, aural fullness, or restlessness or agitation 
(see Table 1). Symptoms normally seen in migraine, such as nausea, vomiting, 
photophobia and phonophobia, are reported by a significant proportions of cluster 
patients (Bahra, et al., 2002; Schurks, et al., 2006) and aura has also been reported 
(Rozen, 2011). The vast majority of CH patients report restlessness or even 
aggressiveness during the attacks (Bahra, et al., 2002) and, therefore, this feature has 
been incorporated into the ICHD-II and ICHD-IIIβ diagnostic criteria (Headache 
Classification Subcommittee of The International Headache Society., 2004; Headache 
Classification Subcommittee of The International Headache, 2013).  
 
The principal precipitants for CH attacks include: alcohol, nitroglycerine and elevated 
bodily or environmental temperature. Alcohol induces acute attacks, usually within one 
hour of intake, in the vast majority of cluster headache sufferers, which contrasts with 
migraine sufferers who generally have headache some hours after alcohol intake. 
Alcohol triggers attacks during a cluster bout, but not in a remission (Schurks, et al., 
2006). 
 
CH is classified according to the duration of the bout. About 80-90% of patients have 
episodic cluster headache (ECH), which is diagnosed when they experience recurrent 
bouts, each lasting for more than a week and separated by remissions lasting more than 
four weeks. The attacks follow a striking circadian rhythmicity, with some patients 
reporting that the attacks occur at the same time each day. The majority of patients with 
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ECH have one or two bouts per annum, lasting between one and two months. Often, a 
striking circannual periodicity is seen in ECH sufferers, with bouts occurring in the 
same month of the year. The remaining 10-20% of patients have chronic cluster 
headache (CCH) in which either no remission occurs within one year or the remissions 
last less than one month (Headache Classification Subcommittee of The International 
Headache, 2013).  
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1.2.1.4.    Differential diagnosis 
The major differential diagnostic considerations for CH are the TACs characterised by 
paroxysmal short-lasting headache attacks with no inter paroxysmal background 
continuous pain (Table 2) and secondary causes of CH. The vast majority of CH 
patients have a primary headache syndrome, with symptomatic causes only being 
identified in a very small minority. However, the true prevalence of symptomatic causes 
of CH is unknown as there are no prospective population-based neuroimaging studies. 
A review of retrospective case reports published in the medical literature suggests that 
the TACs may be associated with pituitary tumors, although this most likely reflects a 
considerable element of publication bias (Cittadini, et al., 2009). Similarly, an 
observational study of headache disorders in patients with pituitary tumors reported that 
A.  At least 5 attacks fulfilling criteria B-D 
B.  Severe unilateral orbital, supraorbital and/or temporal pain lasting 15-
180 minutes (when untreated). 
C.  Either or both of the following: 
      1.  At least one of the following symptoms or signs, ipsilateral to the 
headache: 
a) Conjunctival injection and/or lacrimation. 
            b) Nasal congestion and/or rhinorrhoea 
            c) Eyelid oedema  
            d) Forehead and facial sweating 
            e) Forehead and facial flushing 
            f) Sensation of fullness in the ear 
            g) Miosis and/or ptosis 
  2. A sense of restlessness or agitation  
D.  Attacks have a frequency of one every other day and eight per day for 
more than half of the time when the disorder is active. 
Adapted from The International Headache Society Classification Committee of (2013) 
 
 
 
Table 1. International Headache Society diagnostic criteria for cluster headache 
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CH occurred in 4% and SUNCT in 5%, but the study was conducted in a tertiary referral 
neurosurgical centre and, therefore, does not give a meaningful indication of the 
prevalence of these headaches in patients with pituitary disorders (Levy, et al., 2005). 
It remains unclear whether every TAC patient requires neuroimaging, although, if it is 
considered, then magnetic resonance imaging (MRI) is the preferred modality. Some 
authors suggest that all patients with TACs should have dedicated pituitary imaging. 
However, approximately one in 10 of the general population has an incidental pituitary 
microadenoma (<1 cm diameter) on routine MRI, and up to one in 500 will have a 
macroadenoma (Ezzat, et al., 2004). This approach is therefore likely to identify a 
significant number of incidental lesions, which could then be erroneously considered 
to be the cause of the TAC syndrome. One way of addressing this clinical dilemma 
could be that all TAC patients should be carefully assessed for pituitary disease-related 
symptoms and that further investigations with MRI of the pituitary gland should be 
undertaken in patients with atypical features, abnormal examination or those resistant 
to the appropriate medical treatments. 
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Table 2. Clinical features of the Trigeminal Autonomic Cephalalgias 
 
 Cluster        
headache 
Paroxysmal 
hemicrania 
SUNCT/SUNA 
Sex F:M 1:2.5-7.2 1:1 1:1.5 
Pain: 
Type 
 
Sharp, Throbbing 
 
Sharp, Throbbing 
 
Stabbing, Burning 
Severity Very severe Very severe Very severe 
Site  Orbit, temple Orbit, temple Orbit, temple 
Attack frequency 1/alternate day –
8/day  
>5/day when 
disorder is active 
≥1/day when 
disorder is active 
Duration of attack 15-180mins 2-30mins 1-600secs 
Circadian 
periodicity 
70% 45% Absent 
Autonomic features Yes Yes Yes† 
Restless or agitated 90% 80% 65% 
Migrainous features Yes Yes Rare 
Triggers: 
Alco   Alcohol 
Cut     Cutaneous 
 
++ 
- 
 
+ 
- 
 
- 
++ 
Indometacin effect - (rarely +) Absolute response - 
Abortive treatment Sumatriptan 
injection 
Sumatriptan or 
Zolmitriptan nasal 
spray 
Oxygen 
 
Nil 
 
Nil 
Prophylactic 
treatment 
Verapamil 
Methysergide 
Lithium 
Topiramate 
Indometacin Lamotrigine 
Topiramate 
Gabapentin 
 
Transitional 
treatment 
Corticosteroids 
GONB 
GONB GONB 
IV lidocaine 
 
†SUNCT: prominent conjunctival injection and lacrimation by definition. 
†SUNA: only one or neither of conjunctival injection and lacrimation by definition [1]. 
F, female; GONB Greater occipital nerve block; IV, intravenous; M, male; SUNA, Short-lasting Unilateral 
Neuralgiform headache attacks with autonomic symptoms; SUNCT, Short-lasting Unilateral Neuralgiform 
headache attacks with Conjunctival injection and Tearing 
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1.2.1.5. Treatment 
The European Federation of Neurological Societies (EFNS) (May, et al., 2006) and the 
American Academy of Neurology (AAN) (Francis, et al., 2010) have published an 
overview of the recommendations for CH abortive and preventive treatments. The AHS 
provided a recent update on the AAN guidelines (Robbins, et al., 2016). 
 
Abortive agents 
 
 
Subcutaneous sumatriptan 
 
Sumatriptan 6 mg subcutaneous (SC) injection is the drug of choice as abortive 
treatment of a cluster attack (Ekbom, et al., 1992; The Sumatriptan Cluster Headache 
Study, 1991). In CH, unlike in migraine, subcutaneous sumatriptan can be prescribed 
at a frequency of twice daily, on a long-term basis if necessary, without risk of 
tachyphylaxis or rebound (Ekbom, et al., 1995; Gobel, et al., 1998). Level of evidence: 
Class I. 
 
 Oxygen 
 
Inhalation of 100% oxygen, at 7–12 L/min is rapidly effective in relieving pain in the 
majority of sufferers (Kudrow, 1981; Fogan, 1985; Cohen, et al., 2009). It should be 
inhaled continuously for 15–30 min via a non-rebreathing facial mask. However, up to 
25% of the patients note that oxygen simply delays the attack for minutes to hours rather 
than completely aborting it (Kudrow, 1981). Level of evidence: Class I. 
 
Intranasal triptans 
 
Sumatriptan nasal spray (20 mg) and zolmitriptan nasal spray (5 mg and 10 mg) are 
both more effective than placebo (Van Vliet, et al., 2003; Cittadini, et al., 2006; 
Rapoport, et al., 2007). Given the efficacy of both zolmitriptan 5 mg and 10 mg doses, 
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it has been advised that 10 mg might be the optimal initial dose for those with very 
severe attacks occurring only once per day or every other day, while 5 mg should be 
the initial dose for those with more frequent attacks or poor tolerability. Level of 
evidence: Class I. 
 
Sphenopalatine ganglion stimulation 
 
The American Headache Society (AHS) has granted Class I evidence to a recent 
randomised-controlled study evaluating the safety and efficacy of sphenopalatine 
ganglion (SPG) stimulation, using a wireless microstimulator implanted in the 
pterygopalatine fossa Autonomic Technologies, Inc. [ATI] Neurostimulator)  
(Schoenen, et al., 2013). This treatment will be more extensively discussed in the 
paragraph on preventive treatments for CH.  
 
Topical lidocaine 
 
Lidocaine solution, given as nasal drops (10% lidocaine solution) or a spray deep in the 
nostril on the painful side has been studied in an open-label study and in a small double-
blind placebo-controlled study. Both studies reported a mild to moderate relief in 
patients during a CH attack, although only a few patients obtain complete pain relief 
(Robbins, 1995; Costa, et al., 2000). Level of evidence: Class II. Therefore, intranasal 
lidocaine may serve as a useful adjunct to other abortive treatments but is rarely 
adequate on its own. 
 
Subcutaneous octreotide 
 
Subcutaneous octreotide 100 μg, a somatostatin analog, was found to be an effective 
abortive treatment in CH in a randomized, double-blind, two-attacks, crossover study 
versus placebo. The primary outcome measure of the trial was a reduction in headache 
from moderate, severe, or very severe to nil or mild within 30 minutes from the injection 
(Matharu, et al., 2004). Level of evidence: Class I. 
Dihydroergotamine nasal spray 
 
 28 
Dihydroergotamine (DHE) nasal spray 1 mg has been studied in a double-blind, 
placebo-controlled, crossover trial (Anderson, et al., 1986). There was no difference in 
the headache frequency or duration, but the pain intensity was significantly reduced 
with DHE compared with placebo. The dosage used (1 mg) was rather low; therefore, 
DHE nasal spray at a dose of 2 mg or 4 mg may be more effective than 1 mg, although 
this needs to be studied in a controlled fashion. 
 
Indometacin 
CH is generally considered a disorder unresponsive to indometacin. Nevertheless, in 
the literature, there are a few case reports/series of CH responsive to indometacin in 
some cases with long term follow-ups. Very large doses of indometacin (up to 300 
mg/day) were needed in the majority of patients reported to obtain a complete response. 
Indometacin has also been tried as an abortive CH attack treatment. Intravenous (IV) 
and intramuscular (IM) indometacin treatments have been reported to be able to 
successfully treat CH attacks in some patients (Prakash, et al., 2010). However, there 
are no placebo-controlled studies of indometacin in cluster headache and these reports 
of “indometacin-responsive cluster headache” may simply represent placebo 
responders.  
 
The complete and consistent response to indometacin given as preventive treatment in 
patients with a CH phenotype may enforce the concept of a continuum between the 
TACs with overlapping clinical characteristics and response to certain medications. An 
alternative potential explanation would be that all patients with the phenotype of cluster 
head and paroxysmal hemicrania who respond to indomethacin are likely to have the 
same pathophysiology as paroxysmal hemicrania; hence, “indometacin-responsive 
cluster headache” may be best categorised as paroxysmal hemicrania for now. This is 
a controversial issue and often debated in headache circles.  
 
In clinical practice, indometacin may be used in those forms of established primary CH 
with atypical features, such as short-lasting attacks, high attack frequency or lack of 
response to sumatriptan injections and high flow oxygen, to rule out PH. In some cases, 
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indometacin could be used as an abortive treatment in CH, if the main treatments are 
ineffective or poorly tolerated.   
 
 
Transitional treatments 
 
There can be a lag of several days to a few weeks before the efficacy of preventive 
treatments becomes apparent. Transitional treatments, which produce a rapid 
suppression of the attacks for a limited period of time or cannot be used for prolonged 
periods, can be used when waiting for the beneficial effect of a preventive treatment to 
become evident. Transitional treatments can be also be used in patients with ECH to 
treat relatively short bouts (≤1 month), without the need to start a preventive drug. 
 
Corticosteroids 
 
Several investigators have reported the beneficial effect of oral or parenteral 
corticosteroid regimens in the treatment of CH (Couch, et al., 1978; Kudrow, 1980). 
The methodological quality of these studies is low, with uncontrolled and inconclusive 
studies being the norm (Level of evidence: Class IV). However, these studies have 
nearly uniformly reported positive treatment effects, and this is consistent with the 
clinical experiences of most physicians caring for CH patients (Shapiro, 2005). Caution 
has to be exercised in their use because of the potential for serious side effects. Thus, a 
tapering course of prednisone or prednisolone for 3 weeks is prudent. Unfortunately, 
relapse almost invariably occurs as the dose is tapered. For this reason, steroids are used 
as an initial therapy in conjunction with preventives, until the latter are effective. A 
shared protocol used in clinical practice suggests starting patients on oral prednisone 1 
mg/kg, to a maximum of 60 mg daily, for five days and thereafter decrease the dose by 
10 mg every three days. 
 
Greater occipital nerve block 
 
 30 
A double blind, placebo-controlled study of suboccipital injection with a mixture of 
rapid- and long-acting betamethasone have been performed in CH (Ambrosini, et al., 
2005). The authors studied 16 ECH and seven CCH patients. Eleven of 13 (85%) CH 
patients treated with betamethasone suboccipital injection became pain-free within one 
week compared with none of the ten patients treated with placebo. This effect was 
maintained for at least four weeks in the majority of the patients. Given the relatively 
good evidence of efficacy, suboccipital steroid injection has been recommended in the 
treatment of CH (Francis, et al., 2010). A Class I randomised, double-blind, placebo-
controlled study, 43 CH patients received either cortivazol 3.75 mg ipsilateral to the 
CH attack or normal saline. Injections were performed three times, each 48-72 h apart 
with the view to achieving short-term prophylaxis of CH attacks. The group treated 
with cortivazol experienced a statistically significant reduction in number of attacks up 
to 15 days post-treatment, suggesting a rapid short-lasting therapeutic effect of 
suboccipitally delivered corticosteroid in CH (Leroux, et al., 2011). A recent open-label 
prospective study tested the efficacy and consistency of response of greater occipital 
nerve blocks (GONB) in 83 CCH patients. A positive response was observed in 57% 
of patients, lasting a median of 21 days. The overall rate and average duration of 
response remained consistent after the second (n = 37, 31 responders: 84%; median 
duration: 21 days), third (n = 28, 20 responders: 71%; median duration: 25 days), and 
fourth (n = 14, 10 responders: 71%; median duration: 23 days) injections, suggesting 
that, performed three monthly, GONB may have a useful role also in the management 
of CCH (Lambru, et al., 2014). GONB is generally a well tolerated procedure. No 
serious adverse events have been reported in the RCTs and in the open label trials. Side 
effects reported across the studies include: tenderness in the injection site, neck stifness, 
dizziness post-procedure. 
Level of evidence in ECH: Class I. Level of evidence in CCH: Class II. 
 
Intravenous dihydroergotamine 
 
Repetitive intravenous DHE administered to inpatients over a period of 3 days was 
reported to be very useful in some cases of both ECH and CCH. In a study of 54 patients 
with intractable CH (23 episodic, 31 chronic), the open-label use of repetitive 
intravenous DHE rendered all patients, headache free (Mather, et al., 1991). At 12-
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month follow-up, 83% and 39% of the patients with ECH and CCH, respectively, 
remained free of headache. A retrospective analysis evaluated the efficacy and safety 
of intravenous DHE for the treatment of refractory CH in 70 patients, and showed a 
complete resolution of the pain at one month after treatment in 62% of the cases, partial 
improvement in 14% and failure in 24%. Side effects were transient and well tolerated 
in most patients (Magnoux, et al., 2004). More recently a retrospective audit was 
conducted in 34 CCH and four ECH patients who were treated with IV DHE given for 
five consecutive days to prevent the attacks. Thirty-two out of 38 patients (84.2%) were 
rendered headache-free during treatment with DHE. The mean time for attacks to return 
was 17 days. At the time of discharge 45% of the treated patients were started on a CH 
preventive treatment, making the assessment of time to return to the pre-DHE attacks 
frequency difficult to ascertain accurately (Nagy, et al., 2011). A range of adverse 
events have been reported with the use of IV DHE. Nausea is the most commonly 
reported, followed by leg cramps, chest tightness, shortness of breath, insomnia, 
diarrhoea and paresthesia. No side effects were life-threatening in the above-mentioned 
studies. Level of evidence: Class IV. 
 
Preventive treatments 
 
The preventive agents used include verapamil, lithium, topiramate, methysergide, 
gabapentin, melatonin and valproate. Verapamil is the first-line agent of choice. 
Second-line agents include lithium and topiramate, while methysergide is a reasonable 
choice for a third-line agent. 
 
Verapamil 
Verapamil is the preventative drug of choice in both episodic and chronic CH (Bussone, 
et al., 1990; Leone, et al., 2000). Dosages commonly employed range from 240 mg to 
960 mg in divided doses (two or three times a day). Verapamil can cause heart block 
by slowing conduction in the atrioventricular node. Observing for PR interval 
prolongation on electrocardiogram (ECG) can monitor potential development of heart 
block. There is only one formal guideline in the literature for the titration of the 
verapamil dose (Cohen, et al., 2007). After performing a baseline ECG, patients are 
usually started on 80 mg tds and, thereafter, the total daily dose is increased in 
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increments of 80 mg every 10-14 days. An ECG is performed prior to each increment. 
The dose is increased until the cluster attacks are suppressed, side effects intervene, or 
the maximum dose of 960 mg daily is achieved. ECG monitoring should be performed 
periodically in patients on long-term verapamil. Level of evidence: Class II. 
 
Lithium 
 
Lithium is an effective agent for CH prophylaxis, although the response is less robust 
in ECH than in CCH (Ekbom, 1981; Bussone, et al., 1990). Most patients will benefit 
from dosages between 600 mg and 1200 mg daily or at plasma concentrations 
comprised between 0.8 mEq/L and 1.0 mEq/L. Renal and thyroid function tests are 
performed prior to and during treatment in view of the long-term risk of hypothyroidism 
and nephrogenic diabetes insipidus. Level of evidence: Class III. 
 
Topiramate 
 
Five open-label studies have reported the efficacy of topiramate in the preventive 
treatment of CH (Wheeler, et al., 1999; Förderreuther, et al., 2002; Mathew, et al., 2002; 
Lainez, et al., 2003; Leone, et al., 2003). The dose of topiramate used in these studies 
ranged from 25 mg to 250 mg daily. The side-effect profile of this agent, including 
cognitive slowing and depression, often limits its use. Level of evidence: Class III. 
 
Methysergide 
 
Methysergide has long been used for the treatment of CH (Kudrow, 1980; Dodick, et 
al., 2001). It is an ideal choice in patients with short cluster bouts, which last less than 
4–5 months. Doses up to 12 mg daily can be used, if tolerated. Prolonged treatment has 
been associated with fibrotic reactions (retroperitoneal, pulmonary, pleural and 
cardiac). For this reason, a 1-month holiday every six months of therapy and check for 
evidence of pulmonary, cardiac, renal or abdominal pathology yearly is normally 
advised if repetitive courses of treatment are required over a prolonged period. In view 
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of the possible serious fibrotic reactions, this medication was discontinued in the UK 
in 2013, so it is no longer in use. Level of evidence: Class IV. 
 
Other preventive treatments 
 
In a double-blind, placebo-controlled trial of melatonin 10 mg, five of ten subjects 
randomized to melatonin were rendered pain free within five days, while none of the 
ten subjects taking placebo derived any benefit (Leone, et al., 1996). Recently, Peres 
and Rozen reported two chronic CH patients inadequately managed on verapamil 640 
mg daily who were rendered pain free with add-on therapy with melatonin 9 mg daily. 
The authors concluded that melatonin could be a useful adjunctive treatment for CH 
prophylaxis (Perez, et al., 2001). Level of evidence: Class II.  
Gabapentin was tried at the dose of 900 mg/day in an open-label fashion in eight ECH 
and four CCH patients (Leandri, et al., 2001). All patients were rendered pain free 
within eight days of initiating therapy. Patients with ECH discontinued gabapentin after 
60 days of treatment without recurrence of the attacks. The four CCH patients remained 
pain free at follow-up of four months. This high response rate needs to be reproduced 
in controlled trials. Level of evidence: Class IV. 
New randomised, double-blind controlled trials have been recently published on 
warfarin, frovatriptan, candesartan and cimetidine, a histamine H2 receptor antagonist 
(Siow, et al., 2004; Trovnik, et al., 2013; Anthony, et al., 1978). The preventive effect 
of warfarin was evaluated in a Class II crossover study of 34 patients with CCH. 
Warfarin was administered in order to keep an International Normalized Ratio (INR) 
range of 1.5 to 1.9 over a 12-week treatment period. Subsequently after a wash out 
period of two weeks, patients were crossed over from one treatment to the other. The 
primary outcome was the occurrence of remission lasting at least four weeks. In the 
intention to treat analysis, 50% underwent remission for 4 weeks during the warfarin 
period compared with 11.8% patients during the placebo period (P = .004). The number 
needed to treat was 2.6 (95% CI 1.7-5.5). No serious adverse events were reported 
(Hakim, 2011). 
 
A Class III multi-center, placebo-controlled, randomised, double-blind study was 
designed to assess the efficacy of Frovatriptan 5 mg/day as a short preventive strategy 
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in CH. The study was discontinued prematurely due to slow recruitment and major 
protocol violations (Pageler, et al., 2011).  
 
A Class II parallel group study evaluated candesartan 16 mg daily for one week 
followed by 32 mg daily for two weeks was conducted in ECH prophylaxis. Thirty-two 
patients were enrolled (candesartan=19 patients; placebo=13 patients). The primary 
efficacy variable was the number of attacks per week. The study failed to meet the 
primary endpoint, compared to placebo. The difference in attack numbers between 
week 1 and 3 was not statistically significant (p = 0.38). However, the Authors noticed 
a progressive reduction of the attacks frequency during week 3 of the study in both 
groups, though the proportion of patients with reduced attacks was higher in the 
candesartan group (61%) as opposed to the placebo group (38%)., suggesting that larger 
studies may be needed to explore the role of this medication in the prevention of CH 
(Trovnik, et al., 2013). 
 
 
 Surgery 
 
Surgical approaches are alternative options in patients with headache-related poor 
quality of life. These treatments should be considered in patients refractory to medical 
management because of inefficacy and/or poor tolerability. Historically, destructive 
procedures, like trigeminal sensory rhizotomy and radiofrequency trigeminal ganglio-
rhizolysis, have been tried in CH (Mathew, et al., 1988; Jarrar, et al., 2003). However, 
they are associated with considerable morbidity and therefore have been largely 
abandoned. Neurostimulation therapies that entail peripheral or central nervous system 
targets are emerging as very promising approaches (Figure 1). Candidates for peripheral 
and central neurostimulation therapies should be medically refractory according to 
shared guidelines. Recently, the members of the European Headache Federation have 
published a consensus statement on the definition of refractory CCH for clinical and 
research use. The diagnostic criteria require the presence of at least three severe CH 
attacks per week that impact patients’ quality of life. Patients have to fail prophylactic 
trials with at least three established treatments such as verapamil, lithium, oral or 
intravenous steroids, greater occipital nerve infiltration, topiramate, methysergide, 
ergots, civamide and long acting triptans, at the maximum tolerated dose over a 
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sufficient period of time. Secondary CH has to be ruled out by appropriate 
investigations (Mitsikostas, et al., 2014).  
 
Ventral tegmental area deep brain stimulation 
 
Based on the functional neuroimaging finding of ipsilateral posterior inferior 
hypothalamic activation in CH (May, et al., 1998), various headache centers have 
treated intractable CCH patients by electrode implantation and stimulation of this 
region (Leone, et al., 2001; Leone, et al., 2008; Schoenen, et al., 2005). The vast 
majority of the studies were conducted in an open label fashion. To date only one 
multicentre, randomized, double blind, crossover study using hypothalamic deep brain 
stimulation (DBS) for the management of refractory CCH has been published. The 
study enrolled 12 patients, with only 11 undergoing surgery. The randomised phase 
compared active and sham stimulation during a 1-month period. The primary study 
outcome was change in weekly CH attacks. Results were not encouraging in the blinded 
crossover phase. However, the very short crossover assignment was criticised. Such a 
short period may not have allowed the treatment to exert its effect in full since it is 
thought that central and peripheral neuromodulation therapies in primary headache may 
require months to display their full effectiveness. Indeed, in the same study, during the 
open phase, six of 11 patients became responders, suggesting that a longer randomised 
phase may have led to different results (Fontaine , et al., 2010). Sixty-four drug-
resistant CCH patients treated with DBS of the posterior hypothalamic region have been 
reported in the literature so far (Magis, et al., 2012). Of these, 42% became pain free 
and 22% experienced a ≥50% improvement in headache frequency and/or intensity, 
supporting the utility of this procedure in this sub-group of patients.  
Although studies on DBS claim that the posterior hypothalamic region was stimulated, 
subsequent anatomical studies have established that in fact the precise localization of 
the stimulation was the ventral tegmental area (VTA) rather then the posterior 
hypothalamus, posing challenging issues regarding the precision of the 
neuroanatomical target used in DBS studies (Matharu, et al., 2010). Recently an open-
label prospective study reported favourable outcomes of VTA DBS in a cohort of 21 
medically refractory CCH patients. At a median follow-up of 18 months, 60% of the 
patients reported a 60% improvement of the headache frequency and 30% of the 
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headache severity. This improvement was reflected in the reduction of abortive 
treatments and improvement in the disability and mood scales employed, providing 
class IV evidence of efficacy of DBS targeting the VTA (Akram , et al., 2016). 
VTA DBS is not a risk-free procedure. One patient died from an intracerebral 
haemorrhage along the electrode track a few hours after microelectrode-guided 
implantation (Schoenen, et al., 2005).   
 
Occipital nerve stimulation 
 
In 1999, Weiner and Reed used occipital nerve stimulation to successfully treat what 
was thought to be drug-resistant occipital neuralgia (Weiner, et al., 1999). This work 
opened the way for observational studies of this moderately invasive method of 
neurostimulation in various chronic primary headache disorders. 
Studies conducted in small cohorts of medically intractable CCH patients have shown 
occipital nerve stimulation (ONS) to be a promising therapy. Magis and colleagues 
treated eight patients with medically intractable CCH using unilateral ipsilateral to the 
side of the pain ONS. After a mean follow-up of 15 months, two patients were pain 
free; three patients had a 90% reduction in attack frequency while two patients had 
improvement of around 40%. Interruption of ONS was followed within days by 
recurrence and increase of attacks in all improved patients (Magis, et al., 2007). Burns 
and colleagues treated 14 patients with medically intractable CCH using bilateral ONS. 
At a median follow-up of 17.5 months, ten of the 14 patients reported improvement that 
was sufficiently meaningful for them. Subjective self-reporting of improvement was 
90% or more in three patients, 40–60% in three patients and 20–30% in four patients. 
Benefit from stimulation was not immediate, with maximal effect noted after several 
months (Burns, et al., 2009). In a recently published review, out of 91 CCH patients 
treated with ONS, 61 (67%) experienced a significant improvement in terms of 
reduction of headache frequency and intensity (Magis, et al., 2012). The most common 
device-related adverse events include: lead migration, infection in the battery site and 
lead breakage. A recent open-label study confirmed the very long-term efficacy 
(median of six years) of this neurostimulation treatment in about two-third of refractory 
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CCH patients (Leone, et al., 2017). At present ONS and SPG stimulation are considered 
the surgical treatments of choice for CCH (Martelletti , et al., 2013).  
 
Sphenopalatine ganglion stimulation 
 
The rationale for targeting the sphenopalatine ganglion (SPG) is based on the close 
relation between headache and autonomic activation in the TACs. The parasympathetic 
autonomic symptomatology of the TACs is mediated by crosstalk between trigeminal 
nociceptive afferents and cranial parasympathetic efferent fibres that arise from the 
superior salivary nucleus. The SPG receives preganglionic parasympathetic fibres from 
the superior salivatory nucleus in the brain stem via the greater petrosal nerve, which 
forms the Vidian nerve. Postganglionic parasympathetic fibres innervate the lacrimal 
gland, the nasopharyngeal mucous membranes and meningeal vessels (Figure 2) 
(Ruskell , 2003). When activated, these fibres release neurotransmitters and 
vasodilators that activate sensory trigeminal fibres causing further activation of the 
trigeminal pain pathway which, in turn, causes further parasympathetic outflow, 
referred to as the trigeminal-autonomic reflex (Goadsby, et al., 1997). A non-
destructive approach using acute percutaneous SPG stimulation with a removable 
electrode was initially examined in five patients with CH. This proof of concept study 
showed complete pain relief in 11/18 (61.1 %) of the attacks, partial resolution (50 % 
VAS reduction) in 3/18 attacks (16.7 %) and minimal to no relief in 4/18 attacks 
(22.2 %). Stimulation also resolved the associated autonomic features of CH 
(Ansarinia , et al., 2010). Based on these preliminary findings, a new implantable 
microstimulator was developed. This device is positioned in the pterygopalatine fossa 
(PPF), powered and controlled transcutaneously by radio frequency waves generated 
by an external remote controller (Autonomic Technologies Inc., Redwood City, CA, 
USA). A multicentre randomised double blind and sham-controlled trial has been 
conducted to examine the efficacy of acute SPG stimulation in refractory CCH 
(Schoenen, et al., 2013). In this study, 32 CCH patients experiencing a minimum of 
four attacks per week were included. The design of the study consisted of a 4-week 
baseline period followed by a post-implant stabilisation and therapy titration period. 
The experimental period lasted until 30 CH attacks were treated or, if attack frequency 
was not high enough, for a maximum of 8 weeks. During this period, patients were 
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instructed to use the stimulator to treat each attack for 15 min. The primary endpoint of 
pain relief after 15 min of stimulation was achieved in 67.1 % of full stimulation-treated 
attacks compared to 7.4 % of sham stimulation-treated attacks. Fourteen out of 28 
patients (50%) experienced an acute response for at least 50% of the attacks treated. 
Moreover, some patients did not manage to treat 30 attacks during the study period, 
because they experienced an attack frequency reduction of 50% from baseline, 
suggesting that a proportion of CH patients treating the attacks acutely may experience 
a preventive effect. Five device or procedure-related side effects occurred. There were 
three lead revisions and two neurostimulators were explanted. Sensory disturbances 
occurred in 81 % of patients with complete resolution in the majority of patients. Two 
patients experienced infections, though in both cases they were resolved with antibiotic 
therapy.  
 
SPG stimulation offers several major advantages as opposed to the traditional 
neurostimulation approaches. It has shown, for the first time in the headache 
neuromodulation field, the ability to provide abortive therapy. The device delivers a 
‘‘on demand’’ treatment for the management of the acute attacks, as opposed to the 
continuous stimulation of the traditional ONS. This allows patients to apply it multiple 
times per day without any limitation due to cardiovascular risks, as are associated with 
the use of sumatriptan injections. As far as the SPG stimulation device is concerned, 
the wireless stimulation avoids those hardware-related complications that are routinely 
reported by patients treated with ONS. Moreover, since the microstimulator is fixed 
with two or three bone screws to the zygomatic process of the maxillary bone, the 
chance of electrode migration or breakage is unlikely, as opposed to the significantly 
high lead migration rate that has been reported using traditional ONS (Dodick, et al., 
2015). SPG stimulation using this advanced wireless on demand technology certainly 
constitutes a step forward in the management of refractory CH. Nonetheless, long-term 
data on SPG stimulation efficacy is required and better designed randomised controlled 
studies with more reliable sham stimulation should be performed to confirm the 
preliminary findings of the Pathway CH-1 study. Moreover, despite the use of wireless 
technology, the device remains expensive and access to the therapy can be difficult. 
This aspect paired with the lower efficacy compared to sumatriptan injection, limits the 
SPG therapy to a small proportion of CH patients.  
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Figure 1 From left to right: Ventral tegmental area deep brain stimulation, occipital nerve 
stimulation and sphenopalatine ganglion stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Anatomy of the sphenopalatine ganglion. 
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Vagus nerve stimulation 
 
Vagus nerve stimulation (VNS) is a well-established treatment for intractable epilepsy 
and depression. Initial positive data on the efficacy of VNS in migraine was gathered 
from retrospective analysis of patients implanted for the treatment of epilepsy. A 
positive effect of VNS was reported in two CCH patients who also suffered from severe 
depression (Mauskop, 2005). Invasive VNS consists of a subcutaneous pulse generator 
(Cyberonics) typically implanted in the left chest wall connected by a wire to the bipolar 
lead wrapped around the left cervical vagus nerve. The stimulation consisted of 
electrical pulses, 30 s in duration at intervals of 5 min. 
The rationale of using non-invasive VNS for headache management derives from initial 
animal studies showing that VNS alleviates trigeminal allodynia and pain in rats after 
only two minutes of stimulation, without the need for an implantable device. Moreover, 
microdialysis experiments demonstrate that non-invasive VNS stimulation suppresses 
the increase in extracellular glutamate in allodynic rats after glycerin trinitrate (GTN) 
treatment. The suppression of the increased glutamate levels seems to take place in the 
trigeminal nucleus caudalis (TNC), which is a key structure involved in the 
pathophysiology of primary headaches (Oshinsky , et al., 2014). 
A non-invasive, portable transcutaneous VNS device (gammaCore) has recently been 
tested in the acute and preventive treatment of primary headaches, including the TACs. 
Non-invasive VNS was audited in 25 patients with episodic or chronic CH over a 12-
month period in an open label fashion. The treatment was given acutely (three 
consecutive doses) to treat an attack or in a preventive fashion (two to three consecutive 
doses) twice daily. Patients were trained to deliver the stimulation on the side of the 
neck ipsilateral to the majority of the cluster attacks. The outcomes were collected from 
patients’ subjective opinion. Nineteen out of 25 patients were included in the final 
analysis. Fifteen out of 19 patients (79%) reported a reduction of approximately 50 % 
in CH attack frequency during the treatment period. Four patients did not report any 
improvement. In addition to a prophylactic effect, some patients also obtained a 
favourable abortive effect in approximately 11 min. The treatment was generally well 
tolerated (Nesbitt , et al., 2015). This initial experience was corroborated by a 
prospective open-label study that randomised CCH patients on standard of care alone 
and patients on standard of care plus nVNS. During the randomised phase, the group 
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treated with nVNS showed a greater reduction in number of CH attacks/week vs 
controls (-5.9 vs -2.1) and about 40% of patients treated with nVNS experienced at least 
50% reduction in mean number of attacks/week compared to 8.3% of the controls 
(Gaul , et al., 2016). This initial evidence may suggest a useful role of nVNS in CH 
patients before consideration for invasive neurostimulation therapies. 
 
1.2.2. Paroxysmal Hemicrania 
 
1.2.2.1. Introduction and background 
Paroxysmal hemicrania (PH), like CH, is characterized by strictly unilateral, brief, 
excruciating headaches that occur in association with cranial autonomic features. PH 
differs from CH mainly in the higher frequency and shorter duration of individual 
attacks, although there is a considerable overlap in these characteristics. However, 
unlike CH, PH responds completely to indometacin (Headache Classification 
Subcommittee of The International Headache, 2013), thereby underlining the 
importance of distinguishing it from CH. 
 
1.2.2.2. Epidemiology 
PH is a rare syndrome. However, with increasing awareness, it is being recognized 
more frequently. The prevalence of PH is not known and seems to occur equally in 
females and males (Cittadini , et al., 2008). It can begin at any age, although the most 
common age of onset is the second or third decade of life (Boes , et al., 2002).  
 
1.2.2.3. Clinical features 
The attack profile of PH is highly characteristic (Antonaci , et al.). The headache is 
strictly unilateral. The maximum pain is most often centred on the ocular, temporal, 
maxillary or frontal regions; less often, the pain is centred on the neck, occiput or the 
retro-orbital regions. The pain is typically excruciating in severity and described as a 
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throbbing, aching or boring sensation. The headache usually lasts 10–30 minutes but 
can range from 2 minutes to 45 minutes. It has an abrupt onset and cessation. Interictal 
discomfort or pain is present in up to 60% of the patients (Cittadini , et al., 2008). 
Attacks of PH invariably occur in association with ipsilateral cranial autonomic 
features. The IHS classification criteria for chronic paroxysmal hemicrania require the 
attacks to be accompanied by at least one of the following, which have to be present on 
the pain side: conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, ptosis 
or eyelid oedema (Headache Classification Subcommittee of The International 
Headache, 2013). Photophobia and nausea may accompany some attacks, although 
vomiting and phonophobia are rare. During episodes of pain, approximately 50–80% 
of the sufferers are agitated and restless, and one-quarter are described as being 
aggressive during the pain. In PH, the attacks occur at a high frequency. Typically, 
patients have more than five attacks daily, although the frequency of attacks shows a 
considerable fluctuation, ranging between one and 40 daily. The attacks occur regularly 
throughout the 24-h period, without a preponderance of nocturnal attacks as in CH. 
While the majority of attacks are spontaneous, approximately 10% of the attacks may 
be precipitated mechanically, either by bending or by rotating the head. Attacks may 
also be provoked by external pressure against the transverse processes of C4-5 and C2 
root or the greater occipital nerve. Alcohol ingestion triggers headaches in only 7% of 
the patients (Antonaci , et al.).  
 
1.2.2.4. Classification 
PH is classified depending on the presence of a remission period (Headache 
Classification Subcommittee of The International Headache, 2013). About 35% of the 
patients have episodic paroxysmal hemicrania (EPH), which is diagnosed when there 
are clear remission periods between bouts of attacks. The remaining 65% of the patients 
have chronic paroxysmal hemicrania (CPH), which is diagnosed when patients have 
either no remission within one year or the remissions last less than one month 
(Cittadini , et al., 2008).  
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Table 3. International Headache Society diagnostic criteria for Paroxysmal 
hemicrania 
 
A. At least 20 attacks fulfilling criteria B-D 
B. Severe unilateral orbital, supraorbital and/or temporal pain lasting 2-30 minutes 
C. At least one of the following symptoms of signs, ipsilateral to the pain: 
1) Conjunctival injection and/or lacrimation. 
            2) Nasal congestion and/or rhinorrhoea 
            3) Eyelid oedema  
            4) Forehead and facial sweating 
            5) Forehead and facial flushing 
            6) Sensation of fullness in the ear 
            7) Miosis and/or ptosis 
D. Attacks have a frequency above five per day for more than half of the time.  
E. Attacks are prevented absolutely by therapeutic doses of indomethacin 
F. Not better accounted for by another ICHD-3 diagnosis 
        
 Adapted from The International Headache Society Classification Committee of (2013) 
 
1.2.2.5. Differential diagnosis 
The differential diagnoses that need to be considered are: secondary causes of PH and 
other TACs. PH can be differentiated from CH and SUNCT, with a trial of indometacin. 
No cases of SUNCT responding completely to indometacin have been reported. 
Conversely, cases of CH responsive to indometacin have been rarely described. 
Although these cases should instigate new research studies aiming to understand the 
mechianisms of action of indometacin, in clinical practice, indometacin-responsive CH, 
if needed, should be treated with medications known to be effective in both CH and 
PH, namely: topiramate, verapamil and GONB. HC is a strictly unilateral headache that 
is continuous and associated with ipsilateral cranial autonomic symptoms. Both PH and 
HC are exquisitely responsive to indometacin and have to be differentiated on the basis 
of the clinical phenotype (Matharu , et al., 2003).  
A large number of secondary cases of PH have been described, although a causal 
relationship is difficult to ascertain in most of these cases (Cittadini, et al., 2009). An 
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MRI brain scan is a reasonable screening test in all patients with PH. As with CH, an 
association with pituitary tumors has been reported, suggesting that all TAC patients 
should be carefully assessed for pituitary disease-related symptoms, but further 
investigations with MRI of the pituitary gland should only be undertaken in patients 
with atypical features, abnormal examination or those resistant to the appropriate 
medical treatments. 
 
1.2.2.6. Treatment 
 
Indometacin 
 
The treatment of PH is prophylactic. Indometacin is the treatment of choice and, in fact, 
has been deemed the sine qua non for establishing the diagnosis (Headache 
Classification Subcommittee of The International Headache, 2013). Complete 
resolution of the headache is prompt, usually occurring within 1–2 days of initiating 
the effective dose. The typical maintenance dose ranges from 25 mg to 100 mg daily, 
but doses up to 300 mg daily are occasionally required (Cittadini , et al., 2008). In 
patients with EPH, indometacin should be given for slightly longer than the typical 
headache bout and then gradually tapered. In patients with CPH, long-term treatment 
is usually necessary, although drug withdrawal should be advised at least once every 6 
months. Gastro-protective agents should always be considered for patients who require 
long-term treatment. 
To circumvent some of the problems with oral indometacin administration (i.e., 
difficulties with achieving adequate dose due to side-effects), an intramuscular trial of 
indometacin, the “Indotest,” has been shown to be a rapid and useful test for PH and 
HC (Antonaci , et al., 1998), although the role of a placebo response is not defined. 
Therefore, a modified indotest (placebo-controlled intramuscular indometacin 100 mg) 
has been proposed and validated in a small cohort of patients with HC (Matharu , et al., 
2004). The modified indotest has been shown to be a useful alternative to oral 
indometacin also in a series of PH patients (Cittadini , et al., 2008). 
 
Other medications 
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There has been some limited success in the treatment of PH with cyclooxygenase-2 
(COX-2) inhibitors, rofecoxib (Lisotto , et al., 2003; Chakravarty , et al., 2004; Siow , 
2004) and celecoxib (Siow , 2004; Mathew , et al., 2000). However, prolonged use of 
both of these agents has recently been linked with an increased risk of myocardial 
infarctions and strokes, and this culminated in the withdrawal of rofecoxib from the 
market worldwide (Lenzer , 2005). In view of this, the available COX-2 inhibitors 
should be prescribed only with great caution in PH. Topiramate has been found to be 
effective in three cases of PH (Cohen , et al., 2009; Camarda , et al., 2008). GONB has 
been described as helpful in this condition (Afridi , et al., 2006; Rossi , et al., 2005) and 
can, therefore, be tried, especially in view of its relatively safe adverse effect profile. 
Further data are necessary in order to clarify the consistency of its effect in PH. 
 
 
1.2.3. Hemicrania Continua 
 
1.2.3.1. Introduction and Background 
Hemicrania continua (HC) unlike PH and CH, is a continuous strictly unilateral 
headache with superimposed exacerbations. The headache is associated with facial 
autonomic symptomatology and restlessness. HC is an indometacin-responsive 
headache and, similarly to PH, it responds absolutely to therapeutic doses of 
indometacin. 
 
1.2.3.2. Epidemiology 
The mean age of onset of HC is in the thirties, but the condition can begin at any age. 
The condition has a slight female preponderance with a sex ratio of 1.6:1 (Cittadini , et 
al., 2010; Peres , et al., 2001). 
 
1.2.3.3. Clinical Features 
HC is characterised by a unilateral, continuous headache of mild to moderate intensity, 
centred over the temporal, orbital, retrorbital and frontal regions (Cittadini , et al., 
2010). Exacerbations of moderate or severe headache can occur daily to weekly, though 
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in a minority of patients the severe attacks can occur on a monthly basis and they can 
last few hours to several days. The constant background pain or the more severe 
exacerbations are associated with at least one of the common cranial autonomic 
symptoms and restlessness seems to occur in about 70% of patients (Cittadini , et al., 
2010). The vast majority of HC patients report at least one migraine feature with the 
headache, especially photophobia, phonophobia and nausea. The presence of a 
migraine biology (that is personal and/or family history of migraine) in HC patients is 
remarkably high (Kuhn , et al., 2005; Palmieri , et al., 2004; Peres , et al., 2002; 
Cittadini , et al., 2010).  
 
The latest version of the IHS classification proposed that HC is subclassified as HC, 
remitting subtype, where the headache is interrupted by remission periods of at least 
one day and HC unremitting subtype, where the headache is continuous for at least one 
year without any remissions (Headache Classification Subcommittee of The 
International Headache, 2013). Most patients with HC display the chronic unremitting 
form. 
 
A complete response to indometacin is a prerequisite for diagnosis according to the IHS 
classification criteria (Headache Classification Subcommittee of The International 
Headache, 2013) (Table 4). 
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Table 4. International Headache Society diagnostic criteria for Hemicrania continua 
 
A.   Unilateral headache fulfilling criteria B-D 
B.   Present for > 3 months, with exacerbations of moderate or greater intensity 
C.   Either or both of the following: 
      1.  At least one of the following symptoms or signs, ipsilateral to the headache: 
a) Conjunctival injection and/or lacrimation. 
            b) Nasal congestion and/or rhinorrhoea 
            c) Eyelid oedema  
            d) Forehead and facial sweating 
            e) Forehead and facial flushing 
            f) Sensation of fullness in the ear 
            g) Miosis and/or ptosis 
            f) A sense of restlessness or agitation, or aggravation of the pain by movement  
D. Responds absolutely to therapeutic doses of indomethacin 
E. Not better accounted for by another ICHD-3 diagnosis 
 
   Adapted from The International Headache Society Classification Committee of (2013) 
 
 
Medical and Surgical management 
 
By definition, HC must show a complete response to indometacin. Alternatives to 
indometacin have been studies in case series only, hence their level of evidence is low. 
They include: selective COX-2 inhibitors (celecoxib, rofecoxib), which have been 
shown to be effective for the treatment of HC, but due to cardiovascular side effects, 
particularly at higher doses, caution should be used with this class of medication. 
Topiramate (Matharu , et al., 2006; Brighina , et al., 2007; Camarda , et al., 2008), 
Gabapentin (Spears , 2009; Moura , et al., 2012) and melatonin (Rozen , 2006; Spears , 
2006) have also shown to be beneficial in patients with HC. Other antiepileptic drugs 
such as valproic acid (Lambru , et al., 2008) or pregabalin (Coşkun , et al., 2014) have 
been used with variable response for HC. Cases of HC responsive to verapamil have 
also been reported (Rajabally , et al., 2005; Rozen, 2006). Interestingly high flow 
oxygen and injectable or oral sumatriptan seem not to exert any abortive effect during 
the severe HC exacerbations (Cittadini , et al., 2010).  
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Trigeminal and occipital nerve blocks in HC have been used in the management of HC 
with success. Guerrero and colleagues tested the outcome of at least one anaesthetic 
block of the GON (greater occipital nerve) or SON (supraorbital nerve), or an injection 
of corticosteroids in the trochlear area in nine patients with HC who did not tolerate 
indometacin. All these patients experienced total or partial improvement lasting from 
two to 10 months. Moreover, it seemed that in those patients where the blocks were 
repeated, the response duration increased (Guerrero , et al., 2012). 
 
ONS has shown promising evidence in some small open-label studies of patients with 
refractory HC. Schwedt and colleagues reported two patients with HC who were treated 
successfully with ONS (Schwedt , et al., 2006). Subsequently, Burns and colleagues 
used a BION microstimulator in six people with HC. At a follow-up of 6–21 months, 
four patients had pain reduction of 80–90%, suggesting the efficacy of this therapy also 
in this condition (Burns , et al., 2008).  
 
 
1.2.4. Short-Lasting Unilateral Neuralgiform headache with 
Conjunctival injection and Tearing (SUNCT) and Short-Lasting 
Unilateral Neuralgiform headache with autonomic symptoms 
(SUNA) 
 
1.2.4.1. Introduction and background 
Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and 
tearing (SUNCT) is a recently-described headache disorder characterised by short-
lasting unilateral headache attacks accompanied by ipsilateral lacrimation and 
conjunctival injection. In recognition of the possibility that all patients with generically 
the same condition might not have both conjunctival injection and tearing, the IHS 
Classification Committee considered that SUNCT syndrome may be a subset of a 
broader entity called short-lasting unilateral neuralgiform headache attacks with 
autonomic symptoms (SUNA). In SUNA only one cranial autonomic feature is 
sufficient to fulfil the diagnostic criteria (Headache Classification Subcommittee of The 
International Headache, 2013).  
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1.2.4.2. Epidemiology 
SUNCT is relatively rare, with a recent study showing a prevalence of 6.6/100,000 and 
an incidence of 1.2/100,000 (Williams , et al., 2008). The disorder has a male 
preponderance, with a gender ratio of 2:1. In a small case series of nine SUNA patients, 
the disorder seemed to display a female preponderance with a gender ration of 2:1. The 
typical age of onset is between 40 and 70 years, with a mean age of onset at 48 years 
(Cohen , et al., 2006). 
 
1.2.4.3. Clinical features 
SUNCT is a primary headache disorder first described in 1978 (Sjaastad, et al., 1978). 
The full description of the syndrome stems from 1989 (Sjaastad , et al., 1989). The first 
case series of 21 patients with SUNCT was published six years after the first description 
(Pareja , et al., 1997). The Authors found a robust male preponderance (male: 17, 
female: 4), similarly to CH. However, unlike CH, the mean age at onset of the condition 
was 51 years old. Attacks were strictly unilateral, most frequently centred over the 
orbital/periorbital area, with an erratic temporal pattern characterized by bouts of pain 
and remissions period where the condition would go quiescent. The attacks were 
burning, electrical, or stabbing in character and moderate to severe in intensity. 
Conjunctival injection and lacrimation were both constant and prominent 
accompaniments of an attack. Rhinorrhea or nasal obstruction were also frequent, 
although not invariably present and possibly less marked. In 18 patients, conjunctival 
injection, lacrimation, and rhinorrhea or nasal stuffiness were all present. Some patients 
also reported eyelid oedema, ptosis, facial redness, nausea and photophobia during the 
attacks. The onset of pain was invariably abrupt, and the maximum intensity was 
usually reached within a few seconds. The attack duration varied between patients, 
ranging between 5-300 seconds. The attacks could follow different patterns: "plateau-
like," "repetitive," saw-tooth-like," and "plateau-like plus exacerbations”. The attack 
frequency also varied broadly amongst patients, ranging from less than one attack/day 
to 30 attacks/hour. Attacks could occur at any time of the day. Nocturnal attacks were 
also reported. In 18 out of 21 patients (86%) attacks could be precipitated by several 
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stimulations in the trigeminal territory ipsilaterally to the side of the pain, seldom in the 
extratrigeminal territory (neck rotation). The reported triggers included: mastication 
(61.1%), neck movement (50%), touching forehead (44.4%), touching ala nasi (33.3%), 
touching hair (16.7%), touching eyelids (22.2%), rapid eye movements (27.8%), 
blowing nose (27.8%), neck rotation towards symptomatic side (27.8%), washing face 
(22.2%), eating (22.2%), coughing (22.2%), brushing teeth (22.2%), swallowing 
(22.2%), talking (16.7%), squeezing eyelids (16.7%), pressing tongue against palate 
(16.7%), sneezing (11.1%), yawning (11.1%), eating ice cream (11.1%), bright light 
(11.1%), eye strain, touching face (11.1%), touching upper lip (11.1%), neck extension 
(11.1%), touching cheek (5.5%), drying face (5.5%), shaving, tasting spicy foods 
(5.5%), tongue movements (5.5%), neck flexion (5.5%), bending forward (5.5%) cold 
air (5.5%) and loud noise (5.5%). The majority of patients presented with both triggered 
and spontaneous attacks. Only two patients had exclusively spontaneous attacks. There 
seem not to be any refractory period following a triggered attack in all but one patient.   
Subsequently, Matharu and colleagues reviewed the epidemiology, clinical features, 
aetiology and management of the SUNCT patients published until 2003 (Matharu , et 
al., 2003). This study confirmed most of the clinical findings reported in the first series. 
SUNCT was confirmed to be a condition with male preponderance. However, 
compared to the initial cases description, there was a trend towards increasing female 
preponderance (gender ratio of 1.3:1). In terms of clinical phenotype, it emerged that 
very rarely the pain in SUNCT can alternate sides or even occur on both sides of the 
head simultaneously. Unlike the first series of patients described in the literature, where 
the severity of the cranial autonomic symptomatology was more pronounce that the 
severity of the headache, it emerged that the pain in SUNCT was more often severe, 
rather than mild or moderate. The short-lasting duration of the SUNCT attacks was 
confirmed in this study. However, several case reports suggested that attacks could last 
longer than thought (600 seconds to 120 minutes). SUNCT was thought not to be 
associated with a background inter-paroxysmal pain. However, six out of 50 patients 
reviewed (12%), described the occurrence of a dull interictal ipsilateral mild pain over 
the same site that could be continuous (four cases) or intermittent (two cases). In terms 
of periodicity, the initial descriptions of SUNCT suggested that the condition occurred 
with an episodic periodicity, similar to CH. However, in Matharu’s review, 11 patients 
displayed a chronic form of SUNCT, mainly chronic from onset. 
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In terms of aetiology of SUNCT, most cases described in the literature at that time were 
primary, though secondary cases were reported. The most frequent pathologies causing 
SUNCT-like symptoms were posterior fossa abnormalities and pituitary tumors. Seven 
case reports of SUNCT secondary to a posterior fossa abnormality were described at 
that time. They included: cerebellopontine angle arteriovenous malformations in two 
patients (Bussone, et al., 1991; Morales , et al., 1994); a brainstem cavernous 
hemangioma (De Benedittis , 1996); a posterior fossa lesion in a patient with HIV/AIDS 
(Goadsby, et al., 1997); severe basilar impression causing pontomedullary compression 
in a patient with osteogenesis imperfecta (ter Berg , et al., 2001); craniosynostosis 
resulting in a foreshortened posterior fossa (Morís , et al., 2001); and ischemic 
brainstem infarction (Penart , et al., 2001). MRI evidence of neurovascular conflict with 
the ipsilateral trigeminal nerve by the superior cerebellar artery was also identified in a 
SUNCT patient (Zidverc-Trajkovic , et al., 2005). Pituitary adenomas began to be 
associated with SUNCT. Two of the patients with SUNCT-like phenotype had a 
microprolactinoma and two had a macroprolactinoma with cavernous sinus invasion 
(Massiou , et al., 2002).  
The largest series of SUNCT along with the first, albeit small, series of SUNA patients 
was described by Cohen and colleagues in 2006. They prospectively studied the clinical 
and epidemiological characteristics of 43 patients with SUNCT and nine patients with 
SUNA (Cohen , et al., 2006).  
As far as the defining clinical features of SUNCT and SUNA syndromes are concerned, 
the study confirmed the preponderance of the painful attacks on the right-hand side 
(42%) as opposed to the left (38%). Nine patients had unilateral, side-alternating attacks 
and one SUNCT patient had bilateral attacks. Although 78% of the patients had pain in 
peri-orbital, retro-orbital and temporal regions, 33% of SUNCT and SUNA patients 
had pain in the V2 trigeminal territory and 33% of the SUNA patients had pain in V3 
trigeminal territory. By definition, all of the SUNCT patients had both ipsilateral 
conjunctival injection and lacrimation associated with the attacks. Almost half of the 
patients also reported eyelid oedema and ptosis during the pain; 40% had nasal 
blockage and 53% of the patients had ipsilateral rhinorrhoea associated with their 
attacks. Nine percent of the SUNCT patients had facial flushing, two of which were 
unilateral and two bilateral. Seven percent of patients had facial sweating, two of which 
 52 
were unilateral and two bilateral. Nine percent had other cranial autonomic symptoms. 
The vast majority of patients rated their attacks as very severe and occurring following 
three patterns: single stabs, group of stabs or saw-tooth pattern of stabs. The single stabs 
pattern was more often associated with shorted-lived attacks as opposed to the groups 
of stabs and the saw-tooth profiles, which were associated with longer lasting episodes. 
The number of daily attacks was quantifiable in most patients ranging from two to 
600/day, though there were some patients in whom the attacks were so numerous that 
they could not be accurately quantified. The vast majority of SUNCT patients had both 
triggered and spontaneous attacks. One patient had triggered attacks only and six 
patients had entirely spontaneous attacks. The vast majority of SUNCT patients (79%) 
could trigger their attacks by various cutaneous stimulations. Touching the face 
ipsilaterally to the side of the pain, chewing, eating, wind blowing on the face, washing 
the face and brushing teeth were the most prevalent types of triggers. Alcohol was not 
a trigger. Given the presence of cutaneous and intraoral triggers, the concept of 
refractory period, which has traditionally been described in the trigeminal neuralgia 
(TN) literature, has also been applied in SUNCT. A refractory period is the lack of the 
ability of triggering an attack immediately after the cessation of the previous one by 
continuining with the triggering action. All except two SUNCT patients denied the 
presence of a refractory period. 
As far as the non-defining clinical criteria were concerned, the study confirmed a male 
preponderance in SUNCT as well as the mean age of onset, which was in the late 
forties-early fifties (48 years, range: 19–75 years). In terms of other features associated 
with the pain, 25 out of 40 SUNCT patients felt agitated during an attack and 
approximately one third of SUNCT patients reported a combination of nausea, 
photophobia and phonophobia during the SUNCT attacks. Interestingly 47% of 
SUNCT patients experienced a background interictal pain, with a negative indometacin 
test.  
In terms of pattern of occurrence, this study confirmed the initial trend noticed in 
Matharu and colleagues review (Matharu , et al., 2003). Indeed, 70% of SUNCT 
patients had a chronic form and 30% an episodic form, which is in contrast to the pattern 
described by Pareja and Sjaastad, where most patients reported an episodic pattern 
(Pareja , et al., 1997).  
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1.2.4.4. SUNA: initial clinical description 
SUNA was introduced in the Appendix of the ICHD-2 and its diagnostic criteria 
proposed mainly for research purposes, aiming to unravel the definite phenotype of the 
condition and to clarify whether SUNA and SUNCT should be kept separate or 
considered one clinical entity (Headache Classification Subcommittee of The 
International Headache Society., 2004).  
The clinical description of the first, although small, series of SUNA patients suggested 
that the SUNA clinical phenotype may be similar to that of SUNCT in terms of the 
length, frequency and severity of attacks; the character of the pain; the triggerability of 
the attacks, the lack of refractory period between attacks, and the nocturnal occurrence 
of the pain. Unlike SUNCT, all of SUNA patients seem to display a chronic pattern. 
Although in SUNA the pain was mainly centred in V1, the temple and V3 territories 
were involved more often than in SUNCT. Light touch of the face ipsilaterally to the 
side of the pain was not reported to be a trigger in the nine SUNA patients, unlike 
SUNCT where about two thirds of SUNCT patients reported touching the face as a 
precipitating factor. Cranial autonomic symptoms were more varied and less 
pronounced in SUNA, where the combination of conjunctival injection and lacrimation 
was not allowed. Despite this initial description, the SUNA phenotype has not been 
fully detailed and comparison with SUNCT has not been possible. For this reason, 
SUNCT and SUNA have been kept separate in the latest revision of the IHS 
classification (Headache Classification Subcommittee of The International Headache, 
2013). 
 
1.2.4.5. Nosological status 
In 1997, Goadsby and Lipton (Goadsby, et al., 1997) proposed the first set of diagnostic 
criteria for SUNCT. They proposed that SUNCT should be characterized by headache 
attacks of unilateral moderately severe orbital or temporal stabbing or pulsating pain 
lasting from 15-120 seconds and occurring 3 to 100 times/day. Pain needed to be 
associated with at least one of conjunctival injection, lacrimation, nasal congestion, 
rhinorrhea, ptosis and eyelid oedema. Conjunctival injection needed to be most often 
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present and very prominent. In view of the combination of pain in the trigeminal 
territories associated with ipsilateral cranial autonomic symptoms, they proposed to 
classify SUNCT together with CH and PH under the TACs. 
After validating its phenotype in 50 patients, SUNCT syndrome was included in the 
second edition of the ICHD (Table 5), whereas SUNA was included in the Appendix 
of the classification and its diagnostic criteria were proposed (Table 6), hoping for 
further research in the field to clarify whether SUNCT and SUNA were two sides of 
the same coin or two separate entities (Headache Classification Subcommittee of The 
International Headache Society., 2004). The proposed criteria for SUNA differed to the 
one of SUNCT for the number of cranial autonomic symptoms required, with at least 
one in the former and two in the latter condition; in terms of attack duration, which was 
extended up to 10 minutes for SUNA; attack frequency, which was generically set at 
≥1/day for more than half of the time. The IHS classification Committee also 
acknowledged the high proportion of attacks triggered by trigeminal cutaneous 
stimulation and added the concept of absence of a refractory period following a 
triggered attack. Of note, the array of cranial autonomic signs and symptoms that 
normally accompany the pain in the other TACs was shrunk to only a few (Table 6).  
 
 
 
Table 5. International Headache Society diagnostic criteria for SUNCT  
A. At least 20 attacks fulfilling the following criteria B-D: 
B. Attacks of unilateral orbital, supraorbital, or temporal, stabbing or pulsating pain 
lasting from 5-240 seconds 
C. Attack frequency from 3 to 200/day 
D. Pain is accompanied by ipsilateral conjunctival injection and lacrimation 
E. Not attributed to another disorder 
 
Adapted from Headache Classification Committee of The International Headache Society (2004) 
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Table 6. International Headache Society diagnostic criteria for SUNA (Appendix) 
A. At least 20 attacks fulfilling the following criteria B-E: 
B. Attacks of unilateral orbital, supraorbital, or temporal, stabbing or pulsating pain 
lasting from 2 seconds to 10 minutes 
C. Pain is accompanied by one of:  
1. Conjunctival injection and/or lacrimation 
2. Nasal congestion and/or rhinorrhoea 
3. Eyelid oedema 
D. Attacks occur with a frequency of ≥ 1 per day for more than half of the time 
E. No refractory period follows attacks triggered from triggers areas 
F. Not attributed to another disorder 
Adapted from Headache Classification Committee of The International Headache Society (2004) 
 
In the revised beta version of the IHS classification recently published, SUNCT and 
SUNA were grouped together under the umbrella term “Short-lasting unilateral 
neuralgiform headache attacks” within the TACs group. SUNCT and SUNA were still 
classified as two different subtypes and were kept separated from each other, in view 
of the lack of further studies after Cohen and colleagues work (Cohen , et al., 2006). In 
the new proposed set of diagnostic criteria, the criterion of lack of refractory period 
following attacks triggered from triggers areas was removed. Similarly, to the other 
TACs, SUNCT and SUNA were sub-classified into the episodic form, with attacks 
occurring in periods lasting from seven days to one year, separated by pain-free periods 
lasting at least one month; or the chronic form, with attacks occurring for more than 
one year without remission, or with remission periods lasting less than one month 
(Headache Classification Subcommittee of The International Headache, 2013).  
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Table 7. International Headache Society diagnostic criteria for Short-lasting unilateral 
neuralgiform headache attacks  
A. At least 20 attacks fulfilling the following criteria B-D: 
B. Moderate or severe unilateral head pain, with orbital, supraorbital, or temporal 
and/or other trigeminal distribution, lasting for 1-600 seconds and occurring as single 
stabs, series of stabs or in a saw-tooth pattern. 
C. At least one of the following cranial autonomic symptoms or signs, ipsilateral to the 
pain: 
1. Conjunctival injection and/or lacrimation 
2. Nasal congestion and/or rhinorrhoea 
3. Eyelid oedema 
4. Forehead and facial sweating  
5. Forehead and facial flushing 
6. Sensation of fullness in the ear  
7. Miosis and/or ptosis 
D. Attacks have a frequency of at least one a day for more than half of the time when 
the disorder is active 
E. No better accounted for by another ICHD-3 diagnosis 
Adapted from Headache Classification Committee of The International Headache Society (2013) 
 
1.2.4.6. Differential diagnosis 
The vast majority of SUNCT and SUNA are primary, though ruling out secondary 
forms of SUNCT is mandatory in view of the potential life-threatening nature of some 
underlying brain pathologies. Within the primary forms of SUNCT, the differential 
diagnosis encompasses a broad group of conditions characterised by unilateral short-
lasting neuralgiform headache and facial pain attacks. This group includes: the other 
TACs, trigeminal neuralgia purely paroxysmal, trigeminal neuralgia with concomitant 
persistent facial pain and primary stabbing headache. Table 8 outlines the main clinical 
differences between SUNCT and SUNA and the other TACs. Since a significant 
proportion of SUNCT and SUNA patients may experience a continuous background 
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pain on the same side and site of the paroxysmal attacks, an indometacin trial may be 
required to differentiate them from HC.  
 
 
 
Table 8. Differentiating features between SUNCT/SUNA and the other TACs (HC 
excluded) 
 
 Cluster        
headache 
Paroxysmal 
hemicrania 
SUNCT/SUNA 
Pain: 
Type 
 
Sharp, Throbbing 
 
Sharp, Throbbing 
 
Stabbing, Burning 
Severity Very severe Very severe Very severe 
Site Orbit, temple Orbit, temple Orbit, temple 
Attack 
frequency 
1/alternate day –
8/day  
>5/day for more than 
half the time 
≥1 day for more than 
half the time 
Duration of 
attack 
15-180mins 2-30mins 1-600secs 
Circadian 
periodicity 
70% 45% Absent 
Autonomic 
features 
Yes Yes Yes 
Restless or 
agitated 
90% 80% 65% 
Migrainous 
features 
Yes Yes Rare 
Triggers: 
Alc      Alcohol 
Cuta      cutaneous 
 
++ 
- 
 
+ 
- 
 
- 
++ 
Indometacin 
effect 
- (rarely +) ++ - 
HC: hemicrania continua. SUNA: short-lasting neuralgiform headache attacks with autonomic 
symptoms. SUNCT: short-lasting neuralgiform headache attacks with conjunctival injection and tearing; 
TACs: trigeminal autonomic cephalalgias.  
 
Differentiating SUNCT from trigeminal neuralgia (TN) can be challenging, as there is 
a considerable overlap in the clinical phenotypes of the two syndromes; indeed, some 
authors postulated that SUNCT may be a TN variant (Sesso, 2001). Some clinical 
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features can aid in differentiating these disorders. These features are outlined in Table 
9. In SUNCT the pain is most frequently centred over the V1 trigeminal territory, 
whereas in TN in mainly centred in V2-V3. The length of each attack is normally longer 
in SUNCT compared to TN. One of the signature features of SUNCT, which should 
not occur in TN is the presence of prominent cranial autonomic signs and symptoms 
ipsilaterally to the side of the pain. Additionally, those SUNCT patients with attacks 
triggered by trigeminal stimulation usually report that they can trigger an attack 
immediately after the termination of the previous one without any breaks (absence of 
refractory period), unlike in TN.  
 
Primary stabbing headache (PSH) is characterized by short-lived episodes of stabbing 
pain centred over the V1 trigeminal territory, occurring in single stabs or cluster of 
stabs. The attacks normally last a few seconds up to a minute and can occur on a daily 
or weekly basis. One of the cornerstone clinical features of PSH is that the stabbing 
attacks tend to change site of occurrence within the trigeminal distribution, normally 
sparing the face. Since the majority of the attacks are spontaneous and there are no 
associated cranial autonomic features, PSH can usually be distinguishable from 
SUNCT and SUNA (Pareja , et al., 1999). 
 
SUNCT-like phenotypes are typically caused by pathologies of the posterior fossa or 
pituitary gland lesions. An observational study that defined the headache characteristics 
in pituitary tumor patients reported SUNCT-like phenotype in 5% of these patients, 
although the patient population studied was not representative of pituitary tumor 
patients as the study was performed in a tertiary referral neurosurgical setting (Levy, et 
al., 2005). In view of the remarkable clinical similarities between SUNCT, SUNA and 
TN, Williams and Broadley systematically looked for trigeminal neurovascular conflict 
with dedicated trigeminal MRI scans. In their small cohort of SUNCT and SUNA 
patients they found a high proportion of ipsilateral vascular loops in contact with the 
trigeminal nerve (88%) (Williams , et al., 2008). Therefore, a full diagnostic work-up 
for SUNCT/SUNA should include a brain MRI scan with dedicated trigeminal and 
pituitary fossa views and a trial of indometacin to exclude indometacin-responsive 
headaches, if appropriate.  
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Table 9.  Differentiating features of SUNCT and trigeminal neuralgia 
 
Feature SUNCT Trigeminal Neuralgia 
Gender ratio (male: female) 1.5:1 1:2 
Site of pain V1 V2/3 
Severity of pain Moderate to severe Very severe 
Duration (seconds) 1-600 <1-120 
Autonomic features Prominent None 
Refractory period Absent Present 
Response to carbamazepine Partial Complete 
SUNCT: short-lasting neuralgiform headache attacks with conjunctival injection and tearing 
 
1.2.4.7. Natural History 
The natural history of SUNCT is poorly understood yet and longitudinal studies are 
needed to clarify the natural history of this disorder. 
 
1.2.4.8. Medical management 
The management of SUNCT syndrome has historically been considered extremely 
challenging. Some reports have pointed towards the possible efficacy of certain classes 
of drugs. However, due to the rarity of these disorders, the series published so far have 
included very small numbers of patients and have produced data on a very limited 
number of medications. No RCTs have been published so far. In addition, in most 
studies, efficacy measures are not described adequately. As far as SUNA is concerned, 
it is still unclear whether medications effective in SUNCT are also effective in SUNA.   
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Abortive treatments 
 
Since the attacks are very short lasting, abortive therapy strategies are not a useful 
concept in SUNCT/SUNA.  
 
Preventive treatments 
 
 
Lamotrigine 
 
Before the use of lamotrigine, SUNCT was considered to be highly refractory to 
medical treatments. Lamotrigine acts mainly by blockade of voltage-dependent sodium 
channel conductance, although antifolate, antiglutamate, and antiaspartate actions have 
been suggested (Zona, et al., 1997; Lees, et al., 1993). The first report of possible 
effectiveness of this medication was the case of a 66-year-old woman with a seven-
month history of SUNCT. The attacks were characterized by a short lasting (5 to 10 
seconds) severe throbbing or stabbing pain centred over the left retro-orbital region and 
accompanied by ipsilateral prominent tearing, conjunctival injection, and nasal 
obstruction. The attacks were all occurring spontaneously with a daily frequency of ten 
to 15 per day. The attacks did not respond to indometacin and carbamazepine, but 
lamotrigine at the dose of 150 mg/day rendered the patient pain free (D'Andrea , et al., 
1999). Since then several case reports and small case series have shown the efficacy of 
lamotrigine in SUNCT (Table 10). Lamotrigine at the dose of 200 mg/day was highly 
effective in a patient with atypical SUNCT due to a microprolactinoma. The headache 
was characterized by bilateral multiple daily attacks centred over the first and second 
trigeminal divisions. The headache did not respond to amitriptyline, sodium valproate, 
carbamazepine, gabapentin, sumatriptan subcutaneous injections and high flow oxygen 
(Zidverc-Trajkovic , et al., 2009). This case suggests that appropriate investigations 
should be arranged even in cases responding to medications, if the phenotype is 
atypical.  
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Table 10.  SUNCT cases responding to lamotrigine 
 
 
Number of 
patients 
Dose achieving 
improvement 
Dose achieving 
pain-freedom 
Side 
effects 
D’Andrea et al 
(1999) 
Patient 1 50 mg/day 150 mg/day None 
Leone et al 
(2000) 
Patient 1: 
Patient 2: 
75 mg/day 
- 
125 mg/day 
100 mg/day 
None 
None  
D’Andrea et al 
(2001) 
Patient 1: 
Patient 2: 
Patient 3: 
Patient 4: 
Patient 5: 
75 mg/day 
50 mg/day 
75 mg/day 
- 
100 mg/day 
125 mg/day 
150 mg/day 
125 mg/day 
150 mg/day 
200 mg/day 
None 
None 
None 
None 
None 
Gutierrez-
Garcia 
(2002) 
Patient 1 150 mg/day 200 mg/day None 
Malik et al 
(2002) 
Patient 1 25 mg/day 400 mg/day None 
Chakravarty 
(2003) 
Patient 1 - 200 mg/day None 
Piovesan et al 
(2003) 
Patient 1 100 mg/day 300 mg/day None 
 
SUNCT: short-lasting neuralgiform headache attacks with conjunctival injection and tearing 
 
Cohen described the outcome of 25 SUNCT and four SUNA patients treated with 
lamotrigine up to a dose of 400 mg/day. Seventeen out of 25 SUNCT patients (68%) 
obtained a meaningful therapeutic effect from the medication. Of the four SUNA 
patients, one (25%) reported some benefit (Cohen, 2007). A subsequent Australian 
series of 24 SUNCT (17 SUNCT, five SUNA and two patients with both 
SUNCT/SUNA phenotypes) of which six were chronic and 11 episodic SUNCT, three 
were chronic and two episodic SUNA and of those with both phenotypes, one had an 
episodic and the other had a chronic pattern. Lamotrigine was used up to the dose of 
600 mg/day. The response to lamotrigine depended on the subtype of SUNCT; 
lamotrigine was reported to produce an excellent response in eight out of the 11 
episodic SUNCT patients, but a poor response in those with the chronic form. Only one 
episodic SUNA patient reported a meaningful benefit with lamotrigine. Side effects 
during lamotrigine trials included skin rash, drowsiness and fatigue (Williams , et al., 
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2008). In another series of 15 SUNCT patients, lamotrigine was tried in 13 out of 15 
patients at a dose ranging from 75 to 150 mg/day. Of these patients 61.5% were 
considered responders. On the basis of the current evidence and although no 
randomised-controlled trials have been published, lamotrigine is at present considered 
the drug of choice for the preventive treatment of SUNCT (May, et al., 2006). 
 
Topiramate 
 
Topiramate has multiple mechanisms of action. It exerts its action through blockade of 
the voltage-gated sodium channels, enhancing GABA-mediated chloride influx 
involving GABA-A receptor and antagonism of the glutamate kainate/AMPA receptor 
(Schneiderman , 1998). Topiramate was reported to be effective in five SUNCT patients 
at doses up to 300 mg daily (Matharu , et al., 2002; Rossi , et al., 2003). Subsequently, 
11 of 21 SUNCT patients (52%) benefited from topiramate given up to a dose of 400 
mg/day in an open-label study whereas the only SUNA patient treated with topiramate 
did not notice any benefit (Cohen, 2007). One out of 15 SUNCT cases described 
recently benefited from topiramate 100 mg/day (Cação , et al., 2016). Topiramate has 
been shown to be effective in atypical cases of SUNCT. Kuhn and colleagues described 
the case of a young man who reported bilateral short lasting (30-120 seconds) multiple 
daily (20-30/day) painful headache attacks centred over the retro-orbital and temporal 
regions. The attacks were accompanied by bilateral tearing and conjunctival injection. 
Topiramate 200 mg/day improved the condition by reducing the frequency of 
occurrence of the attacks (Kuhn , et al., 2005). Another case of SUNCT-like symptoms 
triggered by orgasm and associated with persistent focal neurological signs and 
symptoms with normal detailed imaging of the neuroaxis has been reported to respond 
to high doses of topiramate (800 mg/day) (Khalil , et al., 2014).  
 
Zonisamide 
 
Zonisamide, which has got similar mechanisms of action to topiramate, has been tried 
in a SUNCT patient who did not tolerate carbamazepine with excellent results on long-
term follow-up (Ikawa , et al., 2011). 
 
Gabapentin 
 
SUNCT has been shown to respond to gabapentin, with complete suppression of attacks 
in three of nine patients treated with 800 to 2700 mg daily (Graff-Radford , 2000; Hunt , 
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et al., 2002; Porta-Etessam , et al., 2002). When tried in an open label fashion in 22 
SUNCT and five SUNA patients at up to 3600 mg daily, it was reported to be effective 
in 60% of SUNA but only 45% of SUNCT patients (Cohen, 2007).  
 
Carbamazepine  
 
Carbamazepine acts by blockade of use- and frequency-dependent sodium channels, 
although a blockade of the N-methyl-D-aspartate receptor-activated sodium and 
calcium influx and effects on the purine, monoamine, and acetylcholine receptors also 
have been proposed (Macdonald, et al., 1993). The therapeutic response to 
carbamazepine has been reported in 33 SUNCT cases. In 22 of 33 patients (67%), there 
was no beneficial response with the sole use of carbamazepine. Among the 11 patients 
with a favourable response, eight of the 33 patients had a partial response and three had 
a complete or almost complete response (Matharu , et al., 2003). In a recent open label 
series of 36 SUNCT and five SUNA patients treated with carbamazepine, 40% of 
SUNCT and 20% of SUNA patients reported a favourable response (Cohen, 2007).  
 
Oxcarbazepine 
 
There is a case report of SUNCT responding to oxcarbazepine 600 mg daily (Dora , 
2006). Another SUNCT patient was treated successfully using a combination of 
oxcarbazepine (600 mg daily) and gabapentin (400 mg daily) (Marziniak , et al., 2009).  
 
Botulinum toxin A 
 
OnabotulinumtoxinA inﬁltrated at four points around the orbit, injecting 10 U at each 
site, was reported to be consistently effective in a SUNCT patient refractory to oral 
treatments after 2.5 years of follow-up (Zabalza , 2012).  
 
Other drugs 
 
Several other medications, alone or in combination, have been employed to treat 
SUNCT and SUNA, including clomiphene (Rozen , et al., 2005; Rozen, 2014), and 
verapamil (Narbone , et al., 2005). Given the sparse data available on these drugs, it is 
difficult to comment on their efficacy. 
 
 
Transitional treatments 
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There can be a lag of several days to a few weeks before the efficacy of preventive 
treatments becomes apparent. Transitional treatments, which produce a rapid 
suppression of the attacks for a limited period of time, can be used when waiting for 
the beneficial effect of a preventive treatment to become evident. 
 
Intravenous lidocaine 
 
Lidocaine is thought to mediate its antineuropathic pain effect through blockade of 
sodium channels (Mao, et al., 2000). The administration of intravenous (IV) lidocaine 
at a rate of 1.3 to 3.3 mg/kg/h suppressed the headaches in four patients with SUNCT 
syndrome (Matharu , et al., 2004). Subsequently 11 SUNCT and four SUNA patients 
reported a favourable outcome during administration of IV lidocaine at the dose of 1.5–
3.5 mg/kg/h. Seven SUNCT patients were pain free for times varying between the 
duration of the infusion to six months. Three SUNCT patients had reduced attack 
frequency or severity, and one was lost to follow-up. All SUNA patients were pain free 
for two days to 12 weeks (Cohen, 2007). Given the quick and dramatic, but often short-
lasting effect in most of SUNCT and SUNA patients, it is advisable to use IV lidocaine 
as a short-term treatment in patients who present in a so called “SUNCT status” (Pareja , 
et al., 1996) and also in order to avoid breakthrough attacks while switching from one 
preventive drug to another in patients with high load of attacks. Twenty-four hours 
ECG monitoring is mandatory during the infusion to monitor the occurrence of cardiac 
arrhythmias. Common IV lidocaine side effects include: cognitive impairment, 
dizziness, nausea, diarrhoea and paranoid ideation. 
 
Greater occipital nerve blocks 
 
A sub-occipital injection of a combination of lidocaine and a steroid was beneficial in 
five out of eight SUNCT patients (Cohen, 2007). Greater occipital nerve injections may 
render the patient pain free for weeks or months, allowing the introduction and dose 
escalation of preventive medications. 
 
Corticosteroids 
 
The response to corticosteroids has been reported in 21 SUNCT patients. Eleven 
patients were administered prednisone and six of the 11 patients taking prednisone 
reported a beneficial response; two reported a partial effect, one reported a complete 
response, and one, who was tried on prednisone in combination with valproate and 
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nortriptyline, improved transiently (Matharu , et al., 2003). Two patients, one with 
idiopathic SUNCT and one with SUNCT secondary to a prolactinoma were rendered 
pain free with oral prednisone 40 mg daily within 24-48 hours (de Lourdes Figuerola , 
et al., 2009). There can be a recrudescence of pain on either lowering the dose or 
discontinuing the corticosteroids. 
 
Six of eight patients taking prednisolone or methylprednisolone reported a favourable 
effect (Matharu , et al., 2003). One patient treated with prednisolone and carbamazepine 
reported a complete response and the other treated with intravenous 
methylprednisolone, in combination with carbamazepine and followed by oral 
prednisolone, was seemingly rendered pain-free on three occasions for a variable period 
of time (Raimondi , et al., 1998). Oral administration of methylprednisolone for three 
to six weeks at the daily doses of ≤ 1 mg/kg was efficacious in suppressing bouts of 
SUNCT attacks in three patients with the episodic form of the disorder (Trauninger , et 
al., 2010). Intravenous methylprednisolone administered at the dose of 1 gram for three 
days completely suppressed attacks in a patient with a six-month history of SUNCT 
(Maihöfner , et al., 2013).  
 
Surgical management 
 
Some patients with the chronic form of SUNCT and SUNA are refractory to the 
available medical treatments, although the extent of this problem is unknown. This 
group of patients are left with severe disability. For these patients, surgical approaches 
have been tried. The approaches attempted can be subdivided into three main groups: 
ablative procedures of the trigeminal nerve, microvascular decompression of the 
trigeminal nerve and neurostimulation techniques. Table 11 summarize the status quo 
of the surgical management in SUNCT and SUNA syndromes. 
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Table 11. Surgical treatments for SUNCT and SUNA syndromes 
 
Age (years) 
/Sex 
Type 
Headache 
duration 
(years) 
Follow-up 
(months) 
Outcome Complications 
Trigeminal microvascular 
decompression 
 (19 patients) 
Range: 28-73 
-14/M 
- 5/F 
- 14 SUNCT 
-   5 SUNA 
 
- Range:  
1 month- 26 
years 
-Median 
(range): 
14 (0.5-32) 
12/19 patients:  
pain free 
-5 patients: infection,   
 vertigo, jaw pain) 
-2 patients: hearing  
 loss, ataxia 
VTA deep brain stimulation  
(11 patients) 
 
- 50 (26-67) 
- 6 M and 5 F 
 
- 8 SUNCT 
- 3 SUNA 
9 (range: 4-
20) 
Median 
(range): 
29 (7-63) 
82% of patients 
had 50% benefit 
- 1 system removed 
- 1 IPG repositioned 
- 7 biological events 
Glycerol rhizotomy 
(4 patients) 
- 80/M 
- 72/F 
- 52/M 
- 38/M 
- SUNCT 
- SUNCT 
-SUNCT 
- SUNCT 
- 25 
- 10 
- 8 
- 2 
- 87 
- 90 
- 7 
- 5 
- >50% benefit 
- >50% benefit 
- Pain free 
- Ineffective 
- Facial sensory loss 
- Facial sensory loss 
- Missing data 
- Hypoesthesia 
Gamma knife radiosurgery 
(5 patients) 
- 82/M 
- 39/M 
- 28/M 
- 50/M 
- 83/F 
- SUNCT 
- SUNCT 
- SUNCT 
- SUNCT 
- SUNCT 
- 6 
- 2 
- 10 
- 1 
- 3 
- 39 
- 5 
- 2 
- 4 
- 16 
- Pain free 
- Mild benefit 
- Ineffective 
- Pain free 
- Pain free 
- None 
- Anaesthesia dolorosa 
- Missing data 
- None 
- None 
Gasserian ganglion balloon 
compression  
(2 patients) 
- 66/F 
- 68/F 
- SUNCT 
- SUNCT 
- 0.1  
- 17 
- 120 
- 18 
- Pain free 
- >50% benefit 
- None 
- None 
Radiofrequency 
thermocoagulation 
(2 patients) 
- 45/M 
- 60/F 
- SUNCT 
- SUNCT 
- 5 
- 5 
- 24 
- 36 
- Pain-free 
- Pain-free 
- None 
- Trigeminal hypoesthesia 
F: female; IPG: implanted pulse generator; M: male; SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing 
Ablative procedures of the trigeminal nerve 
 
Data on ablative procedures on the trigeminal nerve are limited to isolated cases reports, and 
there is considerable potential for bias due to under reporting of unsuccessful cases or those 
with adverse outcomes. Additionally, these procedures may have irreversible complications, 
such as residual hypoesthesia, anesthesia dolorosa and keratitis. The most feared of these 
complications is anesthesia dolorosa, but in studies of rhizotomy for TN, this outcome is 
extremely rare (Harries , et al., 2011). Procedures that have been tried in SUNCT syndrome 
include: retrogasserian glycerol rhizolysis, percutaneous trigeminal ganglion compression, 
trigeminal ganglion thermocoagulation and gamma knife surgery.  
 
Glycerol rhizolysis 
 
Three of the four patients (three SUNCT and one SUNA) who underwent glycerol rhizolysis 
achieved complete pain relief lasting from seven months to four years. Two of them were 
successfully treated twice. Another SUNCT patient underwent glycerol rhizolysis with only 
two weeks of pain reduction (Hannerz , et al., 2002; Black , et al., 2002).  
 
Radiofrequency thermocoagulation 
 
Two SUNCT patients showed an apparent benefit following radiofrequency thermocoagulation 
of the trigeminal nerve that lasted for two and three years, respectively (Piovesan , et al., 2003; 
Matharu , et al., 2004).  
 
Percutaneous trigeminal ganglion balloon compression 
 
Three SUNCT patients were pain free after percutaneous balloon compression of the Gasserian 
ganglion with benefits ranging from 16 months to ten years of follow-up (Morales-Asín , et al., 
2000; Hannerz , et al., 2002; Baabor , et al., 2010). Interestingly the SUNCT case with the 
longer lasting response to this procedure was a woman who presented to the authors’ office 
with a six-week history of primary SUNCT (Baabor , et al., 2010). The patient was admitted 
into hospital and trials of NSAIDs, indomethacin 50 mg three times daily, carbamazepine up 
to 800 mg daily, corticosteroids, 100% oxygen via ventimask, opioids, and subcutaneous 
sumatriptan did not produce any benefits. The patient subsequently responded to percutaneous 
balloon compression of the Gasserian ganglion and was pain-free at 10 years follow-up. 
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However, lamotrigine, topiramate and gabapentin, which had been reported to be efficacious 
treatments in SUNCT, had not been tried in this case. Moreover, it can be difficult to establish 
whether the patient improved because of the procedure or because of spontaneous remission of 
an episodic form of SUNCT. 
 
Gamma knife 
 
Two SUNCT patients underwent gamma knife radiosurgery targeting the trigeminal nerve. The 
first experienced near complete pain relief for about two months, then the pain gradually 
recurred and he suffered from anesthesia dolorosa; the second reported no improvement 
(Black , et al., 2002). Two SUNCT patients underwent gamma knife targeting both the 
trigeminal nerve and the sphenopalatine ganglion. The first had complete pain resolution at 39 
months follow-up, without medication (Effendi , et al., 2011); the second experienced only rare 
provoked attacks at four months’ follow-up (Mathew , et al., 2012). A more recent case of 
refractory SUNCT treated with stereotactic radiosurgery using a non-invasive frameless 
technique, targeting both the trigeminal nerve and the sphenopalatine ganglion was described 
(Figure 3). At 16 months' follow-up, the patient was pain free with minimal side effects (Tan , 
et al., 2013), suggesting a better outcome of this procedure when both the trigeminal and 
parasympathetic pathways are targeted.  
 
Figure 3. Non-invasive stereotactic radiosurgery targeting both trigeminal nerve and the 
sphenopalatine ganglion  
 
 
Left image: Novalis frameless radiosurgery system. Right image: image of the treatment plan showing the 
contoured trigeminal nerve (orange) and sphenopalatine ganglion (red) and placement of the isocenter and the 
50% isodose line. Brainstem is contoured green (Figure reproduced from (Tan , et al., 2013).  
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Microvascular decompression of the trigeminal nerve 
 
Trigeminal microvascular decompression is considered the surgical treatment of choice for 
refractory TN with evidence of trigeminal neurovascular conflict (Barker , et al., 1996). In view 
of the clinical overlap between TN, SUNCT and SUNA, Williams and Broadley systematically 
looked for trigeminal neurovascular conflict with dedicated trigeminal MRI scans and found a 
high proportion of ipsilateral vascular loops in contact with the trigeminal nerve in SUNCT 
and SUNA (88%, n=15/17). Ninety percent of the aberrant vessels were pressing on the 
symptomatic trigeminal nerve, compared to only 7% abutting on the asymptomatic nerve 
(Williams , et al., 2008). This supported the notion of microvascular decompression (MVD) 
being a potential treatment for these conditions. To date, ten case reports and a case series of 
nine SUNCT and SUNA patients, who underwent MVD of the trigeminal nerve, have been 
reported (Gardella , et al., 2001; Black , et al., 2002; Lagares , et al., 2005; Sprenger , et al., 
2005; Guerreiro , et al., 2009; Irimia , et al., 2010; Williams , et al., 2010). Only in 12 cases the 
pattern of attacks was reported; 10 of 12 patients had a chronic form. Patients were considered 
resistant to multiple therapies, since they had failed different medical and surgical therapies 
(range: 3-16 therapies). After a median follow-up of 14 months (range: 0.5-32 months), 12 of 
19 (63%) of cases were pain free, whereas in the remaining patients, the procedure had little or 
no effect. Two patients suffered from persistent complications, such as ataxia and hearing loss, 
whereas in five cases transient complications were noted (Figure 4). Although series with 
longer follow-ups would be ideal to assess the long-term efficacy of MVD for chronic 
medically intractable SUNCT/SUNA, at present this approach may be considered a valuable 
option in refractory patients with ipsilateral trigeminal nerve compression due to a vascular 
loop, though possible benefit should be weighed against operation-related risks of permanent 
neurological deficits. 
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Figure 4. Microvascular decompression of the trigeminal nerve in SUNCT 
 
 
 
Axial MRI of the brainstem at the level of the trigeminal nerves. (a) CISS image showing bilateral aberrant arterial 
loops (arrows) preoperatively and (b) T2 image showing placement of a silicone sleeve around the right trigeminal 
nerve (arrow). (Figure reproduced from (Williams , et al., 2010) 
 
 
Central neurostimulation 
 
Deep brain stimulation of the ventral tegmental area 
 
In view of the functional imaging evidence of activation of the posterior hypothalamus region 
being linked to attacks of SUNCT (May , et al., 1999) and the broad experience in the use of 
posterior hypothalamic region DBS in patients with medically intractable CCH, three patients 
with intractable SUNCT have been treated with DBS of the posterior hypothalamus, which is 
now established to be the VTA. The outcome of the three patients was promising, with a 
significant and sustained decrease in attack frequency respectively at 18 months, 12 months 
and 15-month follow-up (Leone , et al., 2005; Lyons , et al., 2009; Bartsch , et al., 2011) (Figure 
5). A recent case series of 11 SUNCT and SUNA patients treated with VTA DBS suggested 
the possible long-term efficacy of this approach in this condition. At the final follow-up, 82% 
of patients (9/11) reported at least 50% reduction in the frequency of the attacks. Improvements 
were also recorded in other outcomes such as quality of life, headache-related disability and 
affect measures. One patient required system removal and another IPG repositioning. These 
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data may suggest that VTA DBS has a role in the management of SUNCT and SUNA refractory 
to other therapies (Miller , et al., 2016). 
 
 
Figure 5. Deep brain stimulation in SUNCT  
 
 
Coronal (left) and axial (right) T-1 weighted MR images demonstrating the DBS lead in the posterior medial 
hypothalamus (Figure reproduced from Leone et al., 2005).  
 
1.2.4.9. Pathophysiology of TACs 
Pathophysiological hypotheses for TACs 
 
Any pathophysiological construct for TACs must account for the three major clinical features 
characteristic of the various conditions that comprise this group: trigeminal distribution pain; 
ipsilateral autonomic features; and, the distinct circadian and circannual periodicity, especially 
in CH.  
 
The pain-producing innervation of the cranium projects through branches of the trigeminal and 
upper cervical nerves to the trigeminocervical complex that is a functional brainstem unit 
within the trigeminal nucleus caudalis, from where the nociceptive pathways project to higher 
centers. This implies an integral role for the ipsilateral trigeminal nociceptive pathways in 
TACs. The ipsilateral autonomic features suggest transient cranial parasympathetic activation 
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(lacrimation, rhinorrhoea, nasal congestion and eyelid oedema) and sympathetic paralysis 
(ptosis and miosis). Animal experiments have demonstrated that stimulation of trigeminal 
system can lead to parasympathetic outflow via functional connectivity between the trigeminal 
nucleus caudalis and the superior salivatory nucleus (Goadsby , et al., 1988) that is the 
trigemino-autonomic reflex (Goadsby, et al., 1997). This reflex is activated as a physiologic 
response to cranial nociceptive input. Indeed, some degree of cranial autonomic 
symptomatology occurs with most primary headaches and facial pains and it is not specific for 
TACs only.  
 
The cranial autonomic symptoms may be prominent in the TACs due to central disinhibition 
of the trigeminal-autonomic reflex. Anatomical studies in animals have identified connections 
between the trigeminal nucleus caudalis and the posterior hypothalamus, defined as trigemino-
hypothalamic tract. This tract forms the afferent pathway to transmission of sensory 
information from the trigemino-cervical complex to the posterior hypothalamus (Malick , et 
al., 1988). In TACs, the prominent cranial autonomic symptoms might be due to a disinhibition 
of the trigemino-autonomic reflex by central functionally deranged structures. Supporting 
evidence has emerged from functional imaging studies (Goadsby, et al., 1997). Positron 
emission tomography studies in CH (May, et al., 1998), PH (Matharu , et al., 2006) and HC 
(Matharu , et al., 2004) and functional MRI studies in SUNCT demonstrated abnormal 
functional activation of the posterior hypothalamic region during spontaneous or triggered 
attacks of TACs (May , et al., 1999; Cohen, 2007).  Importantly, the involvement of posterior 
hypothalamic structures may account for the rhythmicity or periodicity that is such a hallmark 
of CH. Hypothalamic activation is not seen in experimental trigeminal distribution head pain 
(May , et al., 1998). There is robust evidence for a role of the hypothalamus in mediating anti-
nociceptive (Millan , et al., 1893; Dafny , et al., 1996) and autonomic responses (Lumb , et al., 
1993). In fact, there is direct evidence from animal experimental studies for hypothalamic 
activation when intracranial pain structures are activated (Benjamin , et al., 2004).  Moreover, 
the hypothalamic peptides Orexin A and B can elicit pro-nociceptive and anti-nociceptive 
effects in the trigeminal system (Bartsch , et al., 2004). These data have led to the suggestion 
that the TACs are probably due to an abnormality in the hypothalamus with subsequent 
trigeminovascular and cranial autonomic over-activation. An important consideration is that 
the different studies outlined above are unable to resolve the paramount question of whether 
the detected hypothalamic alterations are pathognomonic for TAC or whether they merely 
represent an epiphenomenon of different pain conditions in general. It has recently been argued 
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that hypothalamic derangements may not be specific to TACs (Holle , et al., 
2011). Hypothalamic activation and structural alterations are not exclusively observed in TACs 
but can also be found in other primary headache disorders, including migraine (Denuelle , et 
al., 2007) and hypnic headache (Holle , et al., 2011). Interestingly, hypothalamic changes can 
even be observed in totally different pain conditions, such as angina pectoris, irritable bowel 
syndrome or even conditions that do not involve pain at all. Moreover, neuroendocrine changes 
can be detected not only in CH, but also in fibromyalgia, chronic fatigue syndrome, irritable 
bowel syndrome and migraine. Although the hypothalamus seems to play a key role in the 
pathophysiology of TACs, it is possible that it acts as a facilitator of trigeminal nociceptive 
signalling, rather than being the “TACs generator” (Leone , et al., 2009).  
 
 
Pathophysiological hypotheses for SUNCT and SUNA 
 
The anatomical and functional structures involved in producing pain in the trigemino-cervical 
distribution associated with ipsilateral cranial autonomic features are similar to those 
implicated in the other TACs, namely the trigemino-cervical complex and the trigemino-
autonomic reflex.  
 
In view of the prominent lacrimation and conjunctival injection during the painful attacks, 
studies on intraocular functions have been conducted. Intraocular pressure was found to be 
consistently elevated during attacks on the side of the pain as opposed to the asymptomatic side 
as well as pain free state. Similarly increased corneal temperature was detected during attacks 
(Sjaastad , et al., 1992). During the SUNCT ictal phase elevated blood pressure and bradycardia 
was noted in a few patients (Kruszewski , et al., 1991) along with normal ventilation and 
oxygen saturation levels (Kruszewski , et al., 1992). Some of these findings may possibly 
reflect vasodilation related to the parasympathetic outflow, rather than being considered 
causative factors in SUNCT pathogenesis.  
 
Additionally, change in intracranial blood flow velocities were also tested in SUNCT by 
transcranial Doppler sonography. Middle cerebral artery (MCA) blood flow velocity was 
reduced during some attacks on the symptomatic side and to a lesser degree on the 
asymptomatic side. The reduced blood velocities normalized during the pain free state, 
suggesting a marked short-lived MCA vasodilation (Shen , et al., 1994). This initial evidence 
was not corroborated by a technetium-99m hexamethylpropylene amine oxime single-photon 
emission computed tomography (99mTc-HMPAO SPECT) study in two SUNCT patients during 
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four spontaneous attacks that showed normal tracer uptake and symmetrical perfusion 
(Poughias , et al., 1995).  
 
Besides the two major features of TACs, namely the trigeminal distribution pain and ipsilateral 
autonomic features, pathophysiological constructs for SUNCT and possibly SUNA phenotypes 
should also account for the neuralgiform character of the pain, the triggerability of the pain via 
trigeminal stimulation ipsilaterally to the symptomatic side of the face and the lack of a 
refractory period after a triggered attack. Various hypotheses regarding the pathophysiology of 
SUNCT have been proposed. These hypotheses have attributed the primary pathology to an 
orbital venous vasculitis, a hypothalamic dysfunction and neurochemical derangements of the 
pituitary-hypothalamic axis. Recently it has been proposed that a neurovascular compression 
of the trigeminal sensory root at the root entry zone could also have a role in the 
pathophysiology of this condition.  
 
Hypothalamic dysfunction 
 
Similarly to the other TACs, during SUNCT attacks, a significant activation in the region of 
the ipsilateral inferior posterior hypothalamic grey was demonstrated in the first functional 
MRI study (May , et al., 1999). Subsequently Cohen extended the functional MRI scanning to 
nine patients with idiopathic SUNCT, two with idiopathic SUNA and one with  SUNCT 
secondary to a brainstem abnormality during triggered and spontaneous attacks. In patients 
with primary SUNCT there was positive activation in the region of the posterior hypothalamus, 
which was bilateral in five patients and contralateral to the side of the attack in two patients. 
There was negative activation ipsilateral to the side of the pain in two patients. The patient with 
symptomatic SUNCT showed no hypothalamic activation. In the SUNA patients there was 
negative activation bilaterally (Cohen, 2007) (Figure 6). Sprenger and collaborators performed 
an fMRI study in a patient with right-sided SUNCT attacks triggered by cutaneous touch. They 
reported bilateral hypothalamic activation during the pain attacks. The authors noted ipsilateral 
brainstem activation in the region of the pontomedullary junction, which probably reflects 
spinal trigeminal nucleus activation (Sprenger , et al., 2005).  
 
The functional neuroimaging evidence along with the initial promising experience of DBS 
targeting the posterior hypothalamus in three patients with SUNCT, support the paramount role 
of the hypothalamus in the pathophysiology of SUNCT. Similarly to the other TACs, it has 
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been postulated that a deranged hypothalamus could modulate the trigeminal-autonomic reflex 
activation threshold (Goadsby, et al., 1997), possibly via direct hypothalamic-trigeminal 
pathways (Malick , et al., 1988).  
 
 
Trigeminal sensory root abnormality 
 
SUNCT shares clinical elements with CH, namely pain in the trigeminal distribution mainly in 
the ophthalmic trigeminal branch territory and prominent cranial autonomic features. However, 
many clinical features of SUNCT, namely duration, frequency, and character of the pain, along 
with presence of cutaneous triggers overlap with TN. Moreover, both SUNCT/SUNA and TN 
share similar responses to pharmacological treatments that modulate sodium channels such as 
carbamazepine, oxcarbazepine and lamotrigine. These similarities, along with the high 
proportion of patients showing trigeminal neurovascular conflict ipsilaterally to the side of the 
pain (Figure 7), as well as the encouraging results of MVD of the trigeminal nerve in some 
patients with SUNCT syndrome, support the notion that more peripheral mechanisms, may be 
involved in the complex pathophysiological mechanisms of this disorder (Sebastian , et al., 
2013) (Figure 8). This would imply that SUNCT and SUNA may also share pathogenic 
mechanisms with TN, namely a demyelination of the trigeminal sensory root due to vascular 
compression. This abnormality would be responsible for the short-lived painful paroxysms and 
it would also be responsible for the ephaptic cross talk between fibres that drive sensation and 
nociceptive fibres, explaining the triggerability of the attacks in some SUNCT and SUNA 
patients. A complex interaction between more peripheral and central mechanisms may 
underpin the pathophysiology of SUNCT and SUNA. Further data are needed to confirm this 
hypothesis. 
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Figure 6. Functional magnetic resonance imaging studies showing hypothalamic activation 
in SUNCT  
 
 
 
Reproduced from (A) (May , et al., 1999) and (B) (Cohen, 2007). 
SUNCT, Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing 
 
 
Figure 7. Neurovascular conflict with the trigeminal nerve in SUNCT syndrome 
 
 
High resolution T2 constructive interference in the steady-state images: a neurovascular conflict of the posterior 
inferior cerebellar artery with the trigeminal sensory root ipsilaterally to the side of the pain is shown (Figure 
reproduced from Williams et al, 2010). 
 
A 
 
B 
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Figure 8. Schematic representation principal pathways and nuclei involved in the model of pain 
and autonomic features possibly involved in SUNCT syndrome 
 
                     Figure reproduced from (Sebastian , et al., 2013) 
 
 
Central neuroendocrine hypothesis 
 
Headache is a common and disabling aspect of pituitary disease, especially of small, non-
invasive functional tumours, particularly prolactinomas (Abe , et al., 1998). Trigeminal 
autonomic cephalalgias-like phenotype has been described in patients with headache related to 
pituitary tumours. Several cases of secondary SUNCT syndrome associated with pituitary 
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tumors namely micro- or macro- adenomas have been described (Massiou , et al., 2002; 
Matharu , et al., 2003; Levy , et al., 2003; Larner , 2006; Zidverc-Trajkovic , et al., 2009; 
Rozen , 2006; Rocha Filho , et al., 2006; Leroux , et al., 2006; Adamo , et al., 2008). In a large 
study, where patients with pituitary tumours and troublesome headaches were phenotyped, 
SUNCT, CH and HC represented 5%, 4% and 1% of the study group (Levy, et al., 2005). The 
pituitary tumors most commonly associated with SUNCT seem to be prolactinomas and growth 
hormone secreting tumors. However, in the largest SUNCT series published so far only 8% of 
patients were found to have pituitary tumors on MRI. However, the authors did not specify 
whether they requested specific pituitary fossa’ sequences or whether they relied on routine 
MRI scanning (Cohen , et al., 2006). In one case series from Australia, where 17 SUNCT and 
seven SUNA patients were studied with MRI scans with specific trigeminal sequences, no 
pituitary lesions were detected (Williams , et al., 2008). However, a subsequent case series of 
six patients (five SUNCT and 1 SUNA patients) showed that all five patients with SUNCT 
syndrome were found to have pituitary adenomas, and the tumors were always ipsilateral to 
headache. The SUNA patients did not display any pituitary abnormality on MRI scans. 
Pituitary surgery was performed in an attempt to relieve headache in all SUNCT cases but one. 
Three patients improved dramatically after adenoma removal (Chitsantikul , et al., 2013). The 
authors suggested that one of the possible reasons for a low prevalence of pituitary tumors in 
previous series might have been the lack of detailed views of the pituitary fossa on MRIs. Three 
of their five patients had initial MRI scans reported as normal and the pituitary tumor was only 
discovered on pituitary MRI scanning.  
The pathophysiology of headache related to pituitary tumors is complex and not completely 
understood. A prospective study in 63 patients with headache and pituitary tumors found no 
positive correlation of headache with pituitary tumor volume nor with cavernous sinus 
invasion, demonstrating that dural stretch and local cavernous sinus invasion are probably not 
the primary mechanisms behind pituitary tumor–associated headache in most patients (Levy , 
et al., 2004). It has been postulated that the mechanisms underlying headache associated with 
pituitary tumors involve derangements in hormonal function and hypothalamic 
neurotransmitters. This hypothesis highlights the importance of the dopamine-prolactin axis in 
the pathophysiology of SUNCT (Levy, et al., 2005). Dopamine agonists including 
bromocriptine, lisuride, quinagolide and cabergoline have been reported to induce SUNCT 
attacks in patients with pituitary prolactinoma (Massiou , et al., 2002). It is possible that 
perturbations in the dopamine-prolactin axis may be important in SUNCT and SUNA 
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syndromes. It is conceivable that specific neuroendocrine pathways involving the 
hypothalamic dopaminergic neurons may be capable of activating SUNCT pathophysiology at 
least in a subgroup of patients (Levy, et al., 2005). 
 
 
1.3. Trigeminal Neuralgia 
 
1.3.1. Introduction and background 
Trigeminal neuralgia (TN) is a disorder characterized by recurrent unilateral brief electric 
shock-like pains, abrupt in onset and termination, limited to the distribution of one or more 
divisions of the trigeminal nerve and triggered by innocuous stimuli. It may develop without 
apparent cause or be a result of another diagnosed disorder. TN is currently grouped together 
along with the painful trigeminal neuropathies, glossopharyngeal neuralgia, nervus intermedius 
neuralgia, occipital neuralgia and other forms of central facial pain within the “Painful cranial 
neuropathies and other facial pains” (Headache Classification Subcommittee of The 
International Headache, 2013).   
 
1.3.2. Epidemiology 
TN seems more common in women than in men (F:M ratio=3:2) (Katusic , et al., 1990; 
Maarbjerg , et al., 2014). However, in a large prospective series of 229 TN patients there was 
an even gender distribution (Rasmussen , 1990). The mean age of onset is after the fourth 
decade, with a peak onset in fifth to seventh decades. Katusic and collaborators found that the 
median age of onset in their patients was 67 years, with a range of 24 to 93 years (Katusic , et 
al., 1990). In a large prospective series of TN, the average age of onset of TN was 48 years 
(Rasmussen , 1990). A UK survey showed a peak incidence of TN between 45-59 years (Hall , 
et al., 2006). The annual incidence of TN is 4-5 per 100000 (Katusic , et al., 1990). However, 
recent surveys from UK and the Netherlands showed much higher incidences of 26.8 and 28.9 
per 100000, respectively (Hall , et al., 2006; Dieleman , et al., 2008). Approximately 2% of the 
patients with multiple sclerosis (MS) complain about symptoms identical to those of TN (De 
Simone , et al., 2005).  
 80 
 
1.3.3. Classification 
The diagnostic criteria of TN and its sub-forms have evolved over time, reflecting progress in 
the understanding of the condition. Before the diagnostic criteria of TN were formally 
introduced in the ICHD classification in 1998, some of the authors based the diagnosis on the 
Rushton and Olafson’s diagnostic criteria, which includes the presence of: brief paroxysms of 
severe pain confined to one or more divisions of the trigeminal nerve, unpredictable remissions 
and exacerbations of pain, lack of objective evidence of motor or sensory deficit of the involved 
nerve, and occurrence of trigger zones (Rushton , et al., 1965). In the ICHD-I (Headache 
Classification Committee of The International Headache Society, 1988), TN was classified in 
idiopathic and symptomatic forms. Symptomatic TN was further subdivided on the basis of the 
location of the abnormality causing the pain at the level of the nerve, the ganglion or the central 
nervous system (CNS). In the ICHD-II version (Headache Classification Subcommittee of The 
International Headache Society., 2004), TN was sub-classified as “Classical TN”, where 
pathologies of the brain apart from vascular compression of the trigeminal nerve were thought 
to be responsible for the condition and “Symptomatic TN”, where a demonstrable causative 
structural lesion was detected with appropriate investigations. In the recent beta version of the 
ICHD-III (Headache Classification Subcommittee of The International Headache, 2013), 
classical TN has been further subdivided in two forms: classical TN purely paroxysmal and 
classical TN with concomitant persistent facial pain, which refers to what was previously 
labeled as atypical TN or type 2 TN. This form is characterized by prolonged background pain 
in the affected area between paroxysms. The term symptomatic TN has been replaced by the 
term Painful trigeminal neuropathy. Table 12 outlines the current proposed diagnostic criteria 
for TN, according to ICHD-IIIβ. 
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Table 12. International Headache Society diagnostic criteria for Classical trigeminal 
neuralgia  
 
A. At least three attacks of unilateral facial pain fulfilling criteria B and C: 
B. Occurring in one or more divisions of the trigeminal nerve, with no radiation beyond the 
trigeminal distribution  
C. Pain has at least three of the following four characteristics:  
 1. Recurring in paroxysmal attacks lasting from a fraction of a second to 2 minutes  
 2. Severe intensity  
 3. Electric shock-like, shooting, stabbing or sharp  in quality  
 4. Precipitated by innocuous stimuli to the affected side of the face  
D. No clinically evident neurological deficit  
E. Not better accounted for by another ICHD-3 diagnosis  
Adapted from The International Headache Society Classification Committee of (2013) 
 
1.3.4. Clinical features  
Although the phenotype of TN has been described for many centuries, the vast majority of the 
studies is retrospective in nature and based on postal questionnaires (PEET , et al., 1952; 
Katusic , et al., 1990; Loh , et al., 1998; Jainkittivong , et al., 2012). Additionally, some of the 
largest clinical series of TN were published pre-ICHD-I. Since the inclusion of the TN criteria 
in the IHS classification, some retrospective studies and one large prospective study have been 
published. The following summary of TN phenotype comprises a mixture of findings either 
pre- or post-ICHD. 
 
Laterality and site of pain 
 
In the large Peer and Schneider series, the right side was involved more frequently than the left 
by a ratio of 8:5 (PEET , et al., 1952). In Rasmussen’s series, there was considerable 
preponderance of right-sided facial pain (64%) compared to patients with left-sided facial pain 
(34%). Four out of 229 patients reported bilateral pain (1.7%). Conversely, Katusic and 
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collaborators found no significant difference in the laterality of the pain; in their series, the 
right side was affected in 43, while the left side was affected in 30 patients (p=0.13). Bilateral 
involvement was noted in one patient, and in another patient the side involved was not stated. 
A recent Danish study conducted in a series of 158 TN patients, found that the pain was 
reported more often on the right side (56%) than on the left side of the face (41%). Five out of 
158 patients reported bilateral pain (3%) (Maarbjerg , et al., 2014).  
In Peet and Schneider’s series of 689 TN patients, the maxillary division (V2) of the trigeminal 
nerve was involved alone in 16.5% of patients, the mandibular division (V3) alone in 15.8% 
and the ophthalmic division (V1) alone in 3.4%. The most frequently reported sites of pain 
were the maxillary and mandibular combined (37.3%). The ophthalmic and maxillary 
combined was reported in 13.9%; all three divisions combined in 12.7% and the ophthalmic 
and mandibular combined in 0.1% (Peet and Schneider, 1952). Similar findings were described 
in Katusic and collaborators’ cohort, where the most frequently affected divisions of the 
trigeminal nerve were the maxillary (35% of patients) and mandibular (29%) alone, with 19% 
having both divisions affected. The least affected were the ophthalmic alone (4% of patients) 
and 1% of the patients had all three divisions affected together (Katusic , et al., 1990). In 
Rasmussen’s series, the second and third trigeminal divisions combined were the most 
frequently reported pain territories (24%), followed by the mandibular division alone (22%). 
Only 5% of patients reported pain in the first trigeminal division (Rasmussen , 1991). In a more 
recent Danish study, 33% of the patients reported the pain in V2 and V3 together, 19% in V3 
alone, 17% in V2 alone, 10% in V1-V2, 13% in V1-V2-V3 and 4% in V1 territory alone, 
supporting the predominant involvement of the maxillary and mandibular territories in the 
majority of TN patients (Maarbjerg , et al., 2014).  
 
Character of the pain, frequency and duration of attacks 
 
In Rasmussen’s series, the character of the pain was described as shooting-cutting in 95% of 
patients, boring in 1%, dull in 1.7%, burning in 1.7%, pricking in 1.3% and throbbing in 0.4% 
(Rasmussen , 1990a). In a retrospective study of 188 TN patients, most patients described their 
attack as sharp pain (77.6%). Other pain descriptors included electric shock-like (19.1%), 
stabbing (9.6%), numbness (6.9%), throbbing (6.4%) and burning (4.2%). Also, no differences 
in the description of pain were reported between men and women (Jainkittivong , et al., 2012). 
The frequency of occurrence and durations of attacks in TN is highly variable. In view of the 
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triggerability of the attacks, in most cases the daily frequency of attacks depends upon the 
number of activities that sufferers perform. The pain attacks in TN normally last seconds in the 
vast majority of patients (99.6%) and minutes in the remaining (Rasmussen , 1990). In 
Maarbjerg and collaborators 70% of patients suffered from series of paroxysms, which in most 
cases (89%) lasted less than 1 hour. A high percentage of patients (40%) suffered from more 
than 10 pain paroxysms per day (Maarbjerg , et al., 2014). Katusic and collaborators reported 
that the median number of pain episodes in their series of 75 TN patients was three, with a 
range of 1 to 11 attacks/day. The median length of episode was 49 days and the mean was 116 
days, ranging from 1 to 1462 days (Katusic , et al., 1990). In Maarbjerg and collaborators’ 
series, most patients experienced periods of remission (63%), but there was a great variety in 
the frequency of remission periods. Regarding the length of a remission period, 58 (37%) 
experienced months of remissions, and 100 (63%) experienced years of remissions 
(Maarbjerg , et al., 2014). 
 
Intensity of the pain 
 
TN pain intensity is known to be excruciating. However, moderate attacks have been reported. 
In a recent series of TN patients, 58% of the patients only reported that the intensity of their 
paroxysmal stabbing pain was on average 10/10 though the range was large (range VRS 2-10) 
(Maarbjerg , et al., 2014). This might be due to the fact that most patients with TN are 
medicated as soon as the diagnosis is established.  
 
Trigger zone 
 
One of the hallmark clinical features of TN is the triggerability of the attacks by innocuous 
stimulation of the face and intraoral mucosa ipsilaterally to the side of the pain. Light tactile 
stimulation seems to be the most effective stimulation to evoke pain in TN. Conversely, painful 
and thermal stimulation seem ineffective to elicit pain in TN (Kugelberg, et al., 1959).  
 
In one of the first series of TN, Peet and Schneider found that only 31.6% of their TN patients 
reported one or more trigger zones. The commonest sites were: the upper lip 52%, ala nasae 
42%, angle of the mouth 30%, nasolabial fold 22%, lower lip 2l%, malar eminence 18%, lower 
jaw 14%. Only 2.4% of all the patients had a trigger zone limited to the ophthalmic division 
(PEET , et al., 1952). However, the authors did not mention the proportion of patients who 
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could triggers attacks by cutaneous stimulation, or the types of triggers reported by their 
patients. Similarly, Kugelberg and Lindblom studied the site of the trigger zone in 30 TN 
patients. The trigger zone was most common in the nasolabial fold, on the upper lip, the lateral 
part of the lower lip, and the alveolar gingiva. Some patients had two trigger zones and some 
reported that their trigger zone had shifted from one point to another during the course of the 
disease. One patient stated that she had a trigger zone outside the trigeminal area, located in 
the ipsilateral axilla. In most patients, the trigger zone was small in diameter, whereas in some 
patients it was reported as diffuse (Kugelberg, et al., 1959).  
Subsequently in another series, 96% of patients reported provoked TN attacks and only 4% 
reported only spontaneous attacks. The most frequently reported trigger factor was chewing 
and talking (76% of patients). The vast majority of patients, whom reported chewing as a 
trigger, experienced pain at the start of the mastication process (95%), whereas only in 5% the 
pain started late in the chewing process. Sixty-five percent of patients reported touching as a 
precipitating factor (65%). Of these, 50% (n=144 patients) identified a trigger zone. The trigger 
zones were localized at the nasal wing (37%), upper lip (25%), lower lip (20%), cavity of the 
mouth (17%), diffusely over an area of skin (16%), eyebrow (10%), corner of the mouth (6%). 
Other precipitating factors included cold (48%), movement of the head (2%), psychological 
factors (2%), heat (1%), abdominal contractions (1%) and pressure by denture (0.4%) 
(Rasmussen , 1991a). In a recent retrospective study, 183 out of 188 patients (97.3%) stated 
that their pain was initiated by physical stimuli in the facial area; the majority reacted to more 
than one type of stimulus (Jainkittivong , et al., 2012). The most common trigger was chewing 
(61.2%); other stimuli included speaking (47.3%), face washing (42.6%), face touching 
(39.9%), tooth brushing (30.3%), wind blowing (28.2%), mouth opening (21.8%), swallowing 
(8.5%) and hair combing (0.5%). The high proportion of patients with triggered attacks was 
also confirmed in a subsequent prospective study. Out of a total of 158 TN patients, 91% had 
trigger factors and 68% had also spontaneous attacks. The most frequent trigger factors were: 
chewing (73%), touch (69%), brushing teeth (66%), eating (59%), talking (58%), and cold 
wind (50%). A few patients reported some unusual trigger factors such as loud noises, 
emotional stress, physical strenuous exercise, and movement of the ipsilateral upper limb. In 
general, the area from which the pain could be triggered corresponded to the area of pain (79%). 
It was not clear in this study though what was the proportion of patients with both triggered 
and spontaneous attacks and the proportion of patients with triggered only and spontaneous 
only attacks (Maarbjerg , et al., 2014). 
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Refractory period 
 
In the vast majority of TN patients, a triggered painful attack is normally followed by a period 
of seconds or minutes during which further attacks cannot be provoked. This phenomenon is 
called refractory period (Kugelberg, et al., 1959). The presence of a refractory period between 
triggers attacks in TN has been considered as a possibly clinically relevant difference compared 
to SUNCT (Headache Classification Subcommittee of The International Headache, 2013). 
However, it is not clear whether every patient with TN displays this clinical phenomenon or 
whether there is a minority of patients with TN that can trigger one attack after the other without 
any refractory periods in between.  
 
Associated symptoms 
 
The frequency of occurrence of cranial autonomic symptomatology in TN was poorly 
investigated in the old case series described in the literature. Rasmussen described 98 patients 
out of the 229 (43%) in whom the pain was accompanied by facial autonomic symptoms. 
Lacrimation ipsilaterally to the side of the pain was the most commonly described sign (31%), 
followed by rhinorrhea (9%), increased salivation (7%), facial swelling and flushing (5%). 
There was a slightly increased frequency of lacrimation in the groups where the pain was 
centred over the V1 and V2 trigeminal divisions; rhinorrhea, swelling and flushing were 
predominantly linked with pain in V2; salivation was linked with pain in V3. In 32% of cases 
lacrimation occurred together with one or more of the other autonomic symptoms, rhinorrhea 
occurred in 90%, salivation in 47%, and swelling and flushing in 62% (Rasmussen , 1991a). 
The fact that SUNCT syndrome was firstly being described around the time of publication of 
this study may explain why the authors may not have been aware of the possibility that patient 
with a TN phenotype with cranial autonomic symptoms may in fact have SUNCT or SUNA 
syndromes. 
A Danish study published after the introduction of the latest revised version of the ICHD found 
that 31% (n=48/158) of their TN patients had experienced ipsilateral autonomic symptoms 
during attacks (Headache Classification Subcommittee of The International Headache, 2013). 
Conjunctival injection and/or tearing were the most frequent symptoms (22%). In 8/48 patients 
(16.7%%), the autonomic symptoms were pronounced in every attack. Out of these eight 
patients, one was diagnosed with both TN and SUNA, and one with both TN and SUNCT. One 
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patient was diagnosed with CH and TN. One patient did not fulfill the diagnostic criteria for 
any of the TACs. For the remaining four patients, it was not possible to conclude whether 
SUNCT/SUNA should be added to the diagnosis of TN. Similar to Rasmussen’s series, patients 
with pain in V1 were more likely to report any cranial autonomic features (49%) (Maarbjerg , 
et al., 2014).  
Other Authors have described cranial autonomic symptoms in association with V1 TN. 
Sjaastad and collaborators reported the occurrence of mild lacrimation in eight (42%), 
conjunctival injection in three (16%), and rhinorrhoea in two patients (11%) out of a series of 
19 V1 TN patients. The combination of lacrimation, conjunctival injection and rhinorrhoea was 
reported in two patients (11%) (Sjaastad , et al., 1997). More recently a retrospective survey of 
92 TN patients showed the presence of at least one autonomic symptom in 67% of the patients 
(Simms , et al., 2011). 
 
Differential diagnosis 
 
The differential diagnosis of TN encompasses a broad group of conditions characterised by 
unilateral short-lasting neuralgiform headache and facial pain attacks. The group includes 
dental pathologies, disorders of the jaw and the sinuses, salivary gland disorders, other forms 
of neuropathic pain involving the trigeminal territories, the TACs and persistent idiopathic 
facial pain. Table 13 summarises the conditions that should be considered in the differential 
diagnosis of TN (Obermann , et al., 2011; Zakrzewska , 2013). In many cases a definite 
diagnosis of TN requires a multidisciplinary input from many professionals including dentists, 
ear, nose and throat (ENT) specialists and neurologists. 
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Table 13. The differential diagnosis of trigeminal neuralgia 
 
Dental causes • Dental caries 
• Pulpitis 
• Dental sensitivity 
• Periodontal disorders 
• Pericoronitis 
• Cracked tooth 
• Alveolar osteitis 
Sinus causes • Maxillary sinusitis 
Salivary gland causes • Salivary stone 
Temporomandibular joint causes • Temporomandibular disorders 
Neuropathic pain • Post-herpetic neuralgia 
• Post-traumatic trigeminal neuropathy 
• Painful trigeminal neuropathies 
• Atypical odontalgia 
• Burning mouth syndrome 
• Glossopharyngeal neuralgia 
• Nervus intermedius neuralgia 
Trigeminal autonomic cephalalgias • SUNCT and SUNA syndromes 
• Paroxysmal hemicrania 
• Cluster headache 
• Hemicrania continua 
Other • Persistent idiopathic facial pain 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing 
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1.3.5. Medical management  
There are numerous medical treatment options for TN. However, only few treatments are 
supported by robust evidence. Setting up clinical trials for TN can be challenging for various 
reasons including the rarity of the condition, which can prevent recruitment of sufficient 
numbers of patients, and the severity and disability of the pain which poses ethical issues 
related to the duration of the placebo phase. Furthermore, in view of the episodic pattern of 
occurrence of TN attacks, it can be difficult to establish whether an improvement of the 
condition is to be attributed to the treatment itself as opposed to a spontaneous improvement 
of the condition. These caveats are evident in the placebo-controlled crossover trials and 
comparative trials published, which are outlined in Tables 14. 
 
Carbamazepine 
 
Carbamazepine (CBZ) is the first-line treatment option for TN (dose: 200-1200 mg/day). The 
efficacy of carbamazepine is supported by four randomised double blind controlled trials (Class 
I or III) that included a total of 147 patients (Campbell, et al., 1966; Killian , et al., 1968; Nicol , 
1969; Rockliff , et al., 1966). These studies demonstrated a very high rate of responders to the 
treatment amongst patients versus placebo. The main treatment outcomes assessed in these 
trials included: reduction in pain severity, pain paroxysms and the disappearance of triggers. 
The number needed to treat to obtain a significant improvement was 1.7-1.8. However, these 
trials, conducted several years ago, display some methodological limitations including the 
small sample in two of them, variable treatment outcomes and lack of extensive follow-ups.  
Limitation in the use of carbamazepine includes the relatively low tolerability profile. The 
numbers-needed-to-harm (NNH) showed in these trials was of 3.4 for minor and of 24 for 
severe adverse events. In the largest randomised placebo-controlled trial, 50% of patients on 
carbamazepine experienced at least one side effect compared to 24% of the placebo group. 
However, only one patient on carbamazepine dropped out because of adverse events, namely 
a cutaneous rash (Campbell, et al., 1966). Another potential limitation in the use of 
carbamazepine is the known metabolic interaction with other medications, which can be 
problematic in elderly TN patients with other comorbidities (Cruccu , et al., 2008).  
 
Oxcarbazepine 
 
Oxcarbazepine (OXC) can also be used as initial treatment for TN. Its preference over CBZ is 
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mainly related to its accepted greater tolerability and decreased potential for drug interactions. 
Three double-blind randomised controlled trials including a total of 130 patients compared 
oxcarbazepine (OXC) 600–1800 mg/day to CBZ in TN patients (Beydoun, 2000). The 
reduction in number of attacks and global pain assessments were similar for both CBZ and 
OXC (88% of patients achieving a reduction of pain by >50%). However, no studies comparing 
OXC against placebo have been hitherto conducted (Cruccu , et al., 2008). 
 
Baclofen 
 
Baclofen was studied in a single-crossover double blind study. Ten patients were enrolled. The 
trial involved taking baclofen 10 mg three times a day with 10 mg increment every other day 
or placebo for a week. At the end of this phase, patients were given the other tablet for one 
more week. Seven out of ten patients obtained a significant reduction in painful paroxysms 
with baclofen, whereas none of patients on placebo reported any benefit. One patient dropped 
out because of side effects related to baclofen (Class II) (Fromm , et al., 1984).   
 
Lamotrigine 
 
Lamotrigine was tested in a double-blind placebo-controlled crossover trial in 14 patients with 
TN. Patients continued to take a steady dose of carbamazepine or phenytoin throughout the 
trial over a 31-day period. Patients were randomised (stratified by centre) to receive either LTG 
(LTG/PBO group) or placebo (PBO) (PBO/LTG group) for 14 days in the first arm of the study 
(days 1–14). Following a 3-day washout period on placebo (days 15–17), patients crossed over 
to receive the alternative medication (days 18–31). The maintenance dose of lamotrigine was 
400 mg. Eleven of the 13 patients included in the analysis showed better efficacy on lamotrigine 
compared with placebo. This trial provided Class II evidence of efficacy of lamotrigine in TN 
(Zakrzewska , et al., 1997). More recently the effect of lamotrigine in TN was evaluated in a 
small crossover trial in 21 TN patients. Lamotrigine was compared to carbamazepine. Patients 
on carbamazepine at the time of enrolment were asked to discontinue the medication and after 
a three-day washout period to start titrating lamotrigine. Subjects on no medication were asked 
to start carbamazepine and then swap to lamotrigine. Each phase lasted 40 days. Twenty-one 
TN patients were included. The final titration dose for lamotrigine was 400 mg/day and for 
carbamazepine was 1,200 mg/day. Efficacy of the medications was assessed using a visual 
analogue scale (VAS) and verbal rating scale (VRS). Carbamazepine was effective in 90.5% 
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(19/21) of the patients as opposed to 62% (13/21) who benefitted from lamotrigine. The 
majority of lamotrigine responders (77%) obtained complete pain relief, as opposed to only 
21% of the carbamazepine responders (Shaikh , et al., 2011).  
 
The proportion of patients experiencing side effects on either drug was similar. Fourteen 
patients (67%) out of a total of 21 patients during therapy with the lamotrigine displayed side 
effects attributable to lamotrigine, whereas 12 out of 21 (57%) of the patients on carbamazepine 
displayed side effects attributable to carbamazepine. Five patients on lamotrigine developed a 
skin rash and two patients on carbamazepine developed a Steven-Johnson syndrome. However, 
in terms of the abnormal hematological, renal and hepatic values, 14% of patients on 
lamotrigine compared to 48% of patients on carbamazepine displayed deranged levels in one 
or more of these profiles.  
 
 
Pregabalin  
 
The effect of pregabalin in TN was studied in a prospective open-label single centre study 
conducted in a tertiary referral headache centre. Fifty-three patients were investigated. Of these, 
47 (89%) had idiopathic TN and six (11%) had secondary TN. Thirty-nine patients had classical 
TN without concomitant chronic facial pain, whereas 14 patients had classical TN with 
concomitant chronic facial pain. The dose of pregabalin was titrated from 75 to 600 mg daily 
with a maximum dose increase of 75 mg/week for the first 2 weeks and 150 mg/week 
afterwards. Additional preventive medications such as carbamazepine or lamotrigine were 
permitted after eight weeks and considered in patients without complete pain relief while on 
600 mg/day of pregabalin. Patients were followed-up after four weeks, eight weeks, after six 
months and after one year. Changes in TN symptoms were monitored with the aid of a pain 
diary. The primary outcome of the study was number of patients free of pain or with pain 
reduction > 50% and attack frequency reduction > 50% after eight weeks. The secondary 
outcome parameter was sustained pain relief after one year. After eight weeks of treatments, 
74% of patients responded to treatment on a mean dose of 269.8 mg/day (range 150-600 
mg/day). Of these, 25% experienced complete pain-free relief and 49% reported at least 50% 
pain reduction. The majority, 11 of the 13 patients experiencing complete pain relief at eight 
weeks of treatment, stayed pain free after one year. Fourteen patients (26%) did not respond to 
treatment. Patients without concomitant facial pain showed a much better response rate (32 of 
39; 82%) compared with patients with concomitant chronic facial pain (seven of 14; 50%) 
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within the first eight weeks of treatment. Even when additional medication was started, the 
responder rate of those with concomitant facial pain showed a significantly lower response rate 
at one year compared to those without concomitant facial pain. Twenty-two patients (42%) 
reported side effects during treatment. This study showed encouraging long-term efficacy and 
tolerability of pregabalin in the management of TN (Obermann , et al., 2008). 
Pregabalin was tested in a prospective multicentre observational study conducted in primary 
care in 65 patients with TN who did not respond to analgesic, antidepressant and other 
anticonvulsants. Pregabalin was used in monotherapy in 36 patients and as an add-on to 
paracetamol, opioids or non-steroidal anti-inflammatories (NSAIDs) in 29 patients for three 
months. The mean pregabalin dose was higher in the add-on group (234±107 mg/day) 
compared to the monotherapy group (196±105 mg/day). Pregabalin reduced the baseline pain 
intensity by 55%, with a response rate (pain relief ≥50%) of 59% of patients, 64% in the 
monotherapy group and 54% in the add-on group. Furthermore, within the 90-day treatment 
period, patients experience on average 35 pain-free days, 39 in the monotherapy group and 29 
in the add-on group, suggesting that pregabalin alone could be an effective treatment for TN 
(Pérez , et al., 2009). However, the design of the study, in particular patients’ selection has 
been criticized, suggesting that the effectiveness of pregabalin in TN should be studied in better 
designed trials (Cruccu , et al., 2013).  
Pregabalin effect in TN was also compared to lamotrigine in a randomised open label crossover 
trial. Twenty-two patients with TN were enrolled and randomly allocated into two groups, one 
where patients were given lamotrigine and the other where they were given pregabalin. Both 
groups were kept on a steady dose of carbamazepine. Each group was crossed over to the other 
drug, after a two-week wash out period. The duration of the trial was a total of six weeks. The 
study showed that pregabalin was equally effective compare to lamotrigine and that both 
treatments were statistically superior to carbamazepine alone (Rustagi , et al., 2014). 
 
 
Topiramate 
 
The role of topiramate in the management of TN was evaluated in a randomised placebo-
controlled crossover trial. However, the authors managed to enroll only three patients that 
completed the study. Patients entered a one-week baseline period, followed by two 12-week 
drug treatment periods separated and concluded by two-week washout periods. The treatments 
were given randomly, following this regimen: topiramate staring at 25 mg daily and titrated to 
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a maximum daily dosage of 800 mg or placebo. The primary outcome was change in pain 
intensity. Patient who responded to topiramate in the main study were offered the opportunity 
to enter a confirmatory comparison, which consisted of three 8-week segments. Within each 
segment, the patient took randomly four consecutive weeks of topiramate and four weeks of 
placebo under double-blind conditions. During the placebo-controlled phase, the pain intensity 
decreased by 31%, 42%, and 64% in the three patients, which was statistically superior to 
placebo. However, during the subsequent crossover confirmatory phases no pain reduction was 
noticed in the three patients taking topiramate, suggesting that methodologically more robust 
trials should be conducted to assess the efficacy of topiramate in TN (Gilron , et al., 2001). 
Further small trials have been studied topiramate in TN, though they were all published in the 
Chinese language. 
 
Sumatriptan 
 
Sumatriptan subcutaneous injections 3 mg has been tested against placebo in a crossover trial 
(Kanai , et al., 2006). Fifteen minutes after the injection of sumatriptan but not placebo, the 
baseline VAS decreased from 8.3 to 2.4 cm. Twenty out of 24 patients enrolled in the trial, 
benefited from sumatriptan (83.3%).  
 
Botulinum toxin type A 
 
Open label studies have suggested that Botulinum toxin type A (Botox®) may be effective in 
the management of TN. (Borodic , et al., 2002; Piovesan , et al., 2005; Türk , et al., 2005). 
Recent randomised double-blind placebo-controlled trials provided class I evidence of efficacy 
of Botulinum toxin type A (BoNT/A). 
 
Wu et al studied 40 patients with classical TN according to the ICHD-2 criteria who failed to 
respond to conventional treatment (mean Visual Analog Scale or VAS score ≥ 4, mean attack 
frequency ≥ 4 per day). All the patients’ medication was maintained during the study period. 
Patients were followed up for 12 weeks post-treatment. A period of 12 weeks was chosen as 
this is the typical duration of the motor effects of BoNT/A. Intradermal and/or subcutaneous 
injections of 75 U of BoNT/A (5 U/0.1 mL) or saline were applied at 15 points (0.1 mL per 
point). The primary endpoints were change in painful attack frequency and pain severity. 
Patients with ≥ 50% reduction in mean pain score at week 12 were defined as responders. The 
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primary end points were met and the responder rate in the BoNT/A group was superior (68%) 
to the one of the placebo group (15%). Shehata et al studied 20 subjects with classical TN in a 
randomised, single-blinded, placebo-controlled trial. The active treatment arm consisted of 10 
patients who received 0.1 mL of BoNT/A (5 U/0.1 mL) applied subcutaneously per point (total 
dose ranged from 40 to 60 U) using a “follow the pain” method. After 12 weeks significant 
reductions in VAS scores (a decrease of 6.5 compared with 0.3 for saline) and the frequency 
of paroxysms were observed (Wu , et al., 2012).  
 
Zúñiga et al studied the efficacy of BoNT/A in 36 patients suffering from classical TN in a 
randomised placebo-controlled trial. The BoNT/A group consisted of 20 subjects who received 
50 U of the toxin subcutaneously in various sites 1 cm apart and 16 patients received placebo.  
Three months after the injection, significant differences were observed in the average VAS 
score for subjects treated with BTX and those treated with placebo (VAS 4.75 vs 6.94, 
respectively; t test, P = 0.01) (Zúñiga , et al., 2008). 
 
Finally, Zhang et al conducted a randomised, double-blind, placebo-controlled trial testing the 
effects of different dosages of BoNT/A in 84 patients with classical TN who had failed to 
respond to established TN treatment. Patients were randomized to receive saline, 25 U/mL or 
75 U/mL of BoNT/A intradermally and/or submucosally (total doses were divided by 20 and 
applied at 20 points). The VAS scores of both BoNT/A groups were lower than in the placebo 
group from the first to the eighth week (p < 0.017), and there was no difference between the 
25 U and 75 U groups. Also, the number of responders (individuals with a reduction in mean 
pain score from baseline to endpoint > 50%) was higher for the active treatment groups (p < 
0.017) and there was no difference between the groups that received different doses of BoNT/A 
(Zhang, et al., 2014). Overall these studies point towards a clear efficacy of BoNT/A in TN. 
Side effects included transient facial weakness and transient facial oedema.  
 
 
 
Other medications 
 
Pimozide has been reported to be more effective than CBZ (Lechin , et al., 1989) (Class II) 
while tocainide was reported to be as effective as CBZ (Lindström , et al., 1987) (Class III). 
Tizanidine, in a small group of patients (most having already undergone trigeminal surgery or 
taking concurrent medications), was more beneficial than placebo but its effect wore off within 
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1–3 months (Class III) (Fromm , et al., 1993). Small open label studies (Class IV) have 
suggested some therapeutic benefit from other antiepileptic drugs (clonazepam, gabapentin, 
valproate); however, these medications are generally added on other main treatments, such as 
CBZ or OXC, rather than used in monotherapy (Cruccu , et al., 2008).   
 
Table 14. Summary of medical treatments trials versus placebo or versus carbamazepine in 
trigeminal neuralgia 
 
 Evidence Dose range 
(mg/day) 
Responder rate 
on active drug 
Drop-out rate 
Carbamazepine Class I 800-1200  88% 4/147 patients 
Oxcarbazepine Class II 600-1800  88% 0/48 patients 
Lamotrigine Class II 200-400  62-84.6% 0/14 patients 
Baclofen Class II 30-60  70% 1/10 patients  
Pimozide Class II 4-12  100% 0/48 patients 
Tizanidine Class III 12  80% 3/10 patients 
 
 
1.3.6. Surgical treatments 
Invasive surgical treatments are generally reserved for patients with debilitating pain refractory 
to a sufficient trial of established medications, namely CBZ and OXC. TN is usually associated 
with compression of the ipsilateral trigeminal nerve at the root entry zone by an aberrant vessel, 
ipsilaterally to the side of the pain. The proportion of TN patients with neurovascular conflict 
with the trigeminal nerve varies from 52% to 88% of patients (Majoie , et al., 1997; Benes , et 
al., 2005; Anderson , et al., 2006; Maarbjerg , et al., 2015). Barker and Jannetta described the 
long-term outcome of MVD in 1185 TN patients. In their cohort, the trigeminal root was 
compressed by the superior cerebellar artery in 75% of patients and by the anterior inferior 
cerebellar artery in 10% of patients. A vein contributed to the compression in 68% of patients 
and was the only compressing vessel in 12%. The vast majority of patients had only one 
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operation, though 11% of the cohort had a second operation after recurrence of TN. Immediate 
postoperative relief from TN was achieved in 82% of patients, partial in 16% and no relief in 
2%. One year after the operation, 75% of patients were still pain free and 9% were experiencing 
a partial relief. With the inclusion of the final outcome of surgery for patients who had either 
one or two operations, ten years after operation, 70% were pain free and 4% had partial relief. 
The latter group did not require long-term treatments. The annual risk of recurrence (i.e., of 
transition from the group with excellent outcome to either the good-outcome or the poor-
outcome group) was less than 2% five years after the operation and less than 1% after ten years. 
Operative complications included death in two patients, stroke in one patient, 
cerebral/cerebellar hematoma in four patients, facial paresis in 12 patients (permanent in two, 
transient in ten patients), hydrocephalus in two patients, ipsilateral hearing loss in 16 patients 
(mild in one patient, severe in 15 patients), severe facial numbness in 22 patients, cerebrospinal 
fluid leak in 20 patients, bacterial meningitis in five patients and chemical meningitis in 225 
patients. Predictors of long-term response to MVD were: immediate postoperative relief, male 
sex, absence of venous compression of the trigeminal-root entry zone and duration of 
preoperative symptoms of less than eight years. The study demonstrated that MVD is an 
effective and relatively safe surgical treatment option for patients with TN refractory to medical 
management (Barker , et al., 1996).  
A review of a large group of patients with typical (n=2003) and atypical TN (n=672) treated 
by MVD showed that the rate of complete postoperative pain relief was 84.1% and the rate of 
effective surgical pain control was 98.2% for classical TN patients, but for atypical TN patients 
(now labeled as classical TN with concomitant persistent facial pain), the rate of complete pain 
relief and effective pain control was 46.9% and 86.6%, respectively for 5 years or more follow-
up (Tyler-Kabara , et al., 2002). In a subsequent study comparing the outcome of MVD in 45 
typical TN versus 17 atypical TN, complete pain relief in the typical TN group was reported 
by 93.3% (42/45 patients) at a follow-up of 13 months or more after MVD. In the atypical TN 
group, complete pain relief was achieved by 23.5% only (4/17 patients) at about 13 months 
after MVD (Li , et al., 2005). Overall these findings support the notion that MVD is more 
effective in patients with classical TN purely paroxysmal, as opposed to those with classical 
TN with persistent concomitant facial pain, highlighting the importance of properly 
phenotyping patients with neuralgiform facial pain.   
 
Surgical options for patients in whom MVD is contraindicated or not feasible because of the 
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absence of vascular loop, include: radiofrequency thermocoagulation, glycerol injection, or 
balloon compression. Efficacy of these procedures varies from 91% to 99% initially, with long-
term recurrence rates of 10% to 25% (Peters , et al., 2002). For many patients, pain tends to 
recur within two to three years. Facial numbness frequently occurs as the result of these 
procedures and is of greatest concern for first division lesions because corneal anesthesia can 
lead to keratitis and loss of vision. Rates of anesthesia dolorosa range from 1% to 10% (Lopez, 
et al., 2004). 
Gamma knife radiosurgery has attracted increasing interest because of its minimal 
invasiveness. A highly focused beam of 40 to 90 Gy of radiation is delivered stereotactically 
to a 4-mm target area encompassing the retrogasserian cisternal portion of the trigeminal nerve. 
Recent studies report initial pain relief in 81% to 92% and durable pain relief in 54% to 61% 
of patients (Kano , et al., 2010; Kondziolka , et al., 2010). The safety and efficacy of Gamma 
knife therapy was very recently reported for 497 patients with medically refractory classical 
TN who were never previously treated by Gamma knife. Of these, 456 patients (91.75%) were 
initially pain free after a median time of 10 days (range 1-180 days). Their probabilities of 
remaining pain free without medication at 3, 5, 7, and 10 years were 71.8%, 64.9%, 59.7%, 
and 45.3%, respectively. One hundred fifty-seven patients (34.4%) who were initially pain free 
experienced at least one recurrence, with a median delay of onset of 24 months (range 0.6-
150.1 months). Severe facial hypoesthesia was reported in only three patients (0.6%) (Régis , 
et al., 2016). There is also Class IV evidence that in patients with medically refractory TN, 
early stereotactic radiosurgery as the initial procedure provides faster, better, and longer pain 
relief (Mousavi , et al., 2015). 
 
1.3.7. Natural History 
TN appears to be a lifelong disorder once it starts. The disorder usually involves bouts of daily 
attacks lasting weeks or months alternating with remission periods, which may last months to 
years. However, the natural progression of the disease may involve an increase in frequency of 
attacks and a shortening of remission periods. It has been proposed that patients with classical 
TN who are not treated properly may develop a constant inter-paroxysmal background pain 
overtime (Burchiel , et al., 2000). This group of patients is currently labeled as suffering with 
“Classical TN with concomitant persistent facial pain”, according to the recent revision of the 
IHS classification (Headache Classification Subcommittee of The International Headache, 
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2013). Studies on the medical and surgical management of this group of patients have shown 
a poorer response to sodium channel blockers, such as CBZ and OXC and to MVD, compared 
to patients with classical TN, purely paroxysmal. However, Obermann and collaborators 
recently challenged the theory on the natural history of TN. The authors demonstrated no 
difference in duration of disease between those who had classic TN and those with TN and 
constant background pain. The study also suggested that the pathophysiological substrate of 
classical TN with concomitant persistent facial pain may include a combination of trigeminal 
sensory root demyelination along with central sensitization possibly involving supraspinal 
pathways (Obermann , et al., 2007). This study supports the hypothesis that classical TN with 
concomitant persistent facial pain may in fact be a variant of TN rather than a result of TN 
disease duration.  
 
1.3.8. Pathophysiology 
The pathophysiology of TN is still a matter of debate. The current theory suggests that TN is 
caused by a proximal compression of the trigeminal sensory root near the brainstem (root entry 
zone) by a blood vessel (artery or vein). This mechanical compression may start a process of 
demyelination and remyelination (Rappaport , et al., 1997; Peker , et al., 2006), probably 
mediated by microvascular ischemic damages (Marinković , et al., 2007). These changes lower 
the excitability threshold of affected fibers and promote inappropriate ephaptic propagation 
towards adjacent fibers (Burchiel , 1980). Thus, tactile signals coming from the fast myelinated 
(A-β) fibers can directly activate the slow nociceptive (A-δ) fibers, resulting in the high-
frequency paroxysms characteristic of TN. After a few seconds, these repetitive discharges 
spontaneously run out and are followed by a brief period of inactivity that is called “refractory 
period”, where triggering actions are not able to provoke pain.  
While Jannetta and colleagues described 88% of their investigated patients having a nerve 
vessel conflict, 6% had MS and 6% showed a cerebellopontine angle tumor (Jannetta , 1967), 
more recent investigations demonstrated that not all patients who were considered to have TN 
had a nerve vessel conflict and that at least 25% of individuals without any clinical signs of TN 
had a nerve artery contact on MRI (Adamczyk , et al., 2007). A different study where MRI 
scans were performed for reasons different than facial pain, demonstrated that out of 220 
investigated trigeminal nerves 110 (49%; 51 women and 57 men) showed some degree of 
compression (Kakizawa , et al., 2008). The immediate and sustained pain relief following MVD 
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surgery in the vast majority of patients indicates the key relevance of the trigeminal 
neurovascular compression mechanism. However, it is hard to explain why some patients 
experience recurrence of pain some years after the operation, why some patients do not respond 
to MVD in the first place and what is the underlying pain mechanism in those patients in whom 
no neurovascular conflict is demonstrated on detailed neuroimaging (Gronseth , et al., 2008). 
It was suggested that hyperexcitability of the compressed nerve may represent a risk factor for 
the development of TN, but on its own is not the only cause of the disease (Hamlyn , et al., 
1992).  
The remarkable clinical effect of sodium channels blockers in TN has suggested that an 
abnormal expression of voltage-gated sodium channels could constitute an important 
pathophysiologic correlate and that TN might be a sodium channelopathy. Nav1.7, Nav1.3 and 
Nav1.8 were found to be abnormally expressed in TN and possibly responsible for rapid 
activation and inactivation, as well as maintenance of the action potential (Siqueira , et al., 
2009). Overtime, possible involvement of central mechanisms along with more peripheral 
mechanisms have been postulated to explain the hyperexcitability in the trigeminal system in 
TN. Sensitization of second-order wide dynamic range (WDR) neurons in lamina V of the 
dorsal horns and the trigeminal nerve nuclei due to hypersensitivity of tactile A-β fibers have 
been discussed as an additional pathophysiological mechanism. Since these WDR neurons 
receive convergent information from tactile (A-β) and nociceptive (A-δ and C) fibers, their 
sensitization could promote the perception of pain in response to cutaneous stimulation. Central 
facilitation was recently demonstrated in TN patients with additional constant dull background 
pain besides their typical TN attacks using pain-related evoked potentials and nociceptive blink 
reflex (Obermann , et al., 2007). This provides evidence for the involvement of supraspinal 
structures in TN.  
Functional MRI studies in TN have demonstrated activation of areas of the pain neuromatrix 
and in particular activation of the spinal trigeminal nucleus, brainstem, thalamus, primary and 
secondary somatosensory cortices, anterior cingulate cortex (ACC) following painful 
stimulation of cutaneous triggered zones (Borsook , et al., 2007). The spinal trigeminal nucleus, 
brainstem and the ACC were not activated by non-painful stimulation (Moisset , et al., 2011). 
However, the role of activation of supraspinal structures in TN nociceptive processing needs 
to be further elucidated. 
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1.4. SUNCT, SUNA and trigeminal neuralgia: different disorders or 
variants of the same disorder? 
SUNCT and SUNA are placed within the trigeminal autonomic cephalalgias (TACs) grouping, 
because of the combination of unilateral headache attacks in the trigeminal territory associated 
with cranial autonomic symptoms and the activation of the posterior hypothalamus during 
attacks demonstrated in functional neuroimaging studies. However, besides the occurrence of 
ipsilateral autonomic symptoms during attacks, there are few other similarities between 
SUNCT/SUNA and the other TAC syndromes. Conversely, the demographic characteristics, 
clinical features, neuroimaging findings and therapeutic treatments of SUNCT and SUNA 
overlap with trigeminal neuralgia, challenging the traditional view that they are separate 
disorders.  
 
1.4.1. SUNCT, SUNA and Trigeminal neuralgia: classification criteria 
Since their first appearance in the ICHD-2, the SUNCT diagnostic criteria showed several 
shortcomings, mainly linked to the criterion of the obligatory occurrence of lacrimation and 
conjunctival injection with the pain (Headache Classification Subcommittee of The 
International Headache Society., 2004). This criterion does not reflect the clinical presentation 
of SUNCT, in which a broader array of cranial autonomic symptoms occurs (Pareja , et al., 
1997). Moreover, if the threshold of two cranial autonomic symptoms should be maintained, it 
is arguable that the association of any two amongst the array of cranial autonomic symptoms 
should have been suggested, rather than only conjunctival injection and lacrimation. Strikingly, 
compared to the other TACs’ diagnostic criteria, the SUNCT criteria were the only ones in 
which the association of two rather than one cranial autonomic symptoms were obligatory for 
the diagnosis. Indeed, the criteria for cluster headache state that if the phenotype fulfills the 
other diagnostic criteria without any cranial autonomic features then a sense of restlessness is 
sufficient to make the diagnosis. 
For the aforementioned reasons, the IHS Classification Committee considered that SUNCT 
syndrome may be a subset of a broader condition, SUNA. In SUNA, there may be cranial 
autonomic symptoms other than conjunctival injection and lacrimation, or just one of these 
symptoms may occur (Headache Classification Subcommittee of The International Headache 
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Society., 2004). However, reducing the threshold of cranial autonomic symptoms down to one 
led to the additional criterion of the absence of a refractory period in order to reinforce the 
difference between SUNA and V1 trigeminal neuralgia, in which attacks are often followed by 
a refractory period. Despite the broader SUNA criteria, only a few cases have been reported in 
the literature since 2004, hence the full phenotype still needs to be defined. 
Since the publication of the ICHD-2 criteria, further studies have shed light on the clinical 
aspects of SUNCT and SUNA (Cohen , et al., 2006). In light of this, the IHS Classification 
Committee proposed a new set of diagnostic criteria for SUNCT and SUNA in the ICHD-3 
beta version (Headache Classification Subcommittee of The International Headache, 2013). 
The new set of diagnostic criteria seems to have reinforced the diagnostic overlap between 
SUNCT/SUNA and the other TACs, by changing the frequency description of attacks to at 
least one daily, along with increasing the duration of the SUNCT/SUNA attacks up to 10 min. 
Conversely, despite evidence showing that 74% of SUNCT patients could trigger attacks by 
cutaneous stimulation, no such criterion was included (Cohen , et al., 2006). Moreover, the 
threshold of two cranial autonomic symptoms for the SUNCT criteria still remained 
unchanged. Disregarding the clinical overlap between SUNCT/SUNA and TN may continue 
to create confusion in clinical practice, preventing the publication of meaningful data that could 
shed light upon the neurobiology of these disorders. 
 
1.4.2. SUNCT, SUNA and trigeminal neuralgia: the clinical phenotype 
The difficulty of keeping SUNCT, SUNA and trigeminal neuralgia separate lies in their 
remarkable clinical overlap that includes neuralgiform character of the pain, very short 
duration, high daily frequency of attacks, and presence of attacks triggered by cutaneous 
stimulation. Moreover, in light of the recent description of the SUNA syndrome (Cohen , et al., 
2006), the known clinical differences between SUNCT and trigeminal neuralgia such as the 
maximal intensity of the pain in the ophthalmic division of the trigeminal nerve, the association 
of pronounced cranial autonomic features with the pain, the absence of a refractory period 
following attacks provoked from trigger areas and the absence of a constant background pain 
between the paroxysmal attacks seem to suggest a continuum of symptoms rather than 
neurobiological differences between SUNCT, SUNA and TN (Table 15). 
In the largest SUNCT and SUNA series published, 67% of SUNCT patients complained of 
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pain in V1 (ophthalmic nerve territory) and 33% complained of pain in V2 (maxillary nerve 
territory). In contrast, a higher proportion of SUNA patients reported the maximal intensity of 
the pain in V2 and V3 (mandibular nerve territory) (56% and 33%, respectively), suggesting a 
continuum with trigeminal neuralgia, in which the vast majority of patients report attacks in 
V2, V3 or both (Katusic , et al., 1990). Furthermore, it is possible that the high proportion of 
SUNCT patients with mainly V1 pain is a result of the mandatory association of the pain with 
conjunctival injection and tearing, decided by the IHS Classification Committee. Indeed, 
emerging evidence in SUNCT, SUNA and trigeminal neuralgia has suggested that the cranial 
autonomic symptoms tend to follow the site of the pain, with ocular symptoms occurring 
predominantly with pain in V1 and nasal symptoms with pain in V2 and V3 (Cohen , et al., 
2006; Simms , et al., 2011). It is possible that if the SUNCT criteria allowed a more flexible 
combination of ocular and nasal cranial autonomic symptoms, more cases of SUNCT/SUNA 
with pain in V2 – V3 would be reported. Similarly, a reason why few patients with 
SUNCT/SUNA and pain in V2 – V3 have been reported might be because patients are often 
misdiagnosed with trigeminal neuralgia and therefore are not asked by physicians about the 
presence of associated symptoms. To support this hypothesis, a recent retrospective study in 
92 TN patients who underwent MVD showed at least one cranial autonomic symptom in 67% 
of them regardless of the pain site (Simms , et al., 2011). 
SUNCT is thought to be associated with numerous pronounced cranial autonomic symptoms 
unlike TN. However, when the threshold is reduced from at least two symptoms to one 
symptom (SUNA criteria), the clinical overlap with TN becomes more pronounced. TN with 
cranial autonomic symptoms has been reported in various clinical series. Sjaastad and 
colleagues reported the presence of lacrimation in eight of 19 (42%) patients with V1 
trigeminal neuralgia; conjunctival injection and rhinorrhoea were also present in some patients 
(Sjaastad , et al., 1997). Subsequently, Pareja and collaborators recorded 26 attacks from two 
patients with V1 trigeminal neuralgia, 81% of which were accompanied by mild lacrimation. 
Strikingly, there was a relationship between attack duration and intensity of lacrimation, with 
slightly longer attacks (12 – 22 s) being accompanied by moderate lacrimation (Pareja , et al., 
2002). The authors stated that the mild – moderate degree of cranial autonomic symptoms in 
TN was a clear-cut difference compared to the pronounced autonomic activation reported in 
SUNCT. However, there are no studies that have assessed the degree of autonomic activation 
in SUNCT. As shown for TN, given the wide range of duration of SUNCT/SUNA attacks, it 
may be possible that the degree of intensity and number of cranial autonomic symptoms varies 
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according to the duration of each attack. Short-lasting attacks may not be associated with 
pronounced cranial autonomic symptoms, as opposed to longer-lasting attacks. Although 
clinically meaningful, the different degrees of cranial autonomic activation in SUNCT, SUNA 
and TN, perhaps related to the different duration of attacks, may reflect a different degree of 
involvement of similar pathophysiological mechanisms rather than a distinctive 
neurobiological difference. 
Another difference between SUNCT/SUNA and TN is in the presence of constant pain 
ipsilaterally to the side of the paroxysmal attacks. Approximately 50% of SUNCT and possibly 
SUNA patients report constant background headache (Cohen , et al., 2006). Conversely, in 
classical TN, by definition, patients must be pain free between attacks; otherwise a diagnosis 
of classical TN with concomitant persistent facial pain should be made. Compared to classical 
TN purely paroxysmal, the phenotype of TN with constant pain seems to be characterized by 
a higher occurrence of cranial autonomic symptoms (approximately 40% of patients); minor 
proportion of attacks triggered by cutaneous stimuli; and lower proportion of patients showing 
neurovascular compression on the trigeminal nerve and less impressive response to 
carbamazepine and MVD of the trigeminal nerve (Headache Classification Subcommittee of 
The International Headache, 2013). These clinical features seem remarkably similar to the 
clinical features of the subgroup of SUNCT/SUNA patients with constant pain. It is therefore 
possible that a significant proportion of patients with classical TN with concomitant persistent 
facial pain in fact suffer with SUNCT or SUNA with constant background pain. There has been 
a suggestion that the presence of migraine biology is accountable for the development of central 
sensitization and thus constant pain in SUNCT and SUNA (Cohen , et al., 2006). A similar 
mechanism could also account for TN with constant pain. Patients with TN and migraine 
biology would be more susceptible to central sensitization mechanisms that could influence the 
clinical presentation (background pain, cranial autonomic symptoms, and mainly spontaneous 
attacks) and perhaps the therapeutic outcome (less compelling response to carbamazepine and 
MVD), thus explaining the difference between classical TN and TN with constant pain. 
 
 
 
 
 
 
Table 15. Clinical characteristics of SUNCT, SUNA and trigeminal neuralgia 
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SUNCT SUNA 
Trigeminal 
Neuralgia 
Gender ratio (M:F) 
2:1; 1:1 0.5:1 1:2 
Mean age of onset (years) 
48 44-47 52 
Site of pain 
V1: 67% 
V2: 33% 
V3: 0% 
V1: 56% 
V2: 56% 
V3: 33% 
V1: 10% 
V2: 35% 
V3: 30% 
Severity of pain Severe to very 
severe 
Severe to very 
severe 
Very severe 
Duration (seconds) 1-600 1-600 <1-120 
Frequency/day 1-600 1-600 Triggerable 
Autonomic features Yes (numerous) Yes (less 
numerous) 
None (sparse) 
Cutaneous/intraoral triggers 74% NK 100% 
Refractory period Absent Absent Present 
Background pain 47% NK Absent 
 
SUNCT: short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA: 
short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; V1: Ophthalmic nerve territory; 
V2: Maxillary nerve territory; V3: Mandibular nerve territory; NK: not known due to insufficient data in literature.  
 
 
1.4.3. The aetiology of SUNCT, SUNA and trigeminal neuralgia 
The majority of SUNCT cases are idiopathic, but a significant minority of them seems to be 
secondary to intracranial abnormalities. Similar to secondary cases of other TACs (Cittadini, 
et al., 2009) and secondary TN (Love , et al., 2001; Leone , et al., 2004; Gazioğlu , et al., 2000), 
cases of SUNCT have been attributed to posterior fossa abnormalities and pituitary adenomas 
(Cohen , et al., 2006; Chitsantikul , et al., 2013). In addition, growing evidence supports the 
frequent occurrence of vascular compression of the trigeminal nerve close to the root entry 
zone ipsilaterally to the side of the pain. In a series of 24 SUNCT/SUNA cases, 17 patients 
were studied with dedicated MRI imaging of the trigeminal nerves. Neurovascular compression 
was detected in 15 of 17 patients (88%). In 90% of cases, a vascular loop was impinging on 
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the symptomatic trigeminal nerve, compared to only 7% in which the vascular loop was 
pressing on the asymptomatic nerve, suggesting that this finding was more than a mere chance 
association (Williams , et al., 2008). Should these data be confirmed in a larger sample of 
patients, it would support an aetiological overlap between SUNCT, SUNA and TN; indeed, TN 
seems to be associated with neurovascular compression of the trigeminal sensory root in the 
vast majority of patients. 
 
1.4.4. The treatment of SUNCT, SUNA and trigeminal neuralgia 
The treatment for SUNCT/SUNA and TN is divided into medical and surgical therapies. 
SUNCT, SUNA and TN respond to similar medications. Lamotrigine is considered the oral 
drug of choice for the preventive treatment of SUNCT and SUNA, despite the fact that this 
assumption is based on small open-label studies. Lidocaine is possibly even more effective, but 
its use is limited by the administration route and the side-effects profile (Lambru , et al., 2013). 
Evidence of efficacy has also been reported for topiramate and gabapentin (Cohen, 2007). The 
therapeutic response to carbamazepine has been reported in 33 SUNCT cases. Eleven patients 
(33%) reported a favourable response, the majority of which had only partial benefit (Matharu 
et al., 2003). However, the data on this treatment might have been biased by the selection of 
only those SUNCT and SUNA patients who were misdiagnosed with TN and failed the 
treatment with carbamazepine. Emerging evidence has shown a possible favourable effect in 
monotherapy or polytherapy of oxcarbazepine, which shares similar mechanisms of action with 
carbamazepine but seems to have a better tolerability profile (Dora , 2006; Marziniak , et al., 
2009). Oxcarbazepine and carbamazepine are the drugs of choice for the prophylaxis of TN 
(Cruccu , et al., 2008). Moreover, evidence from a randomized placebo-controlled crossover 
trial also supports the efficacy of lamotrigine as an add-on therapy for the prevention of 
trigeminal neuralgia (Zakrzewska , et al., 1997). Interestingly, the study group consisted of 
patients who failed to respond to carbamazepine or phenytoin, strengthening the importance of 
lamotrigine in the prophylaxis of trigeminal neuralgia.  
 
Despite the lack of homogeneous selection criteria for patients suitable for surgery, several 
ablative procedures on the trigeminal nerve known to be effective in TN have been attempted 
in SUNCT and SUNA, with mixed results (Lambru , et al., 2013). Remarkably, in view of the 
initial observations of the presence of neurovascular conflict with the trigeminal nerve in 
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SUNCT and SUNA syndromes, cases of patients treated with MVD of the trigeminal nerve 
have emerged. To date, 12/19 (63%) SUNCT and SUNA patients treated with MVD obtained 
a complete control of the headache at a mean follow- up of 14 months (range: 0.5 – 32 months) 
(Sebastian , et al., 2013). Larger series with longer follow-ups are required to confirm this 
promising result. Altogether, these findings suggest an overlap of medical and surgical 
treatments between SUNCT, SUNA and TN, supporting the hypothesis that these disorders 
may share underlying pathophysiological mechanisms. 
 
1.4.5. The pathophysiology of SUNCT, SUNA and trigeminal neuralgia 
Any pathophysiological construct on SUNCT and SUNA should account for their major 
clinical characteristics. It has been proposed that some of the clinical features of 
SUNCT/SUNA, namely the occurrence of pronounced cranial autonomic symptoms with the 
pain, imply a central disinhibition of the trigemino-autonomic reflex, similar to the other TACs 
(Goadsby, et al., 1997; Leone , et al., 2009). The cerebral structure implicated in the 
disinhibition mechanism is thought to be the posterior hypothalamus, known to have a 
modulatory role in the nociceptive and autonomic pathways, specifically the trigeminovascular 
nociceptive pathways (Bartsch , et al., 2004). Functional neuroimaging studies have showed 
activation of the posterior hypothalamus during SUNCT/SUNA attacks, supporting its 
paramount role in these disorders (May , et al., 1999; Cohen, 2007). However, this 
pathophysiological model can hardly explain the other key clinical features of SUNCT/SUNA, 
including the neuralgiform type of pain, the very short duration and high frequency of the 
attacks, the triggerability of the attacks, and the absence of a refractory period, which are unique 
characteristics for these disorders amongst the TACs and constitute the core of the clinical 
overlap with TN. 
The pathophysiological model that accounts for the TN features revolves around a complex 
interaction of peripheral and central mechanisms. The ignition hypothesis highlights the role 
of focal demyelination of the trigeminal sensory root because of vascular compression near the 
root entry zone in generating spontaneous ectopic impulses responsible for the short-lasting 
spontaneous attacks (Devor , et al., 2002). Additionally, in the demyelination area ephaptic 
cross talking activities between fibers mediating light touching (A-b) and nociceptive fibers 
(A-d) may account for the attacks triggered by innocuous stimulation. Central mechanisms 
account for the occurrence of TN in patients with no structural damage on the trigeminal nerve, 
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besides explaining the mechanism of the refractory period following triggered attacks. The 
occurrence and the length of a refractory period are functions of the duration and intensity of 
the preceding attack, thus very short-lasting attacks seem not to be followed by a refractory 
period. This mechanism seems to be regulated by the trigeminal nucleus caudalis, highlighting 
the importance of central structures in TN (Kugelberg, et al., 1959). 
The presence of a neurovascular conflict with the trigeminal nerve in a significant majority of 
patients may support similar peripheral mechanisms also in SUNCT/SUNA. A central 
disinhibition of the trigeminal nucleus caudalis may explain the lack of refractory periods in 
SUNCT/SUNA compared to TN. 
Ultimately, SUNCT, SUNA and TN may be attributable to a unifying pathophysiological 
model characterized by different degrees of interaction between peripheral and central 
mechanisms, namely focal demyelination of the trigeminal sensory root and posterior 
hypothalamic dysfunction. Central mechanisms may be more pronounced in patients with at 
least two cranial autonomic symptoms and less pronounced in patients with one or no 
autonomic symptoms. 
 
1.5. Conclusion 
SUNCT and SUNA syndromes are considered TACs due to the occurrence of pain in the 
trigeminal territory associated with cranial autonomic symptoms. Functional neuroimaging 
studies demonstrated posterior hypothalamic activation during SUNCT attacks, supporting a 
shared pathophysiological model for the TACs. However, SUNCT and SUNA display a 
remarkable demographic and clinical overlap with TN. Growing evidence also supports 
aetiological similarities with TN because of the significant proportions of patients with SUNCT 
and SUNA showing a neurovascular conflict with the trigeminal nerve. Preliminary data 
demonstrate the efficacy of MVD of the trigeminal nerve in SUNCT and SUNA, suggesting 
the possible role of damage of the sensory root in the pathophysiology of these disorders. This 
underlying common mechanism could account for the striking clinical similarities between 
these conditions, supporting the hypothesis that SUNCT, SUNA and TN represent variants of 
the same disorder. This disorder would be characterized by unilateral short-lasting 
neuralgiform headache attacks with different degree of cranial autonomic activation, reflecting 
the different degree of involvement of central (posterior hypothalamic dysfunction) and 
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peripheral (trigeminal sensory root damage) mechanisms. This unifying hypothesis carries 
important nosological implications on whether this new clinical entity should belong to the 
TACs or the cranial neuralgias group.  
 
1.6. Aims of the Thesis 
The aim of the thesis is to detail the phenotype of SUNA syndrome and to compare it to that 
of SUNCT. The outcome of such a study may shed light on whether these two conditions need 
to be kept separate or whether they could be unified in the future revision of the IHS 
classification. This thesis also aims to study the proportion and the characteristics of 
neurovascular compression with the trigeminal nerve in SUNCT and SUNA syndromes, with 
the goal to examine the initial findings on this subject. Given the limited armamentarium of 
treatments for such disabling conditions, this thesis will study the efficacy of numerous medical 
treatments in a large series of SUNCT and SUNA patients, aiming to expand the medical 
treatment options for this disabling condition. Additionally, this study will aim to test two 
surgical procedures that have reported to be effective in the other TACs, namely occipital nerve 
stimulation and in TN, namely MVD, in a group of medically refractory SUNCT and SUNA 
patients. Finally, a comparison of demographic and clinical features between large series of 
SUNCT, SUNA and TN will be carried out aiming to shed light on whether SUNCT, SUNA 
and TN represent different clinical entities or variants of the same disorder. 
 
 
 
 
 
 
 
 
 
 
Chapter 2.  A Prospective Clinical and Radiological Study of Short-lasting 
Unilateral Neuralgiform Headache Attacks With Conjunctival 
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Injection And Tearing (SUNCT) Or Cranial Autonomic 
Symptoms (SUNA) 
 
 
2.1. Abstract 
 
Whereas the SUNCT clinical phenotype is well defined, that of SUNA is much less so. Despite 
the similar phenotypes, comparison between SUNCT and SUNA has hitherto not been possible 
due to the dearth of studies validating the phenotype of SUNA and therefore these two 
syndromes have been kept separate in the International Classification of Headache Disorders. 
To validate the clinical phenotype of SUNA and assess similarities and differences with the 
one of SUNCT, 133 patients with SUNA and SUNCT (SUNA=63 and SUNCT=70) underwent 
administration of a face to face semi-structured questionnaire capturing demographic and 
clinical characteristics. Both unadjusted and adjusted logistic regression analyses were used to 
identify predictors of patients suffering SUNA rather than SUNCT. 
 
Of all the clinically relevant variables that characterise these disorders, a multivariate logistic 
regression analysis demonstrated a significant association between ipsilateral ptosis [OR: 3.37 
(95% CI: 1.50, 7.66), p<0.0001] and rhinorrhoea [OR: 2.42 (95% CI: 1.09, 5.41), p=0.034] 
with SUNCT as opposed to SUNA. A significantly higher proportion of SUNCT patients 
(n=56, 80.0%) also reported marked lacrimation compared to SUNA patients (n=20, 46.5%) 
(P<0.001).  
 
Since no major clinical differences between SUNCT and SUNA were found, bar the fact that 
SUNCT is characterised by more prominent cranial autonomic features, which is likely to 
merely reflect the current operational criteria that artificially separate these conditions, it was 
proposed that the two disorders be placed together in the single diagnostic category, SUNA, 
which encompasses cases of SUNCT. New diagnostic criteria for this unified syndrome were 
proposed. These criteria, applied to our cohort, correctly diagnosed all the patients, but two.  
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2.2. Introduction 
Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing 
(SUNCT) is a rare primary headache disorder first described in 1978 (Sjaastad, et al., 1978) 
and further characterised over subsequent years (Sjaastad , et al., 1989; Pareja , et al., 1997). 
The first diagnostic criteria for SUNCT, based on expert opinion, were proposed in 1997 
(Goadsby, et al., 1997). In view of the clinical combination of unilateral pain in the trigeminal 
territory and ipsilateral cranial autonomic symptoms, the authors suggested placing SUNCT 
alongside cluster headache (CH) and paroxysmal hemicrania (PH) within the trigeminal 
autonomic cephalalgias (TACs). SUNCT was subsequently included in “Group 3” of the 
second edition of the International Classification of Headache Disorders (ICHD-2), while 
criteria for SUNA were outlined in the appendix section (Headache Classification 
Subcommittee of The International Headache Society., 2004). In the recently published revised 
version of the classification, SUNCT and SUNA have been encompassed within the group of 
the “Short-lasting unilateral neuralgiform headache attacks” and criteria for the episodic and 
chronic forms have been proposed (Headache Classification Subcommittee of The 
International Headache, 2013). Both the syndromes are currently defined by moderate or severe 
unilateral head pain in orbital, supraorbital, temporal and/or other trigeminal distribution, 
lasting for 1–600 seconds and occurring as single stabs, series of stabs or in a saw-tooth pattern. 
In SUNCT the pain must be accompanied by both ipsilateral conjunctival injection and 
lacrimation, whereas in SUNA only one or neither of conjunctival injection and lacrimation 
(tearing) should be present though the pain has to be accompanied by at least one cranial 
autonomic feature. Attacks have a frequency of at least one a day for more than half of the time 
when the disorder is active.  
 
SUNCT and SUNA are believed to be rare with an estimated prevalence of 6.6 per 100,000 
and an annual incidence of 1.2 per 100,000 (Williams , et al., 2008). To date, two reviews 
(Pareja , et al., 1997; Matharu , et al., 2003) and two prospective clinical series of SUNCT 
patients have defined the clinical phenotype of the syndrome (Cohen , et al., 2006; Williams , 
et al., 2008). In contrast, only a few patients with SUNA have been described in the literature 
thus far (Cohen , et al., 2006; Williams , et al., 2008; Lambru , et al., 2012; Chitsantikul , et al., 
2013) and therefore the full clinical spectrum of the syndrome still needs to be defined. This 
has meant that valid comparisons of SUNCT and SUNA have been lacking and further 
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advances on the issue of whether they are separate syndromes or a unified entity have hitherto 
not been possible.  
 
Moreover, similar to trigeminal neuralgia (TN), a significant proportion of SUNCT patients 
have been reported to display neurovascular conflict with the trigeminal nerve ipsilaterally to 
the side of the pain in a small study (Williams , et al., 2008). Some of those patients also 
benefited from treatment with microvascular decompression of the trigeminal nerve, 
suggesting a pathophysiological overlap between SUNCT, SUNA and TN (Williams , et al., 
2010; Lambru , et al., 2014).  
 
The aim of this chapter was to describe the clinical and demographic characteristics of a large 
clinic-based cohort of SUNA and SUNCT patients, and to compare and contrast these 
characteristics.  
 
2.3.  Methods 
The study group was derived from 147 patients, of whom 66 had SUNA and 81 had SUNCT. 
However, 14 patients were excluded because they could not be followed-up for the following 
reasons: 11 were discharged from our clinic and three deceased for reasons not linked to the 
headache condition. The final study group consisted of 133 patients. The diagnosis of SUNCT 
or SUNA had initially been made according to the ICHD-3 criteria by two consultant 
neurologists and headache experts (M.M. and P.S.) at The National Hospital for Neurology and 
Neurosurgery from 2007 to 2012. Once the diagnosis was established, participants were invited 
to take part in the study and consent was taken. Participants were then administered a 
comprehensive standardized semi-structured questionnaire (see Appendix) in an outpatient 
clinical setting. The interview was conducted face to face by a single researcher (GL) and lasted 
between 60-90 minutes. If any diagnostic concerns were raised, patients were re-phenotyped 
at three to six-month intervals and appropriate investigations undertaken. These included trials 
of oral or intramuscular indometacin to rule out indometacin-responsive headaches (Headache 
Classification Subcommittee of The International Headache, 2013) and trials of sumatriptan 6 
mg subcutaneous injections and high-dose and flow-rate oxygen to evaluate for the possibility 
of a diagnosis of cluster headache (Cohen, 2007). If any of the questions were not able to be 
answered by the participants, then that participant would be re-assessed normally between three 
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to six months.  Data were collated in an electronic password protected spreadsheet and the 
participants files were updated if new or different clinical information became available. 
  
Patients were asked to keep a headache diary for at least two weeks between appointments to 
obtain objective and reliable information about the duration and frequency of the headache 
attacks. Baseline headache characteristics were captured when participants were not on 
preventive treatments or while they were taking preventive medication, which were not 
effective. In addition, where possible, relatives (in particular partners) were questioned 
regarding the presence or absence of autonomic symptoms and other clinical features during 
acute attacks.  
 
The study was approved by Northwick Park Hospital Research Ethics Committee, London, UK 
(REC no:11/LO/1709) 
 
2.3.1. Statistical analysis  
Baseline characteristics were compared between the cohorts of SUNA and SUNCT using Chi-
squared tests or Fisher’s exact tests for categorical variables and Student’s t-tests or Mann 
Whitney U-tests depending on the distribution of the continuous variables. Both unadjusted 
and adjusted logistic regression analyses were used to identify predictors of patients suffering 
SUNA rather than SUNCT. Adjustments were made for characteristics that have previously 
been associated with either condition (i.e. site, quality of the pain, duration, frequency of the 
attacks and cranial autonomic symptoms). Statistical analyses were performed using STATA 
(Stata Corp. 2001. Stata Statistical Software: Version 12.1, College Station, Texas, USA).  All 
reported p-values were two-sided and a significance level less than 5% was considered 
significant. 
 
2.4. Results 
2.4.1. Age, gender and duration of symptoms 
The demographic characteristics of our cohorts of SUNA and SUNCT patients are shown in 
Table 16. Female were more represented than men in our cohort of patients. This gender 
preponderance was significantly more pronounced in SUNA compared to SUNCT patients 
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(p=0.042). It took a median of four years (IQR: 2-7.75 years) for the patients to obtain the 
correct diagnosis. 
 
 
Table 16. Demographic characteristics of SUNA and SUNCT patients 
 
 SUNA  
n (%) 
SUNCT  
n (%) 
TOTAL  
n (%) 
Gender 
Male 18 (28.6%) 32 (45.7%) 49 (36.8%) 
Female 45 (71.4%) 38 (54.3%) 84 (63.2%) 
Mean (95% CI) age 
of onset (years) 
45.03 (±14.1) 42.16 (±15.4) 43.52 (±14.8) 
Age range of onset 16-72 years 13-76 years 13-76 years 
Median duration of 
symptoms (range) 
5 (1-31) years 8 (1-45) years 6 (1-45) years 
Median time to 
make the correct 
diagnosis (range) 
3 (0-30) years 3 (0-45) years 3 (0-45) years 
 
CI: confidence interval; SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; 
SUNCT: short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
 
 
2.4.2. Diagnoses made on previous clinical assessments 
The majority of patients had previously been given a diagnosis of TN (Table 17).  Of the 133 
patients, 110 (82.7%) did not report any other comorbid headache disorder. Of the remaining 
23 patients, nine had a diagnosis of chronic CH, three of HC, two of episodic CH, two of 
primary stabbing headache, two of new daily persistent headache, one patient of TN, one 
patient of trigeminal painful neuropathy, one patient of primary headache associated with 
sexual activity, one of tension-type headache and one of headache attributed to spontaneous 
intracranial hypotension.  
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 Table 17. Diagnoses made prior to definitive diagnosis of SUNCT or SUNA 
 
 
SUNA 
n (%) 
SUNCT 
n (%) 
TOTAL 
n (%) 
Trigeminal neuralgia 34 (54.0%) 34 (48.6%) 68 (51.1%) 
Migraine 10 (15.9%) 17 (24.3%) 27 (20.3%) 
Cluster headache 8 (12.7%) 16 (22.9%) 24 (18.1%) 
Paroxysmal 
hemicrania 
3 (4.8%) 0 (0.0%) 3 (2.3%) 
Hemicrania continua 1 (1.6%) 0 (0.0%) 1 (0.8%) 
Dental pathologies 6 (9.5%) 7 (10.0%) 13 (9.8%) 
TAC not otherwise 
specified 
0 (0.0%) 3 (4.3%) 3 (2.3%) 
Stress/psychiatric 
conditions 
0 (0.0%) 3 (4.3%) 3 (2.3%) 
Horton arteritis 1 (1.6%) 1 (1.4%) 2 (1.5%) 
Occipital neuralgia 0 (0.0%) 3 (4.3%) 3 (2.3%) 
No diagnosis made 13 (20.6%) 9 (12.9%) 22 (16.5%) 
 
Some patients were offered multiple diagnoses prior to the definitive diagnosis. SUNA: short-lasting unilateral 
neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting unilateral neuralgiform 
headache attacks with conjunctival injection and tearing; TAC: trigeminal autonomic cephalalgia 
 
 
2.4.3. Precipitating events 
Seventeen SUNA (25.8%) and 20 SUNCT (28.5%) patients reported possible precipitating 
events prior to the onset of symptoms. The remaining patients were not aware of any events 
that may have had a causative role in the exacerbation of their condition. A list of precipitating 
events is given in Table 18.  
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Table 18. Precipitating events 
 
 
SUNA 
n (%) 
SUNCT  
n (%) 
TOTAL  
n (%) 
Latency between 
event and onset of 
headache 
Period of extreme stress 2 (3.2%) 3 (4.3%) 5 (3.8%) 
-2 SUNCT: 1 month  
-1 SUNCT: 3 weeks   
-2 SUNA: 1 month 
Head injury 2 (3.2%) 3 (4.3%)  5 (3.8%) 
-1 SUNCT: 3 weeks  
-1 SUNCT: 1 week 
-1 SUNCT: 24 hours 
-1 SUNA: 2 months 
-1 SUNA: 1 week 
Infection 
Flu 
symptoms 
2 (3.2%) 0 (0.0%) 2 (1.5%) -2 SUNA: 1 week 
Pneumonia 1 (1.6%) 0 (0.0%) 1 (0.8%) -1 SUNA: 3 weeks 
Herpes 
simplex 
0 (0.0%) 1 (1.4%) 1 (0.8%) -1 SUNCT: 1 week 
Herpes 
Zoster 
1 (1.6%) 1 (1.4%) 2 (1.5%) 
-1 SUNCT: 2 months 
-1 SUNA: 1 month 
Bacterial 
tonsillitis 
1 (1.6%) 0 (0.0%) 1 (0.8%) -1 SUNA: 1 month 
Surgical 
operation 
Dental 1 (1.6%) 2 (2.9%) 3 (2.3%) 
-1 SUNCT: 2 months 
-1 SUNCT: 1 week 
-1 SUNA: 1 week 
Eye 1 (1.6%) 0 (0.0%) 1 (0.8%) -1 SUNA: 3 weeks 
Nasal 0 (0.0%) 1 (1.4%) 1 (0.8%) -1 SUNCT: 1 month 
Ischemic stroke 0 (0.0%) 2 (2.9%) 2 (1.5%) 
-1 SUNCT: 1 week 
-1 SUNCT: 1 week 
Therapeutic 
procedures 
GON 
blockade 
1 (1.6%) 0 (0.0%) 1 (0.8%) -1 SUNA: 1 week 
IV DHE 0 (0.0%) 1 (1.4%) 1 (0.8%) -1 SUNCT: 1 week 
Chemotherapy 1 (1.6%) 0 (0.0%) 1 (0.8%) -1 SUNA: 3 weeks 
Pregnancy 1 (1.6%) 0 (0.0%) 1 (0.8%) 
-1 SUNA: 1 week after   
childbirth 
 
GON: greater occipital nerve; IV DHE intravenous dihydroergotamine; SUNA: short-lasting unilateral 
neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting unilateral neuralgiform 
headache attacks with conjunctival injection and tearing 
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2.4.4. Laterality of attacks 
Thirty-one SUNA (49.2%) and 32 SUNCT patients (45.7%) had exclusively right-sided 
attacks; 24 SUNA (38.1%) and 27 SUNCT patients (38.6%) had exclusively left-sided attacks 
(p=0.820). Seven SUNA (11.1%) and 11 SUNCT patients (15.7%) had side alternating 
unilateral attacks; in eight patients, they were predominantly right-sided (SUNA, n=2; SUNCT, 
n=6), in nine patients they were predominantly left-sided (SUNA, n=4; SUNCT, n=5) and in 
one SUNA patient the attacks occurred equally on either side. One patient with side-alternating 
SUNA attacks also described bilateral attacks.    
 
2.4.5. Site of attacks 
Fifty-one SUNA (81.0%) and 63 SUNCT (90.0%) patients had attacks in the distribution of 
the first branch of the trigeminal nerve (V1) (p=0.136). In 40 SUNA patients (63.5%), V1 
constituted one of starting sites of the painful attacks whereas in 11 patients (17.5%) the pain 
started in another site and radiated to the V1 territory. In 54 SUNCT patients (77.1%), V1 
constituted one of starting sites of the painful attacks whereas in nine patients (12.9%) the pain 
started in another site and radiated to V1.  
 
Forty-nine SUNA (77.8%) and 51 SUNCT (72.9%) patients experienced attacks in the 
distribution of the second branch of the trigeminal nerve, including the temple (V2) (p=0.511). 
In 47 SUNA patients (74.6%), V2 was one of the starting sites of the attacks whereas in two 
patients (3.2%), V2 constituted a site where pain radiated. In 41 SUNCT patients (58.6%), V2 
was one of the starting sites of the attacks whereas in ten patients (14.3%), V2 constituted a site 
where pain radiated.  
 
Twenty-three SUNA (36.5%) and 20 SUNCT patients (28.6%) reported attacks in the 
distribution of the third branch of the trigeminal nerve (V3) (p=0.005). In 18 SUNA patients 
(28.6%), V3 was one of the principal locations of the pain whereas in five patients (7.9%), the 
pain started in another site and radiated to V3. In 13 SUNCT patients (18.6%), V3 constituted 
one the main pain sites whereas in seven patients (10%), V3 was reported as a pain radiation 
site.   
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Extra-trigeminal territory pain (C2-C3) was reported in 14 SUNA (22.2%) and 14 SUNCT 
(20.0%) patients (p=0.753). In nine SUNA (14.3%) and 11 SUNCT patients (15.7%), C2-C3 
was the only or the predominant pain site whereas in five SUNA (7.9%) and three SUNCT 
patients (4.3%), this territory was a pain radiation site. Figure 9 and 10 show the different pain 
distribution sites in SUNA and SUNCT patients, whereas a full list of attack sites is shown in 
Table 19. 
 
Figure 9. Distribution of pain territories in SUNA patients 
 
 
             
 C2/3: second and third cervical roots territories; V1: ophthalmic trigeminal territory; V2: maxillary            
 trigeminal territory; V3: mandibular trigeminal territory;  
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Figure 10. Distribution of pain territories in SUNCT patients 
 
 
   
C2/3: second and third cervical roots territoriesV1: ophthalmic trigeminal territory; V2: maxillary trigeminal 
territory; V3: mandibular trigeminal territory;  
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Table 19. Site of the attacks 
 
 SUNA 
 n (%) 
SUNCT 
n (%) 
 
P-value (<0.05) 
Peri-orbital  30 (47.6%) 47 (67.1%) 0.022 
Retro-orbital 16 (25.4%) 29 (41.4%) 0.051 
Forehead 23 (36.5%) 20 (28.6%) 0.328 
Temporal 28 (44.4%) 31 (44.2%) 0.985 
Parietal 13 (20.6%) 15 (21.4%) 0.910 
Vertex 1 (1.6%)   4 (5.7%) 0.211 
Occiput 14 (22.2%) 13 (18.6%) 0.601 
Neck 0 (0.0%) 1 (1.4%) - 
Cheek 29 (46.0%) 30 (42.9%) 0.712 
Side of nose 10 (15.9%) 7 (10.0%) 0.311 
Ear 5 (7.9%) 6 (8.6%) 0.894 
Retroauricular 1 (1.6%) 0 (0.0%) - 
Jaw 20 (31.8%) 13 (18.6%) 0.079 
Upper teeth 5 (7.9%) 5 (7.1%) 0.862 
Lower teeth 4 (6.4%) 3 (4.3%) 0.594 
Upper lip 4 (6.4%) 5 (7.1%) 0.855 
Lower lip 3 (4.8%) 3 (4.3%) 0.894 
Chin 2 (3.2%) 1 (1.4%) 0.498 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
 
2.4.6. Severity of the pain 
The patients were asked to rate the average severity, along with the maximum and minimum 
severity of their attacks on a verbal rating scale (VRS) of 0 to 10, with 0 being no pain and 10 
being very severe pain. The median severity of the pain was very severe in both groups with a 
VRS of 9 in SUNA (IQR: 8-10) and 10 in SUNCT (IQR: 8-10) (p=0.667). Only one SUNA 
(1.6%) and three SUNCT (4.3%) patients had an average severity of attacks of 6 on the VRS 
(moderate intensity).  
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2.4.7. Quality of pain 
In our cohort, the most commonly described pain qualities were stabbing, sharp, electric shock-
like or shooting (Table 20). All patients had at least one of these four qualities of pain. A 
pulsating nature to the pain was reported in only nine SUNA (14.3%) and ten SUNCT (14.3%) 
(p=1.000) and never as an isolated feature. 
 
Table 20. Quality of pain 
 
 SUNA  
n (%) 
SUNCT  
n (%) 
P-value (<0.05) 
Stabbing 52 (82.5%) 57 (81.4%) 0.867 
Sharp 38 (60.3%) 42 (60.0%) 0.970 
Electric shock 21 (33.3%) 25 (35.7%) 0.773 
Shooting 17 (27.0%) 22 (31.4%) 0.574 
Burning 11 (17.5%) 13 (18.6%) 0.867 
Pulsating 9 (14.3%) 10 (14.3%) 1.000 
Jabbing 5 (7.9%)  5 (7.1%) 0.862 
Pressure 4 (6.3%)  4 (5.7%) 0.877 
Tightening 4 (6.3%)  0 (0.0%) - 
Dull 2 (3.2%)  1 (1.4%) 0.498 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing  
 
2.4.8. Duration and profile of attacks 
The SUNA group had mean attack duration of 158.5 seconds [±200.5, 95%CI: 107.9; median: 
60 seconds; Inter-quartile range (IQR): 30-195 seconds] and SUNCT patients mean attack 
duration of 162.4 seconds (±194.5, 95%CI: 116.0; median: 90 seconds; IQR: 20-240 seconds) 
with no significant difference found between them (p=0.454). In all patients, the usual duration 
of attacks ranged from 1-900 seconds, although, in 23 patients (17.3%) some attacks could also 
last longer, up to one hour (range: 1200-3600 seconds). The vast majority of patients (n=131, 
98.5%) patients had a usual duration of attacks ranging from 1-600 seconds, in line with the 
ICHD-3 criteria. 
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All patients reported attacks resembling at least one of the following profiles: single stabs, 
repetitive stabs (group of stabs), serrated or saw-tooth patterns (in which the pain would not 
return to baseline between attacks) (Matharu et al, 2003) and plateau-like patterns (Pareja and 
Sjaastad, 1994). Ten patients (SUNA: n=5; SUNCT: n=5) described their attack profile as 
plateau-like plus a superimposed stabbing component. In two of them that was the predominant 
attack profile. A substantial proportion of both SUNA and SUNCT patients described their 
attacks using more than one attack profile (Table 21). The median duration of single stabs was 
shorter than the median duration of the other attack profiles (Table 22 and Figure 11).  
  
Table 21. Presence of isolated and multiple attack profiles 
 
 SUNA 
n (%) 
SUNCT 
n (%) 
TOTAL 
n (%) 
Single profile    
Single stabs  4 (6.4%) 1 (1.4%) 5 (3.8%) 
Repetitive stabs  7 (11.1%) 12 (17.1%) 19 (14.3%) 
Serrated stabs  8 (12.7%) 9 (12.9%) 17 (12.8%) 
Plateau-like  3 (4.8%) 4 (5.7%) 7 (5.3%) 
Two profiles 25 (39.7%) 34 (48.6%) 59 (44.4%) 
Three profiles 13 (20.6%) 9 (12.9%) 22 (16.5%) 
All four profiles 0 (0.0%) 1 (1.4%) 1 (0.8%) 
Missing data 1 (1.6%) 0 (0.0%) 1 (0.8%) 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing  
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Table 22. Frequency and duration of the different attack profiles in SUNA and SUNCT 
 
 
SUNA 
n (%) 
Median duration (IQR) 
SUNCT 
n (%) 
Median duration (IQR) 
TOTAL 
n (%) 
Median duration (IQR) 
Single 
stabs 
35 (55.6%) 
10 sec (15-120 sec) 
30 (42.9%) 
7.5 sec (1-10 sec) 
65 (48.9%) 
10 sec (10-120 sec) 
Repetitive 
stabs 
33 (52.4%) 
180 sec (60-450 sec) 
45 (64.3%) 
180 sec (40-270 sec) 
78 (58.7%) 
180 sec (60-300 sec) 
Serrated 
stabs 
31 (49.2%) 
300 sec (60-345 sec) 
33 (47.1%) 
240 sec (40-240 sec) 
64 (48.1%) 
240 sec (60-240 sec) 
Plateau-
like 
12 (19.1%) 
600 sec (300-900 sec) 
15 (21.4%) 
180 sec (20-90 sec) 
27 (20.3%) 
300 sec (20-600 sec) 
Missing 
data 
1 (1.6%) 0 (0.0%) 1 (0.8%) 
 
  IQR: Inter-quartile range 
 
 
   Figure 11. Median attack profile duration in SUNA and SUNCT patients (in seconds) 
 
 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
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2.4.9. Frequency of attacks 
In assessing the frequency of attacks, we considered single stabs, groups of stabs or serrated 
stabs as single episodes. The median attack frequency per day was 20 (IQR: 8-53 attacks/day; 
mean: 44.3, ±61.3) in the SUNA and 30 (IQR: 10-55 attacks/day; mean 48.7, ±52.3) in the 
SUNCT group (p=0.329). Seven SUNA (11.1%) and five SUNCT patients (7.1%) reported an 
average frequency of more than 100 attacks/day.  All other SUNA and SUNCT patients 
(91.0%) had an average attack frequency ranging between 1 and 100 attacks/day. 
 
2.4.10. Cranial autonomic symptoms 
Eight SUNA patients (12.7%) reported conjunctival injection and 43 (68.3%) reported 
lacrimation during acute attacks. Besides the conjunctival injection and lacrimation, which 
exist as a significant clinical difference between SUNCT and SUNA by IHS diagnostic criteria 
definition, ptosis occurred more commonly in SUNCT patients (n=35, 50.0%) compared to 
SUNA patients (n=15, 23.8%) (p=0.001). Rhinorrhoea was also reported more in SUNCT 
(n=36, 51.4%) than SUNA (n=21, 33.3%) but the difference was not statistically significant 
(p=0.055). In SUNA, the cranial autonomic features were strictly unilateral ipsilateral to the 
pain in 53 patients (84.1%) and bilateral in 10 patients (15.9%). In SUNCT, the cranial 
autonomic symptoms were strictly unilateral ipsilateral to the pain in 57 patients (81.4%), 
bilateral in 12 patients (17.1%) and strictly unilateral contralateral to the pain in one patient 
(1.4%). It is noteworthy that facial sweating and flushing were the most frequently reported 
facial autonomic symptoms with bilateral appearance. Conversely, patients with bilateral facial 
symptoms seldom reported ocular and nasal symptoms. A detailed list of cranial autonomic 
symptoms is given in Table 23. 
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 Table 23: Associated cranial autonomic symptoms 
 
 SUNA 
n (%) 
SUNCT 
n (%) 
P-value (<0.05) 
Conjunctival 
injection 
8 (12.7%) 70 (100%) - 
Lacrimation 43 (68.3%) 70 (100%) - 
Ptosis 15 (23.8%) 35 (50.0%) 0.001 
Eyelid oedema 8 (12.7%) 17 (24.3%) 0.087 
Miosis                  2 (3.2%) 6 (8.6%) 0.191 
Rhinorrhoea 22 (33.3%) 36 (51.4%) 0.055 
Nasal blockage 21 (33.3%) 28 (40.0%) 0.426 
Facial sweating 20 (31.7%) 22 (31.4%) 0.968 
Facial flushing 29 (46.0%) 29 (41.4%) 0.592 
Facial swelling 6 (9.5%) 6 (8.6%) 0.848 
Aural  
fullness 
9 (14.3%) 15 (21.4%) 0.284 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
 
The ICHD-II suggested that cranial autonomic features should be prominent features of an 
attack to allow SUNA to be differentiated from ophthalmic division TN (Headache 
Classification Subcommittee of The International Headache Society., 2004). However, the 
actual prominence of cranial autonomic symptoms has yet to be assessed properly in both 
SUNCT and SUNA. The scale previously used to assess lacrimation during first division TN 
was applied to our cohort to assess degree of lacrimation (Pareja , et al., 2002). The scale 
describes “mild lacrimation” as increased conjunctival brightness to increased conjunctival 
meniscus; “moderate lacrimation” as tears clearly seen but hardly overflowing the palpebral 
edge; “severe lacrimation” as tears running down the face. Amongst those with lacrimation 
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associated with the attacks, 20 SUNA patients (46.5%) reported a severe degree of lacrimation 
during the attacks compared to 56 SUNCT patients (80.0%). Twenty-two SUNA (51.2%) 
compared to only 11 SUNCT patients (15.7%) reported a mild or moderate degree of 
lacrimation (P<0.001). Data from one SUNA and three SUNCT patients is missing (Figure 
12). The degree of conjunctival injection was not studied in view of the difficulty that patients 
have assessing its degree of severity. 
 
 Figure 12. Degree of lacrimation in SUNA and SUNCT patients 
 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
 
2.4.11. Triggering of attacks 
Thirty SUNA (47.6%) and 23 SUNCT patients (32.9%) had only spontaneous attacks, whereas 
two SUNA (3.2%) and three SUNCT patients (4.3%) had exclusively triggered attacks 
(p=0.082). Most of SUNA (n=31, 49.2%) and SUNCT (n=44, 62.9%) patients had both 
spontaneous and triggered attacks (p=0.112). Among patients with triggered attacks [SUNA 
n=33 (52.4%); SUNCT, n=47 (67.1%)], 29 with SUNA (88.0%) and 43 with SUNCT (91.5%) 
had attacks that could be provoked by various forms of cutaneous and/or intraoral stimulation. 
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Trigger areas were ipsilateral to the side of pain in all patients. Alcohol was not a trigger factor 
in our cohort. A list of trigger factors is outlined in Table 24.  
 
  Table 24: Trigger factors in SUNA and SUNCT patients with triggerable attacks 
 
 
SUNA 
n (%) 
SUNCT 
n (%) 
P-value (<0.05) 
Chewing/eating* 21 (72.4%) 36 (87.8%) 0.207 
Cold wind* 26 (90.0%) 35 (85.4%) 0.654 
Light touch* 21 (72.4%) 31 (75.6%) 0.830 
Brushing teeth* 21 (72.4%) 32 (78.0%) 0.678 
Washing/Brushing hair* 19 (65.5%) 20 (48.8%) 0.185 
Talking* 8 (27.6%) 21 (51.2%) 0.061 
Washing face* 8 (27.6%) 19 (46.3%) 0.131 
Blowing nose* 5 (17.2%) 8 (19.5%) 0.823 
Shaving* 6 (20.7%) 3 (7.3%) 0.100 
Swallowing* 4 (13.8%) 10 (24.4%) 0.288 
Showering* 2 (6.9%) 3 (7.3%) 0.953 
Valsalva Manoeuvres** 13 (39.4%) 14 (30.4%) 0.371 
Neck movements** 4 (12.1%) 9 (19.6%) 0.401 
Exercise** 3 (9.1%) 2 (4.4%) 0.379 
Bright lights** 0 (0.0%) 4 (8.7%) - 
Loud noises** 3 (9.1%) 3 (6.5%) 0.650 
Alcohol** 0 (0.0%) 0 (0.0%) - 
Strong smells** 0 (0.0%) 1 (1.4%) - 
 
*Frequencies and percentages for cutaneous/intraoral triggers refer to: SUNA = 29 patients and SUNCT = 41 
patients (patients with headache attacks triggered only by cutaneous/intraoral stimulation). 
** Frequencies and percentages for other triggers refer to SUNA = 33 patients and SUNCT = 46 patients 
(patients with headache attacks triggered by any triggers). 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing 
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2.4.12. Refractory period 
Among patients with cutaneous triggers, 23 SUNA (79.3%) and 36 SUNCT (83.7%) patients 
could trigger an attack immediately after the cessation of the previous one thereby displaying 
no refractory period (p=0.633). Conversely, two SUNA (7.0%) and three SUNCT patients 
(7.0%) did experience a refractory period lasting approximately three and ten minutes in the 
two SUNA and two, three and five minutes in the three SUNCT patients. Four SUNA patients 
(13.7%) and three SUNCT (7.0%) were uncertain about the presence of a refractory period. 
We did not have the data on this issue for one SUNCT patient (2.3%).  
 
2.4.13. Other associated symptoms 
Behaviour during attacks. Forty-four SUNA (69.8%) and 49 SUNCT (70.0%) patients 
preferred to stay still during an attack (p=0.544).  Patients with cutaneous triggers were far 
more likely to state a desire to stay still until the end of the attack, as they feared that any 
movement might worsen or trigger further attacks. On the other hand, 18 SUNA (28.6%) and 
21 SUNCT patients (30.0%) felt restless and agitated during their headache. Data for one 
SUNA patient (1.6%) was incomplete. 
Symptoms often associated with migraine. Twenty-one SUNA (33.3%) and 32 SUNCT 
(45.7%) patients reported at least one migrainous symptom during attacks (p=0.145). Nausea 
was present in ten SUNA (15.9%) and 11 SUNCT (15.7%) patients, whereas vomiting in just 
one SUNCT patient (1.4%) during some attacks. Unilateral photophobia ipsilateral to the side 
of the pain was reported by 12 SUNA (19.1%) and 19 SUNCT (27.1%) patients; one SUNA 
and two SUNCT patients complained of bilateral symptoms. Unilateral phonophobia was 
described by six SUNA (9.5%) and nine SUNCT (12.9%) patients; bilateral phonophobia was 
reported by one SUNA (1.6%) and one SUNCT patient (1.4%). One SUNA (1.6%) and five 
SUNCT (7.1%) patients reported osmophobia associated with at least some of their attacks 
while eight SUNA (12.7%) and 15 SUNCT (21.4%) patients reported motion sensitivity. 
Cutaneous allodynia during headache attacks was reported by nine SUNA (14.2%) and 10 
SUNCT (14.3%) patients.  
Aura. Aura symptoms have been reported in TACs (Matharu , et al., 2001; Bahra, et al., 2002; 
Peres , et al., 2002). In our cohort, two SUNA (3.0%) but no SUNCT patients experienced aura 
symptoms during some attacks. One patient experienced visual aura in the form of scintillating 
scotomata lasting ten minutes before subsiding. These symptoms occurred six to seven times 
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per annum. The second patient reported sensory symptoms in the form of paraesthesia 
involving the upper limb and half of the face contralateral to the side of the SUNA attack. 
These episodes lasted five to ten minutes, always at the onset of the pain and occurred with a 
frequency of three to four episodes per month. Neither of these two patients had a personal 
history of migraine but one did have a family history of migraine without aura.  
Diurnal variation and predictability of attacks. Twenty-nine SUNA (46.0%) and 31 SUNCT 
patients (44.3%) experienced attacks exclusively during waking hours (p=0.839). Thirty-four 
SUNA (54.0%) and 38 SUNCT (54.3%) patients also experienced attacks during sleep. Among 
this group, no SUNA but three SUNCT patients had mainly nocturnal attacks and eight SUNA 
and two SUNCT patients experienced attacks equally during sleep and wakefulness. Data was 
not available on one SUNCT patient.  
 
No SUNA (100%) and 63 SUNCT (90.0%) patients could not reliably predict the occurrence 
of their attacks. Five SUNCT patients (7.1%) experienced mostly random attacks along with 
some predictable attacks, which would occur at fixed times. In two SUNCT patients (2.9%) 
attacks were generally predictable: one patient stating that his attacks occurred consistently at 
3am, 8am and 1pm every day and another patient at 1am and 10am.  
 
2.4.14. Periodicity and chronicity of SUNCT and SUNA 
According to the definition of episodic and chronic short-lasting unilateral neuralgiform 
headache attacks proposed in the ICHD-3β criteria (Headache Classification Subcommittee of 
The International Headache, 2013), 58 SUNA (92.1%) and 62 SUNCT patients (88.6%) in our 
cohort could be defined as chronic while five SUNA (7.9%) and eight SUNCT (11.4%) as 
episodic (p=0.498). The median number of bouts per year in the episodic SUNA group was 
four (range: 3-6 per year), each one lasting a median of two weeks (range: 1 week-1 month), 
with patients generally reporting that the remission periods were very variable (range: 7-11 
months). The median number of bouts per annum in the episodic SUNCT group was 1.25 
(range: 0.5-2 per year), lasting a median of three months each (range: 2 weeks to 10 months) 
and alternating with very variable remission periods (range: 3-14 months).  
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2.4.15. Interictal pain in SUNCT and SUNA  
Twenty-seven SUNA (42.9%) and 37 SUNCT patients (52.9%) reported interictal background 
pain between exacerbations (p=0.249). Among these, 17 SUNA (63.0%) and 27 SUNCT 
(73.0%) patients stated that the onset of the interictal pain coincided with the original onset of 
the stabbing pain, whereas in the remaining patients the onset of the interictal pain occurred 
subsequently (p=0.393). Interictal pain occurred on the same side as the headache in 24 SUNA 
(88.9%) and 31 SUNCT patients (83.8%) while it was bilateral in three SUNA and six SUNCT 
patients (p=0.561). The location of the interictal pain corresponded to the site of the paroxysmal 
attacks in 17 SUNA (63%) and 18 SUNCT (48.7%) patients (p=0.255). The median severity 
of the interictal pain was mild for SUNA (VRS 3/10, range VRS: 2-7/10) and moderate for 
SUNCT (VRS 4/10, range VRS: 2-9/10) patients. Among SUNA with interictal pain, 22 
patients (81.5%) had a constant background pain whereas in five patients (18.5%) the pain was 
perceived only immediately after a paroxysmal SUNA attack. Similarly, in SUNCT, the vast 
majority of patients (n=28, 75.7%) complained of a constant background pain with nine 
patients (24.3%) reporting interictal pain only following acute SUNCT attacks. The interictal 
pain following a SUNA or SUNCT attack could last from one minute up to six hours. Although 
in the vast majority of patients the interictal pain occurred on a daily basis, in the two patients 
with episodic SUNA and the three with episodic SUNCT who reported background pain, the 
pain occurred just during the bouts and disappeared during remission periods. Interictal pain 
was generally featureless.  
 
It has been proposed that SUNCT and SUNA patients with a migraine biology (suggested by 
the presence of a personal and/or family history of migraine), especially those who overuse 
analgesics, may be at increased risk of developing interictal background pain (Cohen et al., 
2006). In our series, 40 SUNA (63.5%) and 32 SUNCT (45.7%) patients also suffered from 
migraine (p=0.039). Thirty-one SUNA (49.2%) and SUNCT (44.3%) patients had a first-
degree family history of migraine (p=0.57). Forty-seven SUNA (74.6%) and 41 SUNCT 
patients (58.6%) had a personal and/or family history of migraine, though data were incomplete 
for six SUNA and three SUNCT patients. History of medication overuse headache, defined as 
the use of simple analgesics and non-steroidal anti-inflammatory (NSAID) medications on 15 
or more days per month for at least three months or the use of triptans, ergots, opioids or 
combinations of them for at least ten days per month for at least three months (Headache 
Classification Subcommittee of The International Headache, 2013), was present in 19 SUNA 
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(30.2%) and 21 SUNCT (30.0%) patients (p=0.984). In our cohort of patients, 47 SUNA 
(74.6%) and 41 SUNCT (58.6%) patients had either personal or family history of migraine or 
both, suggesting a migraine biology (p=0.05). In order to assess the relationship between 
interictal pain and migrainous biology, we evaluated the proportion of patients with a 
migrainous biology who presented interictal background headache. Eighteen SUNA (38.3%) 
and 20 SUNCT patients (48.8%) with a migrainous biology developed interictal pain. 
Conversely, 29 SUNA (61.7%) and 21 SUNCT (51.2%) patients with a migraine biology did 
not (p=0.322). Data were incomplete for two SUNA and two SUNCT patients. Similarly, when 
considering the group with migraine biology and a previous history of analgesic overuse, seven 
out of 18 SUNA patients (38.9%) and nine out of 17 SUNCT (52.9%) had interictal pain 
(p=0.404).  
 
2.4.16. Neurological examination findings and MRI findings  
Eleven SUNA (17.5%) and 13 SUNCT patients (18.6%) had abnormal neurological 
examinations.  A reduced sensation to pinprick in the distribution of the first (V1) and second 
(V2) branches of the trigeminal nerve was found in five SUNA and ten SUNCT patients. A 
single SUNA patient had hyperesthesia to pinprick in V2 and one SUNCT patient had a partial 
Horner’s syndrome ipsilaterally to the side of the pain, which was extensively investigated, and 
no cause were found. Two SUNA patients with coexistent hemiplegic migraine had a mild 
persistent hemiparesis involving the upper and lower limbs ipsilaterally to the side of the pain. 
The remaining three patients had signs related to other pathologies including ischaemic stroke, 
Parkinson’s disease and cervical myelopathy.  All patients had neuroimaging scan of the brain. 
Apart from one SUNA patient who had a CT scan of the head rather than an MRI because of 
claustrophobia, the remaining patients had at least an MRI scan of the brain. Thirteen SUNA 
and seven SUNCT patients had the MRI scan in another hospital and another scan was not 
repeated at the time of the data analysis. The remaining MRI scans were performed with 
dedicated imaging of the pituitary fossa (SUNA=49; SUNCT=63). The outcome of the MRI 
scans is showed in Table 25. 
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Table 25. Magnetic resonance imaging results 
 
 SUNA n (%) SUNCT n (%) TOTAL n (%) 
MRI scan performed 62 (98.4%) 70 (100%) 132 (99.2%) 
MRI scan with pituitary  
fossa sequences 
49 (79.0%) 63 (90.0%) 112 (84.9%) 
Pituitary abnormalities 
Microadenoma 
Macroadenoma 
 
2 (4.1%) 
1 (2.0%) 
 
2 (3.2%) 
0 (0.0%) 
 
4 (3.6%) 
1 (0.9%) 
Other abnormalities 
Non-specific white matter 
lesions 
Pineal cyst 
Mid-brain low grade 
astrocytoma 
Vascular loops pressing on 
facial and/or 
glossopharyngeal nerve 
Mature ischaemic strokes 
Cortical dysplasia 
Chronic sinus thrombosis 
 
10 (16.1%) 
0 (0.0%) 
0 (0.0%) 
1 (1.6%) 
 
1 (1.6%) 
1 (1.6%) 
0 (0.0%) 
 
13 (18.6%) 
1 (1.4%) 
1 (1.4%) 
1 (1.4%) 
 
3 (4.3%) 
0 (0.0%) 
1 (1.4%) 
 
23 (17.4%) 
1 (0.8%) 
1 (0.8%) 
2 (1.5%) 
 
4 (3.0%) 
1 (0.8%) 
1 (0.8%) 
Total abnormal 
intracranial appearances 
16 (25.8%) 22 (31.4%) 38 (28.8%) 
 
MRI: magnetic resonance imaging; SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic 
symptoms; SUNCT: short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing 
 
 
2.4.17. Clinical predictors for SUNA or SUNCT 
 
Table 26 outlines the results of the unadjusted univariate logistic regression analysis for 
different demographic and clinical predictors for a diagnosis of SUNCT or SUNA. The clinical 
features were selected from the current diagnostic criteria for SUNCT and SUNA and from 
characteristics that were deemed clinically relevant according to our study. Female gender was 
significantly associated with SUNA [OR: 1.02 (95%CI: 1.02, 4.32), p=0.043]. The only clinical 
predictor for SUNCT rather than SUNA was the presence of ipsilateral ptosis during headache 
attacks [OR: 3.2 (95%CI: 1.51, 6.74), p=0.002]. A backward regression model was then applied 
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to the two cohorts and those variables that were thought to be clinically relevant were selected 
(Table 27). A multivariate logistic regression analysis on these variables, adjusted for age of 
onset of the headache and gender, confirmed the significant link between ptosis and SUNCT 
and also highlighted the association between ipsilateral rhinorrhoea and SUNCT [OR: 2.42 
(95% CI: 1.09, 5.41), p=0.034]. The link between female gender and SUNA was not confirmed 
to be relevant. 
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Table 26. Unadjusted logistic regression analysis outlining demographic and clinical 
predictors for SUNCT compared to SUNA syndrome. 
 
 
SUNCT SUNA 
p-value Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Gender; female versus male 0.46 (0.23, 0.98) 2.11 (1.02, 4.32) 0.043 
Age of onset 0.98 (0.96, 1.01) 1.01 (0.99, 1.03) 0.263 
Side of pain; 
Right 
Left 
Alternating/Bilateral 
 
Ref 
1.09 (0.52, 2.3) 
1.33 (0.47, 3.75) 
 
Ref 
0.92 (0.44, 1.92) 
0.75 (0.27, 2.11) 
 
 
0.820 
0.588 
Site of pain; 
V1 versus not V1 
V2 versus not V2 
V3 versus not V3 
Extra-trigeminal versus not 
 
 2.12 (0.78, 5.78) 
0.77 (0.35, 1.70) 
0.70 (0.34, 1.44) 
0.88 (0.38, 2.01) 
 
 
0.47 (0.17, 1.29) 
1.30 (0.59, 2.88) 
1.44 (0.69, 2.98) 
1.14 (0.50, 2.63) 
 
 
 
0.142 
0.512 
0.329 
0.754 
Quality of pain; 
Stabbing versus not 
Sharp versus not 
Electric versus not 
Shooting versus not 
Burning versus not 
Throbbing versus not 
 
 
0.93 (0.38, 2.25) 
0.99 (0.49, 1.98) 
1.11 (0.54, 2.27) 
1.24 (0.59, 2.63) 
1.08 (0.44, 2.61) 
1.00 (0.38, 2.65) 
 
 
 
1.08 (0.44, 2.61) 
1.01 (0.51, 2.03) 
0.90 (0.44, 1.84) 
0.81 (0.38, 1.71) 
0.93 (0.38, 2.25) 
1.00 (0.38, 2.65) 
 
 
0.868 
0.970 
0.773 
0.574 
0.868 
1.000 
Duration attacks; 
<1 min 
1-2 min 
2-3 min 
3-4 min 
4-5 min 
>5 min 
 
Ref 
1.36 (0.49, 3.84) 
1.17 (0.36, 3.83) 
3.0 (0.30, 30.30) 
0.75 (0.24, 2.4) 
1.5 (0.48, 4.68) 
 
Ref 
0.73 (0.26, 2.03) 
0.85 (0.26, 2.81) 
0.33 (0.03, 3.37) 
1.33 (0.42, 4.25) 
0.67 (0.21, 2.10) 
 
0.849 
Attacks per day 
1-10 attacks/day 
12-25 attacks/day 
30-60 attacks/day 
>60 attacks/day 
 
Ref 
1.32 (0.51, 3.43) 
2.59 (1.01, 6.62) 
2.0 (0.76, 6.25) 
 
Ref 
0.67 (0.29, 1.98) 
0.39 (0.15, 0.98) 
0.5 (0.19, 1.31) 
 
0.185 
Cranial autonomic symptoms: 
 
Ptosis; yes versus not 
Eyelid oedema; yes versus not 
Blocked nose; yes versus not 
Rhinorrhoea; yes versus not 
Facial flushing; yes versus not 
Facial sweating; yes versus not 
Fullness of ear; yes versus not 
 
 
3.2 (1.51, 6.74) 
2.2 (0.88, 5.53) 
1.33 (0.66, 2.71) 
1.97 (0.98, 3.97) 
0.83 (0.43, 1.65) 
0.99 (0.47, 2.05) 
1.64 (0.66, 4.10) 
 
 
 
0.31 (0.15, 0.66) 
0.45 (0.18, 1.14) 
0.75 (0.37, 1.52) 
0.51 (0.25, 1.02) 
1.21 (0.61, 2.40) 
1.01 (0.49, 2.11) 
0.61 (0.25, 1.51) 
 
 
0.002 
0.092 
0.427 
0.057 
0.593 
0.969 
0.288 
Behaviour; restless versus still 0.99 (0.47, 2.10) 1.01 (0.45, 2.12) 0.984 
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Type of attack; 
Spontaneous and triggered 
Spontaneous only 
Triggered only 
 
Ref 
0.54 (0.27, 1.10) 
1.06 (0.17, 6.70) 
 
Ref 
1.85 (0.91, 3.77) 
0.95 (0.15, 6.00) 
 
 
0.090 
0.953 
Headache pattern; 
Chronic 
Episodic 
 
Ref 
1.50 (0.15, 4.84) 
 
 
0.67 (0.21, 2.16) 
 
 
0.500 
 
CI: confidence interval; C2/3: second and third cervical roots territories; Ref: reference; *P<0.05; SUNA: short-
lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: short-lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing; V1: ophthalmic trigeminal territory; V2: 
maxillary trigeminal territory; V3: mandibular trigeminal territory 
 
 
Table 27. Multivariate logistic regression analysis adjusted for demographic and clinical 
variables considered potentially different between SUNCT and SUNA 
 
 SUNCT SUNA 
p-value 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Gender; female versus male 
0.70 (0.32, 1.55) 1.43 (0.65, 3.20) 0.378 
Cranial autonomic symptoms: 
Ptosis; yes versus not 
Rhinorrhoea; yes versus not 
 
3.37 (1.50, 7.66) 
2.42 (1.09, 5.41) 
 
 
 
0.30 (0.13, 0.67) 
0.41 (0.18, 0.92) 
 
 
<0.0001 
0.034 
Type of attack; 
Spontaneous only 
 
 
0.50 (0.23, 1.08) 
 
 
2.02 (0.92, 4.40) 
 
0.078 
     
Ref: reference; *p<0.05; SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic 
symptoms; SUNCT: short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing 
 
 
2.5.  Discussion 
We report the first substantial case series of SUNA, characterising the demographic, clinical 
and radiological features of this rare syndrome. Hitherto, only a small series and a few case 
reports of SUNA have been reported and it has therefore not been possible to fully characterise 
this syndrome (Cohen , et al., 2006; Williams , et al., 2008; Lambru , et al., 2012; Chitsantikul , 
et al., 2013). Furthermore, we have conducted a comprehensive comparison between this case 
series of SUNA and the largest cohort of SUNCT described thus far. This study demonstrates 
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that there are no major clinical differences between SUNCT and SUNA, bar the fact that 
SUNCT is characterised by more prominent cranial autonomic features, which is likely to 
merely reflect differing degrees of autonomic symptomatology rather than any real biological 
diversity between the two conditions.  
 
2.5.1. Demographic and clinical features of SUNA and SUNCT  
2.5.1.1. Gender and Age 
There is a female preponderance in our cohorts of SUNA and SUNCT, which is less 
pronounced in SUNCT, although this difference did not reach statistical significance. The 
female preponderance in SUNA confirms the preliminary findings reported in a small group of 
SUNA patients by Cohen et al (M:F=0.5:1) (Cohen , et al., 2006). However, the absence of a 
male preponderance in SUNCT challenges the traditional concept of SUNCT being considered 
a syndrome with a male preponderance (Pareja , et al., 1997; Cohen , et al., 2006). In this 
respect, it is interesting to observe that there has been a decrease in male:female ratio in cluster 
headache over time with the description of larger case series (Manzoni , 1998). The mean age 
of onset of SUNA and SUNCT is centred on the fifth decade. Overall, our demographic 
findings in SUNCT and SUNA suggest a demographic overlap with TN, with similar age of 
onset and a gender distribution (Katusic , et al., 1990).  
 
2.5.1.2. Laterality of pain 
Attacks of SUNA and SUNCT are typically strictly unilateral and side-locked with the 
exception of a small proportion of patients in whom attacks are strictly unilateral but side 
alternating. There is a preponderance for right sided attacks, which has also been reported in 
the other TACs and TN. One patient with SUNA has occasionally had bilateral attacks. The 
occurrence of bilateral attacks has been described in three cases of SUNCT (Zidverc-
Trajkovic , et al., 2009; Bichuetti , et al., 2006; Kuhn , et al., 2005). In two cases, an underlying 
abnormality with a probable causal relationship was found, whereas in another case no brain 
abnormalities were identified, so the condition was considered idiopathic. Our case is the first 
idiopathic SUNA case with bilateral attacks and normal MRI study.  
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2.5.1.3. Site of pain 
The majority of the patients with SUNA and SUNCT have pain centred on the ophthalmic and 
maxillary trigeminal territory though the pain also radiated to the mandibular trigeminal 
territory and extra-trigeminal (cervical) distribution in a significant minority of patients. Extra-
trigeminal territory pain (C2-C3) was reported in 14 SUNA (22.2%) and 14 SUNCT (20.0%) 
patients (p=0.753). One SUNCT and one SUNA patient experienced the pain exclusively in 
the C2-C3 regions. Extra-trigeminal location of the painful headache episodes is not mentioned 
in the IHS criteria for any of the TACs and may lead to a different diagnosis, including occipital 
neuralgia. However, the SUNCT patient reported profuse ipsilateral lacrimation and 
conjunctival injection during the attacks, which makes the diagnosis of occipital neuralgia 
unlikely. The SUNA patient experienced retroauricular painful paroxysmal attacks associated 
with redness and sweating of the face, did not respond to GONB but responding transiently to 
IV lidocaine. Atypical location of the headache has been reported in other TACs. Boes and 
colleagues described two cases of paroxysmal hemicrania presenting as paroxysmal episodes 
of otalgia, suggesting that cervical painful input may activate the parasympathetic arm of the 
trigeminal-autonomic reflex, without provoking pain perception in the trigeminal territories 
(Boes , et al., 1998).  
 
2.5.1.4. Severity and quality of pain 
The pain of SUNA and SUNCT is usually very severe, thereby highlighting the devastating 
morbidity associated with these syndromes. The most commonly described pain qualities in 
both SUNA and SUNCT were stabbing, sharp, electric-shock like and shooting, reflecting the 
neuralgiform character of these syndromes. Though ICHD-II criteria required pulsating pain, 
this pain quality was relatively rare in our cohort. In line with our observations, the ICHD-III 
criteria removed the pulsating quality of the pain in SUNCT and SUNA. 
 
2.5.1.5. Duration, frequency and temporal profile of attacks 
In our cohorts of SUNCT and SUNA, all patients had an attack duration ranging from 1-900 
seconds while 98.5% had an attack duration ranging between 1-600 seconds. ICHD-II specified 
attack duration of 5-240 seconds for SUNCT and 2-600 seconds for SUNA, while ICHD-III 
requires attack duration of 1-600 seconds for both SUNA and SUNCT. It seems reasonable to 
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retain the attack duration criteria of 1-600 seconds in future classification criteria to avoid 
inclusion of longer lasting TACs. We found that attacks may take on different profiles 
including single stabs, repetitive stabs, serrated stabs and plateau-like attacks in both SUNA 
and SUNCT.  
 
In our cohorts, there was a wide variation in the attack frequency in both SUNA and SUNCT, 
ranging between few attacks per week and several hundred daily. ICHD-2 required an attack 
frequency of 3-200 daily for SUNCT and >1 daily for more than half of the time for SUNA. 
ICHD-3 specifies an attack frequency of at least one daily for more than half of the time when 
the disorder is active. Given the wide variation in attack frequency in these syndromes, the 
criterion specifying attack frequency is unhelpful and relatively meaningless. Removing this 
criterion will help simplify the diagnostic classification. 
 
2.5.1.6. Cranial autonomic symptoms 
Our study showed that patients reporting both conjunctival injection and lacrimation (SUNCT) 
are more likely to display a broader and more prominent array of autonomic features during an 
attack, as opposed to those experiencing either one of these features alone or none (SUNA). In 
addition, our data are in keeping with the suggestion that a stronger degree of activation of the 
facial parasympathetic pathway is more often associated with the occurrence of ocular 
sympathetic deficit (Drummond , 1988), explaining the more frequent occurrence of ptosis in 
SUNCT compared to SUNA. In view of the absence of any other significant differences in 
demographic, clinical and radiological characteristics, these differences are likely to reflect 
differing degrees of autonomic symptomatology rather than any real biological diversity 
between the two conditions. The degree of cranial autonomic symptomatology displayed by 
these two entities likely lies on a spectrum, with more prominent symptoms in SUNCT and 
less prominent symptoms in SUNA. 
 
2.5.1.7. Triggers and Refractory Period 
One of the most important clinical differences between SUNCT and SUNA versus the other 
TACs is the presence of attacks triggered by cutaneous/intraoral stimulation in the former. In 
our cohorts, the majority of patients with SUNA and SUNCT had triggered attacks. The most 
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prominent triggers were cutaneous and intraoral stimulation ipsilateral to the pain. These 
triggers are similar to the ones historically associated with TN painful exacerbations. Unlike 
TN, there was a general lack of refractory period between attacks in the vast majority of SUNA 
and SUNCT. This could serve as a good clinical feature to distinguish TN from SUNA and 
SUNCT. However, establishing the presence of a refractory period can be challenging in a 
clinical setting and despite several attempts to retrieve this clinical information accurately some 
patients may not be able to be certain about the presence of a refractory period. Furthermore, 
five patients in our cohort did experience a refractory period lasting a few minutes after 
triggered attacks, similarly to other three cases previously described in the literature (Paliwal , 
et al., 2012). These cases suggest that the presence of a refractory period by itself is not 
sufficient to discriminate between TN and SUNCT. Pathophysiological mechanisms 
responsible for the presence or absence of refractory periods may be shared between these two 
conditions and at times overlap.  
 
2.5.1.8.  Behaviour 
Agitation and restlessness during attacks are clinical hallmarks of CH and to a lesser degree of 
PH (Bahra, et al., 2002; Cittadini , et al., 2008). A recent prospective study reported restlessness 
during attacks in 62% of SUNCT and 56% of SUNA patients (Cohen , et al., 2006). Our data 
suggests that the vast majority of SUNA and SUNCT patients preferred to stay still during 
attacks, which they mainly attributed to triggerability of the attacks by movement. 
 
2.5.1.9. Interictal pain  
Interictal background pain is traditionally thought not to be associated with SUNCT. However, 
Matharu and collaborators highlighted the presence of continuous and intermittent discomfort 
in a few SUNCT cases while in a recent series of SUNCT and SUNA patients, interictal pain 
was found in 47% and 22% respectively (Matharu , et al., 2003; Cohen , et al., 2006). We have 
described the interictal background pain reported by a significant proportion of SUNA and 
SUNCT patients. Similar to TN with concomitant pain (Obermann , et al., 2007), in SUNCT 
and SUNA the development of a persistent background pain seems not to be related to the 
duration of the disorder, since most patients reported simultaneous onset of stabbing and 
interictal pains. The chronic ab initio pattern along with the high load of attacks displayed by 
most SUNCT and SUNA patients might account for the development of a background pain at 
 138 
early stages. Moreover, given the high prevalence of migraine in our SUNCT and SUNA group, 
it could be postulated that the susceptibility to a central nervous system disorder such as 
migraine, facilitates the occurrence of central sensitization and in turn the simultaneous 
occurrence of both the paroxysmal and the constant background pains in SUNCT and SUNA.  
 
2.5.2. New proposed diagnostic criteria  
On the basis of the direct comparison of the clinical phenotype of SUNA and SUNCT, we 
propose that the distinction between these two syndromes be abandoned and that they be placed 
under a single diagnostic category named SUNA. This nomenclature would allow the wide 
array of autonomic features that can accompany the headaches to be considered. ICHD-3 
encompasses SUNCT and SUNA under the category of “short-lasting unilateral neuralgiform 
headache attacks” but this term would be a misnomer as it potentially also describes TN and 
does not highlight the autonomic features which are central for the diagnosis of SUNCT and 
SUNA. 
 
Of the 70 SUNCT patients, only three (4.3%) satisfied the ICHD-2 diagnostic criteria. The 
main reasons for failing to fulfil these criteria can be found in the limited array for cranial 
autonomic symptomatology allowed; the location of the pain, which is confined to V1 and the 
temple; and, the frequency and duration of the attacks, which can be longer than stated in the 
criterion B. According to our data, the ICDH-3 diagnostic criteria for SUNCT have improved 
upon the previous version, particularly by extending the site of the pain to the three trigeminal 
divisions, increasing the array of cranial autonomic features and the range of attack duration. 
These changes have been reflected in the higher number of SUNCT patients who fulfilled the 
ICDH-3  diagnostic criteria (N=35; 50%). However, the updated criteria do not account for 
pain in non-trigeminal locations and for the plateau-like profiles, which were reported by a few 
patients in our cohort (Figure 13).  
 
Of the 63 SUNA patients, 15 (23.8%) satisfied the ICHD-2. The higher proportion of patients 
fulfilling these diagnostic criteria reflects the broader array of cranial autonomic symptoms and 
the longer duration of attacks allowed for SUNA. The ICHD-3 diagnostic criteria for SUNA 
were met by 35 patients (55.6%), which is a similar proportion to the one found in SUNCT 
patients (Figure 14). 
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he diagnostic yield of the criteria can be refined further. ICHD-3 specifies that patients 
should have attacks occurring as single stabs, series of stabs or in a saw-tooth pattern. However, 
some patients have a plateau-type pain profile without having any of the profiles mentioned in 
the criteria. We propose that instead of a criterion based on pain temporal profile, a criterion 
on the quality of pain (stabbing, sharp, electric-shock like, shooting) is more meaningful and 
better captures the neuralgiform character of the pain. ICHD-3 specifies an attack frequency 
of at least one daily for more than half of the time when the disorder is active. Given the wide 
variation in attack frequency in these syndromes, the criterion specifying attack frequency is 
unhelpful. Removing this criterion will help simplify the diagnostic classification.  
Furthermore, triggering by innocuous stimuli to the affected side of the face with the lack of 
refractory period is a key feature of these syndromes and merits inclusion in the diagnostic 
criteria. On the basis of these considerations, we propose a set of new diagnostic criteria for 
this single unified entity, SUNA (Table 28). These criteria, applied to our cohort, correctly 
diagnosed all the patients, but two, who reported an average attacks duration of 900 seconds.  
 
This study has some limitations. The duration and frequency of occurrence of the headache 
attacks were subjectively estimated by the patients and only seldom objectively measured. 
However, in view of the variable duration of the attacks and often the multiple number of daily 
attacks, it is difficult to ask patients to produce headache-specific diaries and headache diaries 
used for other conditions (migraine and CH) may not be entirely appropriate to SUNCT and 
SUNA.  
 
2.6. Conclusion 
The demographic and clinical characteristics of SUNA have been detailed and refined. The 
clinical phenotype of SUNA did not differ significantly from SUNCT, apart from a different 
degree of activation of the parasympathetic system and dysfunction of the ocular sympathetic 
system, possibly due to the different number of autonomic features set up for SUNCT and 
SUNA in their diagnostic criteria. Based on our data, SUNCT and SUNA could be considered 
as a single clinical entity under the name SUNA, a term that highlights the occurrence of a 
broad array of cranial autonomic features besides conjunctival injection and lacrimation. The 
diagnostic criteria of this unified entity, SUNA, have been proposed.  
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Moreover, the demographic, clinical and pathophysiological overlap between SUNCT, SUNA 
and TN supported by our data, may challenge the traditional view that consider them separate 
disorders. SUNCT, SUNA and TN may constitute a continuum of the same disorder. This 
unifying hypothesis carries important nosological implications on whether SUNCT and SUNA 
should belong to the TACs or the cranial neuralgias group.   
 
 
Figure 13. Comparison of ICHD-2 and ICHD-3 diagnostic criteria in our cohort of SUNCT 
patients 
 
 
  SUNCT cohort 
(N= 70) 
 
Failed to satisfy ICHD-2 criteria for SUNCT  
(N=67; 95.7%) 
 
Reason for exclusion: 
- Cranial autonomic features: 66 
  Site of pain: 35 
  Attack duration: 3 
  Attack frequency: 1  
  Attack duration and site of pain: 12 
  Attack frequency and site of pain: 1 
  Attack frequency and site of pain and attack duration: 1 
- Attack duration and site of pain: 1 
 
Satisfied ICHD-2 criteria for SUNCT 
(N= 3; 4.3%) 
 
Failed to satisfy ICHD-3β criteria for 
SUNCT  
(N=35; 50%) 
 
Reason for exclusion: 
- Site of pain: 14 
- Attack profile: 19 
- Attack duration: 1 
- Site of the pain and attack profile: 1 
 
  
   
Satisfied ICHD-3β criteria for SUNCT 
(N= 35; 50%) 
 
ICHD-2 
Diagnostic criteria 
 
 
ICHD-3 
Diagnostic criteria 
 
 

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Figure 14. Comparison of ICHD-2 and ICHD-3 diagnostic criteria in our cohort of SUNA 
patients 
 
 
 
 
 
 
 
 
 
 
ICHD, International classification for headache disorders; SUNA, Short-lasting unilateral headache attacks with 
autonomic symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUNA cohort 
(N= 63) 
 
Failed to satisfy ICHD-2 criteria for SUNCT  
(N=48; 76.2%) 
 
Reason for exclusion: 
- Cranial autonomic features: 7 
- Site of pain: 7 
- CAF and site of the pain: 29 
- Attack duration and CAF: 1 
- Refractory period + CAF + site of the pain: 2 
- Attack duration + CAF+ site of the pain: 2 
  
 
Satisfied ICHD-2 criteria for SUNCT 
(N= 15; 23.8%) 
 
Failed to satisfy ICHD-3β criteria for SUNCT  
(N=28; 44.4%) 
 
Reason for exclusion: 
- Site of the pain: 9 
- Attack profile: 13 
- Site of the pain and attack profile: 4 
- Attack profile and attack duration: 1 
- Site of the pain and attack profile and attack duration: 
1 
 
  
Satisfied ICHD-3β criteria for SUNCT 
(N= 35; 55.6%) 
 
ICHD-2 
Diagnostic criteria 
 
 
ICHD-3 
Diagnostic criteria 
 
 

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Table 28. Proposed criteria for unified diagnosis of SUNA 
 
A. A. At least 20 attacks of unilateral head pain fulfilling criteria B–E 
 
B. B. Occurring in the first division of the trigeminal nerve, with possible radiation to the 
second and third divisions of the trigeminal nerve and with possible radiation beyond    
the trigeminal distribution 
 
C. C. Pain has at least three of the following five characteristics: 
1. 1. Attacks lasting 1-600 seconds 
2. 2. Moderate or severe intensity 
3. 3. Stabbing, sharp, electric shock-like or shooting in quality 
4. 4. Precipitated by innocuous stimuli to the affected side of the face 
5. 5. No refractory period follows attacks triggered by innocuous stimuli to the affected side 
of the face or head 
 
D. D. At least one of the following cranial autonomic symptoms or signs, ipsilateral to the 
pain: 
1. 1. Conjunctival injection and/or lacrimation 
2. 2. Nasal congestion and/or rhinorrhoea 
3. 3. Miosis and/or ptosis 
4. 4. Eyelid oedema 
5. 5. Forehead and facial sweating 
6. 6. Forehead and facial flushing  
7. 7. Sensation of fullness in the ear  
 
E. E. Not better accounted for by another ICHD-3 diagnosis 
 
SUNA, Short-lasting neuralgiform headache attacks with autonomic symptoms; ICHD-3, International 
classification of headache disorders
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Chapter 3.  Trigeminal Neurovascular Contact in SUNCT and SUNA: 
A Prospective Structural Magnetic Resonance Study 
 
3.1. Abstract 
Emerging data points towards a possible pathophysiological and therapeutic relevance 
of trigeminal NVC in SUNCT and perhaps in SUNA, similarly to TN. The aim of this 
study was to assess the prevalence and significance of trigeminal NVC in a large cohort 
of SUNCT and SUNA. MRI examinations were performed to consecutive SUNCT and 
SUNA patients. The standard imaging protocol included high spatial and nerve-cistern 
contrast resolution imaging acquisitions of the cisternal segments of the trigeminal 
nerves and vessels. MRI studies were evaluated blindly and graded according to the 
presence, location and degree of neurovascular contact. The degree of contact was 
graded as: simple contact, distortion or atrophy. Severe neurovascular contact was 
defined as contact with distortion and/or atrophy.  
 
Seventy-nine patients (53.7%) (45 SUNCT; 34 SUNA) were included. A total of 82 
symptomatic trigeminal nerves (47 in the SUNCT group and 35 in the SUNA group) 
and a total of 76 asymptomatic trigeminal nerves (43 in the SUNCT group and 33 in 
the SUNA group) were analysed. In the SUNCT and SUNA cohorts, the prevalence of 
neurovascular contact on the symptomatic trigeminal nerves was higher (57.3%; 
n=47/82) than the prevalence of neurovascular contact on the asymptomatic trigeminal 
nerves (25%; n=19/76) (P≤0.001). Severe neurovascular contacts were considerably 
more prevalent on the symptomatic side (47.6%; n=39/82), compared to the 
asymptomatic side (11.8%, n=9/76) (P≤0.001). In SUNCT, severe neurovascular 
contacts were considerably more prevalent on the symptomatic compared to the 
asymptomatic nerves [53.2% versus 14.0%, OR: 4.16 (95%CI: 2.55, 20.02) P≤0.001]. 
In SUNA, severe neurovascular contacts were considerably more prevalent on the 
symptomatic compared to the asymptomatic nerves [42.9% versus 12.1%, OR: 3.75 
(95%CI: 2.78, 34.96), P=0.005]. There was no statistically significant difference in the 
proportion of neurovascular contacts on the symptomatic nerves between SUNCT 
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[29/47 (61.7%)] and SUNA [20/35 (57.1%)] (P=0.67). Similarly, there was no 
statistically significant difference in the proportion of severe neurovascular conflict 
between SUNCT and SUNA [25/47 (53.2%) versus 15/35 (42.9%)] (P=0.35)]. The 
analysis of radiological predictors associated with the symptomatic side, indicated that 
the presence of a vascular contact and its location at the root entry zone were strong 
predictors for the nerve to be symptomatic rather than asymptomatic. These findings 
support the aetiological importance of trigeminal neurovascular contact in SUNCT and 
SUNA, further expanding their overlap with TN. The therapeutic relevance of this 
novel findings will be discussed in Chapter 5. 
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3.2. Introduction 
 
SUNCT and SUNA are encompassed within the TACs’ group in view of the presence 
of overlapping clinical characteristics, namely unilateral pain in the ophthalmic 
trigeminal distribution and the prominent cranial autonomic symptomatology. 
Furthermore, functional neuroimaging findings during SUNCT attacks suggest a 
pivotal role of the posterior hypothalamus in SUNCT and possibly SUNA, similarly to 
the other TACs (Cohen, 2007). However, the significance of ictal hypothalamic 
activation is currently unknown. The broad demographic and clinical overlap as well 
as the similar response to medical management between SUNCT, SUNA and TN, has 
led to growing interest in exploring the presence of shared pathophysiological 
mechanisms as the basis of these similarities. The effect of vascular loops in contact 
with the trigeminal nerve ipsilaterally to the side of the pain is thought to constitute one 
of the pivotal pain mechanisms in TN. This finding is seen in about 47–90 % of TN 
cases and the vascular compression often occurs at the region of the root entry zone 
(REZ) (Love , et al., 2001). The pathophysiological importance of the trigeminal 
neurovascular conflict (NVC) is corroborated by the long-term efficacy of trigeminal 
microvascular decompression procedure, which is the gold standard surgical approach 
in TN (Barker , et al., 1996).  
 
A meta-analysis of MRI studies showed that NVC on the symptomatic side is strongly 
linked with TN (88.7%) compared to the control nerves (35.8%) (OR = 16.6; 95% CI 
= 11.8–23.3; P < .0001). Similarly, NVC at the root entry zone (REZ) (REZ was defined 
as the proximal 6-mm segment of the nerve adjacent to the pontine belly) on 
symptomatic nerves were predictive for TN compared to those on asymptomatic nerves 
(OR = 14.7; 95% CI = 8.3–25.8; P < .0001). Conversely there was no significant 
difference between non-REZ NVC on symptomatic and asymptomatic nerves (OR = 
0.8; 95% CI = 0.4–1.7) (P = .58) (Antonini , et al., 2014). A recent study conducted in 
135 TN patients aimed to assess the degree of contact, localization (REZ or distal) and 
type of blood vessel (artery or vein) using a 3 Tesla (T) MRI scanning protocol. The 
authors found that 70% of patients had bilateral neurovascular contact. However 
neurovascular contact on the symptomatic (89%) was more prevalent compared to the 
asymptomatic side (78%) (P = 0.014). ‘Severe neurovascular contact’ was defined as a 
neurovascular contact with displacement or atrophy of the nerve. Severe neurovascular 
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contacts were considerably more prevalent on the symptomatic compared to the 
asymptomatic side (53% versus 13%) (p<0.001). Prevalence of neurovascular contact 
in the REZ was similar on the symptomatic and asymptomatic side (81% versus 70%, 
P = 0.1), but neurovascular contact involving an artery was more prevalent on the 
symptomatic side (74% versus 56%, P = 0.001). The authors concluded that the 
presence itself of any type of trigeminal NVC was not specific for classical TN as they 
were highly prevalent on both the symptomatic and the asymptomatic side. However, 
in view of the strong association between a severe NVC and the symptomatic side, a 
severe neurovascular contact could be considered a major aetiological factor in TN, 
unlike a non-severe NVC on the symptomatic (Maarbjerg , et al., 2015). These findings 
suggest that although trigeminal NVC is of great importance in the pathophysiology of 
TN, other unknown mechanisms may play a role.   
 
Emerging data points towards a possible pathophysiological and therapeutic relevance 
of trigeminal NVC also in SUNCT and perhaps in SUNA. Several case reports of 
trigeminal NVC on the symptomatic side in subjects with SUNCT have been described 
(Table 29). Amongst the more recent case series of SUNCT and SUNA patients, only 
in one study, dedicated views of the trigeminal nerves were obtained (Williams , et al., 
2008). In this case series where dedicated fine cut constructive interference steady state 
(CISS) images of the trigeminal nerves were obtained, 15/17 (88%) patients with 
SUNCT showed an arterial loop. Blinded analysis of the symptomatic versus 
asymptomatic side indicated that 90% of these vessels were contacting the symptomatic 
trigeminal nerve, while only 7% were contacting the asymptomatic nerve (Williams 
and Broadley, 2008). Other series have found a much lower incidence of aberrant 
vessels (2–8%), but in one of these series, dedicated views of the trigeminal nerve were 
not obtained (Matharu, MS; personal communication) and the other was a literature 
review of cases in whom for the vast majority such images were similarly not obtained 
(Cohen , et al., 2006; Matharu , et al., 2003) (Table 30).  
 
In view of these results coming from case reports and small case series, we assess in 
this chapter the prevalence and the significance of trigeminal NVC in a large cohort of 
SUNCT and SUNA. 
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   Table 29. Neurovascular conflict in SUNCT and SUNA patients: case reports 
 
 
Age of 
onset/Sex 
Diagnosis 
Pain 
laterality 
NVC 
Ertsey et al. 2000  - 68/M - SUNCT - R - SCA 
(Gardella , et al., 
2001) 
- 43/F - SUNCT - R - SCA 
(Köseoglu , et al., 
2005) 
- 48/M - SUNCT - L - AICA 
(Lagares , et al., 
2005) 
- 54/F - SUNCT - L - SCA 
(Sprenger , et al., 
2005) 
- 47/M - SUNCT - R - SCA 
(Zidverc-Trajkovic 
, et al., 2005) 
- 68/M - SUNCT - L - VA 
(Jacob , et al., 
2008) 
- 29/M - SUNA - R - VL 
(Guerreiro , et al., 
2009) 
- 57/M - SUNCT - L - SCA 
(Irimia , et al., 
2010) 
- 54/M - SUNCT - L - SCA 
(Maggioni , et al., 
2010) 
- 40/F - SUNCT - R - Artery 
(Bartsch , et al., 
2011) 
- 67/M - SUNCT - R - SCA 
(Chaila , et al., 
2011) 
- 45/M - SUNCT - L - SCA 
(Paliwal , et al., 
2012)  
- 60/M 
- 55/M 
- 64/M 
- SUNCT 
- SUNCT 
- SUNCT 
- R 
- R 
- R 
- VL 
- SCA 
- SCA 
(Rinaldi , et al., 
2013) 
- 60/F - SUNA - R - SCA 
(Lambru , et al., 
2015) 
- 43/M 
- 33/F 
- SUNA 
- SUNCT 
- R 
- R 
- SCA 
- Arterial 
 
SUNCT: short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing;; 
SUNA: short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms; M: 
male; NVC: neurovascular conflict; F: female; L: left; R: right; AICA: anterior inferior cerebellar 
artery; SCA: superior cerebellar artery; VA: vertebral artery; VL: vascular loop 
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Table 30. Neurovascular conflict in SUNCT and SUNA patients: case series 
 
 
Age of 
onset/Sex 
Diagnosis 
Pain 
laterality 
NVC 
(Cohen , et al., 
2006)  
(Total=52) 
- N/A 
- N/A 
- N/A 
- SUNCT 
- SUNCT 
- SUNCT  
- Unilateral 
- Unilateral 
- Bilateral 
- VL 
- Bilateral VL 
- VL 
(Williams , et al., 
2008) (Total= 17) 
- 43/F 
- 53/M 
- 46/F 
- 47/F 
- 17/F 
- 46/F 
- 19/F 
- 58/M 
- 19/M 
- 55/M 
- 65/F 
- 58/M 
- 32/F 
- 54/M 
- 54/M 
- SUNCT 
- SUNCT 
- SUNCT 
- SUNCT 
- SUNCT 
- SUNA 
- SUNCT 
- SUNA 
- SUNCT 
- SUNA 
- SUNCT 
- SUNA 
- SUNCT 
- SUNA 
- SUNCT 
- Bilateral 
- L 
- R 
- R/L 
- Bilateral 
- L 
- L 
- R 
- L 
- R 
- R 
- L 
- R 
- L 
- L 
- Bilateral SCA 
- AICA + V 
- SCA 
- Bilateral A 
- Bilateral A 
- AICA + V 
- A 
- SCA + V 
- SCA 
- SCA 
- SCA 
- A 
- Bilateral A 
- SCA 
- A 
(Cação , et al., 
2016) (Total=15) 
- 50/F 
- 48/M 
- 32/M 
- 57/F 
- SUNCT 
- SUNCT 
- SUNCT 
- SUNCT 
- L 
- R 
- R 
- L 
- NVC 
- NVC 
- NVC 
- NVC 
  
A: artery; AICA: anterior inferior cerebellar artery; F: female; M: male; NVC: neurovascular conflict; 
L: left; R: right; SCA: superior cerebellar artery; SUNCT: short-lasting unilateral neuralgiform headache 
attacks with conjunctival injection and tearing; SUNA: short-lasting unilateral neuralgiform headache 
attacks with cranial autonomic symptoms; V: vein; VL: vascular loop 
 
3.3. Methods 
The study group consisted of 147 patients with SUNCT and SUNA according to the 
ICHD-3𝛃 diagnostic criteria. As part of their assessment, consecutive Magnetic 
Resonance Imaging (MRI) examinations were performed. These images were 
retrospectively reviewed by a consultant neuroradiologist blinded to the diagnosis and 
lateralisation of symptoms. Exclusion criteria were patients with MRI brain without 
high-resolution cisternal imaging, patients with abnormal MRI scans and patients who 
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could not have an MRI brain because of implanted devices (i.e. ONS).  
MRI examinations were performed on a 1.5-Tesla GE Signa Excite (GE Medical 
Systems, Milwaukee), 1.5-Tesla Siemens Avanto (Siemens, Erlangen) or 3.0-Tesla 
Siemens Trio (Siemens, Erlangen) MRI scanner. The standard imaging protocol 
included high spatial and nerve-cistern contrast resolution imaging acquisitions of the 
cisternal segments of the trigeminal nerves and vessels, with 3D Fast Imaging 
Employing Steady-State Acquisition (FIESTA; TE: 1.5ms, TR: 4.9ms, NEX: 4), 3D 
Constructive Interference in Steady State (CISS; TE: 5.3ms, TR: 10.6ms, Excitations: 
1), or 3D Sampling Perfection with Application optimized Contrasts using different flip 
angle Evolution (SPACE; TE: 132ms, TR: 1000ms, Excitations: 2). The slice thickness 
of all examinations ranged from 0.5 mm to 1 mm. High resolution axial and coronal 
T2-weighted sequences through the trigeminal nerves were also obtained with 
acquisitions a slice thickness of 2 mm, in order to assess intrinsic signal hyperintensity. 
When present, Time-Of-Flight Magnetic Resonance Angiography (TOF MRA) was 
used to confirm the location of the cerebellar arteries and veins in close proximity to 
the cisternal segments of the trigeminal nerves on the high-resolution images; high 
signal within vessels on this sequence were considered arteries and the contrary, veins. 
All MRI studies were reviewed and analysed on Coronis high-resolution 3-megapixel 
monitors (Barco Inc, California) on IMPAX 6 Picture Archiving and Communication 
System (AGFA Healthcare NV, Belgium) by the same experienced neuroradiologist 
(I.D.) who was blinded to the diagnosis and the laterality of the headache. Vascular 
contact with the cisternal segments of the trigeminal nerves was assessed on both sides 
on multiplanar reformats of the source high-resolution data. Neurovascular contact was 
defined on the analysis of imaging by no perceptible CSF signal intervening the 
silhouette of the vascular structure (arterial or venous) and the cisternal segment of the 
trigeminal nerve. Contact with the root entry zone (REZ) was the proximal 4 mm of the 
cisternal segment of the trigeminal nerve as it emerged from the pons (De Ridder , et 
al., 2002). 
In addition to the presence or absence of contact and involvement of the REZ, we also 
assessed for the degree of neurovascular contact and type of vessel involved. The 
degree of contact was graded as: simple contact, distortion or atrophy. Distortion was 
defined as indentation or displacement of the trigeminal nerve at the site of the 
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neurovascular contact. Atrophy was defined as reduced volume of the trigeminal nerve 
at the site of the neurovascular contact. Severe neurovascular contact was defined as 
contact with distortion and/or atrophy. MRI studies without high-resolution cisternal 
imaging or which were incomplete or of poor diagnostic quality were excluded. 
The study was approved by Northwick Park Hospital Research Ethics Committee, 
London, UK (REC no:11/LO/1709) 
 
3.3.1. Statistical analysis 
Unadjusted and adjusted multilevel logistic regression models, to account for 
diagnoses, were used to investigate whether presence of vascular contact, degree of 
contact, site of contact within the trigeminal sensory root and type of vessel involved, 
were associated with the symptomatic as opposed to asymptomatic trigeminal nerves 
in SUNA and SUNCT. We used the binomial approximation to the normal distribution 
to compare the proportions between symptomatic and asymptomatic nerves.  
Statistical analyses were performed using ST A T A (Stata Corp. 2001. Stata Statistical 
Software: Version 12.1, College Station, Texas, USA). All reported P-values were two-
sided and a significance level less than 5% was considered significant.  
 
3.4. Results 
Seventy-nine patients (53.7%) had high-resolution cisternal imaging MRI scans 
according to our protocol (45 SUNCT; 34 SUNA). Of the remaining 68 patients, 38 
patients did not have high-resolution cisternal imaging MRI scans due to incorrect MRI 
protocol, 26 had not had trigeminal nerve imaging at our centre and either declined 
further imaging or were not able to have an MRI scan as they had an occipital nerve 
stimulator in situ, three were excluded as they had abnormal MRI scans (mid-brain low 
grade astrocytoma, posterior fossa ischaemic strokes) one declined an MRI scan due to 
claustrophobia.  
 
Of the 79 adequately imaged SUNCT and SUNA patients, 45 had right-sided attacks 
(26 SUNCT; 19 SUNA), 31 had left-sided attacks (17 SUNCT; 14 SUNA) and three 
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had unilateral side-alternating attacks (2 SUNCT; 1 SUNA). A total of 82 symptomatic 
trigeminal nerves, 47 in the SUNCT group and 35 in the SUNA group and a total of 76 
asymptomatic trigeminal nerves, 43 in the SUNCT group and 33 in the SUNA group, 
were analysed.  
 
3.4.1. Neurovascular conflict in the SUNCT and SUNA cohorts 
In the SUNCT and SUNA cohorts, the prevalence of neurovascular contact on the 
symptomatic trigeminal nerves was higher (57.3%; n=47/82), than the prevalence of 
neurovascular contact on the asymptomatic trigeminal nerves (25%; n=19/76) 
(P≤0.001). Severe neurovascular contacts were considerably more prevalent on the 
symptomatic side (47.6%; n=39/82), compared to the asymptomatic side (11.8%, 
n=9/76) (P≤0.001). The prevalence of neurovascular contact within the REZ on the 
symptomatic trigeminal nerves was higher (83.0%; n=39/47) compared to the 
asymptomatic trigeminal nerves (68.4%; n=13/19), but the difference was not 
statistically significant (P=0.19). The vessels involved in neurovascular contact on the 
symptomatic nerves in SUNCT and SUNA were predominantly arteries (76.6%; 
n=36/47) rather than veins (23.4%; n=11/47) (P≤0.001). Similarly, the vessels involved 
in neurovascular contact on the asymptomatic trigeminal nerves in the SUNCT/SUNA 
cohort were predominantly arteries (63.2%; n=12/19). 
 
3.4.2. Neurovascular conflict in the SUNCT cohort 
The presence of trigeminal neurovascular conflict and its characteristics on the 
symptomatic and asymptomatic nerves is outlined in Table 31. There was a 
significantly higher prevalence of neurovascular contact on the symptomatic compared 
to the asymptomatic trigeminal nerves [61.7% versus 23.3%, OR: 5.31, (95%CI: 
2.51,18.55), P≤0.001]. Severe neurovascular contacts were considerably more 
prevalent on the symptomatic compared to the asymptomatic nerves [53.2% versus 
14.0%, OR: 4.16 (95%CI: 2.55, 20.02) P≤0.001]. Neurovascular contact at the REZ 
was more prevalent on the symptomatic compared to the asymptomatic nerves in 
SUNCT. Although arterial contacts were more prevalent than vein contacts, there was 
no statistically significant difference between symptomatic and asymptomatic nerves. 
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Similarly, there was no significant difference in the location of the contacts between 
symptomatic and asymptomatic nerves. 
 
 
 
Table 31. Summary characteristics of trigeminal neurovascular contacts by 
symptomatic and asymptomatic nerves in SUNCT  
  
Symptomatic 
trigeminal nerves 
(n=47) 
Asymptomatic 
trigeminal 
nerves (n=43) 
OR* (95% CI) 
P-
value 
Vascular loop     
Yes 29/47 (61.7%)  10/43 (23.3%) 5.31 (2.51,18.55) ≤0.001 
No 18/47 (38.3%)  33/43 (76.7%) Ref.  
Site of Contact:     
REZ 24/27 (88.9%) 7/10 (70.0%) 6.50 (0.33,13.42) 0.002 
Peripherala 3/27 (11.1%) 3/10 (30.0%) Ref.  
Degree of NVC:     
Severeb 25/47 (53.2%) 6/43 (14.0%) 4.16 (2.55,20.02) ≤0.001 
Simple 4/47 (8.5%) 4/43 (9.3%) Ref  
No contact 18/47 (38.3%) 33/43 (76.7%)   
Type of vessel:     
Artery 20/29 (69.0%) 8/10 (80.0%) 0.90 (0.07, 3.65) 0.857 
Vein 
Missing data 
8/29 (27.6%) 
1/29 (3.4%) 
2/10 (20.0%) 
- 
Ref. 
- 
  
- 
 
*OR comparing the odds of each category on having a symptomatic nerve vs. asymptomatic. 
NCV: neurovascular conflict; Ref: reference; REZ: root entry zone;  
a Defined as >4mm from the site of entry of the trigeminal nerve into the pons 
b Defined as indentation and/or distortion and/or atrophy 
 
3.4.3. Neurovascular conflict in the SUNA cohort 
The presence of a trigeminal neurovascular conflict and its characteristics on the 
symptomatic and asymptomatic nerves is outlined in Table 32. There was a 
significantly higher prevalence of neurovascular contact on the symptomatic compared 
to the asymptomatic trigeminal nerves [57.1% versus 27.3%, OR: 3.55 (95%CI: 
1.82,16.47), P<0.015]. Severe neurovascular contacts were considerably more 
prevalent on the symptomatic compared to the asymptomatic nerves [42.9% versus 
12.1%, OR: 3.75 (95%CI: 2.78, 34.96), P=0.005]. Similarly to SUNCT, the arterial 
contacts were more prevalent than venous contacts; there was no statistically significant 
difference between symptomatic and asymptomatic nerves. Similarly, there was no 
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significant difference in the location of the contacts between symptomatic and 
asymptomatic nerves. 
 
Table 32. Summary characteristics of trigeminal neurovascular contacts by 
symptomatic and asymptomatic nerves in SUNA  
  
Symptomatic 
trigeminal 
nerves (n=35) 
Asymptomatic 
trigeminal 
nerves (n=33) 
OR* (95% CI) 
P-
value 
Vascular loop     
Yes 20/35 (57.1%) 9/33 (27.3%) 3.55 (1.82,16.47)  0.015  
No 15/35 (42.9%) 24/33 (72.7%) Ref.  
Site of Contact   
  
REZ 15/20 (75.0%) 7/9 (77.8%) 1.28 (0.44,18.56) 0.71 
Peripherala 5/20 (25.0%) 2/9 (22.2%) Ref.  
Degree of NVC     
Severeb 15/35 (42.9%) 4/33 (12.1%) 3.75 (2.78,34.96) 0.005 
Simple 5/35 (14.3%) 5/33 (15.2%) 2.42 (0.68,8.68) 0.174 
No contact 15/35 (42.9%) 24/33 (72.7%) Ref.  
Type of vessel     
Artery 14/20 (70.0%) 4/9 (44.4%) 1.30 (0.19-0.81) 0.110 
Vein 6/20 (30.0%) 5/9 (55.5%)    
 
*OR comparing the odds of each category on having a symptomatic nerve vs. asymptomatic. 
NCV: neurovascular conflict; Ref: reference; REZ: root entry zone;  
a Defined as >4mm from the site of entry of the trigeminal nerve into the pons 
b Defined as indentation and/or distortion and/or atrophy 
 
3.4.4. Neurovascular conflict: comparison between SUNCT and 
SUNA cohorts 
There was no statistically significant difference in the proportion of neurovascular 
contacts on the symptomatic nerves between SUNCT [29/47 (61.7%)] and SUNA 
[20/35 (57.1%)] (P=0.67). Similarly, there was no statistically significant difference in 
the proportion of severe neurovascular conflict between SUNCT and SUNA [25/47 
(53.2%) versus 15/35 (42.9%)] (P=0.35)]. The comparison of the other variables 
showed no significant difference between the two cohorts of patients. 
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3.4.5. Analysis of predictors for symptomatic nerves unadjusted and 
adjusted for diagnosis 
 
Table 33 outlines the results of the analysis of radiological predictors associated to the 
symptomatic side, unadjusted and adjusted for the diagnosis of SUNCT and SUNA. 
The estimates of odds ratio indicate that the presence of a vascular contact is a strong 
predictor for the nerve to be symptomatic rather than asymptomatic. Similarly, the 
estimates of odds ratio indicate that the presence of a severe contact at the REZ is 
strongly associated with the nerve being symptomatic rather than asymptomatic.  
 
Table 33. Analysis of radiological predictors for symptomatic compared to 
asymptomatic nerves 
  
Unadjusted 
OR (95%CI) 
Adjusted for diagnosis 
OR (95%CI) 
Vascular loop   
Yes 
4.45 (2.25-8.8) 
p<0.001 
4.45 (2.25-8.8) 
p<0.001 
No Ref  
Site of Contact   
REZ 
3.87 (1.5-9.98) 
p=0.005 
3.81 (1.47-9.98) 
p=0.006 
Peripherala Ref  
Degree of NVC   
Severeb 
4.0 (1.27-12.66) 
p=0.019 
 4.0 (1.23-12.82) 
p=0.021 
Simple Ref  
Type of vessel   
Artery 
1.27 (0.49-3.23) 
p=0.629 
1.27 (0.50-3.26) 
p=0.616 
Vein Ref  
NCV: neurovascular conflict; Ref: reference; REZ: root entry zone;  
a Defined as >4mm from the site of entry of the trigeminal nerve into the pons 
b Defined as indentation and/or distortion and/or atrophy 
 
3.5. Discussion 
This is the first prospective, consecutive blinded MRI study, conducted in a large cohort 
of patients, demonstrating that trigeminal neurovascular contact ipsilaterally to the side 
of the pain is a common neuroanatomical variant in SUNCT and SUNA. The presence 
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of any type of neurovascular contact was significantly more prevalent on the 
symptomatic side compared to the asymptomatic, suggesting that this anatomical 
finding may be contributory to these conditions. There was no significant difference in 
the prevalence of neurovascular contacts between SUNCT and SUNA, enforcing the 
likelihood that the two conditions belong to the same clinical entity. In the vast majority 
of cases, the neurovascular contact was severe and much more prevalent on the 
symptomatic side than on the asymptomatic side. The site of the neurovascular contact 
was predominantly the REZ and was generally caused by an artery in both SUNCT and 
SUNA. We also demonstrated that a severe trigeminal neurovascular contact at the REZ 
is highly associated with the pain side in SUNCT and SUNA. These findings have 
implications in clinical practice, highlighting the importance of MRI scans with 
dedicated trigeminal views to shed light on the aetiology of these disorders and 
potentially for management reasons.  
 
The rate of NVC was lower than that coming from a series of 24 SUNCT and SUNA 
cases, where 17 patients were studied with dedicated MRI imaging of the trigeminal 
nerves. Neurovascular compression was detected in 15 of 17 patients (88%). In 90% of 
cases, a vascular loop was impinging on the symptomatic trigeminal nerve, compared 
to only 7% in which the vascular loop was pressing on the asymptomatic nerve 
(Williams , et al., 2008). The higher prevalence of neurovascular contact in their series 
could be explained by the small size of the sample. Moreover, the authors did not detail 
the scanning protocol and did include in the definition of vascular loop also cases where 
a contact was only observed. It is therefore possible that they overestimated the 
prevalence of vascular loops.  
 
The association between a severe neurovascular contact and the symptomatic side 
raises the possibility that a severe neurovascular contact is an aetiological factor in 
SUNCT and SUNA, similarly to TN. Maarbjerg and colleagues have recently studied 
neurovascular contact in classical TN and reported that there was a high prevalence of 
severe neurovascular contact on the symptomatic (53%) compared to the asymptomatic 
side (13%). It is remarkable that their finding in TN is similar to that of our cohorts of 
SUNA and SUNCT. These findings in SUNA, SUNCT and TN have implications for 
the aetiology of these disorders, suggesting an overlap in the underlying 
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pathophysiological basis of these disorders (Sesso, 2001; Lambru , et al., 2014). 
However, in both our and Maarbjerg et al studies, only about half of the patients 
displayed a severe neurovascular contact on the symptomatic side and since several 
studies in TN patients have shown a high prevalence of neurovascular contacts in non-
TN individuals (Peker , et al., 2006), it could be argued that this neuroanatomical 
finding may not be the only etiologically relevant factor for these disorders. Our data 
suggest that severe neurovascular contacts at the REZ may play an important 
aetiological role in SUNCT and SUNA, similarly to what has been demonstrated in TN 
(Maarbjerg , et al., 2015). Other factors may also play a role in the pathophysiology of 
SUNCT and SUNA. Lambru and colleagues described a co-occurrence between 
SUNCT/SUNA and hemiplegic migraine (HM) in ten subjects. This association raises 
the possibility of a common denominator implicated in the pathogenesis of both 
conditions, with ion channel dysfunction being an attractive hypothesis. It is 
noteworthy that the most effective treatments of SUNCT/SUNA (lamotrigine and 
oxcarbazepine) modulate sodium channel function among others, and that sodium 
channel dysfunction is capable (at least in Familial HM series) of generating hemiplegic 
aura (Lambru , et al., 2012). It is possible that ion channels dysfunction may increase 
susceptibility to the SUNCT/SUNA phenotype and the presence of a neurovascular 
contact in a subgroup of patients may increase vulnerability of the trigeminal nerve to 
trigger factors, allowing precipitation and perpetuation of the condition overtime. 
 
Further evidence that severe neurovascular contact plays a pivotal role in SUNCT and 
SUNA should come from long-term headache freedom after trigeminal microvascular 
decompression (MVD). Initial encouraging evidence from single case reports and a 
small case series suggest that trigeminal MVD in patient with a severe neurovascular 
conflict on the symptomatic nerve could be beneficial in SUNCT and SUNA 
(Sebastian , et al., 2013), though larger studies with longer follow-ups will be required 
to confirm the efficacy of this surgical procedure in these conditions. 
 
3.6. Summary 
This Chapter describes the largest MRI study with dedicated trigeminal sequences in 
SUNCT and SUNA. It demonstrates the important role of neurovascular contact 
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ipsilaterally to the side of the pain, without significant differences between SUNCT and 
SUNA. It supports the possibility that this neuroanatomical finding plays an important 
role in the pathophysiology of SUNCT and SUNA. Along with the clinical similarities 
between SUNCT and SUNA demonstrated in chapter 2, these findings further enforce 
the concept that SUNCT and SUNA should no longer be considered separate entities. 
Furthermore, the radiological overlap with TN along with the initial encouraging results 
of MVD of the trigeminal nerve in some patients with SUNCT syndrome support the 
notion that more peripheral mechanisms, may be involved in the complex 
pathophysiological mechanisms of SUNCT and SUNA (Sebastian , et al., 2013). This 
would imply that a subgroup of SUNCT and SUNA may also share pathogenic 
mechanisms with TN, namely demyelination of the trigeminal sensory root due to 
vascular compression. This abnormality would be responsible for the short-lived 
painful paroxysms and it would also be responsible for the ephaptic cross talk between 
fibres that drive sensation and nociceptive fibres, explaining the triggerability of the 
attacks in some SUNCT and SUNA patients. A complex interaction between more 
peripheral and central mechanisms may underpin the pathophysiology of SUNCT and 
SUNA. Further data are needed to confirm this hypothesis.  
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Chapter 4.  The medical treatment of SUNCT and SUNA syndromes: 
a prospective exploratory study 
 
4.1. Abstract 
 
The management of SUNCT and SUNA is considered challenging due to paucity of 
data and lack of knowledge of its biological mechanisms. To assess the efficacy of 
medical treatments in these conditions, the response to treatments was evaluated in a 
prospective exploratory study. A semi-structured questionnaire was administered face 
to face to 161 consecutive SUNCT and SUNA patients. Treatment outcome was 
classified as: ineffective (no improvement), mild (<50% improvement), good (≥50% 
improvement) and excellent improvement (pain-free or almost pain-free). Responders 
were defined as those patients who obtained a good or excellent improvement from a 
given treatment.  
Lamotrigine was found to be the most effective treatment (responders: SUNCT= 
53.5%, SUNA= 57.9%) followed by oxcarbazepine (responders: SUNCT= 44.8%, 
SUNA= 47.0%) in both groups of patients; duloxetine and topiramate were more 
effective in SUNCT rather than SUNA (duloxetine responders: SUNCT= 45.0%, 
SUNA: 11.8%; p= 0.027; topiramate responders: SUNCT= 33.3%, SUNA= 10.7%; p= 
0.028). Amongst transitional treatments intravenous lidocaine given at a dose ranging 
from 1.3 to 3.3 mg/kg/h for 7–10 days, with an infusion speed that varies from from 60 
to 240 mg/h, led to a significant, albeit short-lasting, headache improvement in 83.3% 
SUNCT (n=25) and in 76.5% SUNA (n=13) patients (p=0.73). A greater occipital nerve 
block (GONB) injecting a mixture of steroid and local anaesthetic was tried in 77 
patients. A 50% or more headache improvement was obtained by 27.3% (n=21) in our 
cohorts of patients, without any significant difference between SUNCT (24.4%; n=11) 
and SUNA (37.0%; n=10) patients (p=0.42). In those who benefited from the 
procedure, the improvement lasted for a median of 21 days (IQR: 53 days; range: 1 to 
150 days). We found intravenous dihidroergotamine able to worsen or even to 
precipitate a de novo SUNCT/SUNA when administered for a different primary 
headache disorder.  In conclusion, SUNCT and SUNA seem to respond to sodium 
channel blockers, similarly to TN. These findings delineate a treatment algorithm of 
SUNCT and SUNA and further expand the overlap between SUNCT, SUNA and TN. 
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4.2. Introduction 
The management of SUNCT and SUNA syndromes has historically been considered 
challenging. The rarity of SUNCT has meant that the majority of published treatment 
studies have been conducted in single cases or small case series. As far as SUNA is 
concerned, only the therapeutic outcome of a small series of patients has hitherto been 
reported (Cohen, 2007). It is therefore still unclear whether medications effective in 
SUNCT are also effective in SUNA. 
 
To date there are no randomised placebo-controlled double-blind trials conducted in 
the pharmacological management of SUNCT and SUNA. Difficulties in setting up such 
trials may include slow and incomplete participants’ enrolment due to the rarity of the 
conditions, leading to underpowered studies. Moreover, conducting placebo-controlled 
trials in such excruciating conditions poses ethical issues related to the use of a placebo 
compound and the duration of the placebo phase. Since preventive treatments normally 
used in headache management require relatively slow titration and high daily dosages, 
a short controlled phase may not allow proper drug titration, hence masking the full 
potential of a treatement.  
 
Given the clinical overlap between the other TACs and TN, a plethora of medical and 
injectable treatments deemed to be effective have been tried in SUNCT and much less 
frequently in SUNA, with inconsistent results (Pareja , et al., 2013).  
 
In this chapter we conducted a prospective exploratory study of preventive medical 
treatments tested in a large cohort of SUNCT and SUNA patients, with the aims of:  
1) Describing the outcome of oral long-term and short-term preventive treatments, 
previously reported to be effective in SUNCT, in a large series of SUNCT and SUNA 
patients.  
2) Describing the response to preventive treatments in a large series of SUNA and 
comparing it to the one of SUNCT patients.  
3) Reporting the outcome of therapies for which there is no evidence of efficacy 
in SUNCT and SUNA. 
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4.3. Methods 
4.3.1. Study design and study population 
This study was a prospective single centre open-label observational study aiming to 
assess the effectiveness and tolerability of preventive treatments in SUNCT and SUNA 
patients. Consecutive patients with a diagnosis of SUNCT and SUNA, according to the 
ICHD-2 and ICDH3β diagnostic criteria, who attended our headache and facial pain 
outpatient clinics between 2010 and 2013, were included in the study. Details on 
medical treatments were collected directly from patients in outpatient or inpatient 
settings using a semi-structured standardised questionnaire (see Appendix) and, when 
necessary, from the clinical notes or telephone follow-ups. Data were subsequently 
entered onto a clinical electronic database SPSS version 21 (IBM® SPSS® Statistics). 
Data including demographics, headache clinical characteristics, type of medication, 
dose, side effects, length of the trial, and reasons for discontinuation (when appropriate) 
were captured. Patients were usually followed-up at three or six-monthly intervals with 
telephone follow-up in the interim, if needed. This allowed us to assess the outcome of 
a certain treatment and monitor its effect overtime. 
 
4.3.2. Data collection and treatments outcome 
Patients’ estimate of benefit was used to evaluate the outcome of medication trials in 
view of the absence of standardised diaries designed to capture the multiple (sometimes 
hundreds) short-lasting daily SUNCT and SUNA attacks.  
Patients’ baseline daily attacks frequency, severity and duration were recorded in the 
research questionnaire and compared to the same clinical parameters after each 
treatment trials, looking for any changes. 
 
Headache improvement was defined as reduction in daily attacks frequency and/or 
intensity and/or duration. Treatment improvement was classified as: mild (<50% 
improvement), good (≥50% improvement) and excellent (pain-free or almost pain-
free). Responders were defined as those patients who obtained a good or excellent 
improvement from a given treatment.  
 
 161 
To assess differences in treatment responses between SUNCT and SUNA, we 
compared responders to treatments between the two groups of patients. 
 
Most treatments were tried in monotherapy, though sometimes combination of two or 
more treatments was required when the first medication was only partially beneficial. 
All treatments outcomes were assessed prospectively, with the exception of 
carbamazepine and gabapentin, which had in some occasions been tried by other 
clinicians by the time the patients were referred to our service. However, we only 
included outcomes on these two medications if the information provided was detailed 
and accurate as well as being confirmed by the patients.  
 
The study was approved by Northwick Park Hospital Research Ethics Committee, 
London, UK (REC no:11/LO/1709) 
 
4.3.3. Statistical analysis 
All data were analysed using Statistical Package for the Social Sciences, SPSS version 
21 (IBM® SPSS® Statistics). Chi square test and Fisher’s exact test were used for 
categorical variables. Paired sample T-test was used for non-categorical variables. All 
reported p-values are two-sided and a significance level less than 5% was considered 
significant.  
 
4.4. Results 
The demographic and clinical characteristics of the cohort of SUNCT and SUNA 
patients are summarised in Table 34. There was a preponderance of female patients, 
particularly in SUNA. The vast majority of patients displayed a chronic pattern with 
daily or daily severe headache attacks occurring on a median frequency of 22 
attacks/day, each lasting a median of 60 seconds.  
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Table 34. Demographic and clinical features of the SUNCT and SUNA cohorts 
 
 
S:spontaneous attacks; S only: spontaneous attacks only; SUNCT: short-lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing; SUNA: short-lasting unilateral 
neuralgiform headache attacks with autonomic symptoms; T: triggered attacks; T only: triggered 
attacks only; VRS: verbal rating scale (0= no pain, 10= worst pain)  
 
 
 SUNCT (N=85) SUNA (N=76) TOTAL (N=161) 
Gender 
Male 40 (47.1%) 23 (30.3%) 63 (39.1%) 
Female 45 (52.9%) 53 (69.7%) 98 (60.9%) 
Median age of onset in years  41 (range: 13-76) 45 (range: 16-72) 42 (range: 13-76) 
Median headache duration in 
years 
8 (range: 1-45) 6 (range: 1-32) 6 (range: 1-45) 
Headache 
course 
Episodic 10 (11.8%) 7 (9.2%) 17 (10.6%) 
Chronic 75 (88.2%) 69 (90.8%) 144 (89.4%) 
Laterality 
Right 41 (48.2%) 39 (51.3%) 80 (49.7%) 
Left 31 (36.5%) 28 (36.8%) 59 (36.6%) 
Side-variable 13 (15.3%) 8 (10.5%) 21 (13.0%) 
Bilateral 0 (0%) 1 (1.3%) 1 (0.6%) 
Median attack frequency daily 
30 
(range: 0.1-250) 
20 
(range: 2-250) 
22 
(range: 0.1-250) 
Median attack severity (VRS) 
10 
(range: 6-10) 
9 
(range: 4-10) 
9 
(range: 4-10) 
Median attack duration 
(Seconds) 
120 
(range: 5-1200) 
60 
(range: 1-900) 
60 
(range: 1-1200) 
Missing data - 1 (1.3%) 1 (0.6%) 
Attack triggerability 
T + S 53 (62.4%) 40 (52.6%) 93 (57.8%) 
S only 27 (31.8%) 31 (40.8%) 58 (36.0%) 
T only 5 (5.9%) 4 (5.3%) 9 (5.6%) 
Missing data  - 1 (1.3%) 1 (0.6%) 
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4.4.1. Therapeutic outcomes: oral preventive treatments 
Several treatments were tried in our cohorts. Some of them, including lamotrigine, 
topiramate, carbamazepine, oxcarbazepine and gabapentin, were tried because of initial 
evidence of efficacy reported mainly in SUNCT (Cohen, 2007). Other medications such 
as pregabalin, duloxetine, lacosamide and mexiletine, which are not supported by any 
published evidence, were tried on the basis of their mechanisms of action and/or their 
favourable tolerability profile. Table 35 outlines the number of patients who tried each 
medication, the median doses, therapeutic outcomes for each medication tried, as well 
as the proportion of patients who discontinued the medications because of unacceptable 
side effects. Figure 13 outlines the comparison between responders to oral medications 
in the SUNA and SUNCT cohorts. 
   
Lamotrigine 
Lamotrigine was tried by the majority of our SUNCT and SUNA patients (n=134/161, 
84.5%) at a median dose of 250 mg/day (IQR: 250 mg; range: 25-700mg) for a median 
of eight months at the time of the assessment (range: 15 days to 7 years; data on duration 
for which drug was taken were incomplete for 16 patients). Lamotrigine led to a 
headache improvement in 97 of 128 patients in our cohorts [75.8%, missing data (md): 
6 patients]: 54 SUNCT (73.0%) and 43 SUNA patients (71.7%) (p=0.749). A 50% or 
more benefit was observed in 53.5% of SUNCT (n= 38) and 57.9% of SUNA patients 
(n=33) (p=0.621). One patient experienced a worsening of SUNCT while on 
lamotrigine and therefore she discontinued it. Data on efficacy were incomplete for 
three SUNCT and three SUNA patients. The medication was tolerated by 83.3% of 
SUNCT patients (n=55), though it was discontinued because of side effects in 14.9% 
(n=11) of SUNCT patients. Similarly, lamotrigine was tolerated by 81.4% of SUNA 
patients, though it had to be discontinued because of side effects in 18.3% (n=11) 
patients. Data on drug tolerability were incomplete for 11 patients.   
 
Carbamazepine 
Carbamazepine was tried by 87 patients at the median dose of 600 mg/day (IQR: 500 
mg; range: 100-2000 mg) for a median of 7.5 months at the time of the assessment 
(range: 1 month to 25 years). Carbamazepine led to a headache improvement in 42 out 
of 84 patients in our cohorts (50.0%, md: 3 patients): 16 SUNCT (37.2%) and 26 SUNA 
(63.4%) patients (p=0.016). A 50% or more headache improvement was observed in 
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36.6% of SUNA (n=15) compared to 16.3% of SUNCT patients (n=7) (P=0.034). 
Amongst all patients who trialled carbamazepine, in both SUNCT and SUNA, 
approximately 20% of patients had to discontinue the trial because of unbearable side 
effects.  
 
Gabapentin 
Gabapentin was tried in 80 SUNCT and SUNA patients at a median dose of 1800 
mg/day (IQR: 1800 mg; range: 200-4800 mg) for a median trial duration of six months 
at the time of the assessment (range: 1 month to 11 years). Gabapentin led to a headache 
improvement in 26 of 80 patients in our cohorts (32.5%): 32% of SUNCT (n=16) and 
33.3% of SUNA patients (n=10) (p=0.76). The majority of SUNCT and SUNA patients 
either reported a mild improvement or no improvement at all on gabapentin. A 50% or 
more headache improvement was observed in 10% of SUNCT (n=5) and SUNA (n=3) 
patients (p=1.0). Side effects led to treatment discontinuation in a greater proportion of 
SUNA (19.4%, n=6) compared to SUNCT patients (8.7%, n=4). 
 
Topiramate 
Topiramate was tried in 79 patients at a median dose of 200 mg/day (IQR: 300 mg; 
range: 25-800 mg) for a median duration of four months at the time of the assessment 
(range: 1 month to 5 years). Topiramate led to a headache improvement in 36 of 76 
patients in our cohorts (47.4%; md: 3 patients): 26 SUNCT (54.2%) and 10 SUNA 
(35.7%) patients (p=0.12). A greater proportion of SUNCT (33.3%, n=16) compared 
to SUNA patients (10.7%, n=3) obtained at least 50% or more headache improvement 
(p=0.028). The majority of SUNCT and SUNA patients though reported a mild 
improvement or no improvement at all on topiramate. One SUNCT and one SUNA 
patients reported a worsening of the attacks while on topiramate. Side effects led to 
discontinuation of the medications in 35.4% of SUNCT (n=17) and 22.6% of SUNA 
patients (n=7). 
 
Pregabalin 
Pregabalin was tried in 66 patients. However, data were not satisfactory for most 
outcomes in one patient, hence 65 patients were considered for the analysis. Pregabalin 
was tried in our cohort at a median daily dose of 500 mg/day (IQR: 375 mg; range: 25-
600 mg). The median duration of the trial at the time of the assessment was four months 
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(range: 1 month to 5 years). Similar to gabapentin, pregabalin led to headache 
improvement in a small proportion of patients: 19 of 64 in our cohorts (29.7%, md=2 
patients), 11 SUNCT (30.6%) and eight SUNA (28.6%) patients (p=0.863). A 50% or 
more headache improvement was observed in 11.1% of SUNCT (n=4) and 10.7% of 
SUNA patients (n=3) (p=0.959). No patients exposed to pregabalin reported an 
excellent headache benefit. Moreover, the proportion of patients who discontinued 
pregabalin because of tolerability issues, was slightly higher than the proportion of 
patients who discontinued gabapentin (SUNCT: 16.2% vs 8.2%; SUNA: 20.7% vs 
19.4%).  
 
Oxcarbazepine 
Oxcarbazepine was tried by 63 SUNCT and SUNA patients at a median daily dose of 
1200 mg (IQR: 600 mg; range: 300-3600 mg) for a median duration of four months 
(range: 1 week to 5 years) at the time of the assessment. Oxcarbazepine led to a 
headache improvement in 45 of 63 patients in our cohorts (71.4%): 69% of SUNCT 
(n=20) and 73.5% of SUNA (n=25) patients (p=0.689). A 50% or more headache 
improvement was observed in 44.8% of SUNCT (n=13) and 47.0% of SUNA patients 
(n=16) (p=0.859). The proportion of patients who had to discontinue oxcarbazepine 
due to side effects was 17.2% (n=5) of SUNCT and 29.4% (n=10) of SUNA patients. 
 
Of the 63 patients who tried oxcarbazepine, 47 (72.3%) patients (SUNCT=21; 
SUNA=26) previously used carbamazepine. Of these, 11 patients did not tolerate 
carbamazepine (17.5%). Only one patient who did not tolerate carbamazepine had 
responded to it but was swapped to oxcarbazepine because of tolerability issues. Of the 
remaining 33 patients who tolerated carbamazepine, 12 were responders and 19 were 
non-responders. It is likely that responders experienced side effects, which were not 
severe enough to discontinue the medication, but enough to warrant a replacement with 
another medication, in this case with oxcarbazepine. Of the 12 responders to 
carbamazepine, eight (66.7%) also responded to oxcarbazepine, whereas four reported 
a marginal or no response at all to the latter medication. 
 
 
Duloxetine 
 166 
Duloxetine was tried in a more challenging-to-treat subgroup of patients who had failed 
to respond or tolerate medications such as lamotrigine, topiramate, carbamazepine, and 
gabapentin. Duloxetine was tried in 37 patients at a median dose of 90 mg/day (IQR: 
30 mg; range: 30-120 mg/day), for a median follow-up of four months (range: 3 weeks 
to 1 year) at the time of the assessment. Duloxetine led to a headache improvement in 
18 of 37 patients in our cohorts (48.6%), 60.0% of SUNCT (n=12) and in 35.3% of 
SUNA patients (n=6) (p=0.134). A 50% or more headache improvement was observed 
in 45.0% of SUNCT (n=9) and 11.8% of SUNA (n=2) patients (P=0.027). One SUNCT 
patient reported a worsening of the headache while of duloxetine. Unacceptable side 
effects led to drug discontinuation in 25.0% of SUNCT (n=5) and 17.6% of SUNA 
(n=3) patients. 
 
Mexiletine 
Mexiletine was tried in 15 patients at a median daily dose of 850 mg/day (IQR: 600 
mg; range: 400-1220 mg). At a median follow-up of four months (range 1month-4 
years) nine patients in our cohorts (60%), 75% of SUNCT (n=6) and 42.9% of SUNA 
(n=3) patients (p=020) reported a headache improvement. A 50% or more headache 
improvement was obtained by 37.5% (n=3) of SUNCT and 28.6% of SUNA (n=2) 
patients (p=0.71). Side effects led to drug discontinuation in 25% (n=2) of SUNCT and 
57.1% (n=4) of SUNA patients. 
 
Lacosamide 
Lacosamide was tried in nine patients, refractory to most of the other medications 
reported in this study at a median dose of 250 mg/day (IQR: 175 mg; range: 100-400 
mg). At a median follow-up of three and a half months (range: 1 month to 14 months) 
one SUNCT and one SUNA obtained a 50% or more headache improvement. Two 
SUNCT patients could not tolerate the medication and had to discontinue it.  
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Table 35. Doses, duration of trials, therapeutic outcome and discontinuation of oral preventive treatments in SUNCT and SUNA 
 
 
Median dose 
mg (range) 
Mild 
Improvement 
N (%) 
Good 
Improvement 
N (%) 
Excellent 
improvement 
N (%) 
Non-responders 
N (%) 
Treatment 
discontinuation 
N (%) 
Lamotrigine 
(Total: 134) 
SUNCT 
(n=74) 
200 
(25-700) 
16 
(21.6%) 
30 
(40.5%) 
8  
(10.8%) 
17  
(23.0%) 
11  
(14.9%) 
m.d. 12 (16.2%) 3 (4.1%) 6 (8.3%) 
SUNA 
(n=60) 
300 
(25-600) 
10 
(16.7%) 
22 
(36.7%) 
11  
(18.3%) 
14  
(23.3%) 
11  
(18.3%) 
m.d. 4 (6.7%) 3 (5.0%) 5 (7.8%) 
Carbamazepine 
(Total: 87) 
 
SUNCT 
(n=44) 
600 
(100-1600) 
9 
(20.5%) 
6 
(13.6%) 
1 
(2.3%) 
27  
(61.4%) 
9  
(20.5%) 
m.d. 10 (22.7%) 1 (2.3%) 1 (2.2%) 
SUNA 
(n=43) 
700 
(200-2000) 
11 
(26.8%) 
12 
(29.3%) 
3 
(7.3%) 
15  
(36.6%) 
8  
(20.0%) 
m.d. 5 (11.6%) 2 (4.7%) 3 (7.0%) 
Gabapentin 
(Total: 80) 
SUNCT 
(n=50) 
1800 
(300-4500) 
11 
(22.0%) 
4 
(8.0%) 
1 
(2.0%) 
34 
(68.0%) 
4  
(8.2%) 
m.d. 9 (18.0%) 0 (0%) 4 (8.0%) 
SUNA 
(n=30) 
1800 
(200-4800) 
7 
(23.3%) 
3 
(10.0%) 
0 
(0%) 
20  
(66.7%) 
6  
(19.4%) 
m.d. 5 (16.7%) 0 (0.0%) 2 (6.7%) 
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Median dose 
mg (range) 
Mild 
Improvement 
N (%) 
Good 
Improvement 
N (%) 
Excellent 
improvement 
N (%) 
Non-responders 
N (%) 
Treatment 
discontinuation 
N (%) 
Topiramate 
(total: 79) 
SUNCT 
(n=48) 
200 
(50-800) 
10 
(20.8%) 
15 
(31.3%) 
1 
(2.1%) 
22 
(45.8%) 
17  
(35.4%) 
m.d. 1 (2.1%) 0 (0%) 0 (0%) 
SUNA 
(n=31) 
200 
(25-700) 
7 
(22.6%) 
3 
(9.7%) 
0 
(0%) 
20  
(64.5%) 
7  
(22.6%) 
m.d. 3 (9.7%) 3 (9.7%) 2 (6.5%) 
Pregabalin 
(Total: 66) 
 
SUNCT 
(n=37) 
500 
(25-600) 
7 
(18.9%) 
4 
(10.8%) 
0 
(0%) 
25  
(67.6%) 
6  
(16.2%) 
m.d. 4 (10.8%) 1 (2.7%) 4 (10.8%) 
SUNA 
(n=29) 
300 
(75-600) 
5 
(17.2%) 
3 
(10.3%) 
0 
(0%) 
20  
(69.0%) 
6  
(20.7%) 
m.d. 5 (17.2%) 1 (3.6%) 4 (13.8%) 
Oxcarbazepine 
(Total: 63) 
SUNCT 
(n=29) 
1200 
(300-2400) 
7 
(24.1%) 
12 
(41.4%) 
1 
(3.4%) 
9  
(31.0%) 
5  
(17.2%) 
m.d. 1 (3.4%) 0 (0.0%) 0 (0.0%) 
SUNA 
(n=34) 
1200 
(600-3600) 
9 
(26.5%) 
13 
(38.2%) 
3 
(8.8%) 
9  
(26.5%) 
10  
(29.4%) 
m.d. 3 (8.8%) 0 (0.0%) 2 (5.9%) 
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Median dose 
mg (range) 
Mild 
Improvement 
N (%) 
Good 
Improvement 
N (%) 
Excellent 
improvement 
N (%) 
Non-responders 
N (%) 
Treatment 
discontinuation 
N (%) 
Duloxetine 
(total: 37) 
SUNCT 
(n=20) 
90 
(30-120) 
3 
(15.0%) 
7 
(35.0%) 
2 
(10.0%) 
8  
(40.0%) 
5  
(25.0%) 
m.d. 0 (0%) 0 (0.0%) 4 (20.0%) 
SUNA 
(n=17) 
90 
(30-120) 
4 
(23.5%) 
1 
(5.9%) 
1 
(5.9%) 
11  
(64.7%) 
3  
(17.6%) 
m.d. 1 (5.9%) 0 (0.0%) 5 (29.4%) 
Mexiletine 
(total: 15) 
SUNCT 
(n=8) 
600 
(400-1200) 
3 
(37.5%) 
3 
(37.5%) 
0 
(0%) 
2  
(25%) 
2  
(25%) 
m.d. 1 (12.5%) 0 (0%) 0 (0%) 
SUNA 
(n=7) 
950 
(400-1200) 
1 
(14.3%) 
2 
(28.6%) 
0 
(0%) 
4  
(57.1%) 
4  
(57.1%) 
m.d. 0 (0%) 0 (0%) 0 (0%) 
Lacosamide 
(total: 9) 
SUNCT 
(n=4) 
200 
(100-400) 
0 
(0%) 
1 
(33.3%) 
0 
(0%) 
2  
(66.7%) 
2  
(50.0%) 
m.d. 0 (0%) 1 (25.0%) 0 (0%) 
SUNA 
(n=5) 
300 
(200-400) 
0 
(0%) 
0 
(0%) 
1 
(33.3%) 
2  
(66.7%) 
0  
(0%) 
m.d. 1 (20.0%) 2 (40.0%) 2 (40.0%) 
  m.d.= missing data; N= number; SUNA= short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT= short-lasting neuralgiform headache    
  attacks with conjunctival injection and tearing; 
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Figure 15. Comparison between SUNCT and SUNA responders to oral medical treatments  
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4.4.2. Therapeutic outcome: injectable preventive treatments 
These treatments aim to produce a rapid suppression of headache attacks for a limited 
period of time while waiting for the beneficial effect of a preventive treatment to 
become evident. Additionally, they can be used to give some relief to patients who 
present with breakthrough headache attacks. Table 36 summarises the outcome and 
duration of improvement of intravenous (IV) lidocaine and greater occipital nerve 
blockade (GONB) tested in our study cohorts. Tables 37-39 summarise our experience 
with IV dihydroergotamine (DHE) in SUNCT and SUNA.  
 
4.4.2.1. Intravenous lidocaine 
Our protocol consists of using IV lidocaine ranging from 1.3 to 3.3 mg/kg/h for 7–10 
days, with an infusion speed that varies from from 60 to 240 mg/h according to the 
outcome and side effects. Twenty-four hours ECG monitoring is mandatory during the 
infusion in view of the potential risk of cardiac arrythmia (Lambru , et al., 2013).  
A 50% or more headache improvement during IV lidocaine infusion was obtained by 
83.3% SUNCT (n=25) and in 76.5% SUNA (n=13) patients (p=0.73). Data was 
incomplete for one SUNCT patient. The majority of responders with SUNCT (n=19/25) 
and SUNA (10/13), experienced the maximum benefit with an average infusion speed 
of 120 mg/h. In 58.6% of patients with SUNCT (n=17/29) and 41.2% of SUNA 
(n=7/17) who benefited from IV lidocaine, the attacks recurred immediately after the 
end of the infusion period, whereas in the remaining responders the median duration of 
the improvement was 10 days (range: 3-90 days; SUNCT= median 11 days; IQR: 16 
days; range 3-90 days; SUNA=median 10 days; IQR: 25 days; range 4-30 days). Data 
was incomplete for two SUNCT patients. One SUNCT and two SUNA patients had to 
discontinue the lidocaine infusion because of unacceptable side effects, such as 
cognitive slowing and paranoid thoughts. 
 
4.4.2.2. Greater occipital nerve blockade   
A greater occipital nerve blockade (GONB) was performed using a mixture of 
methylprednisolone 80 mg and 2 ml of lidocaine 2% delivered around the GON 
territory ipsilaterally to the side of the pain. Two patients received bilateral injections 
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in view of their headache laterality. The infiltration technique used to perform a GONB 
consists of a mixture of methylprednisolone 80 mg and 2 ml of 2% lidocaine, injected 
in the suboccipital area at a point lying on the medial third of a line drawn between the 
inion and mastoid process ipsilateral to the pain. The needle is inserted until it starts to 
touch bone. One-third of the solution is then injected in that area, one-third is injected 
slightly medially and one-third slightly laterally (Lambru, et al., 2014). 
 
A GONB was tried in 77 patients. A 50% or more headache improvement was obtained 
by 27.3% (n=21) in our cohorts of patients, without any significant difference between 
SUNCT (24.4%; n=11) and SUNA (37.0%; n=10) patients (p=0.42). Data were 
incomplete for one SUNCT and four SUNA. In those who reported some improvement 
after the procedure, the improvement lasted for a median of 21 days (IQR: 53 days; 
range: 1 to 150 days). SUNA reported longer median duration of benefit compared to 
SUNCT (30 days vs 21 days; p<0.05) patients. Four SUNCT (8.9%) and five SUNA 
(18.5%) patients reported worsening of headache after the procedure. The headache 
worsened for a median of eight days in SUNCT (IQR: 11 days; range: 7-21 days) and 
for a median of nine days in SUNA patients (IQR: 29 days; range: 9-60 days).  
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Table 36. Outcome and duration of response to intravenous lidocaine and greater occipital nerve blockade 
 
 
Mild benefit 
N (%) 
Good Benefit 
N (%) 
Excellent benefit 
N (%) 
Responders 
N (%) 
Median duration of 
benefit in days 
(range) 
Non-responders 
N (%) 
IV 
Lidocaine 
(Total: 58) 
SUNCT 
(n=31) 
4 
(13.3%) 
11 
(36.7%) 
14 
(46.7%) 
25 
(83.3%) 
11 
(3-90) 
0  
(0%) 
SUNA 
(n=17) 
1 
(5.9%) 
6 
(35.3%) 
7 
(41.2%) 
13 
(76.5%) 
10 
(4-30) 
3  
(%) 
GONB 
(Total: 77) 
SUNCT 
(n=46) 
4 
(8.9%) 
7 
(15.6%) 
4 
(8.9%) 
11 
(24.4%) 
21 
(1-90) 
26  
(57.8%) 
SUNA 
(n=31) 
4 
(14.8%) 
6 
(22.2%) 
4 
(14.8%) 
10 
(37.0%) 
30 
(7-150) 
9  
(56.3%) 
 
GONB: greater occipital nerve blockade; IV: intravenous; SD: standard deviation; SUNCT: short-lasting unilateral neuralgiform headache attacks with conjunctival injection 
and tearing; SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms
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4.4.2.3. Intravenous dihydroergotamine  
Following an initial observation that patients with coexistent chronic migraine (CM) or 
CH and SUNCT/SUNA receiving IV DHE for the former had complained of dramatic 
worsening of the latter, we reviewed the case notes of patients assessed between 2008 
and 2013 with CM or CH co-existent with SUNCT/SUNA, who underwent at least a 
trial of IV DHE. Diagnoses were assigned according to the ICHD-II (Headache 
Classification Subcommittee of The International Headache Society., 2004). Data on 
the outcomes were gathered from our detailed clinical notes that included copies of the 
headache diaries that patients admitted for IV DHE are asked to fill prior to, during and 
after admission. Patients who required repeated courses of IV DHE and reported 
exacerbations of SUNCT/SUNA whilst on treatment were also prospectively assessed 
by the same researcher (G.L.) on the ward. The DHE protocol we use is outlined in 
Table 37. 
 
Table 37: Intravenous Dihydroergotamine regimen for chronic migraine and cluster 
headache 
 
DAY 1 • First dose: 0.5 mg in 100 mL of normal saline over 1 hour 
DAY 2–5 
• Second dose, 8 hours later: 0.75 mg in 250 mL of normal saline 
over 1 hour. 
• Third and subsequent doses: 1 mg in 250 mL of normal saline 
over 1 hour every 8 hours for 10 doses with the goal of a 
cumulative total dosage of 11.25 mg (±1 mg) 
Nausea 
management 
• Ondansetron: 4 mg IV every 8 hours, 30 minutes before each 
DHE infusion. 
• Domperidone 10–20 mg orally or by suppository 
• Metoclopramide, if necessary. 
 IV: intravenously; mL: millilitre; DHE: Dihydroergotamine 
 
The study group consisted of 24 patients with a diagnosis of chronic SUNCT (n= 8) or 
SUNA (n= 16) coexistent with CM (n= 19) or CCH (n= 5), who had been treated with 
IV DHE. All the patients were offered the treatment with the aim of improving their 
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refractory CM or CCH. In 16 out of 24 patients (Table 38), IV DHE had no effect 
(66.7%); in one patient with CM and SUNCT, IV DHE was significantly effective for 
the former, but only marginally beneficial for the latter. IV DHE led to a dramatic 
worsening of the SUNCT/ SUNA in five patients, and it triggered a de novo onset 
SUNA in two patients (n=7, 29.2%). The main clinical features of the different 
headaches, investigations, treatments and outcome of IV DHE are summarised in 
Tables 39 and in Figure 16. 
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Table 38. Principal diagnosis, headache comorbidities and treatment’ outcome in those 
whose SUNCT/SUNA did not worsen with intravenous dihydroergotamine 
 
 
Diagnosis 1 Diagnosis 2 
Number of IV 
DHE treatments 
Outcome of IV 
DHE on 
CM/CCH 
Outcome of IV 
DHE on 
SUNCT/SUNA 
1 SUNA CM 
Every 4 monthly 
since 2008 
Pain free for 3 
months 
Ineffective 
2 SUNA CM 1 (2009) Ineffective Ineffective 
3 SUNA CM 1 (2008) Ineffective Ineffective 
4 SUNA CM 2 (2009) Ineffective Ineffective 
5 SUNA CM 1 (2009) 
Pain free for 3 
weeks 
Ineffective 
6 SUNA CM 1 (2008) 
30% reduction in 
headache severity 
for 2 weeks 
Ineffective 
7 SUNA CM 1 (2008) Ineffective Ineffective 
8 SUNA CCH 1 (2009) 
50% reduction in 
headache 
frequency for 1 
month 
Ineffective 
9 SUNCT CM 
Every 4 monthly 
(2008) 
75% 
improvement for 
3-5 months 
20% 
improvement for 
1 month 
10 SUNCT CCH 1 (2008) Ineffective Ineffective 
11 SUNCT CM 2 (2009) 
Pain free for 2 
weeks 
Ineffective 
12 SUNCT CM 2 (2009-2010) 
Pain free for 1 
month 
Ineffective 
13 SUNCT CM 1 (2009) 
80% reduction in 
headache severity 
Ineffective 
14 SUNCT 
CM 
SHM 
1 (2009) Ineffective Ineffective 
15 SUNA CM 2 (2008, 2009) Ineffective Ineffective 
16 SUNA CM 2 (2010, 2011) 
Pain free for 1 
week 
Ineffective 
17 SUNA CM 1 (2010) Ineffective Ineffective 
 
SUNCT: Short lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and 
Tearing; SUNA: Short lasting Unilateral Neuralgiform headache attacks with cranial Autonomic 
symptoms; CM: chronic migraine; CCH: chronic cluster headache; SHM: sporadic hemiplegic migraine 
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Table 39: Clinical characteristics of SUNCT/SUNA whose headache worsened 
during intravenous dihydroergotamine 
 
 
 
Diagnosis 
 
Sex 
 
 
Age of 
onset 
 
 
Site of 
pain 
 
 
 
*Duration 
 
 
 
**Frequency 
 
CAS 
 
Triggers 
1 
Chronic 
SUNA 
F 37 V1 120-180 10-15 
L,  
BN, 
AF 
S + T 
2 
Chronic 
SUNCT 
F 55 V1 20-300 60-70 
L,  
CI 
S 
3 
Chronic 
SUNA 
F 55 V1, V2 30-120 12-30 
L,  
EO, 
FR 
S + T 
4 
Chronic 
SUNCT 
F 51 
V1, 
C2-3 
180-600 15-80 
L,  
P,  
BN 
S 
5 
Chronic 
SUNA 
M 44 V1 30-45 20-30 
L,  
BN 
S 
6 
Chronic 
SUNA 
F 40 
V1-2, 
C2 
30-300 20-50 
L,  
P 
S 
7 
Chronic 
SUNCT 
F 34 
V1, 
V2, V3 
30-120 40-50 
L,  
CI,  
P 
S + T 
 
AF: aural fullness; BN: blocked nose; C: cervical; CI: conjunctival injection; EO: eyelid oedema; F: 
female; FR: facial redness; L: lacrimation; M: male; P: ptosis; RN: runny nose; S: spontaneous; T: 
triggered by cutaneous stimulation; V1: ophthalmic division of the trigeminal nerve; V2: maxillary 
branch of the trigeminal nerve; V3: mandibular branch of the trigeminal nerve. 
*Duration: duration of attacks in seconds 
**Frequency: frequency of attacks/day 
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Figure 16. Timing of exacerbation of SUNCT/SUNA during intravenous 
dihydroergotamine infusion in patients who reported a worsening/new onset of the 
condition. 
 
 
 
 
Patient 1: A 41-year-old woman was referred to our headache service in 2008 for a 
headache disorder that fulfils the criteria for CM. Unfortunately, she failed trials of 
propranolol, amitriptyline, dosulepin, topiramate, sodium valproate, gabapentin, 
pregabalin, flunarizine and methysergide. Bilateral greater occipital nerve blocks were 
moderately effective for three to four weeks. She was offered the first IV DHE 
treatment in 2009. This led to a complete suppression of the migraine for six weeks. 
Given the limited management options, the treatment had been repeated every three to 
four months since. In 2010, with no precipitant triggers, a new headache began. The 
headache phenotype fulfilled the ICHD-II criteria for chronic SUNA (Headache 
Classification Subcommittee of The International Headache, 2013). An MRI scan of 
the head with pituitary and trigeminal views was normal. In December 2010 she had a 
further course of IV DHE for her CM. While the CM improved similarly to the previous 
times, she experienced a dramatic worsening of the SUNA attacks from day 4 
(cumulative DHE dose: 9.25 mg), with three to four attacks/hour lasting two to three 
minutes each, both spontaneous and triggered by cutaneous stimulation, which 
disrupted her regular eating and intake of fluids. This exacerbation of SUNCT lasted 
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for two weeks, before the headache gradually subsided. Subsequently, she had three 
more courses of IV DHE, as it was the only effective treatment for the migraine, 
followed by seven days of IV lidocaine (1.5–3.5 mg/kg/h) due to the consistent 
worsening of the SUNA. An occipital nerve stimulator (ONS) was implanted in 2012 
with dramatic improvement of the SUNA and 50% reduction in migraine days. 
 
Patient 2: A 58-year-old woman presented to our headache service in 2010 with a nine-
year history of a chronic daily headache fulfilling the ICHD-II criteria for CM 
(Headache Classification Subcommittee of The International Headache, 2013). She had 
trials of propranolol, atenolol, amitriptyline, gabapentin, pregabalin, topiramate, 
methysergide and Onabotulinum toxin type A, with no appreciable improvement. She 
was therefore admitted for a course of IV DHE in May 2011. She derived a 50% 
reduction in migraine days from the infusion for a period of six weeks. The treatment 
was repeated four months later with expected initial improvement in the migraine. 
However, a new headache started from day three (cumulative DHE dose: 6.25 mg). The 
new headache phenotype fulfilled the IHS criteria for SUNCT. The DHE infusion was 
discontinued and the patient was started on IV lidocaine for seven days, with 
suppression of the attacks during the infusion and for the following two weeks. 
Subsequently the headache relapsed, leaving the patient with daily SUNCT attacks 
since then. A 50% reduction in attack frequency was achieved on lamotrigine 500 
mg/day. Since DHE was the only treatment providing transient but significant 
improvement of her CM, she had four further IV DHE treatments four months apart, 
which consistently led to a dramatic worsening of the SUNCT attacks from days 3–4 
of the infusion that were treated with a seven-day course of IV lidocaine.  
 
Patient 3: A 60-year-old woman was referred to our headache service for the 
management of a headache disorder, which started at the age of 33 with the features of 
chronic cluster headache (CCH). The CH was managed with a combination of 
verapamil, topiramate and three monthly greater occipital nerve blocks. However, in 
2009, with no precipitating triggers, a new headache began. A diagnosis of chronic 
SUNA was made after paroxysmal hemicrania was ruled out with an indometacin test. 
Lamotrigine at high dose as well as carbamazepine and oxcarbazepine did not produce 
any meaningful benefit. Duloxetine 120 mg/day led to a 50% reduction in the SUNA 
attack frequency. An MRI scan of the head with pituitary and trigeminal sequences was 
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normal. In July 2010 she was admitted for an IV DHE treatment for her CCH. Although 
the CH attacks subsided for eight weeks after discharge, the SUNA attacks worsened 
dramatically from day 4 of infusion. The attack frequency increased to 60/day on day 
4 and for the following two weeks, before they settled. Three months later she had the 
second IV DHE treatment, which similarly to the first, led to a worsening of the SUNA 
attacks from day 4. The patient was commenced on IV lidocaine for seven days with 
complete suppression of the SUNA attacks. Since then, she had further five IV DHE 
treatments, three months apart, followed by IV lidocaine for seven days, as soon as the 
SUNA worsened. Since 2012, her SUNA and CCH have been successfully managed 
with an ONS.  
 
Patient 4: A 55-year-old woman was referred to our headache service for the 
management of a headache disorder that started at the age of 40 and became 
progressively more frequent, until it was occurring on a daily basis. At that time, she 
used to take codeine and paracetamol on a daily basis. The headache had the features 
of CM and medication-overuse headache (MOH). The CM was managed with a 
combination of sodium valproate (2 gr daily) and pregabalin (600 mg daily) with partial 
benefit. In 2010 a new headache disorder, fulfilling the IHS diagnostic criteria for 
SUNCT, began. The headaches were strictly unilateral on the left side, centred over the 
retro-orbital region and radiating to the occiput. The SUNCT attacks have been 
occurring on nearly daily basis with no significant remissions since the onset, 
suggesting a chronic form. An MRI scan of the head with pituitary and trigeminal 
sequences was unremarkable. In 2011 she had her first IV DHE treatment for CM 
management. The headache improved during the infusion and she obtained a 70% 
reduction in headache days, according to her headache chart, for further six weeks after 
discharge. The SUNCT attacks remained unchanged. In 2012 she repeated the DHE 
infusion treatment. From day 3 (DHE cumulative dose: 6.25 mg) she went into a 
‘SUNCT status’, with multiple attacks per hour occurring relentlessly throughout the 
day for 10 days, before they subsided. She had IV DHE treatments two more times 
since, followed by IV lidocaine for seven days to control the SUNCT worsening.  
 
Patient 5: A 46-year-old man was assessed in our headache clinic for the management 
of CCH, which began at the age of 43 with no precipitants. His CH management 
included high-dose and flow oxygen for the acute attacks (he could not tolerate 
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sumatriptan 6 mg injections) and verapamil 960 mg, which was moderately effective 
for CH prevention. The negative indometacin trial ruled out indomethacin-responsive 
headaches. An MRI scan of the head showed an arterial (superior cerebellar artery) loop 
pressing on the trigeminal nerve ipsilaterally to the side of the pain. In view of the 
disappointing response to lithium, topiramate, methysergide, sodium valproate, 
melatonin, baclofen, greater occipital nerve blocks, which were beneficial for a week 
only, he was offered an admission for IV DHE. During the infusion period he did not 
experience any CH attacks, but remarkably, at day 5, after the last DHE dose 
(cumulative dose: 10.25 mg), he started complaining of a new-onset headache with the 
features of SUNA. A few hours later the patient was commenced on IV lidocaine, with 
complete resolution of the SUNA attacks by day seven and no further attacks for the 
following ten days. Subsequently the SUNA attacks relapsed and have been occurring 
regularly since. The patient is currently managing the SUNA and the CH attacks with 
oral preventive treatments and ONS.  
 
Patient 6: A 44-year-old woman has been under our care for two types of chronic daily 
headaches possibly secondary to a craniopharyngioma operated at the age of 7. The 
first headache condition has the features of CM complicated by medication overuse. 
The second headache type fulfilled the ICHD-II criteria for chronic SUNA. Over time 
she had a few MRI scans which showed stable post-operative changes. Her pituitary 
function tests showed slightly reduced thyroid-stimulating hormone (TSH) levels. In 
2010 she underwent her first IV DHE treatment, which was highly beneficial for the 
CM, with 60% reduction in headache days for three weeks. However, from day 3 of 
DHE infusion, her SUNA attacks worsened dramatically, from a baseline of 20/day 
(last two weeks prior to IV DHE), to approximately 80–100 on day 3. For this reason, 
she was started on IV lidocaine for eight days, which led to an 80% reduction in the 
SUNA attacks frequency. She had further five IV DHE treatments every four months, 
followed by seven days of IV lidocaine to suppress the consistent worsening of the 
SUNA attacks.  
 
Patient 7: A 39-year-old woman was referred to our service for the management of a 
chronic headache disorder, which fulfilled the ICHD-II criteria for CM. In 2009, with 
no precipitants, a new headache developed. A diagnosis of chronic SUNCT was made. 
An MRI scan of the head with pituitary and trigeminal sequences showed an arterial 
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loop distorting the trigeminal nerve ipsilaterally to the side of the pain. The combination 
of lamotrigine and topiramate led to a significant improvement for the SUNCT, though 
it only marginally helped the CM. However, other preventive treatments including 
amitriptyline, gabapentin, pregabalin, sodium valproate and greater occipital nerve 
blocks proved to be ineffective or not tolerated. For this reason, a trial with IV DHE 
was offered. During the infusion period and for the subsequent eight weeks after 
discharge, the migraine improved significantly. From day 4 (cumulative DHE dose: 
9.25 mg), the SUNCT attacks frequency worsened dramatically to approximately 120 
attacks on day 4 and ranging between 100 and 150 during the subsequent two weeks, 
before they subsided. The patient had five further IV DHE treatments, three months 
apart, with similar outcome and therefore the DHE treatment was always followed by 
seven days of IV lidocaine, which promptly suppressed the SUNCT exacerbation. 
 
4.5. Discussion 
The aims of this open-label prospective study were to assess the effectiveness and 
tolerability of medical treatments in SUNCT and SUNA as well as to establish whether 
SUNCT and SUNA patients respond differently to medical treatments. Our findings 
suggest that lamotrigine and IV lidocaine are the medications of choice for both 
SUNCT and SUNA patients and that sodium channel blockers may be the most 
promising class of drugs in the prevention of headache in these conditions. Response 
to treatments did not differ between SUNCT and SUNA patients except for topiramate 
and duloxetine, which were effective in a greater proportion of SUNCT compared to 
SUNA, and carbamazepine, which was effective in a greater proportion of SUNA 
compared to SUNCT. 
 
The strengths on this study include the large number of patients included and the 
prospective nature of the study. These elements have allowed us to study the effect of 
medications in the largest cohorts of SUNCT and SUNA patients ever described and to 
compare the response to medical treatments between SUNCT and SUNA cohorts.  
 
The study also has numerous limitations. The main limitation is the lack of a placebo 
arm. It is possible that the outcome of certain drugs has been exaggerated, partially 
reflecting a placebo effect. To try and minimise this, we used 50% cut off improvement 
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that we considered as a clinically relevant outcome measure, to define responders. This, 
along with the duration of improvements in patients with a protracted preceding chronic 
phase, may have reduced the likelihood that responders benefited significantly from a 
medication only by chance. Furthermore, open-label trials have the important role of 
providing evidence in rare disorders, where conducting randomised-controlled trials 
can be difficult for reasons related to recruiting participants and ethical issues due to 
administration of placebo. Another limitation includes the lack of objective tools to 
collect evidence of headache improvement. In the vast majority of patients, the 
outcomes of treatment trials were obtained were patients’ subjective opinion. However, 
this caveat reflects the lack of a disease specific and patient-friendly headache charts 
for SUNCT and SUNA as well as for other short-lasting neuralgiform disorders, namely 
TN. It is imperative that future research should focus on validating headache diaries 
specific for short-lasting headache and facial pain conditions like SUNCT, SUNA and 
TN. Finally, our study group included predominantly patients with the chronic subtypes 
of SUNCT and SUNA, hence our findings may not be relevant in patients with the 
episodic form of these conditions. However, the vast majority of SUNCT and SUNA 
patients display a chronic pattern making our results meaningful for the majority of 
them.  
 
One of the caveats of the IV DHE study includes its retrospective design. However, 
patients who required courses of IV DHE and reported exacerbations of SUNCT/SUNA 
whilst on treatment were assessed with daily clinical observations during admissions. 
Additionally, their headaches pattern was monitored with prospectively filled headache 
diaries.  
 
4.5.1. Oral treatments 
Our findings confirmed the initial observation that lamotrigine may be the most 
effective drug for SUNCT, suggesting that it should be considered the first line 
treatment for this condition. The proportion of responders in our study was slightly less 
prominent compared to another prospective open-label study conducted in 25 patients, 
where lamotrigine was found to be effective in 68% of them. However, the definition 
of efficacy was not detailed in that study, making it difficult to directly compare with 
our study. Unlike the outcome reported in four SUNA patients from a previous study 
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(Cohen, 2007), our data confirmed that lamotrigine is the most effective drug in SUNA 
patients as well, with a similar proportion of responder to SUNCT. 
 
Interestingly, oxcarbazepine was the second most effective medication in SUNCT and 
SUNA patients. Oxcarbazepine has been reported to be effective in two case reports 
only thus far. Our findings support the view that oxcarbazepine should be considered 
as a second option in patients not responding or not tolerating lamotrigine, or as an add-
on treatment to lamotrigine, when lamotrigine alone is not sufficient to control the 
headache. Interestingly carbamazepine was effective in a smaller proportion of patients 
compared to oxcarbazepine and SUNA patients showed a significantly better response 
to carbamazepine compared to SUNCT. The difference in outcome between 
carbamazepine and oxcarbazepine might partly reflect their different tolerability 
profiles. Furthermore, the different response rate of SUNCT and SUNA to 
carbamazepine may constitute a selection bias. Indeed, since a significant proportion of 
SUNA patients was previously diagnoses with TN, it is possible that those who did not 
report a significant response to carbamazepine were then referred to our clinic where 
the diagnosis was changed to SUNA. Conversely carbamazepine may not have been 
considered early in the management of SUNCT patients, given that the majority of them 
were referred from other neurologists who have traditionally been informed that 
carbamazepine is ineffective in SUNCT, hence it is possible that carbamazepine was 
tried in a subgroup of SUNCT patients more refractory to treatment; this may account 
for the less remarkable outcome. 
  
Unlike the outcome of a previous study where topiramate was effective in 11/21 (52%) 
SUNCT patients, only a third of SUNCT patients responded to topiramate and a 
significantly lower proportion of SUNA patients reported meaningful benefit in our 
study (Cohen, 2007). Similar to the figures of patients on carbamazepine, a significant 
proportion of SUNCT and SUNA patients had to discontinue topiramate due to side 
effects. The poor tolerability profile of this drug might have therefore contributed to the 
disappointing outcome in this study.  
 
A case series where 22 SUNCT and 5 SUNA patients were treated with gabapentin, 
reported that SUNA may respond better (60 %) than SUNCT (45 %) to this medication 
(Cohen, 2007). In another series of eight SUNCT patients treated with gabapentin in 
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monotherapy, five patients became headache free after one month of treatment and 
three obtained a significant reduction of the headache load (Etemadifar , et al., 2008). 
These encouraging results were not confirmed in our study, where only approximately 
10% of patients benefited significantly from this drug. Very similar outcomes were 
reported by patients treated with pregabalin, suggesting that perhaps both drugs might 
be helpful mainly in combination with another drug, rather than in monotherapy 
(Marziniak , et al., 2009).  
 
In view of positive data in the management of neuropathic pain, duloxetine was tested 
in 43 SUNCT and SUNA patients (Wernicke , et al., 2006). Surprisingly the proportion 
of responders to duloxetine was higher than the proportion of responders to topiramate 
and carbamazepine, suggesting a possible role of duloxetine in management of 
SUNCT. Moreover, a significantly greater proportion of SUNCT responded to 
duloxetine compared to SUNA. This difference may be due to the small patient size 
treated. In view of the better tolerability profile of duloxetine compared to topiramate, 
our data suggest that duloxetine may be a preferable option to topiramate in patients 
who fail lamotrigine or oxcarbazepine. 
 
In view of the striking effect of sodium channel blockers, such as lidocaine and 
lamotrigine in SUNCT and SUNA management, we tested the efficacy of lacosamide 
and mexiletine. Lacosamide is a novel anti-epileptic drug, which has been shown to be 
possibly effective in the treatment of painful diabetic neuropathy (Wymer , et al., 2009). 
Mexiletine is a lidocaine derivative that belongs to the class of 1B antiarrhythmic drugs 
(Marmura , 2010). Their main mechanism of action in pain disorders involves blocking 
of voltage-gated sodium channels, although lacosamide enhances the slow-inactivating 
state of voltage-gated sodium channels, sparing the fast inactivating ones 
(Niespodziany , et al., 2013). Both the drugs were effective in a significant proportion 
of SUNCT but also SUNA patients. However, they displayed a poor tolerability profile, 
with a high discontinuation rates amongst patients. Nonetheless, given that the group 
of patients that tried both these medications was refractory to all the above-mentioned 
treatments, these drugs might be considered in refractory cases, where otherwise more 
invasive approaches would be considered. 
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The different medical treatments tested in our SUNCT and SUNA patients were 
stratified in a three-tier algorithm taking into account both the efficacy and side effect 
profile of these treatments (Table 40). 
 
 
Table 40. Proposed Algorithm for medical management of SUNCT and SUNA 
  
 
Medications (maximum dose)  
1st line treatment • Lamotrigine (up to 700 mg/day) 
2nd line treatments 
• Oxcarbazepine (up to 2400 mg/day) 
• Duloxetine (up to 120 mg/day) 
• Carbamazepine (up to 1600 mg/day) 
• Topiramate (up to 800 mg/day) 
3rd line treatments 
• Gabapentin (up to 4800 mg/day) 
• Pregabalin (up to 600 mg/day) 
• Lacosamide (up to 400 mg/day) 
• Mexiletine (up to 1200 mg/day) 
              
GONB: greater occipital nerve blockade; IV: intravenous; SD: standard deviation; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA: short-lasting 
unilateral neuralgiform headache attacks with autonomic symptoms  
 
 
4.5.2. Injectable treatments 
Our data on IV lidocaine are in line with the results of previous series, showing 
excellent response in the vast majority of SUNCT and SUNA patients (Cohen, 2007; 
Matharu , et al., 2003). Other authors administered lidocaine either as an IV infusion, 
or as a subcutaneous injection for a mean infusion time of six to eight days. Thirteen of 
their 14 patients had excellent results, with most patients becoming headache-free, 
suggesting that either route of infusion could be successfully employed (Williams , et 
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al., 2008). In terms of duration of improvement, in approximately 40% of our patients 
the benefit lasted for the duration of the infusion only, though in the remaining 
responders a median length of response of 10 days was shown.  
 
Preliminary data on the outcome of blockade of the greater occipital nerve has been 
reported as temporary or partially effective procedure in nine SUNCT and SUNA 
patients (Cohen, 2007). Our findings were less impressive than that reported by Cohen 
and collaborators. It is possible that this difference is due to the different patients group 
size. However, when effective, the benefit can last a median of 21 days in SUNCT and 
30 days in SUNA patients.  
 
IV DHE has a long history of efficacy in CM, including the medically intractable forms 
as showed in several open-label and retrospective trials (Raskin , 1986; Silberstein , et 
al., 1992). IV DHE has also been reported to be effective in CH. Open-label studies in 
episodic and chronic CH suggested a rapid and sustainable efficacy in the vast majority 
of patients (Mather, et al., 1991; Magnoux, et al., 2004). However, little is known about 
the efficacy of DHE in the other TACs (Miller , et al., 2014). To the best of our 
knowledge, only one case of a SUNCT patient who failed to respond to IV DHE (3 mg) 
has been reported (Goadsby, et al., 1997). In view of the lack of any published data 
supporting the efficacy of DHE in SUNCT and SUNA, it is not routine practice to treat 
these patients with IV DHE. We therefore studied a group of patients who tried IV DHE 
for the management of their refractory CM or CCH who also suffered with SUNCT or 
SUNA. While IV DHE led to a remarkable improvement of the baseline primary 
headache (CM or CCH) in a significant proportion of our refractory patients, it was 
essentially ineffective in SUNCT and SUNA. Furthermore, in almost a third of our 
patients IV DHE improved the baseline headache disorder but led to consistent 
exacerbations of the SUNCT/SUNA condition. These findings suggest that DHE may 
not represent an effective treatment option for SUNCT and SUNA syndromes; 
therefore, it should not be considered amongst the armamentarium of transitional 
treatments for these conditions. Physicians should be careful about administering IV 
DHE in patients with SUNCT and SUNA as it can worsen these syndromes; 
additionally, all patients receiving this treatment should be cautioned that IV DHE can 
lead to de novo onset of SUNCT/SUNA. Interestingly, none of the patients who did not 
benefit from DHE reported a worsening of the SUNCT/ SUNA. This may be purely 
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coincidental. It would be rather unlikely that the improvement of the baseline CM or 
CCH has simply unmasked the coexistent SUNCT/SUNA syndromes, leading to a 
consequent amplification of the latter. The concomitant coexistence of more than one 
primary headache disorder in the same individual is usually characterised by a specific 
response to diagnosis-specific treatments, allowing clear differentiation between 
headache disorders (Totzeck , et al., 2014). Conversely, it may be possible that certain 
DHE neurochemical effects are responsible for the exacerbations of SUNCT and 
SUNA during infusion. DHE has a complex pharmacology. It interacts with multiple 
receptors, including serotonin, dopamine and a-adrenoceptors, with different degrees 
of affinity (Silberstein , et al., 2003). Preclinical studies have demonstrated the ability 
of DHE to prevent the development of neurogenic inflammation in the dura by blocking 
the peripheral C or A delta fibres (Markowitz , et al., 1988). This effect, similar to the 
mode of action of triptans, is thought to be facilitated by the high affinity of DHE for 
5-HT1B and 5-HT1D receptors located on the dural sensory fibres (Buzzi , et al., 1991). 
DHE has been shown to be able to bind to central nervous system structures, including 
the brainstem, dorsal horn of the cervical spinal cord and the cerebral cortex (Goadsby , 
et al., 1991), as well as possibly acting within the trigeminal nucleus caudalis to inhibit 
trigeminal neuron activity (Hoskin , et al., 1996). The inhibition of peripheral and 
possibly central sensitisation via modulation of serotoninergic circuits may explain 
DHE efficacy in migraine and partly also in CH. SUNCT and perhaps SUNA 
pathophysiology is thought to be similar to CH and the other TACs, involving a 
derangement in the hypothalamic-trigeminal circuits, perhaps leading to an abnormally 
activated trigemino-autonomic reflex (Goadsby, et al., 1997). Nonetheless, neither IV 
DHE, nor subcutaneous sumatriptan 6 mg, which are highly effective in CH seem to 
display any effect in SUNCT/SUNA syndromes (Magnoux, et al., 2004; The 
Sumatriptan Cluster headache Study Group, 1991; Lambru , et al., 2013). It could be 
argued that the enhanced neuronal serotoninergic tone produced by DHE might be of 
only marginal importance in SUNCT/SUNA pathophysiology, thus explaining why 
DHE is ineffective. However, other mechanisms might help explain the opposite 
therapeutic response of DHE in CH compared to SUNCT/ SUNA. Ergot alkaloids are 
potent dopamine receptors agonists, with full intrinsic activity at D2 and D3 receptors 
whereas they are fairly weak antagonists or partial agonists at D1 receptors (Silberstein , 
et al., 2003). Dopaminergic pathways are thought to play an important role in the 
pathophysiology of primary headaches including CH, where a downregulation of 
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hypothalamic dopaminergic neurons has been demonstrated in endrocrinological 
studies (Lepper , et al., 2013). Hence one possible hypothesis is that dopamine agonists, 
such as DHE, might help restore the decreased sensitivity of dopaminergic neurons in 
the hypothalamus in CH patients. The role of the central dopaminergic system in 
SUNCT and SUNA is unknown. Dopamine agonists including bromocriptine, lisuride, 
quinagolide and cabergoline have been reported to induce SUNCT attacks in patients 
with pituitary prolactinoma (Ferrari , et al., 1988; Massiou , et al., 2002; Levy , et al., 
2003; Levy, et al., 2005; Larner , 2006). The worsening effect of DHE in some of our 
patients could support the importance of neuroendocrine mechanisms involving the 
dopamine prolactin axis in modulating SUNCT and SUNA. However, none of our 
patients had neuroradiological or laboratory evidence of prolactinoma or 
hyperprolactinemia. Nonetheless our findings raise the possibility that perturbations in 
the dopamine-prolactin axis may be important even in primary SUNCT/SUNA 
syndrome. It is conceivable that specific neuroendocrine pathways involving the 
hypothalamic dopaminergic neurons may be capable of activating SUNCT 
pathophysiology at least in a subgroup of patients. According to this hypothesis, 
antidopaminergic drugs may then be useful in at least a sub-group of SUNCT and 
SUNA patients, by restoring the balance in the dopamine neurons. However, there are 
no data in the literature on this subject. In this study, domperidone was used in variable 
daily doses for the management of nausea, not only by all the patients who worsened 
with IV DHE, but also by the remaining patients included in this study. Moreover, 
domperidone only minimally penetrates the blood-brain barrier, so it would be difficult 
to postulate any involvement of this drug in the worsening of the SUNCT/ SUNA 
attacks in our patients. Metoclopramide was rarely needed by most of our patients. 
 
In summary, the scarcity of reports on potentially effective medications, has prevented 
the delineation of effective management options for SUNCT and SUNA. Open-label 
observational studies are important for generating hypotheses on medications that could 
be studied in future better-designed clinical trials. Our study supported, in a large 
cohort, the efficacy of medications that were reported to be beneficial in previous 
studies, such as lamotrigine and shed light on the possible role of other drugs with very 
little or no evidence of efficacy in the literature, such as oxcarbazepine and duloxetine. 
The ultimate confirmation of the utility of these drugs in the management of SUNCT 
and SUNA syndromes should come from randomized double-blind, placebo-controlled 
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clinical trials. However, generating meaningful data from placebo-controlled trials in 
rare painful disorders is often challenging, for methodological reasons related to low 
numbers of patients to recruit and for ethical reasons, such as exposing patients with a 
severe pain disorder to placebo for extended periods. 
 
4.5.3. Mechanisms of action of drugs effective in SUNCT and SUNA 
and pathophysiological implications 
 
The clinical similarities between SUNCT, SUNA and TN, have led to testing 
neuromodulators with a known effect in neuropathic pain as prophylactic therapies. 
Whereas drugs like topiramate, gabapentin and pregabalin have yielded rather 
disappointing effects in SUNCT/SUNA and TN, drugs such as, lamotrigine, 
oxcarbazepine, IV lidocaine and carbamazepine, have been reported to be effective in 
all these disorders. Moreover, duloxetine, lacosamide and mexiletine seem to be new 
promising therapeutic tools in SUNCT and SUNA treatment, though they have not been 
reported in TN yet. Amongst their multiple mechanisms of action, all these drugs have 
in common the inhibition of voltage-gated sodium channels that in turn inhibiting the 
release of glutamate from glutamatergic neurons (Bhattacharya , et al., 2009). In 
addition, lidocaine, lamotrigine, carbamazepine and oxcarbazepine have been shown to 
be able to inhibit nicotinic acetylcholine (Ach) -evoked current in neurons, suggesting 
their contribution in inhibition of parasympathetic ganglionic transmission (Cuevas , et 
al., 1994; Zheng , et al., 2010; Di Resta , et al., 2010). 
 
A novel pathophysiological model that accounts for the clinical similarities between 
SUNCT, SUNA and TN, has been recently proposed (Lambru , et al., 2014). According 
to this model, SUNCT, SUNA and TN pathophysiology may be characterized by 
different degrees of interaction between peripheral and central mechanisms, namely 
focal demyelination of the trigeminal sensory root, due to vascular compression, 
disinhibition of the trigemino-autonomic reflex and posterior hypothalamic region 
dysfunction. Differences in the clinical phenotype between SUNCT, SUNA and TN in 
terms of presence and degree of cranial autonomic symptomatology, site and duration 
of the attacks and their triggerability may reflect different degree of involvement of 
similar central and peripheral pathways. In this context, the efficacy of sodium channels 
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blockers in SUNCT and SUNA and TN suggest a common denominator in the 
pathogenesis of these conditions, with sodium channels dysfunction being an attractive 
candidate. In TN, a downregulation of Nav1.7 and upregulation of Nav1.3 has already 
been reported (Siqueira , et al., 2009). In addition, the relatively high efficacy of 
lamotrigine in SUNCT/SUNA and carbamazepine in TN may be attributed to further 
mechanisms, perhaps their different effect on cholinergic parasympathetic pathways at 
central (hypothalamic) and peripheral (sphenopalatine ganglion) levels of the two 
drugs.  
 
4.6. Conclusion 
SUNCT and SUNA seem to have similar responses to pharmacological treatments. The 
higher proportion of SUNCT responders with topiramate and duloxetine along with the 
higher response of SUNA with carbamazepine may be due to patient selection bias. It 
also possible that since the SUNA patients experienced less cranial autonomic 
symptoms and often described pain in V2-V3, they responded better to carbamazepine 
because they may share biological mechanisms with TN. Lamotrigine should be 
considered the drug of choice for the management of SUNCT and SUNA. 
Oxcarbazepine, duloxetine and topiramate can be useful options for patients who fail 
to respond to lamotrigine or as add-on options. IV lidocaine is an extremely effective 
treatment for patients with frequent, severe attacks, but it may not be available in every 
hospital. Conversely, GONB is a more minimally invasive procedure but only effective 
in 1/3 of patients. When effective though, it may produce significant headache relief 
for a clinically relevant duration of time. IV DHE seems to be ineffective and in some 
cases, may exacerbate the SUNCT/SUNA headache phenotype, hence should be not 
offered in SUNCT and SUNA. Ultimately more definitive answers on the management 
of SUNCT and SUNA should come from controlled studies. SUNCT and SUNA 
response to drugs is similar to TN and differs from the other TACs. The efficacy of 
sodium channels blockers in the former conditions raises the possibility that one of the 
biological hallmarks in SUNCT, SUNA and TN may be a dysfunction in certain sodium 
channels. Thus, sequencing of sodium channel genes in SUNCT/SUNA patients may 
provide additional insight into this complex disorder and eventually lead to the 
development of more specific drugs, which can convincingly relieve the symptoms of 
these highly disabling conditions. 
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Chapter 5.  The Surgical Management of SUNCT and SUNA: 
Prospective Single Centre Open-label Studies 
 
 
5.1. Abstract 
 
A small undetermined proportion of chronic SUNCT and SUNA patients can be 
intractable to medical therapies. The surgical management of SUNCT/SUNA is 
controvartial and little is known on the role of surgical treatments deemed effective in 
other TACs and in TN. We present outcomes of two uncontrolled open-label 
prospective studies respectively in a group of medically-intractable SUNCT and SUNA 
with occipital nerve stimulation (ONS) and in another group of medically-intractable 
SUNCT and SUNA with trigeminal microvascular decompression (MVD). ONS at a 
median follow-up of 38 months (range 24-55 months) led to a marked headache 
improvement in eight of the nine patients implanted (89%). Four of nine patients 
became and remained completely pain-free for the whole duration of the follow-up 
except when the stimulator was switched off or malfunctioned. Four patients reported 
a marked improvement in their condition but were not rendered pain-free. Two of these 
four patients estimated that their headaches had improved by 95%, while the headache 
score, derived from the prospective headache diaries, showed an improvement of 97% 
and 98% in these patients. The other two patients estimated that their headaches had 
improved by 50-60%, though the headache scores revealed an improvement of 81% 
and 96%. One patient did not report any benefit from the stimulator at 24 months’ 
follow-up and opted to have the ONS explanted. Trigeminal MVD was tried in ten 
SUNCT and SUNA patients with MRI evidence of ipsilateral trigeminal neurovascular 
conflict.  At a mean follow-up fo 19.6 months (range: 12-36 months), seven patients 
(70%) became headache free after the operation. Five of the seven patients (71.4%) 
remained headache-free at the last follow-up. The remaining two patients were 
headache-free respectively for 9 and 12 months before the headache relapsed. There 
were no major surgical and post-surgical complications. These studies support that 
ONS and trigeminal MVD may be safe and effective therapies for refractory SUNCT 
and SUNA patients who failed conventional treatments.  
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5.2. Introduction 
The vast majority of patients with SUNCT and SUNA syndromes display a chronic 
headache pattern, with attacks occurring daily or nearly daily, thereby having a 
significant impact on the quality of life of the majority of these patients. In addition, 
the limited arsenal of effective medical treatments means that a significant minority of 
sufferers prove to be refractory to medical management. The extent of this problem is 
not as clearly defined as in other commoner primary headache disorders such as 
migraine and CH and no consensus on the definition of “refractory” SUNCT and SUNA 
exists, it is nonetheless commonly observed in clinical practice that a significant 
proportion of SUNCT and SUNA patients are refractory to medical management. For 
these patients, surgical approaches need to be considered. Evidence on surgical options 
available in SUNCT and SUNA are limited and quality of the studies rather poor 
(Lambru , et al., 2013).  
Several destructive or invasive approaches targeting the trigeminal nerve have been 
tried in these patients. The effectiveness of these procedures is uncertain as the reported 
results are often conflicting and the follow-up period is generally very limited. These 
procedures are also known to be associated with various complications including 
corneal anesthesia, anesthesia dolorosa, jaw deviation, diplopia, and vestibular 
disturbance (Harries , et al., 2011). 
Neurostimulation therapies that entail stimulation of peripheral or central nervous 
system targets have emerged as promising approaches for the management of medically 
intractable headache disorders. Based upon the finding of posterior hypothalamic 
region activation in SUNCT (May , et al., 1999), three medically intractable SUNCT 
patients treated with ventral tegmental (VTA) area deep brain stimulation (DBS) have 
been reported in the literature. The therapy led to a significant improvement of the 
headache load at follow-ups ranging between 12 to 18 months, with only minor adverse 
events, suggesting that DBS of the VTA (previously considered to be the posterior 
hypothalamic region), could be a therapeutic option for medically refractory SUNCT 
and SUNA patients (Leone , et al., 2005; Lyons , et al., 2009; Bartsch , et al., 2011). 
Recently the first case series of 11 SUNCT and SUNA patients treated with VTA DBS 
with a long follow-up was published. The vast majority of patients (82%) benefited 
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significantly from the surgery with only one patient requiring removal of the system 
due to wound infection (Miller , et al., 2016). However, given the potentially fatal 
complications of DBS, peripheral neurostimulation targets have been more recently 
tested in TACs. Open label case series using ONS has shown promising evidence of 
safety and efficacy in the management of refractory CH and HC (Magis, et al., 2012). 
In view of the clinical and pathophysiological similarities between the TACs and 
SUNCT/SUNA, it is reasonable to postulate that ONS may also be beneficial for 
medically refractory SUNCT and SUNA syndromes. 
Another surgical approach that finds its rationale in the clinical similarities between 
SUNCT, SUNA and TN, is microvascular decompression (MVD) of the trigeminal 
nerve. To date, there are ten case reports and one case series of nine patients with 
SUNCT/SUNA who have had trigeminal MVD. Twelve out of nineteen (63%) SUNCT 
and SUNA patients treated with trigeminal MVD reported complete relief of headaches 
at a mean follow-up of 14 months (range: 0.5 – 32 months). Transient complications 
were reported in five cases (wound infection, chest infection, vertigo, jaw pain and 
dural sinus bleed). More persistent symptoms of hearing loss and ataxia were seen in 
2/19 (11 %) of cases (Sebastian , et al., 2013).  
In this chapter we sought to determine the following: 
1. Long-term safety and efficacy of ONS for the management of medically 
refractory SUNCT and SUNA syndromes.  
 
2. Safety and efficacy of MVD of the trigeminal nerve in SUNCT/SUNA.  
 
We hypothesised that both the procedures may have an important role in the surgical 
management of these conditions.  
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5.3. Occipital nerve stimulation in SUNCT and SUNA 
 
5.3.1. Methods 
 
5.3.1.1. Case material 
Patients with medically intractable, chronic SUNCT and SUNA under our care were 
offered an occipital nerve stimulator. The diagnosis of SUNCT was established 
according to International Classification of Headache Disorders (ICHD-2) criteria, 
while the proposed appendix criteria were used for the diagnosis of SUNA (Headache 
Classification Subcommittee of The International Headache Society., 2004). All 
patients fulfilled the standard diagnostic criteria, except for one SUNA patient who had 
facial redness and sweating but none of the cranial autonomic features delineated in the 
standard criteria. While all patients fulfilled the standard diagnostic criteria for duration 
of attacks, some patients also had longer lasting attacks, which have been described in 
the largest clinical series of SUNCT and SUNA patients (Cohen , et al., 2006). All 
patients had a trial of oral indometacin or a modified indo-test (100 or 200 mg of 
intramuscular indomethacin versus saline placebo) (Matharu , et al., 2004) to rule out 
indomethacin-responsive headaches. Patients with attacks lasting longer than four 
minutes also had trials of high flow oxygen and subcutaneous sumatriptan, which can 
be beneficial in cluster headache but are ineffective in SUNCT and SUNA. 
 
Patients were considered suitable for ONS if they had highly disabling, medically 
intractable, chronic SUNCT or SUNA for at least two years. Unlike in cluster headache, 
the concept of medically refractory SUNCT/SUNA is not clearly defined in the 
literature (Mitsikostas, et al., 2014). In this study patients were considered medically 
refractory if they failed to respond to adequate trials, at appropriate doses for an 
appropriate length of time, of lamotrigine, topiramate, gabapentin, pregabalin, and one 
of either carbamazepine or oxcarbazepine. These agents were selected on the basis of 
the available evidence of the efficacy of these agents (Cohen, 2007; Williams , et al., 
2008) and our experience. A failed trial was defined as an unsatisfactory response, 
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development of intolerable side effects, or contraindication to the use of the agent.  
 
A temporary stimulation trial is performed for several days before the permanent 
implantation in some centers, with a view to improving the selection of candidates for 
permanent stimulation. This practice is not used at our unit and therefore it was not a 
selection criterion. Similarly, most patients had a greater occipital nerve blockade 
(GONB), with a mixture of 2 mL of 2% lidocaine and methylprednisolone 80 mg, but 
the response to the GONB was not a selection criterion. The patients were given 
implants on compassionate grounds. The study was an audit of outcomes, and as such, 
it did not require ethics board approval under UK guidelines. All patients gave written 
informed consent. 
 
5.3.1.2. Surgical procedure 
The anatomy of the nerves of the occipital region has been well described (Natsis , et 
al., 2006). There are three nerves that innervate the occipital region, namely the greater, 
lesser and least occipital nerves. The greater occipital nerve is a branch of the C2 spinal 
root. It proceeds between the inferior oblique and the semispinalis capitis muscle in a 
superomedial fashion. The nerve then crosses above the rectus capitis posterior major 
muscle and arises medial to the semispinalis capitis muscle, which it occasionally 
pierces. It then penetrates through the trapezius muscle to join the occipital artery. It 
provides innervations to an occipito-parietal area 6–8cm wide and ascending 
paramedially from the subocciput to the vertex (Poletti , 1991). The lesser occipital 
nerve is composed of branches of the C2 and C3 spinal roots. It runs lateral to the 
greater occipital nerve, crossing over the sternocleidomastoid muscle, and courses 
superolaterally towards the region behind and above the ear. The medial branch of the 
posterior division of the C3 root gives off a branch called the least occipital nerve, 
which pierces the trapezius and ends in the skin of the lower part of the back of the 
head. It lies medial to the greater occipital nerve and communicates with it. There is an 
anatomical and functional overlap of trigeminal and cervical afferents throughout the 
trigeminocervical complex from the level of the caudal trigeminal nucleus to at least 
the C2 segment (KERR , et al., 1961). This convergence explains how nociceptive 
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activation at either end of this structure can result in both trigeminal and cervical 
distribution pain.  
Bilateral ONS electrodes, leads, and battery were implanted after informed consent was 
obtained. The implant technique has evolved overtime in our center. In earlier SUNCT 
and SUNA cases, the insertion point was at the spinous process of C1, passing laterally 
and superiorly, using a Tuohy needle curved to follow the cervical fascia. However, in 
order to reduce possible complications such as unwanted stimulation of the neck 
muscles, which can limit the amplitude of stimulation that can be applied and erosion 
of the electrode tip through the skin, the implantation level in more recent cases has 
been aimed at stimulating the greater occipital nerve, as it emerges superior to the 
nuchal line. This means that the electrode is superior to the cervical muscles, thus 
reducing the chance of unwanted muscle stimulation. Since the electrode can be passed 
in the loose subgaleal plane at this level, we did not use a sharp insertion technique 
(Tuohy needle) but instead passed the electrodes using a blunt plastic tube, thus 
reducing the chance that the tip would be tunnelled closer to the skin than intended, at 
the extreme lateral tip of the electrode. Figure 15 illustrates patients operated with the 
earlier technique, where electrodes originated from the level of the spinous process of 
C1 (Cases 1, 2, 4, 6) and those implanted using the later technique, with electrodes 
placed superior to the nuchal line (Cases 7 and 8). It is unlikely that this difference in 
the implant technique could account for a difference in therapeutic outcome since the 
target is still stimulation of the greater occipital nerve. The difference was only aimed 
to reduce ONS-related adverse events. 
A single-stage procedure in 2 parts was used to allow an intraoperative stimulation trial. 
The first part was performed under local anesthetic and gentle sedation, with care taken 
to avoid anesthetizing the occipital nerves. The patient was placed in a lateral position 
and a sterile field was established. A midline posterior cervical incision was made and 
bilateral cylindrical-style, octad electrodes (Medtronic, Minneapolis, MN) were 
introduced using the two different techniques described above. A dual program pulse 
generator (Medtronic Prime Advanced® Medtronic) was then used to test stimulation 
and confirm that paresthesias were felt bilaterally. The second part of the insertion was 
done under a general anesthetic. The electrodes were looped and anchored to the 
cervical fascia, then tunneled to a lateral cervical or subclavicular skin crease 
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intermediate incision. A left subclavicular or abdominal incision was made (according 
to the patient’s preference) to form a pocket to implant the pulse generator. Electrodes 
were tunneled to the intermediate incision and a pair of extension leads (Medtronic) 
was attached. Silicone sheaths were used to protect the lead connections. A topical 
antibiotic cover with gentamicin was introduced around the pocket and the incisions 
were closed. 
Patients were provided remote controls and instructed how to use them to communicate 
with the implanted pulse generators. They could adjust their stimulator settings with 
the remote control, although the pulse generators were programmed to provide 
continuous stimulation. Patients could turn the stimulator on or off, and vary the pulse 
width, frequency, or amplitude, although most of them tended only to vary the 
amplitude. The polarity of the electrodes was adjusted during follow-up visits to 
achieve comfortable bilateral paresthesias in the occipital region. Patients remained in 
the hospital for several days after implantation before being discharged. 
 
Figure 17. Electrodes placement in SUNCT and SUNA patients treated with occipital 
nerve stimulation 
 
X-rays for patients 3, 5 and 9 are not available. However similar electrode positioning have been used. 
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5.3.1.3. Follow-up and Data Collection 
Data were collected prospectively from patients’ records, outpatient visits, inpatient 
admissions, mail, and telephone and included demographics, diagnosis, previous and 
current treatments, ONS settings, pre- and post-implantation headache characteristics, 
patients’ estimates of change in headaches, and complications. Patients were asked to 
fill in a headache diary in order to record the frequency, severity on a verbal rating scale 
(VRS; 0 = no pain to 10 = very severe pain) and duration of attacks for four weeks 
before implantation and two weeks prior to each postoperative outpatient follow- up 
visit. These sessions were scheduled every three months for the first year and every six 
months thereafter. Extra visits or phone consultations were scheduled as required. 
These prospectively collected data were used at each follow-up to calculate a “headache 
score,” which has been validated elsewhere (Levy , et al., 2004), using the following 
formula: Σ (duration X severity) of each attack for a 2-week period. This score takes 
into account not only changes in the frequency of attacks, but also any variation in 
severity and duration of attacks, giving a comprehensive measure of the response to the 
treatment. Since specific tools for measuring the disability of TACs have not been 
alidated yet, disability was assessed and monitored using the Migraine Disability 
Assessment Scale (MIDAS) (Stewart , et al., 1999) and the Headache Impact Test-6 
(HIT-6) (Kosinski , et al., 2003). MIDAS and HIT-6 have been used extensively to 
assess primary headache disorders and have already been used to assess the disability 
of patients with CH and hemicrania continua (HC) treated with ONS (Schwedt , et al., 
2007; Burns , et al., 2008). As per the recommendations by Leone and collaborators 
(Leone , et al., 2007), quality of life and mental state were assessed pre- and post-
surgery. The Short Form 36 (SF- 36) was used to assess health-related quality of life at 
baseline and after stable improvements in those who responded, or after a year of 
continuous stimulation in those who did not respond (Mueller , et al., 2011). The 
Hospital Anxiety (HAD-A) and Depression (HAD-D) scales were used to evaluate the 
presence and degree of anxiety and depression before and after surgery (Mykletun , et 
al., 2001). All data were collated at baseline and after every postoperative follow-up in 
an electronic database (Microsoft Excel® spreadsheet, Microsoft Corporation, 
Redmond, WA). 
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5.3.2. Results 
Five women and four men with a median age at the operation of 52 years (range: 33–
74 years) received stimulator implants (Table 41). Six patients had SUNCT and 3 had 
SUNA. The median duration of the disorder was 7 years. Three SUNCT and one SUNA 
patient presented with the episodic form, which subsequently evolved into the chronic 
form. The remaining patients were chronic from the onset. The median duration of the 
chronic phase was 4 years. Table 42 shows the headache frequency, severity, and 
duration characteristics as reported by the patients prior to ONS. All patients had a brain 
magnetic resonance imaging scan, which revealed evidence of ipsilateral neurovascular 
conflict in 2 patients (Cases 1 and 6). 
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Table 41. Patient demographics  
 
 
 
Age at 
time of 
implant 
Sex 
Subtype of 
diagnosis 
Duration 
from onset to 
time of 
implant 
(years) 
Duration of 
chronic phase 
at time of 
implant (years) 
1 74 M 
Secondary 
chronic SUNCT 
7 4 
2 61 F 
Primary chronic 
SUNA 
4 4 
3 44 M 
Primary chronic 
SUNCT 
7 7 
4 52 M 
Secondary 
chronic SUNCT 
17 9 
5 53 F 
Secondary 
chronic SUNCT 
7 4 
6 56 M 
Primary chronic 
SUNCT 
8 8 
7 34 F 
Primary chronic 
SUNA 
2 2 
8 33 F 
Secondary 
chronic SUNA 
6 3 
9 49 F 
Primary chronic 
SUNCT 
22 22 
Median 
(range) 
52 
(33-74) 
M=4 
F=5 
SUNCT=6 
SUNA=3 
7 
(2-22) 
4 
(2-22) 
 
F: female; M: male; Primary chronic: chronic form of disorder from onset; Secondary chronic: episodic 
form of disorder that subsequently evolved into chronic form; SUNA: short-lasting unilateral 
neuralgiform headache attacks with cranial autonomic features; SUNCT: short-lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing 
 
 
 202 
 
Table 42. Clinical features 
 
 
 
B: both Triggered and spontaneous attacks; F: female; L: left side; (L): Attacks can present occasionally 
on the left side; M: male; R: right side; (R): Attacks can present occasionally on the right side; REZ: root 
entry zone; S: Spontaneous attacks only; SCA: superior cerebellar artery; T: Attacks triggered from 
triggers zones; V1: Cutaneous territory innervated by the first division of the trigeminal nerve; V2: 
Cutaneous territory innervated by the second division of the trigeminal nerve; **Patient 1 had a maximum 
of 3-5 pain free days /month 
 
 
 
All patients failed to obtain sustained or substantial benefit from preventive 
medications administered as single or combination therapy, as well as from drugs such 
as pregabalin, mexiletine, and melatonin, which although lacking published evidence 
of efficacy, can occasionally be effective in these disorders (Table 43). All patients 
 Diagnosis 
Side/Site 
of the 
attacks 
Quality of 
pain 
Duration 
of attacks 
seconds 
(range) 
Frequenc
y of 
attacks/d
ay 
(range) 
Triggered 
spontaneo
us or both, 
attacks 
1 SUNCT R/V1 
Stabbing, 
burning, 
sharp 
660 
 (120-900) 
46  
(0-97)** 
B 
2 SUNA L/V1 
Stabbing, 
sharp, 
pulsating 
240 
 (120-600) 
33  
(8-52) 
B 
3 SUNCT R/V1 Stabbing 
32 
 (20-1920) 
30  
(16-40) 
B 
4 SUNCT 
L(R)/V1
+ 
occipital 
Stabbing, 
jabbing, 
sharp 
120 
 (60-360) 
12 
(3-20) 
S 
5 SUNCT L/V1-V2 Stabbing 
25 
 (5-75) 
90  
(48-150) 
T 
6 SUNCT R(L)/V1 
Stabbing, 
sharp 
120 
 (60-600) 
30  
(6-103) 
S 
7 SUNA R/V1-V2 
Shooting, 
sharp 
5 
 (1-1800) 
20.5  
(16-42) 
B 
8 SUNA 
L(R)/V1
+ 
occipital 
Stabbing, 
sharp 
120 
 (5-600) 
79  
(5-154) 
S 
9 SUNCT 
R/V1+ 
retro 
auricular 
Stabbing, 
shooting, 
burning 
10 
 (5-1800) 
72 
 (18-96) 
S 
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showed a very good, albeit short-lived, response to intravenous lidocaine, while only 
three patients obtained transient benefit from GONB. Five patients had a single-blinded 
placebo-controlled indomethacin test and four had a course of oral indomethacin at 
doses of 150 to 225 mg daily, showing no effect on their SUNCT/SUNA attacks (Table 
44). Three out of seven patients who had a GONBs, experience some headache 
improvement. However, when the procedure was repeated it did not lead to any 
appreciable improvement (Table 45). Seven patients tried subcutaneous sumatriptan 6 
mg or high-flow oxygen inhalation or both to abort their SUNCT/SUNA attacks 
without any appreciable benefit. 
 
Table 43. Preventive treatments tried in SUNCT and SUNA patients without 
significant improvement and respective doses (total mg per day) 
 
 LMG TPM GBP PGB CBZ OXC MXT MLT 
Other drugs 
(mg/day) 
1 350  175 4500 500 NK NT NT 12  
Amitriptyline (NK) 
Lithium (NK) 
2 300 700 2400 350 1600 NT 1200 9 
Amitriptyline 25 
Tizanidine (NK) 
3 400 200 3600 600 NK NK NT NT 
Amitriptyline 20 
Sertraline 100 
4 300 75 900 300 NT 1200 NT 12 
VPA 600 
Propranolol (NK) 
5 400 150 3000 600 NK 1500 600 9 
Phenytoin (NK) 
Propranolol 120 
6 50 125 3000 300 300 NT NT 12 
VPA 600 
Pizotifen 1.5 
Propranolol 160 
7 250 150 3600 600 NT 1500 NT 15 
Amitriptyline 50 
VPA 1000 
8 200 200 3600 400 NT 1200 NT 12 
Amitriptyline 50 
Pizotifen 3 
9 500 400 3600 600 NK 2400 1200 NT 
Amitriptyline 150 
VPA 800 
 
For this group, side effects were the usual reason for not attaining maximum doses. NK: dose not 
known; NT: not tried. CBZ: carbamazepine; GBP: gabapentin; LMG: lamotrigine; MLT: melatonin; 
MXT: Mexiletine; PGB: pregabalin; TPM: topiramate 
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Table 44. Acute and transitional treatments tried for SUNCT and SUNA, and 
therapeutic responses: indometacin and lidocaine infusion 
 
 
Indometacin 
(duration of 
trial) 
Lidocaine infusion (given over 7-10 days) 
SUNCT/SUNA 
improvement 
Number 
given 
Duration of response 
1 
225 mg 
(2 weeks) 
Pain free 2 During infusion only 
2 
225 mg 
(3 weeks) 
Pain free 1 During infusion only 
3 
150 mg 
(2 weeks) 
Moderate 
improvement 
1 During infusion only 
4 
225 mg 
(4 weeks) 
Pain free 1 During infusion only 
5 
100 mg 
(indo-test) 
Pain free 1 During infusion only 
6 
100 mg 
(indo-test) 
Moderate 
improvement 
1 
During infusion and 2 
weeks afterwards 
7 
100 mg 
(indo-test) 
Moderate 
improvement 
1 During infusion only 
8 
100 mg 
(indo-test) 
Moderate 
improvement 
1 During infusion only 
9 
200 mg 
(indo-test) 
Pain 
free/Moderate 
improvement 
4 During infusion only 
 
Indo-test: double blinded intramuscular indometacin vs normal saline 22 ; SUNA: short-lasting unilateral 
neuralgiform headache attacks with cranial autonomic features; SUNCT: short-lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing 
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Table 45. Transitional treatments tried for SUNCT and SUNA, and therapeutic 
responses: greater occipital nerve blockades 
 
 
GON injection (lidocaine and steroids) 
 SUNCT/SUNA 
improvement 
Side of injection Duration of response 
1 Yes R×2 3 days/no response 
2 Yes L×2 5 days/no response 
3 No R - 
4 No L - 
5 NT - - 
6 Yes R×2 3 days/no response 
7 NT - - 
8 No L - 
9 No R - 
 
GON: greater occipital nerve blockade; L: left side; NT: not tried; R: right side; SUNA: short-lasting 
unilateral neuralgiform headache attacks with cranial autonomic features; SUNCT: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
 
 
The characteristics of SUNCT and SUNA attacks pre- and post-ONS, derived from 
prospective diaries, are listed in Table 46. At a median follow-up of 38 months (range 
24-55 months) after the stimulator implantation, eight of the nine patients (89%) 
reported a marked improvement of their condition. Four of nine patients became and 
remained completely pain-free for the whole duration of the follow-up except when the 
stimulator was switched off or malfunctioned. Four patients reported a marked 
improvement in their condition but were not rendered pain-free. Two of these four 
patients estimated that their headaches had improved by 95%, while the headache score, 
derived from the prospective headache diaries, showed an improvement of 97% and 
98% in these patients. The other two patients estimated that their headaches had 
improved by 50-60%, though the headache scores revealed an improvement of 81% 
and 96%. One patient did not report any benefit from the stimulator at 24 months’ 
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follow-up and opted to have the ONS explanted. All patients, except the one who failed 
to respond, would recommend the use of ONS to another patient in a similar situation. 
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Table 46. Effect of occipital nerve stimulation on SUNCT/SUNA attack frequency, severity and duration 
 
 
Follow-up after 
ONS (months) 
Median frequency/day 
(range) 
Median severity on 
Verbal Rating Scale 
(range) 
Median duration in seconds 
(range) 
Daily headache score 
Percentage of 
improvement of the 
headache score 
Patients 
estimation 
of benefit 
Before After Before After Before After Before After   
1 43 
46  
(0-97) 
Pain free 7 (3-10) Pain free 
660 
 (120-900) 
Pain free 50135 0 100% 100% 
2 55 
33  
(8-52) 
Pain free 
10  
(7-10) 
Pain free 
240 
 (120-600) 
Pain free 15904 0 100% 100% 
3 24 
30  
(16-40) 
Pain free 9 (7-10) Pain free 
32 
 (20-1920) 
Pain free 13741 0 100% 100% 
4 52 
12 
(3-20) 
1  
(0-2) 
7 (5-10) 5 (4-8) 
120 
 (60-360) 
120  
(53-360) 
2444 97 96% 60% 
5 55 
90  
(48-150) 
41  
(26-50) 
10  
(8-10) 
5 (4-10) 
25 
 (5-75) 
23  
(3-68) 
5592 1075 81% 50% 
6 38 
30  
(6-103) 
Pain free 8 (5-10) Pain free 
120 
 (60-600) 
Pain free 12235 0 100% 100% 
7 28 
21  
(16-42) 
7  
(0-12) 
7 (5-8) 5 (3-8) 
5 
 (1-1800) 
5  
(1-20) 
1920 64 97% 95% 
8 28 
79  
(5-154) 
9/week (6-
12/week) 
10  
(7-10) 
8 (6-10) 
120 
 (5-600) 
120  
(5-240) 
15049 287 98% 95% 
9 24 
72 
 (18-96) 
74  
(15-91) 
10  
(6-10) 
10  
(6-10) 
10 
 (5-1800) 
10  
(5-1500) 
11038 11019 0% 0% 
Median  
(range) 
38 
(24-55) 
33  
(0-154) 
1 
(0-97) 
9 
(3-10) 
5  
(3-10) 
120 
(5-1800) 
5 
(1-1500) 
12235 64 
98%  
(Mean 87%) 
99% 
(Mean 
78%) 
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There was a marked improvement in health-related quality of life, disability, and 
affective scores following ONS. The median baseline scores in all SF-36 domains were 
low, particularly in role functioning-physical (RP), bodily pain (BP) and social 
functioning (SF). Following ONS, patients reported a remarkable improvement in all 8 
domains, with mean scores similar to the British normative SF-36 mean scores for 
adults aged 55-64 years old (Table 47). 
 
Table 47. Effect of occipital nerve stimulation on health-related quality of life     
 
 
SUNCT/SUNA patients British  
normative data 
 
Mean, ±SD 
Pre-ONS 
Mean, ±SD, 
median (range) 
Post-ONS 
Mean, ±SD,  
median (range) 
PF 
52±22 
60 (30-85) 
79±26 
85 (30-100) 
80±22 
RP 
0±0 
0 (0) 
64±48 
100 (0-100) 
79±36 
BP 
4±5 
0 (0-10) 
60±37 
50 (10-100) 
79±24 
GH 
30±28 
10 (10-80) 
71±18 
70 (40-100) 
68±23 
V 
27±28 
10 (0-60) 
59±30 
75 (0-80) 
63±20 
SF 
14±20 
0 (0-50) 
75±37 
100 (0-100) 
87±23 
RE 
33±33 
33 (0-100) 
81±38 
100 (0-100) 
86±30 
MH 
35±22 
44 (0-64) 
77±34 
88 (0-100) 
78±17 
 
PF, Physical Functioning; RP, Role Functioning-Physical; BP, Bodily Pain; GH, General Health; VT, 
Vitality; SF, Social Functioning; RE, Role Functioning-Emotional; MH, Mental Health. 
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The median baseline MIDAS and HIT-6 scores were 182 (range 150–270) and 74 
(range 68–78), respectively; these scores are consistent with severe disability. When 
the response to ONS had reached a plateau, the median MIDAS and HIT-6 scores had 
reduced to 20 (range 0–180) and 52 (range 36–78), respectively, which are consistent 
with moderate disability. The anxiety (HAD-A) and depression (HAD-D) scores were 
within the severely impaired range for the majority of patients at baseline. Following 
ONS, the median HAD-A score reduced from 13 (range 8–16) to 6 (range 0–18) while 
the median HAD-D score reduced from 11 (range 8–16) to 5 (range 0–16). 
Patients who responded to ONS were able to discontinue or reduce their preventive 
medications for SUNCT/SUNA. Six of the nine patients were able to discontinue all 
preventive treatments. One patient (Case 7) was able to maintain significant 
improvement of her SUNA with a slight reduction of the doses of lamotrigine from 250 
mg (pre-ONS) to 100 mg (post-ONS) and oxcarbazepine from 1500 mg (pre-ONS) to 
1200 mg (post-ONS), but further reduction led to recrudescence of attacks; he therefore 
opted to continue on the reduced doses of these agents. Case 5 reported a marked benefit 
with ONS but was unable to reduce the dose of mexiletine (600 mg) without a 
worsening of attacks. 
Most patients obtained a clear benefit from the stimulator after a few days (median 11 
days), though it took a few months to achieve maximum improvement (median 3.5 
months). To ensure that the clinical improvement was related to ONS, the stimulator 
was switched off (with patient consent) in Patients 1, 3 and 5, which in all cases led to 
a worsening of the attacks within 48 hours. There was also worsening of the headaches 
in Patients 1, 2, 4, and 7 following battery failure; in most cases this was experienced 
within 1–5 days of failure though, interestingly, Case 2 remained pain-free for 3 months 
after the battery ran out, following 34 months of continuous stimulation. Case 9, who 
was unresponsive to ONS, did not report any change in her headache when the 
stimulator was switched off. The other two patients declined to switch the stimulator 
off. 
The range of stimulation parameters and the patterns of use are reported in Table 7. The 
stimulator was switched on continuously in all patients. The patients experienced 
occipital paresthesia, which is known to be a requirement for clinical effect. Four 
patients reported adverse events from ONS (Table 48). Electrode migration was noted 
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in one patient (Case 4), which led to a marked worsening of the headache. Interestingly, 
a month after surgery, Case 1 developed a continuous background pain of moderate 
intensity at the same site as the SUNCT attacks, with superimposed exacerbations of 
up to an hour associated with ipsilateral conjunctival injection and lacrimation. A 
diagnosis of HC was confirmed by a double-blind indotest. The patient was started on 
oral indometacin and became completely pain-free, but the HC recurred every time 
reduction of the indomethacin dose was attempted. Case 9 had lead site pain and 
variable occipital paresthesia, which failed to improve despite trials of various 
stimulation parameters. She opted to have the ONS explanted after 24 months as she 
had not derived any benefit. In Patients 1, 2, 4, and 7 the battery discharged after 23, 
34, 26, and 25 months, respectively. In these cases the battery was replaced with a 
rechargeable one (Restore Advanced®, Medtronic). 
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Table 48. Occipital nerve stimulation parameter settings and complications 
 
 
Amplitude 
(V)  
Frequency 
(Hz) 
Pulse width 
(µs) 
Complications Action taken 
1  1.9-3.1 100 450 
-New onset of HC 
-Infection over the 
ONS scar site 
-Battery discharged 
after 23 months 
-Started Indometacin 
150 mg/day 
-Resolved with oral 
antibiotics 
-Replaced with a 
rechargeable battery 
2 0.8 60 450 
-Battery discharged 
after 34 months 
-Replaced with a 
rechargeable battery 
3  1.0-1.8 70 450 None None 
4 1.5-2.5 70 450 
-Electrode migration  
-Skin erosion and 
exposed electrode 
-Battery discharged 
after 26 months 
-Surgical revision 
-Surgical revision    
-Replaced with a  
rechargeable battery 
5 0.9-1.6 100 450 
-None 
 
6 0.3 130 450 
-None 
 
7  1.5-3.2 70 450 
-Battery discharged 
after 25 months 
-Replaced with a 
rechargeable battery 
8  0.4-2.1 65 450 
-Moderate neck 
stiffness. Severe 
pulling pain over the 
leads due to muscle 
recruitment 
- Surgical revision  
9  0.4-1.3 30-130 450 
-Lead site pain and 
variable paraesthesia 
over the occiput 
-No improvement 
after various trails of 
different stimulation 
parameters; ONS 
explanted after 24 
months 
 
Hz: Hertz; mg: milligrams; µs: milliseconds; ONS: occipital nerve stimulation; V: voltage 
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5.3.3. Discussion 
 
This is the first case series that provides evidence for long-term effectiveness of 
occipital nerve stimulation in medically intractable SUNCT and SUNA. The 
remarkable improvement obtained by 8 out of 9 patients provides evidence, albeit on 
an open-label basis, that ONS may have a role in the management of chronic, medically 
refractory SUNCT and SUNA. This is borne out by the substantial reduction in 
disability and improvement of quality of life and affective scores seen in these 
responders. Additionally, most of the responders were able to stop or reduce preventive 
medications for SUNCT or SUNA. 
A limitation of this observational study is the absence of a control group, raising the 
possibility that the effect of ONS in this patient group might be attributable to placebo 
or natural history. However, blinding with ONS is particularly challenging since it 
seems that occipital paresthesia is a requirement for clinical effect. Several observations 
in this report suggest more than natural history or a placebo effect, including: a 
protracted preceding chronic phase, lack of response to several other treatments, the 
relatively robust response rate, sustained long-term improvement, and the rapid 
deterioration and recovery after technical failures. 
A particular strength of this study is the relatively long duration of follow-up. In most 
of the series published hitherto, patients were followed for a period ranging from 13.5 
to 17.5 months  (Burns , et al., 2007; Burns , et al., 2008; Palmisani , et al., 2013). The 
importance of long-term follow-up was highlighted by Fontaine and collaborators who, 
in a series of 13 chronic cluster headache patients treated with ONS, reported a patient 
who completely lost therapeutic benefit initially obtained with ONS at 16 months 
follow-up (Fontaine , et al., 2011). The results of our series indicate a robust and long-
lasting improvement from continuous stimulation over a median follow-up period of 
38 months. With the stimulator working properly, none of our patients reported a loss 
of the improvement achieved, suggesting that ONS has a long-lasting reliability and 
consistency in this patient group. 
Other series of ONS for headache demonstrated that it is a relatively safe procedure 
with no reports of any serious adverse events. Common complications reported include 
electrode migration, lead site pain, myofascial incision site pain, neck stiffness, battery 
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site pain, and contact dermatitis. In this case series with a median follow-up of 38 
months, there were a range of complications including electrode migration, skin erosion 
resulting in electrode exposure, infection, lead site pain, muscle recruitment, and neck 
stiffness. Four of the 9 patients needed a new battery during the follow-up period. 
Battery depletion is not strictly a complication but it does require a further operation. 
However, given the recent availability of rechargeable batteries, the need for repeat 
operations for new batteries in the future will be reduced. 
There is sparse literature on the ability of a percutaneous trial to predict the long-term 
benefit of an ONS implant (Palmisani , et al., 2013). There are 3 multicenter 
randomized control trials of ONS in primary headaches, all of which have been 
conducted in chronic migraine (Lipton, et al., 2009; Saper , et al., 2011; Silberstein , et 
al., 2012). A subgroup analysis of data from the PRISM study reported that a favorable 
response to a percutaneous treatment trial was moderately predictive of a 12- week 
response (Lipton, et al., 2009). However, this study has only been reported in abstract 
form and just the short-term data are available, making it difficult to ascertain the actual 
importance of trial stimulation in predicting a response to ONS. Moreover, it is arguable 
that longer periods of stimulation in those who failed the trial might have resulted in a 
benefit in the longer term, given that ONS usually induces improvements over weeks 
or months (Fontaine , et al., 2011). A large randomized controlled trial of ONS in 177 
patients with chronic migraine reported that 89% of them demonstrated a favorable 
response to a percutaneous trial; these patients then had a permanent device implanted, 
but only 17% responded favorably (defined as a > 50% reduction in mean visual analog 
score [VAS]) at 12 weeks (Silberstein , et al., 2012). It is interesting to compare this 
with the ONSTIM study of ONS in chronic migraine, in which all patients had 
permanent implants, without percutaneous trial stimulation. This study reported that 
39% of them responded favorably (defined as a > 50% reduction in headache days or > 
3-point reduction in VAS) at 12 weeks (Saper , et al., 2011). 
The open-label series of ONS in headache disorders also report a relatively high 
response (> 80%) to trial stimulation, in keeping with response rates reported in 
randomized controlled trials (Schwedt , et al., 2007; Palmisani , et al., 2013; Brewer , 
et al., 2013; Mueller , et al., 2013). This reported benefit of a short percutaneous trial 
might represent a placebo effect in a cohort of patients who have high expectations 
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from surgery after failing most available treatments. However, the ability of a trial test 
to select long-term favorable responders appears poor in controlled studies, especially 
given that more than 80% of patients go onto full implantation anyway. In our study, 
the majority of patients obtained a significant response after a median of 3.5 months 
from the implant. By using a 1–2 weeks’ trial, we would have excluded patients that 
would have benefited from ONS. Hence, a stimulation trial does not appear to be a 
reliable predictor of long-term success with ONS in headache disorders. Larger 
prospective ad hoc studies are needed to further clarify this issue. 
Given the costs and level of invasiveness, identifying predictors for response to ONS 
has been a subject of interest. Initial evidence coming from a small study suggested that 
GONB was not a predictor of favorable response to ONS in patients with medically 
intractable, chronic primary headaches (Schwedt , et al., 2007a). In our study, GONBs 
were performed in 7 out of 9 patients (Table 4). Three (Patients 1, 2, 6) out of 7 patients 
responded to the first procedure, but did not derive any improvement from the second 
one. They all became pain-free with ONS. Among those who did not respond favorably 
to GONB (Patients 3, 4, 8, 9), 3 patients obtained a favorable response from ONS 
(respectively 100%, 96%, and 98% improvement of the headache score), whereas one 
patient did not respond favorably to ONS treatment. This data, although coming from 
a small series of patients, suggests that the response to GONB may not be considered a 
predictor of the therapeutic effect from ONS. However, these finding were not 
confirmed in a large open-label study conducted after our analysis, which looked at 
predictors of response in refractory chronic primary headaches including 20 patients 
with short-lasting neuralgiform headache attacks. Indeed, the study demonstrated that 
a previous positive response to GON block was associated with a positive response to 
ONS (Miller , et al., 2017).  
 
The mechanisms by which peripheral neurostimulation mediates the antinociceptive 
effect are poorly understood. Several sites of action within the peripheral and central 
nervous system have been proposed, including the peripheral nerve, spinal segmental 
level and supraspinal levels. It is likely that peripheral neurostimulation exerts its effect 
by multiple mechanisms and that these mechanisms may differ in the various headache 
and pain syndromes. Direct effects of neurostimulation on peripheral nerve fibre 
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excitability have been described, including transient slowing of conduction velocity, 
increase in electrical threshold and decrease in response probability (Ignelzi , et al., 
1979). However, ONS did not significantly modify pain thresholds in CCH, which 
argues against a diffuse analgesic effect (Magis, et al., 2007). 
A widely accepted theory for the antinociceptive effect of neurostimulation is the gate-
control theory of pain which proposes that the activation of large diameter afferent 
nerve fibres in the spinal dorsal horn inhibit onward transmission in small diameter 
primary afferent nociceptive fibres, thereby preventing the nociceptive signals from 
reaching the higher neural centres and being interpreted as pain (Melzack , et al., 1965). 
Indeed, a number of physiological studies have confirmed that afferent activity set up 
by peripheral neurostimulation blocks nociceptive transmission in the spinal cord 
(Garrison , et al., 1996; Chung , et al., 1985; Woolf , et al., 1982). The explanation for 
the antinociceptive effect of spinal cord stimulation (SCS) model, according to the gate-
control theory is that nociceptive input from the periphery could be inhibited at the first 
dorsal horn relay by stimulation-induced antidromic activation of collaterals of large 
dorsal column fibres projecting onto the same spinal segment (Dubuisson , 1989; 
Foreman , et al., 1975). However, the gate theory does not adequately explain some of 
the animal and human experimental data and therefore several additional mechanisms 
of action for neurostimulation have been postulated. Some of the theories proposed 
include: activation of supraspinal mechanisms; alteration of putative neurotransmitter 
levels; and blockade of sympathetic mechanisms (Meyerson , et al., 2000; Krames , 
1999). 
The involvement of supraspinal sensory pathways is a requisite for the orthodromic 
transmission of the activation resulting from neurostimulation. The key issues are 
whether the ascending and descending pain pathways are involved in mediating an 
antinociceptive effect and, if so, then which supraspinal structures are involved. 
Antinociception in animal models produced by sensory afferent stimulation is reduced 
by spinal transaction, thus implicating the involvement of supraspinal mechanisms 
(Woolf , et al., 1980). Similarly, with SCS it has been argued that the inhibitory effects 
on nociceptive transmission in the spinal dorsal horn cannot be entirely attributed to 
antidromic activation of the dorsal columns because they persist after dorsal column 
transection caudal to the stimulating electrode (Saadé , et al., 1985). Furthermore, on 
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the basis of animal studies, various supraspinal structures have been proposed as 
candidates for mediating the antinociceptive effect including the periaqueductal grey 
(PAG) and thalamus (Stiller , et al., 1995; Nyquist , et al., 1973). 
A positron emission tomography (PET) study investigated the effect of SCS in patients 
with refractory angina pectoris (Hautvast , et al., 1997). The study was performed when 
the patients were not in pain and therefore the regional cerebral blood flow changes 
reflect the effects of SCS solely. During stimulation, activation was noted in the PAG, 
dorsomedial and the pulvinar nuclei of the thalamus, prefrontal cortex, medial temporal 
gyrus, posterior caudate nuclei and posterior cingulate cortex, while a relative decrease 
in regional cerebral blood flow was observed in the insulae and anterior cingulate 
cortex. Furthermore, a functional magnetic resonance imaging study in three patients 
with chronic pain syndromes showed primary and secondary somatosensory cortex and 
anterior cingulate cortex activation with SCS (Kiriakopoulos , et al., 1997). 
A PET study investigated the brain structures modulated by ONS in chronic migraine 
(Matharu , et al., 2004). Eight patients with a marked beneficial response to bilateral 
ONS were studied in three states: during stimulation when the patient was pain free; 
during pain with the ONS switched off; and during partial stimulation and varying 
levels of pain and paraesthesia. Stimulation suppressed the headache within 30 min and 
pain recurred within 20 min of switching off the device. Stimulation evoked local 
paraesthesia, the presence of which was a criterion of pain relief. There were significant 
changes in regional cerebral blood flow in the dorsal rostral pons, anterior cingulate 
cortex and cuneus correlated to pain scores, and in the anterior cingulate cortex and left 
pulvinar correlated to stimulation-induced paraesthesia scores. The activation pattern 
in the dorsal rostral pons in this study is highly suggestive of a role for this structure in 
the pathophysiology of chronic migraine. However, this brainstem region may also be 
a locus for neuromodulation by ONS. The PAG has long been proposed as a candidate 
for mediating the antinociceptive effects of neurostimulation. Stiller and collaborators 
performed microdialysis studies on transmitter release in the PAG of rats receiving 
SCS. They observed that SCS affected a decrease in gamma-aminobutyric acid 
(GABA) levels but not of serotonin or substance P. As GABA neurons in the PAG exert 
a tonic depressive effect on the activity in descending pain inhibitory pathways, the 
authors proposed that a decreased GABA level in this region following repeated SCS 
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might indicate increased pain inhibition (Stiller , et al., 1995). 
Magis and colleagues studied 10 patients with medically intractable CCH treated with 
ONS and 39 drug-free healthy volunteers using 18- fluorodeoxyglucose (FDG) PET 
(Magis , et al., 2011). The 10 patients with CCH underwent an 18 FDG PET scan after 
ONS, at delays varying between 0 and 30 months. All were scanned with ongoing ONS 
and with the stimulator switched off. After 6–30 months of ONS, three patients were 
pain free and four had a reduction of attack frequency of at least 90% (patients who 
responded). In all patients compared with controls, several areas of the pain matrix 
showed hypermetabolism, including the ipsilateral hypothalamus, midbrain and 
ipsilateral lower pons. All normalized after ONS, except for the hypothalamus. 
Switching the stimulator on or off had little influence on brain glucose metabolism. The 
perigenual anterior cingulate cortex was hyperactive in patients who responded to ONS 
compared with those who did not respond. These results may support the hypothesis 
that ONS exerts its beneficial effects via slow neuromodulatory processes in the central 
pain matrix. The finding of a possible selective perigenual anterior cingulate cortex 
(PACC) in patients who responded raises the possibility that ONS activates descending 
pain control systems in a top-down manner and restores an equilibrium in 
antinociceptive opioidergic pathways. The study also reported persistent 
hypermetabolism of the ipsilateral posterior hypothalamus outside of an attack, which 
might be a hallmark of cluster headaches and also explains why attacks rapidly recur 
after interruption of ONS. 
SUNCT/SUNA have clinical and pathophysiological features that overlap with CH and 
TN, suggesting an underlying complex pathophysiology characterized by an interaction 
between peripheral and central structures of the brain (Goadsby, et al., 1997; Lambru , 
et al., 2014). Patients with SUNCT and SUNA treated with ONS showed better 
outcomes, compared to the series of patients with CH already published, in terms of a 
higher proportion of those who responded favorably (n = 8/9 [89%] in our series versus 
n = 61/91 [67%] in CH series as well as rate and degree of improvement (Magis, et al., 
2012). This effect might reflect differences in the biology of SUNCT/SUNA and CH, 
with the former possibly characterized by a prominent involvement of more peripheral 
areas of the nociceptive system. Furthermore, besides a slow neuromodulatory process 
of areas belonging to the pain matrix, which has been suggested to be the main 
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mechanism of action of ONS in primary headaches, a plastic modulation of structures, 
like the trigeminocervical complex, might explain the rapid and substantial 
improvement observed in the majority of patients with SUNCT and SUNA (Lambru , 
et al., 2014). 
In conclusion, this study shows a beneficial response to ONS in patients with chronic, 
medically intractable SUNCT or SUNA, which then continued over a median follow-
up of 38 months. There was a substantial reduction in headache-related disability and 
improvement of affective symptoms. The stimulator proved to be safe and generally 
well tolerated. Given the potential adverse events of other surgical procedures and their 
inconsistent results, ONS might be considered the surgical option of choice for 
medically intractable, chronic SUNCT and SUNA. The efficacy of ONS in SUNCT 
and SUNA further extends the potential therapeutic spectrum of action of this surgical 
procedure, strengthening its role in the management of chronic, medically refractory 
primary headache disorders. 
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5.4. Microvascular decompression of the trigeminal nerve in 
SUNCT and SUNA  
 
5.4.1. Methods 
 
5.4.1.1. Case material 
Ten patients three females and seven males were included in the case series. Seven 
patients had an IHS diagnosis of chronic SUNCT and three of chronic SUNA. The 
mean duration of the condition at the time of the operation was 5.5 years (range: 5-13 
years). In the absence of any published consensus, we used the definition of refractory 
or intractable SUNCT and SUNA that was previously employed in the ONS study 
(Lambru , et al., 2014). Patients were considered medically refractory SUNCT and 
SUNA when they failed to respond or tolerate adequate dosages of lamotrigine, 
topiramate, oxcarbazepine or carbamazepine, pregabalin or gabapentin, duloxetine and 
greater occipital nerve blockades. Intravenous lidocaine normally leads to a transitional 
headache improvement in SUNCT and SUNA patients and it improved the headache in 
all our patients, though the benefit lasted mainly for the duration of the infusion therapy. 
All candidates for trigeminal MVD had MRI scans with high-resolution sequences of 
the trigeminal nerves showed significant neurovascular compression ipsilaterally to the 
side of the pain (Table 49). We offered MVD rather than ONS when patients decided 
not to wait for funding for ONS or funding was declined.   
 
5.4.1.2. Outcome measures 
Pre-and post-operative data were prospectively collected from patient records and 
outpatient visits. Frequency, severity and duration of attacks at baseline were compared 
to headache characteristics at follow-ups post-MVD. Use of preventive medications 
and adverse events following the operation were also assessed. Finally, patients’ 
opinion on the efficacy of the procedure was evaluated. 
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5.4.1.3. MRI protocol 
The MRI protocol is detailed in Chapter 2. In summary, MRI examinations were 
performed on a 1.5-Tesla GE Signa Excite (GE Medical Systems, Milwaukee), 1.5-
Tesla Siemens Avanto (Siemens, Erlangen) or 3.0-Tesla Siemens Trio (Siemens, 
Erlangen) MRI scanner. The standard imaging protocol included high spatial and nerve-
cistern contrast resolution imaging acquisitions of the cisternal segments of the 
trigeminal nerves and vessels, with 3D Fast Imaging Employing Steady-State 
Acquisition (FIESTA; TE: 1.5ms, TR: 4.9ms, NEX: 4), 3D Constructive Interference 
in Steady State (CISS; TE: 5.3ms, TR: 10.6ms, Excitations: 1), or 3D Sampling 
Perfection with Application optimized Contrasts using different flip angle Evolution 
(SPACE; TE: 132ms, TR: 1000ms, Excitations: 2). Vascular contact with the cisternal 
segments of the trigeminal nerves was assessed on both sides on multiplanar reformats 
of the source high-resolution data. Neurovascular contact was defined by our 
neuroradiologist (I.N.) on the analysis of imaging by no perceptible CSF signal 
intervening the silhouette of the vascular structure (arterial or venous) and the cisternal 
segment of the trigeminal nerve. Contact with the root entry zone (REZ) was considered 
by our neuroradiologist the proximal 4 mm of the cisternal segment of the trigeminal 
nerve as it emerged from the pons (De Ridder , et al., 2002). 
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Table 49. MRI scan findings in SUNCT and SUNA patients undergoing microvascular 
decompression of the trigeminal nerve. 
 
 
Type of vessel Degree of compression Site of contact 
1 SCA Distortion REZ 
2 SCA Contact REZ 
3 AICA Contact REZ 
4 SCA Distortion REZ 
5 SCA Indentation REZ 
6 SCA + VEIN Distortion REZ 
7 AICA Contact REZ 
8 SCA Distortion REZ 
9 SCA Distortion REZ 
10 SCA Contact REZ and distally 
 
AICA: anterior inferior cerebellar artery; REZ: root entry zone; SCA: superior cerebellar artery  
 
 
5.4.2. Results 
The baseline demographic and clinical characteristics of these patients is summarised 
in Table 50. All patients were considered medically refractory, since they failed to 
respond to adequate trials, at appropriate doses for an appropriate length of time, of 
lamotrigine, topiramate, gabapentin, pregabalin, at least one of either carbamazepine or 
oxcarbazepine and duloxetine (Table 51). GONBs and IV lidocaine only provided 
transient improvement of the condition. A failed trial was defined as an unsatisfactory 
response, development of intolerable side effects or contraindication to the use of the 
medication. 
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Table 50. Demographic and clinical characteristics of SUNCT and SUNA patients who 
underwent microvascular decompression of the trigeminal nerve 
 
 Gender Diagnosis Headache 
duration 
Laterality Site Triggers 
1 F SUNCT 6 years Right V2-V3 S 
2 M SUNCT 12 years Right V1-V2 T 
3 F SUNCT 7 years Left V1-V2-C2 S + T 
4 M SUNCT 6 years Right V1-V2 T 
5 M SUNCT 13 years Right V1-V2-C2 S + T 
6 M SUNCT 7 years Left V1-V2 S 
7 F SUNCT 8 years Right V1-V2 S 
8 M SUNA 7 years Right V1-V2-V3 T 
9 M SUNA 5 years Left V1-V2 S + T 
10 M SUNA 5 years Right V1 S + T 
 
F: female; M: male; SUNA: short-lasting unilateral neuralgiform headache attacks with cranial 
autonomic features; SUNCT: short-lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing; S: spontaneous attacks; T: Attacks triggered from triggers zones; V1: Cutaneous 
territory innervated by the first division of the trigeminal nerve; V2: Cutaneous territory innervated by 
the second division of the trigeminal nerve; V3: Cutaneous territory innervated by the third division of 
the trigeminal nerve. 
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Table 51. Preventive treatments tried in SUNCT and SUNA patients without significant improvement and respective doses (total mg per day) 
 
 LMG TPM GBP PGB CBZ OXC MXT DUL Other drugs (mg/day) 
1 200 150 900 150 400 1200 600 100  
Baclofen 45; Lacosamide 
400; Tizanidine 24; IV 
lidocaine; GONB 
2 200 100 NK 500 NK 600 1200 NT 
Melatonin 9; prednisolone; 
GONB; verapamil 
3 NK 300 2400 100 300 NT NT 30 
Lacosamide 100; GONB 
IV lidocaine; Melatonin 15 
Indometacin 225 
4 400 400 2700 225 600 1050 NT 12 
Indometacin 200; Melatonin 
5; GONB; IV lidocaine 
5 200 250 NT 150 800 1200 NT NT GONB 
6 350 25 300 600 NK 2400 NT 30 IV lidocaine; GONB 
7 800 200 2700 50 NK 600 400 NT 
IV lidocaine; GONB; 
Indometacin 225; Melatonin 
15 
8 800 400 1800 600 400 NT NT 90  - 
9 400 200 3600 600 NK 1200 NT 90 
IV lidocaine; GONB; 
Indometacin 
10 200 75 NT NK 800 NT NT 100 Amitriptyline 20; VPA 1600 
CBZ: carbamazepine; DUL: duloxetine; GBP: gabapentin; GONB: greater occipital nerve blockade; IV: intravenous; LMG: lamotrigine; MXT: mexiletine; NK: not 
known; NT: not tried; OXC: oxcarbazepine; PGB: pregabalin; TPM: topiramate; VPA: sodium valproate 
 
 
CBZ: carbamazepine; DUL: duloxetine; GBP: gabapentin; GONB: greater occipital nerve blockade; IV: intravenous; LMG: lamotrigine; MXT: mexiletine; NK: not 
known; NT: not tried; OXC: oxcarbazepine; PGB: pregabalin; TPM: topiramate; VPA: sodium valproate 
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All patients underwent a MVD according to Jannetta’s procedure (Figure 16). 
Intraoperatively, a vascular loop contacting the REZ of the trigeminal sensory root was 
found in all ten cases. Table 52 summarises the outcome from MVD surgery.  
 
 
Figure 18. Intraoperative image of the pons showing a vascular loop contacting the 
trigeminal sensory root at the root entry. Intraoperative image after Teflon is positioned. 
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Table 52. Outcome from trigeminal microvascular decompression surgery in SUNCT and SUNA patients 
 
*Patient 1 became pain free for 9 months before pain relapsed. 
**Patient 5 became pain free for 12 months before pain relapsed.  
               MVD: microvascular decompression 
 Attacks frequency 
(per day) 
Attacks severity 
(1-10/10) 
Attacks duration 
(seconds) Follow-up 
(months) 
Pre-MVD Post-MVD Pre-MVD Post-MVD Pre-MVD Post-MVD 
1 20-40 2/week 10/10 5-7/10 120-180 3-5 36 
2 30-100 Pain-free 8-10/10 Pain-free 10-600 Pain-free 16 
3 20-60 2-3 7/10 5/10 30-240 30-240 12 
4 30-40 Pain-free 10/10 Pain-free 2-15 Pain-free 16 
5 60-100 60-100 9-10/10 9-10/10 10-20 10-20 24 
6 100-120 1/week 10/10 5-8/10 30-300 2-5 17 
7 20-50 Pain-free 8/10 Pain-free 10-60 Pain-free 17 
8 60-100 Pain-free 10/10 Pain-free 60 Pain-free 12 
9 40-60 10-30 8-10/10 5-7/10 20-30 20-30 34 
10 50-75 Pain-free 10/10 Pain-free 180-1200 Pain-free 12 
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Seven patients (70%) became headache free after the operation. Five of the seven 
patients (71.4%) remained headache-free at the last follow-up. The remaining two 
patients (patient 1 and 5) were headache-free respectively for 9 and 12 months before 
the headache relapsed. A post-operative MRI brain did not show any further vascular 
conflict. When returned, the headache attacks were less frequent, less severe and 
shorter-lasting in patient 1, whereas the headache load returned to the same level in 
patient 5. Low dose of carbamazepine (200 mg/day) enabled a sufficient control of 
SUNCT attacks in this case. Low dose of carbamazepine was not effective in keeping 
the pain under control prior to the operation in the same patient. The other three patients 
(patient 3, 7 and 9) reported a marked improvement post-operatively, with an 
improvement ranging between 50-90%. The patients who became and remained pain-
free were able to discontinue their prophylactic medications. There were no major 
surgical and post-surgical complications. One patient experienced a transient CSF leak 
and one patient developed neuropathic pain around the scar area.  
 
5.5. Discussion 
MVD of the trigeminal nerve is an established relatively safe surgical technique for 
refractory TN according to the international guidelines (Cruccu , et al., 2008). Our 
series suggests that MVD of the trigeminal nerve may also be an effective surgical 
treatment for medically refractory SUNCT/SUNA syndrome, when there is an evidence 
of vascular contact of the trigeminal nerve at the REZ. At a median follow-up of 16.5 
months, 80% of our patients experienced a meaningful improvement of their conditions, 
which is in keeping with the figures for MVD in TN patients at 1-year follow-up 
(Barker , et al., 1996). Two of our patients reported a relapse of their condition within 
a year from the operation. However, in both cases their headache condition remained 
significantly more manageable than baseline, with and without the aid of adjunctive 
pharmacological treatments. Overall the outcome of trigeminal MVD in our series is 
similar to the outcome of the only other series of SUNCT/SUNA patients operated with 
the same procedure (Williams , et al., 2010). The consistency of promising results in 
two series of patients coming from different centres suggest that this procedure may 
have an important role in the management of refractory forms of SUNCT/SUNA 
syndrome. However, in view of the short follow-up of our preliminary study, caution 
in interpretation of our data is required and our patients need to be followed up overtime 
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to establish the rate of relapse per annum. However trigeminal MVD may be considered 
a good surgical option for refractory SUNCT and SUNA with MRI evidence of a 
vascular loop, in view of the immediate pain relief in responders, no need of 
programming and the lack of hardware-related adverse events. Consersely, ONS may 
be a better option than MVD for older persons who could not tolerate a major invasive 
operation and for patients who suffer from alternating side headache attacks. While 
ONS can theoretically be used in every patient, only patients with a demonstrable 
trigeminovascular conflict ipsilateral to the pain would be suitable for MVD. On the 
other hand, the overall data on the 29 patients with SUNCT/SUNA treated with 
trigeminal MVD (19 published and 10 from this study) makes this procedure the most 
widely used in refractory cases, hence a reasonable option to consider in patients with 
neurovascular conflict, though more long-term efficacy data from larger series are 
required.  
 
The immediate relief from pain achieved from MVD in our and other series, raises the 
question about the pathophysiological role of the sensory root entry zone compression 
in SUNCT and SUNA. In view of the clinical similarities with TN, it is possible that in 
SUNCT/SUNA the vascular compression near the REZ may generate spontaneous 
ectopic impulses responsible for the short-lasting spontaneous attacks. Furthermore, the 
cross-talk activities between fibers mediating light touching (A-) and nociceptive 
fibers (A-) may account for the attacks triggered by innocuous stimulation. Unlike TN, 
in SUNCT/SUNA the pain is accompanied by cranial autonomic symptomatology, 
which implies hyperactivation of the trigemino-autonomic reflex. It is unknown 
whether this overactive trigemino-parasympathetic reflex is due to lack of central 
inhibition mediated by deranged posterior hypothalamic function, or whether it is due 
to irritation of the trigeminal arm of the trigemino-autonomic reflex by a vascular 
compression, or both. The general absence of reported episodes of cranial autonomic 
symptoms without pain, may indicate that the peripheral trigger plays an important role 
in maintaining the overactivity of the reflex at least in some patients.  
 
This study suggests the efficacy of MVD in the management of medically refractory 
SUNCT/SUNA patients. The main limitation of this study includes the relatively short 
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follow-up. However, our preliminary findings, along with the other cases reported in 
the literature, may suggest that trigeminal MVD, along with ONS could be considered 
as the first-line surgical options for medically refractory cases. This study also draws 
attention on new potential neuronal targets involved in the pathophysiology of this 
disorder, supporting a pathophysiological overlap between SUNCT/SUNA and TN. 
These conditions may constitute a clinical continuum due to a complex interaction 
between central and more peripheral mechanisms perhaps responsible for the clinical 
and therapeutic similarities and differences between them.  
 
5.6. Summary 
This chapter describes the efficacy and safety of ONS in a series of nine medically 
refractory SUNCT/SUNA patients and the safety and efficacy of trigeminal MVD in 
another series of ten medically refractory chronic SUNCT/SUNA patients. Both the 
procedures showed a remarkable outcome in most patients at follow-ups of variable 
lengths. These findings support the possible effectiveness of two therapeutic options 
for the management of patients with SUNCT/SUNA refractory to medical management. 
In view of the outcome of both the procedures, it is reasonable to propose that ONS and 
trigeminal MVD should be the first line treatments for refractory forms of 
SUNCT/SUNA. Caveats of these treatments include the high costs for ONS and the 
limitation of MVD to those patients with MRI evidence of neurovascular conflict with 
the trigeminal nerve ipsilaterally to the side of the pain. The efficacy of non-destructive 
approaches, such as ONS and trigeminal MVD should discourage the use of ablative 
procedure of the trigeminal pathway to treat refractory cases. 
 
Although the efficacy of ONS is seen in several primary and secondary headache 
disorders, thus implying non-specific pain relief mechanisms, the outcome of 
trigeminal MVD in SUNCT/SUNA may potentially shed light on novel mechanisms 
involved in the pathophysiology of this disorder that warrants further research.  
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Chapter 6.  A prospective study comparing the clinical phenotype of 
SUNCT/SUNA and trigeminal neuralgia 
 
6.1. Abstract 
Several clinical aspects suggest a striking clinical overlap between SUNCT/SUNA and 
TN. However, no direct clinical comparisons of these disorders has hitherto been 
conducted. To evaluate similarities and differences between SUNA (according to the 
new criteria of Chapter 2) and TN the demographic and clinical phenotype of 133 
SUNA patients was compared to the one of consecutive 79 TN patients. Patients 
underwent administration of a face to face semi-structured questionnaire capturing 
demographic and clinical characteristics. Both unadjusted and adjusted logistic 
regression analyses were used to identify predictors of patients suffering SUNA rather 
than TN. 
 
The clinical comparison highlighted several similarities and some clinical predictors of 
SUNA rather than TN such as: pain location in V1(OR: 11.29 95%CI: 3.92, 35.50, 
p<0.001), spontaneous only attacks (OR: 44.40, 95%CI: 4.50, 437.83, p=0.001) and a 
chronic pattern (OR: 13.19, 95%CI: 4.04, 43.08, p<0.001). Equally we found some 
clinical predictors for TN rather than SUNA. They included: duration of the attacks <1 
minute (OR: 7.95, 95%CI: 2.30, 27.57, p=0.001) and the presence of a refractory period 
in between triggered attacks (OR: 0.06; 95%CI: 0.02, 0.28, p-value <0.001). On the 
basis of this analysis we proposed new diagnostic criteria for trigeminal neuralgia. In 
conclusion, these findings suggest that SUNA and TN constitute different variant of a 
clinical continuum that could be named “Short-lasting trigeminal neuralgiform 
attacks”. This clinical view will hopefully open novel research directions towards a 
better understanding of the complex biological mechanisms underlying these similar 
disorders. 
 
 
 
 230 
 
6.2. Introduction 
The ICHD 3β classifies short lasting neuralgiform headache attacks and TN in different 
diagnostic categories. Short lasting neuralgiform headache attacks are subclassified into 
SUNCT and SUNA, and are included among the TACs, whereas TN is classified under 
the painful cranial neuropathies and other facial pains (Headache Classification 
Subcommittee of The International Headache, 2013). The TN diagnostic criteria have 
been based upon relatively old, methodologically poor studies (PEET , et al., 1952; 
Rasmussen , 1990; Jainkittivong , et al., 2012). More recently the Danish headache 
group conducted a series of studies in TN, including a detailed prospective clinical 
analysis of 158 face to face interviewed TN patients (Maarbjerg , et al., 2014). 
 
The proposed SUNCT and SUNA diagnostic criteria have been updated since 2004 on 
the basis of a prospective study conducted on a good-sized cohort of SUNCT but only 
a small number of SUNA patients (Cohen , et al., 2006). The comparison between the 
IHS diagnostic criteria for the Short-lasting unilateral neuralgiform headache attacks 
and classical TN highlights what are considered the distinguishing features between 
these disorders (Table 53). They include: the moderate or severe pain intensity in 
SUNCT/SUNA compared to the severe intensity of the TN episodes; the longer 
duration of SUNCT/SUNA attacks compared to the very short TN attacks; the presence 
of at least one cranial autonomic feature ipsilateral to the side of the pain during attacks 
in SUNCT/SUNA and the absence of any cranial autonomic features during TN attacks. 
Furthermore, attacks can be precipitated by innocuous stimulation of the affected side 
of the face in TN, whereas no triggers are mentioned for SUNCT/SUNA attacks. 
However, in the comments of the diagnostic criteria, the IHS Classification Committee 
states that SUNCT/SUNA attacks are usually triggerable. Moreover, the prospective 
series of patients published between the publication of the ICHD-2 and the ICDH-3β, 
suggested that extra-trigeminal pain location can occur in almost 30% of the SUNCT 
patients (the SUNA group was too small to comment on findings) (Cohen , et al., 2006). 
The current proposed diagnostic criteria for TN do not mention the association between 
pain and cranial autonomic features, which could lead to diagnostic confusion for those 
SUNCT/SUNA patients that could conceivably be classified as TN, if the TN criteria 
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are fulfilled despite association with cranial autonomic features.  (Headache 
Classification Subcommittee of The International Headache, 2013). 
 
A careful evaluation of the proposed ICHD-3 diagnostic criteria, reveals the difficulty 
in keeping SUNCT, SUNA and TN separate in view of their remarkable clinical overlap 
in most domains of their phenotypic presentation. Since the largest prospective clinical 
phenotype studies in TN took place before SUNCT and SUNA were recognized as 
independent clinical conditions, they did not evaluate in details clinical features that 
could distinguish TN from SUNCT/SUNA, hence preventing any indirect comparison 
between these conditions. Moreover, no SUNCT and SUNA series have been compared 
to TN series to formally establish the presence of any significant phenotypical 
difference between these disorders. 
 
In this chapter we aim to compare the clinical characteristics of a large cohort of 
SUNCT/SUNA patients with the ones of a large cohort of TN patients to determine the 
presence of clinical significant differences between these disorders.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 232 
 
Table 53. Comparison of International Classification of Headache Disorders 3 beta 
diagnostic criteria for classical trigeminal neuralgia and short-lasting unilateral 
neuralgiform headache attacks 
 
 SUNCT SUNA Trigeminal 
neuralgia 
Number of 
attacks 
At least 20 At least 20 At least 3 
Intensity Moderate or severe Moderate or severe Severe 
Pain location V1-V2-V3 V1-V2-V3 V1-V2-V3 
Pain duration 1-600 seconds 1-600 seconds 
Faction of a 
second to 120 
seconds 
Pain quality Stabbing Stabbing 
Electric shock 
like, shooting, 
stabbing or sharp 
Associated 
autonomic 
features 
Conjunctival 
injection and 
lacrimation 
1 cranial autonomic 
symptoms/signs None 
Triggers - - 
Precipitated by 
innocuous stimuli 
to the affected 
side of the face 
Attacks 
frequency 
≥1 attack/day for 
more than half of the 
time when the 
disorder is active 
≥1 attack/day for 
more than half of the 
time when the 
disorder is active 
- 
 
SUNA: Short-lasting neuralgiform headache attacks with autonomic symptoms; SUNCT: Short-lasting 
neuralgiform headache attacks with conjunctival injection and tearing; V1: ophthalmic trigeminal 
territory; V2: maxillary trigeminal territory; V3: mandibular trigeminal territory;  
 
6.3. Methods 
The SUNCT and SUNA study group includes the 133 patients phenotyped in Chapter 
2 (for methodological details see Chapter 2). The study conducted in chapter 2 
demonstrated the lack of significant clinical differences between SUNA and SUNCT, 
hence it was decided to amalgamate these two groups of patients for the purposes of 
this study. Furthermore, it was proposed that as SUNCT is likely to be a subset of 
SUNA, all these patients can be classified in the unified diagnosis of SUNA. In this 
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chapter, the previously diagnosed SUNCT or SUNA patients were unified under the 
term SUNA. As outlined in chapter 2, ICHD-3 encompasses SUNCT and SUNA 
under the category of “short-lasting unilateral neuralgiform headache attacks” but this 
term would be a misnomer as it potentially also describes TN and does not highlight 
the autonomic features which are central for the diagnosis of SUNCT and SUNA. 
Hence, we have opted to use the term “SUNA” to encompass this group rather than 
“short-lasting unilateral neuralgiform headache attacks” 
 
The TN study group consisted of consecutive patients seen at the Facial Pain clinic 
within the National Hospital for Neurology and Neurosurgery from 2010 to 2012. 
Diagnosis was based on ICDH-2 criteria (Headache Classification Subcommittee of 
The International Headache Society., 2004). The Facial Pain clinic is a tertiary referral 
clinic in the UK and receives patients from all over the Country, referred by general 
practitioners, dentists, maxillo-facial surgeons as well as neurologists and 
neurosurgeons. All patients were interviewed face to face by a single researcher (GL) 
using a comprehensive standardized semi-structured questionnaire (Appendix) and data 
were collated onto an electronic database (SPSS). In view of the potential high attack 
load during an active pain period, headache/facial pain charts were not used in this 
study. If any patients could not accurately report any of the clinical features needed, or 
could not remember because they were out of a bout of TN attacks, they were re-
phenotyped at three to six-month intervals during their clinical follow-ups to ensure 
collection of accurate information. 
 
The study was approved by Northwick Park Hospital Research Ethics Committee, 
London, UK (REC no:11/LO/1709). 
 
6.4. Statistical analysis  
Baseline characteristics were compared between the cohorts of SUNA and TN using 
Chi-squared tests or Fisher’s exact tests for categorical variables and Student’s t-tests 
or Mann Whitney U-tests depending on the distribution of the continuous variables. 
Both unadjusted and adjusted logistic regression analyses were used to identify 
predictors of patients suffering SUNA rather than TN. Adjustments were made for 
characteristics that have previously been associated with either condition (i.e. site, 
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quality of the pain, duration, frequency of the attacks and cranial autonomic symptoms). 
Statistical analyses were performed using STATA (Stata Corp. 2001. Stata Statistical 
Software: Version 12.1, College Station, Texas, USA). All reported P-values are two-
sided and a significance level less than 5% is considered significant. 
 
6.5. Results 
The clinical and demographic characteristics of a SUNA cohort (n=133) were compared 
to those of a TN cohort (n=80). However, one TN patient was excluded from the final 
analysis because of incomplete clinical information provided. Of the 79 TN patients 
included in the analysis, 70 patients had classical TN purely paroxysmal and nine 
patients had classical TN with concomitant persistent facial pain.   
 
6.5.1. Age, gender and duration of symptoms 
The demographic characteristics of our cohorts are shown in Table 54. Female were 
more represented than men in both the SUNA and TN cohort of patients. There was no 
statistically significant difference in the proportion of female in the two cohorts. The 
mean age of onset of TN was approximately a decade later than the SUNA onset 
(p<0.0001). 
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 Table 54. Demographic characteristics of SUNA and SUNCT patients 
 
CI: confidence interval; SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic 
symptoms; SUNCT: short-lasting unilateral neuralgiform headache attacks with conjunctival injection 
and tearing;  
 
6.5.2. Diagnoses made on previous clinical assessments 
The majority of patients with SUNA had previously been given a diagnosis of TN 
(n=68, 51.1%). A proportion of patients with TN were correctly diagnosed before 
coming to our clinic (n=18, 22.8%). However dental pathologies were incorrectly 
diagnosed in 19 patients (24.1%) and a non-specific diagnosis of facial pain was 
proposed in 34 patients (43.0%). Data on this subject was missing for 7 patients (8.9%). 
 
6.5.3. Precipitating events 
Unlike the SUNA cohort (n= 37, 27.8%), only nine of 79 TN patients reported 
precipitating events prior to the onset of symptoms (11.4%). These included facial 
trauma, flu-like symptoms and dental procedures performed before the facial pain 
started rather than once it had already occurred. The remaining 70 TN patients were not 
aware of any events that may have had a causative role in the exacerbation of their 
condition.  
 
 SUNA  
n (%) 
Trigeminal 
Neuralgia n (%) 
p-value 
(<0.05) 
Gender 
Male 50 (37.6%) 31 (39.2%) 
0.811 
Female 83 (62.4%) 48 (60.8%) 
Mean (95% CI) age of 
onset (years) 
43.52 (±14.8) 53.33 (±13.3) 
 
<0.001 
Age range of onset 13-76 years 19-83 years 
 
- 
Median duration of 
symptoms (range) 
6 (1-45) years 8 (1-39) years 
 
- 
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6.5.4. Laterality of attacks 
Sixty-three SUNA patients (47.4%) and 49 TN patients (62%) had exclusively right-
sided attacks (p=0.038); 51 SUNA (38.3%) and 28 TN (35.4%) patients had exclusively 
left-sided attacks (p=0.672). A significant higher proportion of SUNA (n=18, 13.5%) 
compared to TN patients (n=2, 2.5%) had side alternating unilateral attacks (one patient 
predominantly centred over the right hand side and one patient had side alternating 
unilateral attacks equally distributed between sides) (p=0.008). None of the TN patient 
had bilateral attacks. Table 55 outlines the comparison between SUNA and TN 
laterality of attacks.  
 
 
Table 55. Laterality of attacks in SUNA and trigeminal neuralgia 
 
 
SUNA 
(numbers) 
Trigeminal  
Neuralgia 
(Numbers) 
p-value  
(<0.05) 
Right-sided 63 49 0.038 
Left-sided 51 28 0.672 
Alternating 
(Unilateral) 
18 2 0.008 
Bilateral 1 0 - 
               
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms 
 
6.5.5. Site of attacks 
Figure 17 outlines the difference in pain distribution within the trigeminal territories 
between the SUNA and TN cohorts. Pain exclusively in the V1 territory was reported 
by a higher proportion of SUNA patients (n=19, 14.3%) compared to TN patients (n=1, 
1.3%). Conversely, pain in V2 only and in V3 only was reported by a significantly 
higher number of TN patients (V2: n=14, 17.7%; V3: n=18, 22.8%) compared to SUNA 
patients (V2: n=4, 3.0%; V3: n=1, 0.8%). A significantly higher proportion of SUNA 
(n=43, 32.3%) compared to TN patients (n=12, 15.2%) reported pain in both V1 and 
V2 trigeminal territories, whereas a significantly higher proportion of TN patients 
(n=23, 29.1%) experienced pain in both V2 and V3 territories compared to SUNA 
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patients (n=12, 9.0%). A similar proportion of SUNA (n=26, 19.5%) and TN patients 
(n=11, 13.9%) reported pain in all trigeminal territories. Extra-trigeminal territory pain 
(C2-C3) was reported in 28 SUNA (21.1%) patients. None of the TN patients reported 
pain in extra-trigeminal territories. A full list of attack sites is shown in Table 56. 
 
 
 
Figure 19. Distribution of pain territories in SUNA and TN cohorts 
 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; a; TN: 
trigeminal neuralgiV1: ophthalmic trigeminal territory; V2: maxillary trigeminal territory; V3: 
mandibular trigeminal territory 
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Table 56. Site of the attacks in SUNA and trigeminal neuralgia cohorts 
 
  
SUNA 
N (%) 
 
Trigeminal neuralgia 
N (%) 
 
p-value 
(<0.05) 
Peri-orbital 77 (57.9%) 15 (19%) <0.001 
Retro-orbital 45 (33.8%) 2 (2.5%) <0.001 
Forehead 43 (32.3%) 28 (35.4%) 0.642 
Temporal 59 (44.4%) 19 (24.1%) 0.003 
Parietal 28 (21.1%) 1 (1.3%) <0.001 
Vertex 5 (3.8%) 1 (1.3%) 0.289 
Occiput 27 (20.3%) 0 (0%) - 
Neck 1 (0.8%) 0 (0%) - 
Cheek 59 (44.4%) 53 (67.1%) 0.001 
Side of nose 17 (12.8%) 10 (12.7%) 0.979 
Ear 11 (8.3%) 0 (0%) - 
Retroauricular 1 (0.8%) 0 (0%) - 
Jaw 33 (24.8%) 47 (59.5%) <0.001 
Upper teeth 10 (7.5%) 25 (31.6%) <0.001 
Lower teeth 7 (5.3%) 18 (22.8%) <0.001 
Upper lip 10 (12.7%) 9 (6.8%) 0.339 
Lower lip 5 (6.3%) 6 (4.5%) 0.223 
Chin 4 (5.1) 3 (2.3%) 0.755 
                  
 SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; 
 
6.5.6. Severity of the pain 
The patients were asked to recall the average severity, along with the maximum and 
minimum severity of their attacks when they were not on effective treatments. A verbal 
rating scale (VRS) of 0 to 10, with 0 being no pain and 10 being very severe pain was 
used. The median severity of the pain was very severe in both groups with a VRS of 10 
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in the SUNA (IQR: 8-10) and 8 in the TN group (IQR: 8-10) (P=0.04, Z-score: 2.0). A 
significantly higher proportion of TN (n=9, 11.4%) compared to SUNA patients (n=4, 
3.0%) reported an average severity of attacks of 6 on the VRS (moderate intensity) 
(p=0.002).  
6.5.7. Quality of pain 
In our cohorts, the most commonly described pain qualities were stabbing and sharp. 
The pain descriptors “electric-shock like” and “shooting” were significantly more 
represented in the TN group than in the SUNA group (Table 57). All patients had at 
least one of the above four qualities of pain. A pulsating nature to the pain was reported 
in 19 SUNA (14.3%) and 14 TN patients (17.7%) and never as an isolated feature. 
 
Table 57. Quality of pain 
 
 SUNA 
 n (%) 
Trigeminal 
neuralgia n (%) 
p-value 
(<0.05) 
Stabbing 109 (82.0%) 63 (79.7%) 0.691 
Sharp 80 (60.2%) 44 (55.7%) 0.524 
Electric shock 46 (34.6%) 56 (70.9%) 0.001 
Shooting 39 (29.3%) 36 (45.6%) 0.016 
Burning 22 (16.5%) 7 (8.9%) 0.115 
Pulsating 19 (14.3%) 14 (17.7%) 0.504 
Jabbing 10 (7.5%) 0 (0%) - 
Pressure 8 (6.0%) 1 (1.3%) 0.097 
Tightening 4 (3.0%) 0 (0%) - 
Dull 3 (2.3%) 0 (0%) - 
Ache 0 (0%) 2 (2.5%) - 
 
  SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms;  
 
6.5.8.  Duration and profile of attacks 
The SUNA group had a median duration of attacks of 60 seconds (mean duration: 160.5 
seconds ±196.7, range: 1-900 seconds) whereas the TN group had a median duration of 
attacks of 15 seconds (mean duration: 47.7 seconds ±87.6, range: 1-600 seconds) (P= 
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<0.001, Z-score: 6.4). The vast majority of SUNA patients (n=131, 98.5%) had a usual 
duration of attacks ranging from 1-600 seconds, in line with the ICHD-3 criteria. 
However, 37 (27.8%) patients reported some longer lasting attacks ranging from 900 
to 3600 seconds.  
All but four TN patients (n=75, 94.9%) had a usual attack duration ranging from 1-120 
seconds, in line with the ICHD-3 criteria. However, 25 TN patients (31.6%) reported 
some longer lasting attacks ranging from 180 to 900 seconds.  
 
The comparison between different attack profiles in SUNA and TN patients is outlined 
in Table 58 and 59. A higher proportion of TN compared to SUNA reported a single 
stab profile (p<0.001). Conversely, a higher proportion of SUNA compared to TN 
reported attacks following the plateau-like profile (p=0.006). Of those who reported 
only one attack profile, a single stab profile was reported by a significantly higher 
proportion of TN patients compared to SUNA (p=0.001). A substantial proportion of 
both SUNA and TN patients described their attacks using more than one attack profile. 
The proportion of SUNA patients that reported three attack profiles was significantly 
higher than the one of the TN group (p=0.031).  
 
 
  Table 58. Frequency and duration of the different attack profiles in SUNA and TN 
 
 
SUNA 
n (%) 
Median duration (IQR) 
Trigeminal neuralgia  
n (%) 
Median duration (IQR) 
p-value* 
(<0.05) 
Single stabs 
65 (48.9%) 
10 sec (10-120 sec) 
62 (78.5%) 
5 sec (1-120 sec) 
<0.001 
Repetitive stabs 
78 (58.7%) 
180 sec (60-300 sec) 
42 (53.2%) 
60 sec (3-7200 sec) 
0.436 
Serrated stabs 
64 (48.1%) 
240 sec (60-240 sec) 
30 (38.0%) 
105 sec (4-600 sec) 
0.150 
Plateau-like 
27 (20.3%) 
300 sec (20-600 sec) 
5 (6.3%) 
60 sec (60-600 sec) 
0.006 
Missing data 1 (0.8%) 1 (1.3%) 0.708 
 
IQR: Inter-quartile range; SUNA: short-lasting unilateral neuralgiform headache attacks with 
autonomic symptoms; *P-value relates to the differences in number of events between SUNA and 
trigeminal neuralgia. 
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Table 59. Presence of isolated and multiple attack profiles 
 
 SUNA 
n (%) 
Trigeminal 
neuralgia n (%) 
p-value 
(<0.05) 
Single profile 48 (36.1%) 25 (31.6%) 0.510 
Single stabs  5 (3.8%) 13 (16.5%) 0.001 
Repetitive stabs  19 (14.3%) 4 (5.1%) 0.036 
Serrated stabs  17 (12.8%) 5 (6.3%) 0.136 
Plateau-like  7 (5.3%) 3 (3.8%) 0.626 
Two profiles 59 (44.4%) 46 (58.2%) 0.054 
Three profiles 22 (16.5%) 5 (6.3%) 0.031 
All four profiles 1 (0.8%) 0 (0%) - 
Missing data 1 (0.8%) 0 (0%) - 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: 
short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing  
 
 
6.5.9. Frequency of attacks 
In assessing the frequency of attacks, we considered single stabs, groups of stabs or 
serrated stabs as single episodes. The median daily attack frequency was 25 in the 
SUNA group (mean: 46.6 attacks/day ±56.6; range: 1-250) and 15 in the TN group 
(mean: 23.1±23.9; range: 2-100). However, in the TN patients, the frequency of the 
attacks was countable by 57 out of 79 patients (72.2%); the remaining 22 patients stated 
that the attacks were so frequent that they could not count them. Conversely the number 
of the attacks was countable in every SUNA patients, although in patients with 
numerous attacks an estimate of the attacks per hour multiplied per number of hours of 
pain per day, was provided. For this reason, a statistical comparison of the attack 
frequency between the two groups was not performed. In fact, assuming that the 22 TN 
patients had >100 attacks/day, the proportion of patients with an average frequency of 
more than 100 attacks/day was higher in TN (27.8%) than in SUNA (n=12, 9.0%) 
(p<0.001).  
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6.5.10. Cranial autonomic symptoms 
Although cases of TN with cranial autonomic features have been described prior to the 
publication of the latest version of the classification, the ICHD-3β does not include the 
cranial autonomic features domain in the TN diagnostic criteria (Rasmussen , 1990a; 
Sjaastad , et al., 1997; Simms , et al., 2011). In our cohort 10 TN patients reported 
lacrimation during some of the attacks (12.7%). Of these, the degree of lacrimation was 
mild in nine and moderate in one patient. One patient reported ipsilateral lacrimation, 
conjunctival injection and blocked nose with few of the attacks and another patient 
reported ipsilateral lacrimation and rhinorrhoea seldom associated with the pain. Of the 
10 patients with TN and some degree of cranial autonomic activation, the pain also 
involved the V1 territory in six patients (60%). This percentage is remarkably higher 
compared to the involvement of the V1 territory in the remaining of the TN cohort 
(30.4%), suggesting a link between pain location and type of autonomic feature, which 
is this cohort was mainly lacrimation. Using the cut-off of 120 seconds for TN attack 
duration, our data showed that seven out of ten patients who reported some degree of 
autonomics had attacks lasting 120 seconds and only three patients experienced 
autonomic features during longer lasting attacks. In these patients the duration of the 
attacks was 180 seconds, 600 seconds and 180 seconds and followed a serrated pattern 
in one and a repetitive stabs pattern in two of them. This support initial evidence 
suggesting that the occurrence of cranial autonomic features was not associated with 
longer attacks duration (Haviv , et al., 2016). Table 60 summarises the main clinical 
features of the group of TN patients with cranial autonomic features. 
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Table 60. Clinical features of trigeminal neuralgia with cranial autonomic features 
 
 Trigeminal neuralgia with cranial autonomic features 
Gender Female: male = 5:5 
Age of onset Median=53.5 years old (range: 30-70 years old) 
Pattern Chronic: episodic = 5:5 
Pain side Right: left = 8:2 
Pain intensity Severe: moderate = 9:1 
Attacks duration Median = 30 seconds (IQR: 56, range: 2-80 seconds) 
Attack frequency: 
Median = 9/day (IQR: 24/day, range: 5-70/day; attacks 
were not countable in 4 patients) 
Behaviour during 
attacks 
Still: restless = 10:0 
Attacks 
triggered/spontaneous 
Both triggered and spontaneous: triggered only = 9:1 
Refractory period Yes: no = 1:1 (7 patients were unsure; 1 md) 
Interictal pain Yes: no = 5:5 
Response to CBZ 
50% improvement = 5 patients 
50% improvement = 1 patient 
md: 2 patients; not tried = 2 patients 
MRI findings 
Trigeminal conflict: YES:NO = 6:4 (in one case conflict is 
bilateral) 
CBZ: carbamazepine; md: missing data: MRI: magnetic resonance image 
 
6.5.11. Triggering of attacks 
The comparison between the proportions of patients with spontaneous and/or triggered 
attacks in SUNA and TN patients is outlined in Table 61. A significantly higher 
proportion of SUNA compared to TN patients had spontaneous attacks only (p<0.001). 
Conversely a significantly higher proportion of TN compared to SUNA patients had 
triggered attacks only (p<0.001). Among SUNA patients with triggered attacks (n=80, 
60.2%), 72 (90%) had attacks that could be provoked by various forms of cutaneous 
and/or intraoral stimulation. All TN patients with triggered attacks (n=74, 93.7%) had 
attacks that could be provoked by various forms of cutaneous and/or intraoral 
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stimulation. Trigger areas were ipsilateral to the side of pain in all patients. A list of 
trigger factors is outlined in Table 62.  
 
 
Table 61. Proportion of patients with spontaneous, triggered or both 
 
 SUNA 
Trigeminal 
neuralgia 
p-value 
(p<0.05) 
Spontaneous and 
triggered 
75 (56.4%) 55 (70.5%) 0.055 
Spontaneous only 53 (39.8%) 4 (5.1%) <0.001 
Triggered only 5 (3.8%) 19 (24.4%) <0.001 
Missing data 0 (0%) 1 (1.3%) - 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; 
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Table 62. Trigger factors in SUNA and TN patients with triggerable attacks 
 
 
SUNA 
n (%) 
Trigeminal 
neuralgia 
p-value 
(p<0.05) 
Cold wind 61 (76.3%) 40 (54.1%) <0.001 
Chewing/eating 57 (71.3%)  67 (90.5%) 0.002 
Brushing teeth 53 (66.3%) 65 (87.8%) 0.001 
Light touch 52 (65.0%) 62 (83.8%) 0.007 
Washing/Brushing hair 39 (48.8%) 8 (10.8%) <0.001 
Talking 29 (36.3%) 42 (56.8%) 0.010 
Washing face 27 (33.8%) 33 (44.6%) 0.167 
Swallowing 14 (17.5%) 3 (4.1%) 0.016 
Blowing nose 13 (16.3%) 8 (10.8%) 0.325 
Shaving 9 (11.3%) 16 (21.6%) 0.081 
Showering 5 (6.3%) 1 (1.4%) 0.116 
 
Valsalva Manoeuvres 27 (34.2%) 7 (9.5%) <0.001 
Neck movements 13 (16.5%) 8 (10.8%) 0.325 
Exercise 5 (6.3%) 2 (2.7%) 0.291 
Bright lights 4 (5.1%) 0 (0%) - 
Loud noises 6 (7.6%) 0 (0%) - 
Alcohol 0 (0.0%) 0 (0%) - 
Strong smells 1 (0.8%) 0 (0%) - 
Stress 3 (3.8%) 5 (6.8%) 0.400 
Moving/vibrations 7 (8.8%) 7 (9.5%) 0.878 
Cold/hot weather 3 (3.8%) 2 (2.7%) 0.714 
 
*Frequencies and percentages for cutaneous/intraoral triggers refer to: SUNA = 70 patients and TN = 74 
patients (patients with headache attacks triggered only by cutaneous/intraoral stimulation). 
** Frequencies and percentages for other triggers refer to SUNA = 80 patients and TN 74 patients 
(patients with headache attacks triggered by any triggers). 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT: 
short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; TN: 
trigeminal neuralgia 
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6.5.12. Refractory period 
Among patients with cutaneous triggers, 59 SUNA (81.9%) and 24 TN (32.4%) could 
trigger an attack immediately after the cessation of the previous one, thereby displaying 
no refractory period (p<0.001). Conversely, five SUNA (6.9%) and 32 TN patients 
(43.2%) did experience a refractory period (p<0.001). Seven SUNA (9.7%) and 19 TN 
patients (25.7%) were uncertain about the presence of a refractory period (p=0.011). 
We did not have the data on this subject for one SUNA patient (1.4%) (Figure 18). 
 
The mean duration of the refractory period was 240 seconds in SUNA and 189.5 
seconds (median 150 seconds, range: 10-900 seconds) in TN patients (p=0.23, Z-score: 
-1.1). However only 20 of the 32 TN patients who reported a refractory period could 
confidently remember the average duration of the refractory periods (62.5%).  
 
 
Figure 20. Refractory period after triggered attacks in SUNA and TN 
 
 
SUNA: short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; 
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6.5.13. Other associated symptoms 
Behaviour during attacks. Ninety-three SUNA (70.5%) and 72 TN (91.1%) patients 
preferred to stay still during an attack. On the other hand, 39 SUNA (29.5%) and 7 TN 
patients (8.9%) felt restless and agitated during the pain episodes (p<0.001). Data for 
one SUNA patient (0.8%) was incomplete. 
Symptoms often associated with migraine. Fifty-three SUNA (39.8%) patients reported 
at least one migrainous symptom during attacks. Two TN patients reported migrainous 
symptoms during some of the attacks. One patient reported nausea and one ipsilateral 
photophobia. Both patients had a personal and family history of migraine.  
Aura. In our cohort, two SUNA (1.5%) and no TN patients experienced aura symptoms 
during some attacks.  
Diurnal variation and predictability of attacks. Sixty SUNA (45.5%) and 49 TN 
patients (64.5%) experienced attacks exclusively during waking hours. Seventy-two 
SUNA (16.7%) and 27 TN (35.5%) patients also experienced attacks during sleep. 
Among this group, three SUNA and one TN patient had mainly nocturnal attacks. Data 
was not available for one SUNA and three TN patients.  
 
One hundred and twenty-six SUNA (94.7%) and all TN patients (100%) could not 
reliably predict the occurrence of their attacks. Five SUNA (3.8%) experienced mostly 
random attacks along with some predictable attacks, which would occur at fixed times. 
In two SUNA patients (1.5%) attacks were generally predictable: one patient stating 
that his attacks occurred consistently at 3am, 8am and 1pm every day and another 
patient at 1am and 10am. Only one TN patient (1.3%) stated that her attacks were 
mostly random with one predictable attack, which would occur at 4 am.  
 
6.5.14. Periodicity and chronicity of SUNA and trigeminal neuralgia 
According to the definition of episodic and chronic short-lasting unilateral neuralgiform 
headache attacks proposed in the ICHD-3β criteria (Headache Classification 
Subcommittee of The International Headache, 2013), 120 SUNA (90.2%) in our cohort 
could be classified as chronic and 13 (9.8%) as episodic. Although the ICDH-3β criteria 
for TN do not subdivide the condition in chronic and episodic, TN is considered a 
recurrent episodic disorder. In our cohort, 43 patients displayed an episodic pattern 
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(54.4%) and 34 a chronic pattern (43.0%); of the latter group, 21 patients reported a 
chronic pattern from the onset of the condition and in 13, the condition started as 
episodic and became chronic over time. Two patients could not make any statement on 
their facial pain pattern, since they had always been on preventive medications. 
The median number of bouts per year in episodic SUNA and “episodic” TN were two 
(SUNA range: 1 every two years to 12 per year) (TN range: 1-6 per year), each one 
lasting a median of 2.75 months in SUNA (range: 1 week to 16 months) and three 
months in TN (range: 15 days to 10 months). 
 
6.5.15. Interictal pain in SUNA and trigeminal neuralgia  
Sixty-four SUNA (48.1%) patients reported interictal background pain between 
exacerbations. In the TN cohort, 70 patients had classical TN purely paroxysmal and 
nine patients had classical TN with concomitant persistent facial pain. Twenty-three 
TN patients (29.1%) reported some degree of intermittent interictal background facial 
pain: these included all patients with TN with concomitant persistent facial pain and 14 
of the 70 patients with classical TN purely paroxysmal (20.3%). Data were incomplete 
for one patient. In 14 of the 23 TN patients (60.9%) the interictal pain coincided with 
the original onset of the stabbing pain, similarly to the SUNA group (63.0%). In the 
remaining TN patients, two reported the onset of interictal background pain when the 
condition became chronic and two reported the onset of interictal pain 13 and 15 years 
after the onset of the paroxysmal pain. 
 
In our TN cohort, 40 patients had a personal history of migraine (50.6%; 2 missing 
data) and 43 patients (56.6%; 3 missing data) had a migraine biology (suggested by the 
presence of a personal and/or family history of migraine). A migraine biology was 
significantly more represented in the SUNA (n=88 patients, 71%) rather than the TN 
cohort (p=0.037). 
  
6.5.16. MRI findings in trigeminal neuralgia 
Seventy-two TN patients had an MRI scan of the brain, though not all of them had the 
investigation within our National Health Service (NHS) Trust. This prevented us from 
systematically compare the MRI findings in the TN cohort with the ones of the SUNA 
 249 
cohort. Twenty-one patients had no NVC conflict (29.2%), 33 had an ipsilateral NVC 
(45.8%), which was caused by an artery in 31 of 33 patients. Five patients had a 
contralateral loop (6.9%) and 13 patients a bilateral loop (18.1%). A total of 46 patients 
(63.9%) had either a unilateral loop ipsilateral to the pain side, or bilateral loops. With 
the available data we could not comment on the severity of the contact. Data on MRI 
scans was missing for 7 patients.   
 
6.5.17. Clinical predictors for SUNA or trigeminal neuralgia 
Table 63 outlines the results of the unadjusted univariate logistic regression analysis for 
different demographic and clinical predictors for a diagnosis of SUNA or TN. The 
clinical features were selected from the diagnostic criteria for SUNA and TN and from 
characteristics that were deemed clinically relevant based on this study’s outcomes. 
Clinical predictors for SUNA rather than TN included age of onset, alternating side of 
the attacks, occurrence of pain in the ophthalmic trigeminal division, duration of attacks 
longer than 5 minutes, plateau-like profile of the attacks, the presence of spontaneous 
only attacks and the chronic pattern. Clinical predictors for TN included occurrence of 
pain in V3, electric shock-like and shooting quality of pain, duration of the painful 
attacks of <1-minute, single stabs profile of the attacks and the presence of triggered 
only attacks.  
 
A backward regression model was then applied to the two cohorts and those variables 
that were predictive for SUNA or TN according to the unadjusted logistic regression 
analysis in Table 11, were selected The quality of pain variable was not included in the 
adjusted analysis. This is because the electric shock-like, shooting, stabbing and sharp 
are all together included under domain C of the IHS diagnostic criteria of TN, hence of 
limited predictive value. A multivariate logistic regression analysis on these variables, 
adjusted for age of onset of the headache and gender, confirmed that pain in V1 is a 
predictor for SUNA; that attacks duration <1 minute is a predictor for TN, but that 
different attacks profile are not linked with one of the other condition; spontaneous only 
attacks and triggered only attacks are predictors respectively for SUNA and TN and a 
chronic pattern of occurrence the disorder is a predictor for SUNA rather than TN 
(Table 64). 
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The variable “refractory period” was analysed separately from the rest of the clinical 
variables, since it was applicable only for those SUNA and TN patients who reported 
attacks triggered by cutaneous stimulation: n=146 patients, n=71 SUNA patients and 
n=75 TN patients. Data was missing for one SUNA patient. The univariate regression 
analysis for this subgroup of patients showed highly statistically significant association 
between TN and the presence of a refractory period [OR: 0.06; 95%CI: 0.02, 0.28, p-
value <0.001]. Similarly, there was a highly statistically significant association between 
SUNA and the absence of a refractory period [OR: 16.7; 95%CI: 3.6, 50.0, p-value 
<0.001].  
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Table 63. Unadjusted logistic regression analysis outlining demographic and clinical 
predictors for SUNA compared to trigeminal neuralgia syndrome. 
 
 
SUNA 
Trigeminal 
neuralgia 
p-value 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Gender; female versus male 0.93 (0.53, 1.67) 1.07 (0.60, 1.89) 0.811 
Age of onset 1.05 (1.03, 1.07) 0.95 (0.93, 0.97) <0.001 
Side of pain; 
Right 
Left 
Alternating/Bilateral 
 
Ref 
1.42 (0.78, 2.56) 
7.3 (1.64, 33.25) 
 
Ref 
0.70 (0.39, 1.28) 
0.14 (0.03, 0.61) 
 
 
0.250 
0.009 
Site of pain; 
V1 versus not V1 
V2 versus not V2 
V3 versus not V3 
 
13.75 (6.95, 27.21) 
0.96 (0.50, 1.84) 
0.25 (0.14, 0.44) 
 
0.07 (0.036, 0.14) 
1.04 (0.54, 2.00) 
4.00 (2.27, 7.27) 
 
<0.001 
0.901 
<0.001 
 
Quality of pain; 
Electrick shock versus not 
Shooting versus not 
Stabbing versus not 
Sharp versus not 
 
 
0.21 (0.12, 0.39) 
0.49 (0.27, 0.88) 
1.15 (0.57, 2.33) 
1.20 (0.68, 2.11) 
 
 
4.60 (2.52, 8.41) 
2.01 (1.13, 3.60) 
0.87 (0.43, 1.75) 
0.83 (0.47, 1.46) 
 
 
<0.001 
0.018 
0.691 
0.525 
Duration attacks; 
<1 min 
1-2 min 
2-3 min 
3-4 min 
4-5 min 
>5 min 
 
0.22 (0.11, 0.44) 
0.87 (0.38, 1.98) 
Ref 
2.43 (0.26, 2.22) 
   4.54 (1.01, 20) 
10.0 (7.69, 1.28) 
 
4.44 (2.27, 8.67) 
1.15 (2.27, 2.63) 
Ref 
0.41 (0.45, 3.76) 
0.22 (0.05, 0.99) 
0.10 (0.13, 0.78) 
 
<0.001 
0.739 
Ref 
0.433 
0.500 
0.028 
Pain profiles; 
Single stabs versus not 
Repetitive stabs versus not 
Serrated pattern versus not 
Plateau-like versus not 
 
   0.27 (0.14, 0.50) 
1.34 (0.76, 2.35) 
1.54 (0.87, 2.71) 
  3.81 (1.40, 10.34) 
 
3.76 (1.99, 7.10) 
0.75 (0.43, 1.31) 
0.65 (0.37, 1.15) 
0.26 (0.10, 0.71) 
 
<0.001 
0.308 
0.138 
0.009 
Type of attack; 
Spontaneous and triggered 
Spontaneous only 
Triggered only 
 
Ref 
9.70 (3.31, 28.44) 
0.19 (0.67, 0.54) 
 
Ref 
0.10 (0.03, 0.30) 
5.26 (1.49, 1.85) 
 
 
<0.001 
0.002 
Headache pattern; 
Episodic  
Chronic 
Ref 
11.67 (5.64, 24.17) 
 
0.09 (0.04, 0.18) 
 
<0.001 
 
CI: confidence interval; Ref: reference; min: minute; SUNA: short-lasting unilateral neuralgiform 
headache attacks with autonomic symptoms; V1: ophthalmic trigeminal territory; V2: maxillary           
trigeminal territory; V3: mandibular trigeminal territory; 
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Table 64. Multivariate logistic regression analysis adjusted for demographic and 
clinical variables considered potentially different between SUNA and trigeminal 
neuralgia 
 
 
SUNA 
Trigeminal 
neuralgia 
p-value 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Site of pain; 
V1 versus not V1 
V3 versus not V3 
11.29 (3.92, 35.50) 
0.81 (0.29, 2.29) 
0.088 (0.31, 0.26) 
1.24 (0.44, 3.51) 
<0.001 
0.689 
Duration attacks; 
<1 min 
>5 min 
0.13 (0.36, 0.44) 
2.39 (0.17, 33.32) 
7.95 (2.30, 27.57) 
0.42 (0.30, 5.86) 
0.001 
0.518 
Pain profiles; 
Single stabs versus not 
Plateau-like versus not 
 
0.71 (0.25, 1.99) 
3.36 (0.73, 15.60) 
 
 
1.42 (0.50, 3.98) 
0.30 (0.06, 1.38) 
 
 
0.510 
0.121 
Type of attack; 
Spontaneous and triggered 
Spontaneous only 
Triggered only 
 
 
2.94 (0.65, 13.27) 
44.40 (4.50, 437.83) 
Ref 
 
0.34 (0.08, 1.53) 
0.02 (0.00, 0.22) 
0.161 
0.001 
Headache pattern; 
Episodic  
Chronic 
 
Ref 
13.19 (4.04, 43.08) 
 
 
0.076 (0.02, 0.25) 
 
 
<0.001 
 
 CI: confidence interval; Ref: reference; min: minute; SUNA: short-lasting unilateral neuralgiform    
 headache attacks with autonomic symptoms; V1: ophthalmic trigeminal territory; V2: maxillary             
 trigeminal territory; V3: mandibular trigeminal territory; 
 
 
6.6. Discussion 
In this study we compared substantial cohorts of SUNA and TN patients. Clinical 
differences and similarities between these disorders have hitherto come only from 
indirect comparison between small series of SUNCT and SUNA patients and old 
trigeminal neuralgia studies. This study for the first time performed a direct comparison 
of the clinical features of both conditions. This comparison aimed to formalise 
differences and similarities that could help physicians in the diagnostic process of 
patients with short-lasting neuralgiform headache attacks and in turn improve their 
treatment.  
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6.6.1. Demographic and clinical features of SUNA and trigeminal 
neuralgia 
 
6.6.1.1. Gender and age 
This study did not support gender predilection as a useful distinguishing feature 
between SUNA and TN. Indeed, a female preponderance in both SUNA and TN cohorts 
was found. TN begins approximately a decade later than SUNA, supporting preliminary 
findings that reported the average age of onset of SUNCT and SUNA in the fifth decade 
(Cohen , et al., 2006). However a retrospective analysis of the age at symptoms onset 
in 219 classical TN patients, showed that individuals with TN and absence of trigeminal 
NVC have a earlier symptoms onset (mean of 42.6 years) compared to those with 
trigeminal NVC (mean 51.1 years). This difference was statistically significant (Ko, et 
al., 2015). These initial evidence suggest that NVC is neither sufficient nor necessary 
for the development of TN, similarly to the current understanding of SUNA 
pathophysiology.  
 
 
 
6.6.1.2. Laterality of pain 
Unlike in TN, side-alternating cases of SUNCT have been reported (Cohen , et al., 
2006; D'Andrea , et al., 2001; Sabatowski , et al., 2001). In our cohorts the presence of 
unilateral but side alternating headache attacks, albeit rare, was linked with SUNA 
rather than TN. The possible pathophysiological mechanisms that may explain the the 
occurrence of unilateral side-alternating attacks in SUNA may reside in the different 
predilection of central as opposed to more peripheral mechanisms likely to be of 
importance in SUNA pathophysiology. An fMRI study has shown that hypothalamic 
activation during SUNCT/SUNA attacks is not always unilateral ipsilateral to the pain 
side, but it could be bilateral or contralateral (Cohen, 2007). Additionally, severe 
trigeminal neurovascular conflicts are associated with the symptomatic nerve in SUNA 
according to our findings. It is therefore conceivable that in some patients with 
alternating unilateral attacks with a one-sided vascular contact, the presence of bilateral 
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or contralateral hypothalamic activation may be responsible for attacks side shifting. 
 
6.6.1.3. Site of pain 
The current IHS diagnostic criteria for both SUNCT, SUNA and TN state that the pain 
location for these disorders can involve any branches of the trigeminal nerve. Studies 
in SUNCT and TN have consistently demonstrated a predilection for V1 in 
SUNCT/SUNA and for V2 and V3 in TN (Pareja , et al., 1997; Cohen , et al., 2006; 
Rasmussen , 1991). This was confirmed in our study, which showed that pain in V1 is 
a clinical predictor for SUNA rather than TN. Despite several studies demonstrating 
cases of isolated V1 TN, it is still unclear whether the phenotype of these conditions 
modifies overtime manifesting features more in keeping with TN, such as radiation of 
pain in V2-V3 trigeminal territories or in keeping with SUNA, such as combination of 
pain and cranial autonomic activation (Rasmussen , 1991; Maarbjerg , et al., 2014).  
 
6.6.1.4. Severity of the pain 
One of the ICHD-3 diagnostic criteria for TN state that the painful attacks have to be 
severe. This contrasts with the level of severity of the short-lasting neuralgiform 
headache attacks criteria, where the level of pain can be moderate as well as severe 
(Headache Classification Subcommittee of The International Headache, 2013). Our 
findings demonstrate that a moderate level of pain can be seen in TN patients as well 
as in SUNA patients. Our data therefore do not support the use of pain intensity to 
discriminate between SUNA and TN.  
 
6.6.1.5. Duration of attacks 
The attacks duration outlined by the ICHD-3 diagnostic criteria for the Short-lasting 
unilateral neuralgiform headache attacks and for TN ranges respectively between 1-600 
seconds and between a fraction of a second to 120 seconds (Headache Classification 
Subcommittee of The International Headache, 2013). The importance of attack duration 
in TN has been studied in a cohort of 81 patients divided into a short-lasting attack 
group and long-lasting attack group, according to the duration of the attacks (short 
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group= duration of attacks less than 2 minutes; long group= duration of attacks more 
than 2 minutes). The clinical features of the two groups were compared. Individuals 
with long attack duration were more likely to report interictal background pain and 
attacks while asleep. However, there was no difference in the proportion of patients 
with associated autonomic symptoms reported in both groups as well as pain location 
and duration of the condition. The Authors speculated that TN with long attack duration 
may be part of the SUNCT/SUNA spectrum, since a significant proportion of these 
patients also reported interictal background pain and cranial autonomic features 
accompanying the pain (Haviv , et al., 2016). This may also explain why the group of 
patients with longer-lasting attacks responded less to established TN medications used 
in this trial including carbamazepine, baclofen and gabapentin. Interestingly, 
lamotrigine, the drug of choice in SUNA was rarely employed in this study (Benoliel 
et al, 2016).  
In this context, our findings suggesting that attacks lasting <1 minute and >5 minutes 
were predictors for TN and SUNA, respectively, and  thereby suggest the notion that 
patients with longer lasting attacks may belong to the SUNA clinical spectrum.  
 
6.6.1.6. Cranial autonomic symptoms 
Autonomic symptoms have been reported in several case series of TN, perhaps in a less 
intense and consistent fashion than in SUNA (Sjaastad , et al., 1997; Rasmussen , 
1991a; Simms , et al., 2011). In line with previous studies, a small proportion of our 
TN patients reported some level of autonomic activation. In most cases this included 
one single autonomic feature, mild in intensity and sporadic occurrence. Interestingly 
even patients with V2-V3 pain location reported cranial facial autonomic features. This 
characteristic was also reported in a previous study, suggesting that not only in patients 
with V1 TN, a diagnosis of SUNA should be excluded, rather in every TN patient, even 
those with pain in V2-V3, the association with cranial autonomic features is possible 
(Simms , et al., 2011). This renders the differential diagnosis between TN and SUNA 
even more complex and their overlap more prominent.  
 It has been suggested that the presence of autonomic symptoms may not be a function 
of pain intensity nor related to attacks duration (Sjaastad , et al., 1997; Haviv , et al., 
2016). Using the same cut-off for longer attacks of 120 seconds, our data were in 
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keeping with the latter finding, showing that the majority of TN patients that 
experienced some cranial autonomic symptoms had 120 seconds. 
It remains unknown why TN can be accompanied by cranial autonomic activation. It 
has been postulated that since first division nociceptive input results in cranial 
parasympathetic activation and cranial autonomic features are present in migraine, the 
other TACs and experimental head pain, they could also be expected in V1 TN. In this 
context, it has been suggested that the difference between SUNCT and V1 TN would 
not be outlined by the presence of cranial autonomic symptoms but rather the degree of 
intensity and their consistency (Goadsby , et al., 2001). However, it could also be 
speculated that the short-lasting neuralgiform headache attacks group constitute a 
clinical spectrum of disorders, which encompasses core clinical features including the 
neuralgiform type of pain, the very short duration and high frequency of the attacks, the 
triggerability of the attacks, and the presence of a refractory period. This disorder 
manifests itself with different degrees of cranial autonomic signs that if pronounced, 
reflect the SUNA phenotype, whereas if sparse, the TN one (Lambru , et al., 2014).   
 
6.6.1.7. Triggers and Refractory Period 
The vast majority of patients in both cohorts reported spontaneous as well as triggered 
attacks, which were mainly innocuous cutaneous/intraoral stimulations. However, the 
presence of cutaneous triggered attacks only predicted a diagnosis of TN, whereas the 
presence of spontaneous attacks only predicted a diagnosis of SUNA. Furthermore, 
certain triggers such as cold air drafting on the symptomatic side of the face, hair 
brushing and swallowing were significantly more frequently reported by SUNA 
patients. Conversely, chewing, light touch, brushing teeth, talking were significantly 
more prevalent in the TN cohort. This is the first study suggesting that certain triggers 
may have a predilection for SUNA or TN. It is difficult to advance any 
pathophysiological explanation for this difference. It is noteworthy that triggers 
directed to upper part of face or head predominate in SUNA while those that were 
directed to the lower part of the face predominate in TN; this is probably reflective of 
the distribution of pain. Furthermore, neurophysiological studies using conventional 
trigeminal reflexes and trigeminal laser evoked potentials in TN associated with a 
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trigeminal neurovascular contact showed a profile in keeping with possible unilateral 
dysfunction of small nociceptive fibres, namely A fibres, which improved after 
trigeminal microvascular decompression (Truini, et al., 2007; Obermann , et al., 2007). 
Preliminary neurophysiological studies in a small group of SUNCT revealed no 
nociceptive afferents abnormalities. However, the Authors did not specify if patients 
had attacks triggered by cutaneous stimulation or whether MRI scans revealed any 
trigeminal neurovascular conflict (Truini , et al., 2006). It is possible that in SUNA 
patients, alongside a dysfunction in A fibers, there is an involvement of C-fibers 
responsible for cold/wind-triggered attacks as well as the interictal dull background 
headache, which occurs frequently in SUNA patients according to our findings.  
The absence of a refractory period after attacks triggered by innocuous cutaneous 
stimulation in SUNCT and SUNA has been proposed as one of the key clinical 
difference from TN, where patients are known to be able to keep stimulating the trigger 
area without evoking any further pain (Kugelberg, et al., 1959). However, this historical 
notion was not supported by robust evidence. Our study demonstrates the clinical 
validity of the concept of a refractory period applied for SUNA as well as for TN and 
confirms preliminary findings from other studies (Cohen , et al., 2006; Rasmussen , 
1991a). However, it demonstrates that about 1/3 of TN patients do not report a 
refractory period between triggered attacks. This is a novel finding, which contrasts 
with the traditional view expressed in the TN literature and enforces the overlap 
between SUNA and TN. 
The refractory phase is thought to be caused by a neuronal hyperpolarization 
mechanism, which prevents cutaneous stimulation to cross-talk to nociceptive afferents 
for a variable amount of time (Devor , et al., 2002). This phenomenon possibly reflects 
healthy brainstem and diencephalic antinociceptive circuits. The absence of a refractory 
period in SUNA may be caused by a derangement of these antinociceptive structures 
like the hypothalamus, which are perhaps also impaired in those TN patients who do 
not report a refractory phase. Future studies will need to address this hypothesis.  
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6.6.1.8. Interictal pain 
TN patients in whom the paroxysmal pain is associated with background pain have 
traditionally been labelled as “Atypical TN” and more recently as classical TN with 
concomitant persistent facial pain. The presence of a constant background pain seems 
to occur in patients who experience other “atypical” clinical features, namely longer 
attacks duration (Haviv , et al., 2016), less triggerability and poor medical and surgical 
treatment response (Headache Classification Subcommittee of The International 
Headache, 2013). Recent studies on consecutive TN patients showed that the 
occurrence of concomitant persistent facial pain is frequent, ranging between 29-49% 
of TN patients (Maarbjerg , et al., 2014; Haviv , et al., 2016). In SUNA, approximately 
half of patients report background interictal pain, according to our and others’ SUNA 
series (Cohen , et al., 2006). However, SUNA with background pain is not considered 
an atypical subtype of SUNA with purely paroxysmal attacks, partly because of lack of 
comparative studies between SUNA with and without background pain and partly 
because the presence of background pain is an accepted clinical feature for the other 
TACs (Marmura , et al., 2012). Given the higher prevalence of migraine biology in 
SUNA compare to TN, it could be postulated that the susceptibility to a central nervous 
system disorder such as migraine, facilitates the occurrence of central sensitization and 
in turn the simultaneous occurrence of both the paroxysmal and the constant 
background pains more in SUNA rather than in TN patients.  
 
6.6.1.9. Chronic and episodic subtypes 
TN is considered a recurrent disorder with a relapsing remitting pattern of occurrence. 
However, a recent large prospective study showed that 37% of TN patients displayed a 
chronic pattern (Maarbjerg , et al., 2014). Similarly, in our cohort, 43% of patients had 
a chronic unremitting subtype. However, unlike SUNCT and SUNA, there is no 
mention of episodic or chronic subtypes for TN in the ICHD-3 (Headache 
Classification Subcommittee of The International Headache, 2013). We also 
demonstrated that the chronic pattern is predictive of SUNA rather than TN. Together 
these data suggest that the periodicity of occurrence of SUNA and TN is a meaningful 
clinical characteristic to help direct the diagnosis and stratify patients for treatments. 
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On this basis, it would be reasonable to subdivide TN into episodic and chronic 
similarly to the current SUNCT and SUNA criteria.    
 
6.6.1.10. Trigeminal neuralgia diagnostic criteria analysis 
Our clinical findings from the TN cohort were applied to the TN ICHD-3 diagnostic 
criteria. Of the 79 TN patients, 75 fulfilled the criteria, whereas four did not (5.1%). 
Three out of these four patients did not fulfilled the criteria because of attacks duration 
longer than 120 seconds and moderate attacks intensity. One patient because of 
moderate attacks intensity and lack of triggerable attacks. It is noteworthy that none of 
these four patients reported cranial autonomic features with the paroxysmal attacks, so 
a diagnosis of SUNA was ruled out; two patients reported pain in V1 trigeminal territory 
but not as the sole pain location; three patients did not report any interictal background 
pain and one reported some interictal pain; two patients had a family or personal history 
of migraine, hence displaying a migraine biology; finally three patients had a good or 
excellent response to carbamazepine, whereas for one patient data on the medications 
history was not available. Based on these clinical non-ICHD-3 features, we thought 
the diagnosis of TN was the most reasonable one. Furthermore ten TN patients reported 
mild lacrimation with some attacks. All the other clinical features were in keeping with  
the TN ICHD-3 diagnostic criteria, so it was decided to keep them within the TN 
group instead of considering them SUNA where cranial autonomic features normally 
occur with the majority of the attacks (Table 60).  
 
According to our findings, the current TN diagnostic criteria could be refined to reflect 
more accurately the clinical differences with SUNA that emerged in this study. We 
propose a change in criterion A, since we think that three attacks may not be sufficient 
to support a robust diagnosis of TN in view of its complex phenotype and differential 
diagnosis. In view of the fact that the majority of patients with cranial autonomic signs 
or symptoms had pain in V1 associated with lacrimation, we propose criterion D, which 
does not allow a diagnosis of TN to be made in presence of associated cranial autonomic 
symptoms. Finally, since the presence of a refractory period is associated with TN 
according to our analysis, we propose, similarly to the framework of the proposed 
SUNA criteria (Chapter 2), to include the statement regarding the presence of refractory 
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periods following triggered attacks under Criterion C to reflect this clinical link. We 
acknowledge that some patients do not persevere with the cutaneous stimulation that 
triggered the initial attack, in view of its intensity, hence for some patients this criterion 
may not be relevant. However, when the clinical information on a refractory period is 
available, it may facilitate the differential diagnosis between TN and SUNA. The new 
proposed TN diagnostic criteria are outlined in Table 65 and reflect the complexity of 
this disorder, which emerged from our study.  
To complete the TN clinical profile that arose from our analysis, we propose the 
inclusion of some clinically relevant features that may help distinguishing TN from 
SUNA further. Firstly, since pain in V1 is a predictor for SUNA rather than TN, we 
propose the inclusion of a statement suggesting that in TN the pain has a predilection 
for the second and/or third divisions of the trigeminal nerve, with possible radiation to 
the first trigeminal nerve division, We also proposed to include in the TN diagnostic 
criteria’ notes that in TN there is a predilection for an episodic relapsing remitting 
pattern of occurrence rather than chronic. Furthermore, the TN diagnostic criteria’ notes 
should highlight that patients with attacks exclusively triggered by innocuous cutaneous 
stimuli are more likely to have TN. Similarly, the SUNA diagnostic criteria’ notes 
should mention the predilection for the pain to occur more frequently in the first 
division of the trigeminal nerve, with possible radiation to the second and third 
divisions; the predilection for a chronic pattern of occurrence, rather than episodic and 
the likelihood that patients with exclusively spontaneous attacks are more likely to have 
SUNA. Furthermore, since the presence of interictal pain has now been confirmed as 
an established clinical feature of SUNA, occurring in approximately half of patients, 
the possible presence of interictal pain should be reflected in the SUNA diagnostic 
criteria’ notes. Future studies will need to establish whether the presence of interictal 
pain is associated with different clinical, radiological and therapeutic outcomes 
compared to SUNA patients with paroxysmal pain only.  
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Table 65. Proposed criteria for unified diagnosis of trigeminal neuralgia 
 
A. At least 20 attacks of unilateral facial pain fulfilling criteria B–E 
 
B. Occurring in one or more divisions of the trigeminal nerve, with no radiation 
beyond the trigeminal distribution  
 
C. Pain has at least three of the following five characteristics: 
 
1. Attacks lasting a fraction of a second to 120 seconds 
2. Severe intensity 
3. Electric shock-like, shooting, stabbing or sharp in quality 
4. Precipitated by innocuous stimuli to the affected side of the face 
5. A refractory period can follow attacks triggered by innocuous stimuli to the   
affected side of the face 
 
D. No cranial autonomic signs or symptoms accompany the paroxysmal attacks.  
 
E. No clinically evident neurological deficit. 
 
F. Not better accounted for by another ICHD-3 diagnosis 
 
 
This study has some limitations. The duration and frequency of occurrence of the 
headache attacks were subjectively estimated by the patients and only seldom 
objectively measured. However, in view of the variable duration of the attacks and often 
the multiple number of daily attacks, it is difficult to ask patients to produce headache-
specific diaries and headache diaries used for other conditions (migraine and CH) may 
not be entirely appropriate to TN.  
 
6.7. Conclusion 
A detailed comparison of demographic and clinical characteristics in SUNA and TN 
has been conducted. The need for such as study came from the notion that the two 
conditions share several clinical characteristics that are otherwise not commonly seen 
in the other TACs. The laterality, trigeminal distribution of pain and the associated 
cranial autonomic features are characteristics that SUNA shares with the other TACs 
as well as with TN. Conversely, the neuralgiform quality of pain, the very short duration 
of attacks, the triggerability by cutaneous stimulation and the concept of a refractory 
period are features shared solely between SUNA and TN. This striking similarity have 
instigated more interest in the TN phenotype, with recent studies revisiting what was 
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thought to be an established disorder. TN is more complex than previously thought to 
be the case. Recent studies have highlighted certain clinical features in TN patients, 
such as the presence of cranial autonomic signs, the frequent occurrence of interictal 
pain, and the variable duration of the paroxysms (Maarbjerg , et al., 2014; Haviv , et 
al., 2016), which become relevant in the context of the clinical overlap with SUNA and 
call into question whether TN and SUNA should be considered distinct entities or rather 
a continuum of the same disorder (Lambru , et al., 2014). One school of thoughts 
believes that SUNCT, SUNA and TN are distinct disorders, which overlap in view of 
the fact that the symptoms are driven by the trigeminal system, which is the final 
common pathway for these conditions (VanderPluym , et al., 2015). This hypothesis 
does not explain why SUNCT and SUNA share many more clinical features with TN 
as opposed to the other TACs, which also use the trigeminal system as final pathway. 
Another school of thoughts proposed a broader nosological concept where SUNCT, 
SUNA and TN constitute different aspect of the same entity (Lambru , et al., 2014). 
The cornerstone clinical domains of this continuum include: the unilateral occurrence 
of pain; the neuralgiform quality of the pain; the trigeminal distribution of pain; the 
short-lasting duration of painful paroxysms (1 seconds to 600 seconds); the association 
of pain and cranial autonomic features; the triggerability of paroxysms by 
cutaneous/intraoral innocuous stimulation; and, the refractory period. Additionally, the 
response to sodium channel blockers and the radiological association with trigeminal 
neurovascular conflict complete the clinical spectrum. Differences between the clinical 
entities that constitute this spectrum exist and reflect different expressions of the shared 
clinical domains. This study demonstrates that different sites of the pain, attacks 
duration, triggerability of attacks, presence of a refractory period and headache pattern 
are predictors for SUNA or TN. To this list we should add the presence of cranial 
autonomic features, which can occur in a proportion of TN patients as demonstrated in 
several studies (Rasmussen , 1991a; Sjaastad , et al., 1997; Simms , et al., 2011; 
Maarbjerg , et al., 2014; Haviv , et al., 2016). We proposed that patients with clinical 
features otherwise fulfilling the TN criteria but with pain associated with cranial 
autonomic signs and symptoms are now classified as SUNA. In the context of a clinical 
continuum, these differences may help stratifying patients for management purposes 
including medical and surgical approaches, rather than forcing them into different 
diagnostic categories largely dictated by the need to maintain some diagnostic barriers. 
This proposed concept may also stimulate further research onto the understanding of 
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hybrid forms of facial pain with some features of SUNA and TN, which currently have 
no place in the IHS classification, expanding the knowledge of these complex disorders.  
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Chapter 7.  Discussion 
 
 
This thesis investigated and compared the clinical aspects of SUNA, SUNCT and TN 
by prospectively phenotyping large cohorts of patients. This study tried to answer 
unresolved questions of pivotal importance from a clinical, therapeutic, 
pathophysiological and nosological perspectives.  
 
7.1. Are SUNCT and SUNA different entities or variants of the same 
clinical entity? 
Since the publication of the diagnostic criteria in the IHS classification in 2004, SUNCT 
was considered a subtype of a broader entity called SUNA, where the association with 
one cranial autonomic feature was sufficient to meet the diagnostic criteria (Headache 
Classification Subcommittee of The International Headache Society., 2004). However, 
up to now only case reports and small series of patients with SUNA had been described 
calling into question the existence of this condition (Sjaastad , 2008). The clinical 
characteristics of SUNA were described in this study and SUNA was validated as a 
clinical entity. A variety of reasons could account for its rare occurrence. The reduced 
cut-off number of cranial autonomic features to one, means that the diagnostic 
distinction from TN became less defined. It is therefore possible that a significant 
proportion of SUNA patients is misdiagnosed as TN, which is a condition diagnosed 
and managed by multiple specialists including dentists, neurosurgeons, maxillo-facial 
surgeons, ENT and pain specialists as well as neurologists; many of these specialities 
are unaware of SUNCT and SUNA as these are relatively recently described entities 
and the bulk of the literature is published in neurology journals. This may explain the 
small number of SUNA patients referred to a headache or neurology clinic.  
 
Our findings suggest that the clinical phenotype of SUNA does not differ significantly 
from the one of SUNCT, apart from a different degree of activation of the 
parasympathetic system and dysfunction of the sympathetic system, largely reflecting 
the different number of autonomic features decided by the IHS Classification 
Committee for SUNCT and SUNA.  
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In view of the clinical similarities with TN, growing interest around the association 
between SUNCT/SUNA and MRI findings of ipsilateral trigeminal neurovascular 
conflict have been reported (Favoni , et al., 2013). However, the extent and the nature 
of this association have been unknown. Our study demonstrated that trigeminal 
neurovascular contact ipsilateral to the side of the pain is a common neuroanatomical 
variant in SUNCT and SUNA. Furthermore, we demonstrated that a severe 
neurovascular conflict at the REZ was significantly associated with the symptomatic 
trigeminal nerve without any significant difference between SUNCT and SUNA. Based 
on these findings, it could be postulated that severe neurovascular conflict plays an 
important aetiological role in these disorders, at least in patients who demonstrate 
evidence of neurovascular conflict, and that SUNCT and SUNA display a 
pathophysiological overlap. 
 
The medical treatment of SUNCT and SUNA has been considered challenging in view 
of limited quality data. Chapter 4 provided the largest open-label prospective evidence 
on medical treatments’ outcome in SUNCT and SUNA patients. Our results 
demonstrate the remarkable efficacy of sodium channel blockers, namely lamotrigine 
as an oral drug and lidocaine as intravenous formulation, which are the drugs of choice 
for SUNCT and SUNA. Oxcarbazepine and duloxetine were found to be effective as 
well as to a lesser extent carbamazepine, possibly due to patients’ selection bias issues. 
Less impressive results were reported by the use of gabapentinoids and topiramate, 
which may be helpful as add on treatments to the first and second line treatments. 
Lacosamide and mexiletine were also found to be effective in a small number of 
patients, though a significant proportion of patients discontinued the treatments in view 
of tolerability issues. No significant differences between SUNCT and SUNA were 
observed in the outcomes of the most effective treatments, namely lamotrigine, 
oxcarbazepine and IV lidocaine. Furthermore, no significant differences were 
demonstrated in the outcomes of two series of patients with medically refractory 
SUNCT and SUNA patients who underwent trials of ONS and trigeminal MVD. These 
data suggest a therapeutic overlap between SUNCT and SUNA. 
Based on these clinical, radiological and therapeutic findings we propose that SUNCT 
and SUNA are considered a single clinical entity under the name SUNA, a term that 
highlights the occurrence of a broad array of cranial autonomic features besides 
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conjunctival injection and lacrimation.  A new set of diagnostic criteria have also been 
proposed for this unified entity.  
 
7.2. SUNA and trigeminal neuralgia: separate entities or a 
continuum of the same disorder? 
The striking clinical similarities between SUNCT/SUNA (labelled as SUNA according 
to our data from hereon in) and TN, have instigated a wide still unresolved debate on 
whether these disorders constitute different entities or whether they constitute a 
continuum of the same disorder. Several reviews and editorials have supported one or 
the other hypothesis, basing their assumptions on indirect comparison of clinical studies 
(Lambru , et al., 2014; VanderPluym , et al., 2015; Benoliel , et al., 2017; Wöber , 2017; 
Uniyal , et al., 2017). The main clinical arguments supporting the hypothesis that SUNA 
and TN are distinct disorders include pain location, predominantly in V1 in SUNA and 
V2-V3 in TN; the longer duration of attacks in SUNA compared to TN; the presence 
of associated cranial autonomic symptoms in SUNA and their absence in TN and the 
absence vs presence of a refractory period respectively in SUNA and TN. However, 
what clearly transpires from looking at the differential diagnosis between SUNA and 
TN and between SUNA and the other TACs, is that the latter association shares only 
few common clinical domains, namely the association of pain with cranial autonomic 
features, the occurrence of multiple attacks/day and the predilection for the V1 
trigeminal distribution of the headache. Clinical features such as circadian and 
circannual periodicity, predilection for awakening-attacks and restless behaviour 
during attacks and triggerability by alcohol, which are some of the cornerstone clinical 
features of CH and to some extend of the other TACs, are very seldom encountered in 
SUNA patients. Conversely, the comparison between SUNA and TN abounds with 
shared clinical domains that constitute their clinical framework. These include: the 
neuralgiform quality of the painful paroxysms, the very short duration of the attacks, 
the multitude of daily attacks, the triggerability of attacks by innocuous cutaneous 
stimulation and the concept of a refractory period. The discrepancy in cranial autonomic 
activation between SUNA and TN have been claimed as one of the main clinical 
differences between the two disorders. Despite the presence of some degree of 
autonomic symptoms in TN, the prominent degree and consistency of occurrence with 
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most attacks seen in SUNA have been suggested to reflect a different 
pathophysiological substrate compared to TN, namely a hypothalamic dysfunction 
(Goadsby , et al., 2001). To date, no studies have addressed the presence of a 
hypothalamic derangement in TN. A case series of five patients with V1-2-3 TN and 
multiple sclerosis treated with hypothalamic stimulation, showed that the therapy was 
able to control the V1 pain, but not the V2-V3 pain for which, patients required other 
treatments (Cordella, et al., 2009). Although this group of patients did not have classical 
TN, the study results may suggest that the hypothalamus may not play a key role in V2-
V3 trigeminal neuralgiform pain disorders.  
However, it could be postulated that at least in cases of TN transforming into SUNA 
and coexistence of TN and SUNA in the same individual, shared pathophysiological 
mechanisms known to be involved in TN and SUNA, namely an impairment of 
posterior hypothalamic circuits and trigeminal neurovascular conflict may be 
implicated. Although the issue of the role of the hypothalamus in TN cannot be 
currently resolved, our findings nonetheless support the aetiological link between 
severe trigeminal neurovascular conflict and SUNA in a proportion of patients which 
is remarkably similar to TN one (Maarbjerg , et al., 2014). Furthermore, the efficacy of 
trigeminal MVD showed in our study together with the results of a previously published 
case series, support the pathophysiological role of trigeminal neurovascular conflict at 
least in a consistent subgroup of SUNA patients (Williams , et al., 2010). For the 
remaining patients, other pathophysiological mechanisms may play a role. The efficacy 
of sodium channels blockers displayed in our SUNA cohorts suggests another possible 
common denominator in the pathogenesis of SUNA and TN, with sodium channels 
dysfunction being an attractive hypothesis (Lambru , et al., 2012). A sodium 
channelopathy may be one of the pathophysiological substrates in those cases where a 
trigeminal neurovascular conflict is not found or where the degree of contact is mild. 
Although the presence of abnormal hypothalamic activation in SUNA remains the main 
pathophysiological link between SUNA and the other TACs, the lack of any association 
with trigeminal neurovascular conflict along with the lack of efficacy to sodium channel 
blockers in the other TACs may render the pathophysiological link between SUNA and 
the other TACs less robust. 
  
Based on our studies’ findings, we challenge the traditional view that consider SUNCT, 
SUNA and TN separate disorders and propose the concept of a broader nosological 
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entity, named “Short-lasting trigeminal neuralgiform attacks” that represents a clinical 
continuum between SUNA and TN. The clinical framework of this entity is based on 
fundamental clinical domains including: the unilateral trigeminal distribution of the 
pain episodes; the neuralgiform paroxysmal quality of the pain; the short-lasting 
duration of painful paroxysms (1 seconds to 600 seconds); the association of pain with 
a variable degree of cranial autonomic features; the triggerability of paroxysms by 
cutaneous/intraoral innocuous stimulation; and the refractory period. Variations within 
these clinical domains lead to a SUNA or a TN phenotype. Hybrid cases that present 
clinical features of SUNA and TN but that do not fulfil their diagnostic criteria are 
encountered in clinical practice (Authors’ clinical experience) and more research is 
needed to further characterised these cases. In Chapter 6 we identified clinical 
predictors for SUNA rather than TN that include: pain in V1, paroxysms duration >5 
minutes, entirely spontaneous attacks, absence of a refractory period and chronic 
pattern of occurrence. Conversely, clinical predictors for a TN phenotype rather than 
SUNA include: short duration of paroxysms (<1 minute), entirely triggered attacks, 
presence of a refractory period and episodic pattern of occurrence. Based on these 
findings, we proposed a new set of diagnostic criteria for TN that aim to clarify the 
differential diagnosis with SUNA. The presence of cranial autonomic features varies 
across the spectrum, with SUNA patients reporting multiple and prominent cranial 
autonomic symptoms on one end and patients with TN with no autonomic features on 
the opposite end of the spectrum. This unified clinical entity may reflect a unifying 
pathophysiological model, characterized by different degrees of interaction of more 
peripheral and central mechanisms, namely focal demyelination of the trigeminal 
sensory root, a sodium channelopathy and posterior hypothalamic dysfunction. These 
mechanisms could account for the phenotypic variability within this clinical continuum. 
Central mechanisms may be more pronounced in patients with cranial autonomic 
symptoms and less pronounced in patients with one or no autonomic symptoms. 
Additionally, it is possible that within the group of sodium channel blockers with 
reported efficacy in these conditions, the presence of certain clinical features, such as 
cranial autonomic symptoms or the presence of a background interictal pain, imply the 
involvement of more central mechanisms rather than peripheral ones, which may 
explain the different level of efficacy of certain drugs in SUNA and TN. For this reason, 
it is important to carefully phenotype patients with these disorders and obtain MRI 
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scans with specific trigeminal sequences, aiming to stratify them in order to offer them 
more effective medical and surgical treatments.  
 
7.3. SUNA: a trigeminal autonomic cephalalgia or a cranial 
neuralgia? 
This unifying hypothesis carries important nosological implications on whether SUNA 
should belong to the TACs or the cranial neuralgias group. Based on the findings of 
these studies, we proposed a novel clinical entity called “Short-lasting trigeminal 
neuralgiform attacks”, which encompasses SUNA and TN. This entity may be 
classified amongst the cranial neuralgias rather than trigeminal autonomic cephalalgias. 
The recognition of this entity may foster further research aiming to shed light on the 
complex neurobiology of the clinical variants of this continuum and advance the field 
of neuralgiform headache and facial pain disorders, ultimately leading to more specific 
and effective treatments for these patients. 
 
7.4. Future research directions 
The findings of this study may inspire several future research avenues in the field of 
short-lasting neuralgiform headache disorders. The similarities and differences between 
SUNA and TN including pain location, duration of attacks, triggerability, refractory 
periods and headache pattern (chronic vs episodic) may suggest that the hypothalamus 
may play a different role in these disorders, perhaps more relevant in the conditions 
with V1 pain, longer attacks and associated cranial autonomic features and less relevant 
in conditions where the pain is in V2-V3, attacks are very short and cranial autonomic 
symptoms are absent or sparse. A fMRI study assessing the presence of an abnormal 
hypothalamic activation across the spectrum of SUNA and TN would probably clarify 
the central pathophysiological mechanisms of these conditions. On the other end of the 
spectrum SUNA shares some clinical features with CH and the other TACs but it clearly 
lacks of one of the cornerstone features of CH, which is the circadian and circannual 
attacks periodicity, which is thought to be driven in CH by an abnormal functioning of 
the suprachiasmatic nucleus. However during SUNA attacks, abnormal hypothalamic 
activity has been detected and DBS of the VTA seems to be an effective treatment for 
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this condition, similarly to CH. Hence it would be important for future research to 
establish whether hypothalamic dysfunction is a fundamental hallmark of SUNA or 
whether is it only a marker of unilateral short-lasting headache attacks with 
predominantly V1 pain accompanied by cranial autonomic symptoms. 
 
Our preliminary data on the prevalence of trigeminal NVC in SUNA should be 
confirmed in larger studies. Such findings along with the long-term outcomes of 
trigeminal MVD in SUNA patients will clarify the pathophysiological relevance of 
trigeminal NVC in SUNA.  
 
Furthermore, the response to sodium channel blockers may suggest a disfunction of 
these ion channels in SUNA and TN. Genetic studies perhaps using exome sequencing 
technique in these conditions may shed more light upon the contribution of ion channels 
dysfunction in these disorders and offer new more specific therapeutic targets for the 
treatment of these conditions. 
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Appendix A.  
 
To be filled by clinician 
 
Date         /         / 
 
SECTION 1: PERSONAL DETAILS 
 
Surname  Date of Birth         /          / 
First Name  Age  
Hospital Number  
Sex Male          Female               
Handedness Right     Left      Ambidextrous        
  
Marital status Single     Married     Divorced/Separated    
Living with Partner     Widowed    
Occupation • If disabled or retired, describe what 
you did before you stopped working? 
 
Occupation Student  Unemployed  Retired    
❑ Work full time for pay 
 ❑  Work part time for pay 
 ❑ Work as a volunteer 
 ❑ Going to school or training for a new  occupation 
 ❑ Homemaker 
 ❑ Care for a child, elder or sick person 
❑ Long-term disability due to facial pain 
❑ Long-term disability due to other reason 
  
  
SECTION 2: HEADACHE/ FACIAL PAIN 
Please repeat this section for each different type of headache/ facial pain 
 
A.Onset 
 
1. Age of onset of pain  
2. Duration (years)  
3. Was there any initial trigger? Yes      No    
4. Precipitant triggers  Head injury 
 Facial injury 
 Neck injury 
 Operation – face , cosmetic  
 Back trauma 
 Viral infection 
 Illness                    
 Oral surgery-extractions, root canal  
 Episode of extreme stress 
 Airplane flight 
 Pregnancy 
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Stress  
❑Other ……………………………………………………….. 
4. If the answer to Question 3 was ‘Yes’ then 
describe the trigger and state the time of onset of 
the trigger in relation to the onset of the headache 
attacks 
Trigger: …………………………………………………………… 
…………………………………………………………………….. 
Onset of Trigger: ……………………………………………….. 
…………………………………………………………………….. 
 
B.Side and site (EXACERBATIONS) 
 
1. On which side of the head do you experience the 
attacks?  
Right           ……….%       
Left              ……….%     
Alternates     ……….%      
Bilateral        ……….%        
 
 
 
 
2. If the attacks have occurred on both sides, then 
has the pain shifted sides during an attack, in 
different attacks but in the same bout or in 
different bouts? 
Side shifted during a single attack    
Side shifted in different attacks during same bout  
Side shifted in different bouts    
No    



 
3. Tick the regions over which the pain is felt Peri-orbital 
Retro-orbital 
Frontal 
Temple 
Parietal 
Occipital 
Vertex  
Nasal  
Cheek  
Upper teeth 
Lower teeth 
 
 
 
 
 
 
 
 
 
 
 
 
Palate 
Floor of mouth 
Jaw 
Ear 
Chin 
Neck 
V2 
V3 
Shoulder 
Other (describe below) 
……………………………. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RL                                   R                                L        
 
 
 
C.Severity and characteristics of pain 
 
1. Usual severity of the pain VRS: 
2.  Intensity range (Min-Max) VRS: 
3. Which of these descriptions of pain apply to your 
attacks? 
Aching 
Boring 
Shooting 
Electric 
Burning 
Pins and needls  
Dull    
Pressure feeling 
Pressing 
Pulling 
Tingling 
Tender 
 
 
 
 
 
 
 
 
 
 
 
 
Stabbing 
Tearing 
Tightening  
Throbbing  
Sharp 
Sudden 
Gradual   
Suffocating 
Fearful 
Wretching 
Annoying 
Piercing 
 
 
 
 
 
 
 
 
 
 
 
 
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Tiring 
Agonising 
 
 
Cold             
Others (describe below) 
........................................ 
 
 
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D. Duration and frequency 
 
1. How long does the average attack last for? Seconds/mins/hours: 
2. Duration range of an attack (Min-Max) Seconds/mins/hours: 
3a What is the average number of headache attacks that 
occur per day? (For trigeminal autonomic 
cephalalgias/cranial neuralgias and hemicranias 
continua) 
 
3b What is the average number of headache attacks that 
occur per month? (migraine) 
 
4. Frequency range of attacks (Min-Max) Day/week/month: 
 
E.Timing 
 
1. Are the attacks more likely to occur when awake or 
during sleep? (Tick one only) 
Awake  
Sleep   
Both      


 
2. Which is the average percentage? Awake:  ……… %       Sleep:  ………% 
3. Do the attacks occur at a predictable time or randomly? Predictable    
Random  
If predictable, specify the times ……………………. 
 
 
4.   Is there any time in which the attacks get worse? Waking up        
Mid-morning     
Mid-day            
Afternoon          
Evening             
Overnight          
No difference   
 
 
 
 
 


 
 
H. Associated symptoms 
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1. CRANIAL AUTONOMIC 
FEATURES 
 
Redness of the eye 
Watering of the eye  
Drooping of the eyelid 
Miosis  
Swelling of the eyelid  
Blockage of the nose 
Running of the nose  
Facial sweating  
Flushing of the face 
Fullness in the ears               
Swelling of mouth/face   
Hypersalivation 
 
Behaviour during 
attacks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides              
Yes      No    
 
  Restless            Still   
 
 
2. MIGRAINOUS 
FEATURES 
Nausea (feel sick)    
Vomiting  
Sensitivity to light 
Sensitivity to sounds    
Sensitivity to smells 
Motion sensivity    
Vertigo 
 
 
 
 
 
 
 
Everytime    Sometimes        
Everytime    Sometimes        
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Same side    Opposite side    Both sides  
Everytime    Sometimes        
Everytime    Sometimes        
 
3.    AURA   
 
 
- ≥5 min and ≤60 min 
 
-Gradual onset and   
 offset                                        
YES      
NO        
 
VISUAL SYMPTOMS such as blurred vision, flashing lights, zig-zag lines dark 
spots in one visual field                                                                      
 
SENSORY SYMPTOMS such as tingling or numbness                         
 
SPEECH SYMPTOMS (dysphasia/dysarthria)                                          
 
WEAKNESS in one or more limbs 
 
BASILAR: (diplopia, vertigo, tinnitus, ataxia bilateral paraesthesia, decreased  
                  level of consciousness)                                                                 
 
Total number of attacks with headache/month or year .......... 
Total number of attacks without headache/month or year ............ 
Duration of aura (minutes): .............                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
8. ALLODYNIA: areas of 
hyperalgesia 
YES 
NO 
Ipsilateral                                                                                                                 
Contralateral   
 
 
 
 
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Bilateral   
 
 
I . Trigger and relieving factors (if only spontaneous, don’t tick the provoking) 
 
 FACTORS        PROVOKING                                              RELIEVING 
1.       Light touch                     
2. Pressure on the face                   
3. Squeezing eyelids                     
4. Prolonged chewing/ eating                      
5. Start of chewing/ drinking                   
6. Swallowing                   
7. Wind                      
8. Washing face                    
9. Brushing teeth                      
10 Moving  / vibration                    
11 Talking                     
12 Opening wide/yawning                   
13 Washing or brushing hair                      
14 Exercise                      
15 Light                      
16 Shower                      
17 Shaving                      
18 Blowing nose                      
19 Neck rotation towards symptomatic side                      
20 Neck extension/ flexion                      
 
1 Alcohol (within 30 minutes)                   
2 Strong smells (eg perfumes, petrol fumes)                      
3 Warm environment                   
4 Heavy physical effort                   
5 Relaxation from stress                   
 
1  Smoking                   
2 Caffeine                   
 3 Change in weather                   
4 Heat                   
5 Cold                   
6 Stress                   
7 Relaxation from stress                   
8 Tiredness                   
9 Sleep deprivation                   
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10 Sleep excess                   
11 Recreation                   
12 Menstruation                   
13 Hunger/ meal skipping                   
14 Dehydration                   
15 Bright lights                   
16 Loud sounds                   
17 Foods (chocolate, cheese)                   
 
1 Cough and/or sneeze                      
2 Bending over                   
3 Change in posture (lying down/sitting up)                   
 
 Others (Please specify below) 
................................................................... 
                  
 None                   
 
J. Characteristics of the attacks 
 
1. TRIGGERED/SPONTANEOUS attacks Only cutaneous triggered  
Only spontaneous 
Both 
Non cutaneous triggers     
 
 

 
2. If you have both, please quantify the percentage of 
each 
Triggered ……..  %                    
Spontaneous ……… % 
3 Relation between cutaneous triggers and side of pain Ipsilateral triggers                                              
Other triggers                                                             
Contralateral triggers 
Bilateral triggers 
Extra-trigeminal triggers                                                                                                           
 

 
 

 
 
K. Refractory period (for SUNCT/SUNA and cranial nerualgias) 
 
1. Could you have a triggered attack immediately after 
cessation of the previous one? 
No (refractory period)   
Yes (no refractory period)  
No triggers  
Not sure 
 
 
 
 
2. If not, which is the duration of the refractory period? Seconds/minutes: 
 
 
L. Features immediately after a headache/ facial pain attack 
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1. Do you get any of the following symptoms 
immediately after the headache/facial pain 
attack is over? 
Irritability/ moody 
Feeling of being energetic/ 
well-being 
Feeling hungry 
Loss of appetite 
Passing urine frequently 
Diarrhoea  
Constipation 
Tiredness 
Yawning 
None of the above  
 
 
 
 
 
 
 
 
 
 
 
Drowsiness 
Difficulty concentrating 
Abnormal sensations: 
burning, numbness, 
tingling or tenderness 
Other (describe below)   
 
 
 
 
 
 
  Go to section 3 if you get none of the above symptoms 
2. Duration of these symptoms  
3. Do you get these symptoms after each or most 
headache attacks? 
Each      Most      Seldom    
 
 
M. Trigeminal autonomic cephalalgias pattern 
 
1. Number of attacks per bout  
2. Average duration of bouts  
3. Range of duration of a bout (Min-Max)  
4. Number of bouts per year 
 
5. When was the last bout?  
6. Are your bouts more likely to occur in any 
particular month/ months? 
 Yes 
 No 
7. If the answer to Question 6 is yes, then during 
which months are the bouts most likely to occur? 
 January 
 February 
 March 
 April 
 May 
 June 
 July 
 August 
 September 
 October 
 November 
 December 
8.    Over the last 12 months, have you had a pain free 
period lasting more than one continuous month? 
(Remission period) 
 Yes 
 No 
9.    Average duration of remission period  
10.    Range of duration of remission period (Min-Max)  
 
N. Natural history 
 
1 EPISODIC  
2        EPISODIC to CHRONIC  
Age at chronification …………… 
3 CHRONIC from onset  
4 CHRONIC from onset to REMISSION  
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Duration of the remission 
period …………………………………
….. 
5 CHRONIC to EPISODIC   
6 EPISODIC to CHRONIC to EPISODIC  
7 CHRONIC to EPISODIC to CHRONIC  
 
SECTION 3: INTERICTAL PAIN 
 
Have you got any background pain between the headache/facial pain attacks? 
YES          NO  (please continue to Section 4) 
 
A. Onset 
 
1. Age of onset of interictal pain  
2. Temporal GAP between the main pain onset and 
interictal pain onset: 
Weeks/ Months/ Years: 
3. Was there any interictal pain initial trigger? Yes      No  
4. Precipitant triggers  Head injury 
 Facial injury 
 Neck injury 
 Operation 
 Back trauma 
 Viral infection 
 Illness                    
 Oral surgery 
 Episode of extreme stress 
 Airplane flight 
 Pregnancy 
 Prophylactic medication 
 Medication overuse 
 Other ………………………………………………………….. 
5. If the answer to Question 3 was ‘Yes’ then 
describe the trigger and state the time of onset of 
the trigger in relation to the onset of the interictal 
pain 
Trigger: …………………………………………………………… 
…………………………………………………………………….. 
Onset of Trigger: ……………………………………………….. 
…………………………………………………………………….. 
 
 
B. Side and site 
 
1. Side relation between the interictal pain and the 
headache/ facial pain 
Ipsilateral          
Contralateral    
Bilateral   
 
 
 
2. Tick the regions over which the pain is felt Peri orbital 
Retro orbital 
Front 
Temple 
Parietal 
Vertex 
Occipital 
 
 
 
 
 
 
 
Palate 
Floor of mouth 
Jaw 
Ear 
Chin 
Neck 
Shoulder 
 
 
 
 
 
 
 
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Nose  
Cheek  
Upper teeth 
Lower teeth 
 
 
 
 
Same side of the 
exacerbations 
 
 
RL                                   R                                L        
 
C. Severity and characteristics of the pain 
 
1. The usual severity of interictal pain VRS: 
2.  Severity range (Min-Max) VRS: 
3. Which of these descriptions of pain apply to 
your interictal pain? (You can tick more than one 
choice). 
Aching 
Boring 
Shooting 
Electric 
Burning 
Pins and needls  
Burning  
Dull    
Pressure feeling 
Others (describe below) 
 
 
 
 
 
 
 
 
 
 
 
 
Stabbing 
Tearing 
Tightening  
Throbbing  
Sharp 
 
 
 
 
 
 
 
 
 
 
 
D. Duration and frequency  
 
1. Average duration of the pain per day  
2. Range of duration per day (Min-Max)  
3. Constant all the time Yes      No     
4. Background pain only after an attack Yes      No     
5. Number of days of interictal pain per month  
6. Number of months of interictal pain per year  
 
 
E. Associated symptoms 
 
NO  
 
YES  If yes, please specify:  
 
................................................................................................................................................................................................
................................................................................................................................................................................................
................................................................................................................................................................................................ 
................................................................................................................................................................................................
................................................................................................................................................................................................ 
 
 
F. Trigger and relieving factors 
 
 FACTORS        PROVOKING                                     RELIEVING           
1 Headache/ facial pain attacks      
2 Stress                       
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3 Neck movements                          
4 Fasting (missing meals)                       
5 Alcohol                       
6 Smoking                       
7  Sleep deprivation/ excess                       
8 Coffee                        
9 Tiredness                       
10 Change in weather                       
11 Cough and/or sneeze                          
12 Loud sounds                       
13 Strong smells (eg perfumes, petrol fumes)                          
14  Menstruation                       
15 Physical exertion                       
16 Relaxation from stress                       
17 Sleep                       
18 Recreation (Taking your mind off it)                       
19 Others (Please specify below) 
                      
20 None                   
 
 
SECTION 4: LIFESTYLE FACTORS 
 
 
A.Past medical history 
 
1. Have you had any of the following 
illnesses (underline the illness that 
you have or have had) 
Depression, Anxiety, Mental disorders, Stroke, Epilepsy, Heart murmurs, 
High blood pressure, Angina, Heart attack, Rheumatic fever, Asthma, 
Bronchitis, Emphysema, Pneumonia, Tuberculosis, Jaundice, Hepatitis, Gall 
stones, Persistent diarrhoea, Rectal bleeding, Colitis, Kidney stones, Urinary 
tract infection, Arthritis, Diabetes, Thyroid disorders, Blood disorders, 
Cancer,Chronic pain elsewhere , ME fibromylgia ,  MS 
2. Do you have any other illness not 
already mentioned above? 
(Please specify) 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
3. List the operations that you have 
had for any conditions other than 
cluster headaches or TN 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
………………………………………………………………………………………. 
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B.Family history 
 
1. Does any member of your family have your type of 
headache? 
Yes      No    
2. Does any member of your family have migraine? Yes      No    
3. Does any member of your family have any other 
headaches? 
Yes      No    
4. Family history for other diseases?  
Depression ,chronic pain 
Yes      No    
 
C.Developmental migraine markers 
 
Have you ever had any of the following? 
 
 Motion sickness 
 Recurrent abdominal pain 
 Cycling vomiting 
 Vertigo 
 Hangovers 
 
D.Social history 
 
i. Alcohol intake  
 
1. Do you drink alcohol? Yes     
No     
2.       Age of onset  
3.  What is you average alcohol consumption per week? 
(1 UNIT= 1/2 pint, 1 glass of wine, 1 measure of spirit) 
Pints of 
beer                           …………… 
Measures of 
spirits                 …………… 
Glasses of 
wine                      …………… 
4. Did you stop drinking alcohol? Yes      No    
Year: 
5. Did you stop drinking alcohol due to your headaches? Yes      No     
 
6. Any relation between alcohol intake and the pain?   
 
 
ii. Smoking habits 
 
1. Do you smoke cigarettes/cigars/tobacco? Yes     
No     
2. Age of onset  
3. Number of cigarettes per day         
4. If ex-smoker, when did you give up smoking?   …………….     Not given up  
5. Did you stop smoking due to your headaches? Yes      No    Not given up  
 303 
6. Any relation between smoke and the pain?  
 
 
SECTION 5: EXAMINATION AND INVESTIGATIONS 
 
 
A. Examination 
 
1 Neurological examination performed Yes     Date (        /          /           ) 
No      
2 Result  
 
 
 
 
B. Neuroimaging/ pituitary profile 
 
INVESTIGATION  DATE RESULT 
CT Scan    
MRI Scan  
 
 
 
  Normal         
 Pituitary abnormality  
• Type: 
 Abnormal vascular loop:  
• Artery: ............................................................... 
• Vein:  ................................................................ 
 Ipsilateral      
        Contralateral  
   Bilateral         
 Other posterior fossa abnormalities  
• Type: 
 Other findings    
Follow-up MRI Scan    
Cerebral angiography    
Pituitary blood profile 
 
   Normal 
 Abnormality detected : .................................................. 
 
 
 
SECTION 6: TREATMENTS 
 
RESPONSE SCALE:  
 
No response (0): any change in headache frequency or severity 
 
Mild (1): < 50%: Mild reduction in headache frequency and/or severity. 
 
Good (2): 50-90%: marked reduction in headache frequency and/or severity. 
 
Excellent (3): 91-100%: The pain is completely or almost completely gone. 
 
Worsen the headache/facial pain (5). 
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A. Medications to date 
 
 
MEDICATION  Dose  
Year 
tried 
Duration 
of the 
trial 
Effects 
 
Side effects 
 
Stopped 
due to 
side 
effects 
 ABORTIVES 
T
ri
p
ta
n
s
 
Sumatriptan tablets (Imigran)        
Sumatriptan nasal spray 
(Imigran nasal spray) 
       
Sumatriptan injections (Imigran 
injections) 
       
Rizatriptan (Maxalt)        
Zolmitriptan tablets (Zomig)        
Zolmitriptan nasal spray (Zomig)        
Other triptans        
E
rg
o
ts
 
Ergotamine tablets 
(Cafergot, Ligraine, Migril) 
       
Ergotamine suppository 
(Cafergot) 
       
Dihydroergotamine nasal spray 
(Migranal) 
       
N
o
n
-
o
p
io
id
s
 Aspirin        
Paracetamol        
Caffeine        
O
p
io
d
s
 
Codeine        
Dihydrocodeine        
Morphine        
Oxycodone        
 Tramadol        
N
S
A
ID
s
 
Ibuprofen        
Diclofenac (Voltarol)        
Celecoxib (Celebrex)        
Indomethacin        
Mefenamic acid (Ponstan)        
Naproxen        
A
n
ti
-e
m
e
ti
c
s
 
Promethazine (Avomine, 
Phenergan) 
       
Prochlorperazine (Stemetil, 
Buccastern) 
       
Metoclopramide (Maxalon, 
Reglan) 
       
Domperidone (Motilium)        
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O
th
e
rs
 
Oxygen (give flow rate and 
duration taken during attack) 
       
Lignocaine nasal spray / topical 
cream (Lidocaine, Xylocaine) 
       
Steroids (Prednisolone)        
         
 PREVENTIVES 
A
n
ti
e
p
il
e
p
ti
c
s
 
Gabapentin (Neurontin)        
Pregabalin (Lyrica)        
Valproate (Epilim)        
Carbamazepine (Tegretol, 
Carbagen) 
       
Oxcarbazepine (Trileptal)        
Topiramate (Topamax)        
Lamotrigine (Lamictal)        
Phenytoin        
Lacosamide        
T
C
A
 
Amitryptiline (Triptafen)        
Nortryptiline (Allegron, Motival)        
Dothiepin (Dosulepin)        
Imipramine (Tofranil)        
B
e
ta
 
b
lo
c
k
e
rs
 
Propanolol (Inderal)        
Atenolol (Tenormin)        
Metoprolol (Lopressor, Betaloc)        
C
C
B
 
Verapamil        
Flunarizine        
N
S
A
ID
s
 
Indomethacin        
Rofecoxib (Vioxx)        
Celecoxib (Celebrex)        
Naproxen        
O
th
e
r 
Lithium        
Pizotifen (Sandomigran)        
Methysergide (Deseril)        
Theophylline        
Melatonin        
Mexilitine        
Baclofen        
Duloxetine        
Fluoxetine         
Steroids (prednisolone)        
Other drugs        
Escitalopram         
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Diazepam  
Clonazepam  
TRANSITIONAL TREATMENTS 
 GON block        
Multiple cranial nerve blocks        
Botolinum toxin injection        
IV DHE        
IV Lignocaine        
IV Steroids        
IV Caffeine        
 
 
B.  Medication overuse 
 
No  
 
1     Intake of ANALGESIC drugs for ≥15 
days/month on a regular basis for >3 
months 
Yes      No    
2        Intake of TRIPTANS for ≥10 days/month 
on a regular basis for >3 months 
Yes      No    
3 Intake of any OPIOIDS (Codein, 
Tramadol, Morphine) for ≥10 days/month 
on a regular basis for >3 months 
Yes      No    
4 Intake of ERGOTAMINE for ≥10 
days/month on a regular basis for >3 
months 
Yes      No    
5        Intake of COMBINATION drugs for ≥10 
days/month on a regular basis for >3 
months 
Yes      No    
6 Year of overuse 
 
 
 
C. Surgical procedures 
Please repeat this section for each different type of surgical procedure done 
 
1. Have you had any operations or surgical procedures for 
your headache/ facial pain? 
Yes      No    
2. If yes, please list the operations or procedures 
(including the year of the procedure) 
……………………………………………………………… 
……………………………………………………………… 
……………………………………………………………… 
3 Effect of procedure Improvement  
%: 
After how long: 
For how long: 
Reduction of: number of attacks, intensity, duration 
Background pain: 
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Worsening  
After how long: 
For how long: 
Increase of: number of attacks, intensity, duration: 
Background pain: 
 
No change  
 
Adverse events related to the procedure: 
 
Length of follow-up: 
 
 
D. Alternative treatments 
 
None  
 
Type of treatment 
 
Year tried 
Effects 
(0-4) 
 
Duration of the effects 
 
Acupuncture       
Chiropractic     
Herbal treatments     
Homeopathy     
Hypnosis     
Osteopathy     
Reflexology     
Spiritual healing     
Other (please specify) 
Pain managment program  
Physiotherapist 
 
    
 
 
 
SECTION 6: DIAGNOSIS 
 
 
1. How long after the onset of these headaches was the diagnosis 
made? 
 
2. Who made the diagnosis of these headaches?  
3. Please indicate which 
of the following 
doctors you have saw 
BEFORE the 
diagnosis was made 
PRACTITIONER  NUMBER 
SEEN 
DIAGNOSIS 
OFFERRED 
TREATMENT 
GIVEN 
  GP 
 
 
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Neurologist 
 
Dentist  
 
ENT Specialist 
 
Optician 
 
Ophthalmologist  
 
Others (Please specify) 
Maxillofacial surgeon/oral surgeon  
Pain specialist 
Oral physician  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SECTION 7: PAIN DISABILITY SCORES 
 
Type of measure Score 
Headache impact test (HIT-6)  
Migraine disability assessment score (MIDAS)  
Brief pain inventory  
Short form-36 (SF-36)  
Hospital anxiety and depression (HAD) scale 
 
 
Pain catastrophising questionnaire (PCS)  
Chronic graded pain scale  
Adverse events questionnaire  
 
 
 
 
